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Abstract 
 
Adrenomedullin (ADM) is an evolutionarily conserved peptide hormone 
that is essential for a wide variety of physiological functions. Deregulation of 
ADM has been implicated in many pathological conditions including sepsis, 
cardiovascular diseases and cancer. Published data suggest ADM may play a role 
in up to 80% of cancers by acting as an apoptosis survival factor, a proliferative 
agent, an angiogenic factor and helping tumour cells evade the immune system. 
Receptors for ADM are composed of a G protein Coupled Receptor called the 
Calcitonin Like Receptor (CLR) which complexes with either Receptor Activity 
Modifying Protein (RAMP) 2 or 3 resulting in two distinct receptors for ADM 
(RAMP2+CLR or RAMP3+CLR). Since ADM plays a crucial role in tumour 
progression, it was hypothesized that neutralising ADM would have a significant 
impact on reducing tumour growth and its angiogenic potential.  
 
Under hypoxia, cells expressed significantly high levels of ADM, possibly to 
withstand the potentially lethal microenvironment. The effect of over-expression 
of ADM was studied on cell proliferation, migration and invasion. ADM over-
expressing cells migrated faster than control cells in scratch test assay. 
Preliminary analysis on cell proliferation showed no significant difference in cells 
transfected with ADM. Results from these studies demonstrated that ADM 
contributes to cancer cell progression. 
 
  An anti-RAMP3 antibody, JF2, developed in our lab was used to inhibit 
ADM action. A decrease in cell proliferation was seen in Glioblastoma, Pancreatic, 
Breast and Prostate cancer cells when compared to isotype controls. In vivo 
experiments using NOD-SCID mice subcutaneously injected with pancreatic 
cancer cells resulted in significant reduction in tumour size and volume. 
	  
Collectively, it is demonstrated that ADM is elevated in a malignant setting 
and targeting ADM activity would significantly reduce tumour progression. 
Further research on the affinity, toxicity, mechanism of action and downstream 
effects in signalling of JF2 could elucidate its potential as a drug in cancer 
treatment.  
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1.1. Cancer 
 
Cancer is a multifactorial disease characterised by uncontrollable 
proliferation of cells, leading to the formation of tumours. The lifetime risk of 
developing cancer is one in three (Futreal et al. 2001). Figure 1 shows the top 20 
most common causes of cancer deaths worldwide estimated in 2008 by Cancer 
Research UK. When the tumour reaches a certain mass, a small number of cells 
are capable of being carried from the primary tumour by blood or the lymphatic 
system to other parts of the body leading to the formation of secondary cancer 
termed as metastases. Cancers are classified according to their tissue of origin 
and histology. Since there are over 200 types of cells, there are over 200 types 
of cancers (Hanahan and Weinberg 2000).  
 
 
 
 
 
 
Figure 1: Top 20 most common causes of cancer deaths world wide estimated 
in 2008. Picture taken from Cancer Research UK. 
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There are many factors that influence the pathogenesis of cancer, such as 
carcinogens (Gibbs and Berry 2008; O'Reilly et al. 2007; Robert and Dubertret 
1995), lifestyle (Bradley et al. 2002; Salaspuro 2007; Witschi et al. 1997), 
environment (Kampa and Castanas 2008; Ward 1995), viruses (Blattner 1999; 
Frazer 2004; Narisawa-Saito and Kiyono 2007), genetic make-up (Rahman and 
Stratton 1998) and age (Hanahan and Weinberg 2000). All of these factors play 
a role that directly or indirectly alter the normal functioning of the DNA. All 
through life DNA is exposed to various mutagens that alter the replication and 
causes certain mutations in the sequence of the DNA. Studies have shown that 
an average of six to seven mutations are needed to convert a normal epithelial 
cell into an invasive carcinoma (Futreal et al. 2001). The common genes that 
undergo mutations by the above mentioned factors can be broadly classified into 
two categories: 
 
• Proto-oncogenes – When the gene undergoes mutations it becomes an 
oncogene and promote uncontrolled cell proliferation. For example, when 
the RET proto-oncogene undergoes mutations, it becomes an oncogene 
resulting in multiple endocrine neoplasia type 2 which is a syndrome for 
cancer (C. Eng 1999). 
 
• Tumour Suppressor (TS) genes – these genes aid in suppressing the 
events leading towards cancer. They help the inappropriate cell cycle 
progression and maintain low mutation rates by ensuring accurate 
replication and repair, mutation in these genes results in cancer. In order 
to change the normal behaviour of the cell, both alleles of this gene must 
be inactivated / mutated. An example of such a gene is, TP53 that codes 
for p53 which is a tumour suppressor protein and has many anti-cancer 
mechanisms. 60% of cancers have mutations in p53 gene (Bourdon 
2007). 
 
Studies have shown that mutations in the genes lead to cancerous 
phenotypes (Blume-Jensen and Hunter 2001) by amplification of proto-
oncogenes (Pinkel and Albertson 2005), point mutations (Lowy and Willumsen 
1993) and chromosomal translocations (Rabbitts 1994). Genes involved in the 
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development of cancer show a wide variety in structure and function. Due to this 
wide variety, cancer has proved to be a difficult condition to treat (Futreal et al. 
2001). Cancer cells exhibit various characteristics to sustain themselves. 
Hanahan and Weinberg in 2000 and 2011 (Hanahan and Weinberg 2000, 2011) 
outlined the characteristic features of cancer cells which is illustrated in figure 2.  
 
 
 
 
 
 
Studies on cancer cells reveal that many signalling pathways contribute to 
its pathogenesis. Once a cell has undergone the mutations to make it neoplastic, 
it needs to have cell-cell signalling that is dependent on growth factors, 
cytokines and hormones. Cancer cells acquire the ability to proliferate 
uncontrollably by either producing excessive growth factors or by sending signals 
to stimulate non-cancerous cells within the tumour-associated stroma to produce 
growth factors (Bhowmick et al. 2004; Cheng et al. 2008). Cancer cells in turn 
up-regulate the expression of receptor proteins to respond to the excessive 
Figure 2: The different characteristic features of a cancer cell. Picture taken 
from Hanahan and Weinberg, 2010. 
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production of growth factor ligands (Hanahan and Weinberg 2011). One of the 
growth regulatory peptide that is over produced in cancer is Adrenomedullin (F. 
Cuttitta et al. 2002; Martinez et al. 1997; Satoh et al. 1995; Zimmermann et al. 
1996). 
1.2. Adrenomedullin 
   
Adrenomedullin (ADM) is a hypotensive peptide discovered in the 
pheochromocytoma of humans which are tumours present in the adrenal 
medulla, thus giving this peptide its name. It belongs to the Calcitonin super 
family of peptides (Kitamura et al. 1993). ADM is known to elicit the levels of 
cAMP which resulted in elevated blood pressure in rats. ADM is evolutionarily 
conserved for over millions of years playing an important role in various 
physiological functions thereby contributing to survival (Frank Cuttitta et al. 
1999).  Some of the physiological functions that ADM plays a role are cell growth 
(Frank Cuttitta et al. 1999), blood pressure, hormone regulation (T. Yamaguchi 
et al. 1995), angiogenesis (Y. Zhao et al. 1998) and apoptosis (H. Kato et al. 
1997).  
 
1.2.1. Structure 
  
 ADM is a 52 amino acid peptide, having a disulphide bond between two 
cysteine residues located at positions 16 and 21, as illustrated in figure 3. The 
amidation of the C terminal end and the cysteine ring structure is important for 
the biological activity of the peptide. These  structures  are  responsible  for  the  
receptor  binding  and  subsequent  cAMP  generation (Kitamura et al. 1993).  
The C-terminal  fragment  ADM22-52  does  not  contain  the  disulphide ring  and  
does  not  show  any  activity  upon  binding  to  the  ADM  receptors, so it is 
used as an ADM receptor antagonist (Eguchi et al. 1994).  ADM circulates in 
plasma with concentrations between 2-10pM (Kitamura et al. 1993). Circulating 
ADM is bound to an ADM binding protein-1 (AMBP-1) – complement factor H; 
this complex makes it hard to estimate the amount of ADM in plasma (Pio et al. 
2001), therefore circulating ADM levels maybe more than 2-10pM.   
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1.2.2. Expression, Release and Clearance 
 
 
The gene that encodes ADM in humans, is present on chromosome 11 and 
is made up of a single locus and consists of four exons and three introns.  The 5’ 
flanking region consists TATA (-653), CAAT (-755) and GC boxes.  There  are  
multiple  binding  sites  for  Activator  Protein -2  (AP-2), Activator Protein -1   
and  a  cAMP  Regulated  Enhancer (CRE). Protein kinase C and cAMP mediate 
transcription activation through AP-2. A  binding  site  for  the  promoter  Sp  
factor 1  (Spf1)  is  also  adjacent  at  -682  position.  These  elements  are  
responsible  for  binding  of  RNA  polymerase  2  and  basal  activity  of  the  
gene (Ishimitsu et al. 1994). The gene also contains 16 putative Hypoxia 
Response elements (HREs) in the promoter region (Garayoa et al. 2000).  
 
ADM is derived from preproADM which is made up of 185 amino acids.  
After  cleaving  of  the  21  residue  signal  peptide,  preproADM  is  converted  
to  proADM having 164 amino acids,  which is  the  precursor  of  ADM  and  
another  peptide  called  proADM  N terminal  20  peptide  (PAMP) (Beltowski and 
Jamroz 2004; Bunton et al. 2004; Ishimitsu et al. 1994). Figure 4 illustrates the 
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Figure 3: Structure of Adrenomedullin showing the two cysteine residues in 
green where the disulphide bond exists. The figure also shows the amidated C 
terminal end. Figure drawn by self, adapted from Beltowki & Jamroz, 2004 . 
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ADM gene and the transcribed mRNA that is 1.6kb long and the translated 
region. When ADM is cleaved from PAMP, it is a glycine-extended 53 amino acid 
peptide, which is an immature ADM (iADM) that is functionally inactive. An 
amidating enzyme called the Peptidylglycine α-Monooxygenase (PAM) converts 
the iADM to mature ADM (mADM) by amidating the glycine in the C-terminal end 
(Beltowski and Jamroz 2004).  
 
 
 
 
 
 
 
 
 
PAMP iADM 
PAM 
 mADM 
Prepro ADM  
185aa 
Signal 
Peptide 
ProADM-N20 
(PAMP) 
 Adrenomedullin 
 
 
1 125 74 20 
Translated Region 1449 1 157 714 
Exon 1 
1752-1886 
Exon 2 
2335-2453 
Exon 3 
2604-2753 
Exon 4 
2987-4031 
1 2 3 4 1.6kb mRNA 
4605 
Figure 4: Expression of ADM – gene/mRNA/protein. The gene has 4 exons and 3 
introns. The mRNA is 1.6kb and is translated into 185 amino acid protein that 
codes for two peptides – PAMP and ADM. The iADM (immature ADM) is converted 
to mADM (mature ADM) by PAM.  Figure adapted from Ishimitsu et al, 1994 and 
Beltowski and Jamroz, 2004. 
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 ADM is a ubiquitously expressed peptide which is largely secreted by the 
adrenal glands (Kitamura et al. 1993). Since ADM is present in almost all of the 
organs, it is a biologically important peptide (Marutsuka et al. 2003). Smooth 
muscle cells are said to produce 3-4 times more ADM than endothelial cells, but 
the plasma ADM is predominantly secreted from endothelial cells (Sugo et al. 
1994b; Sugo et al. 1994a; Yamaga et al. 2003).  Several factors such as Nitric 
Oxide (NO) (Hofbauer et al. 2002), IL-1  α  and  β,  TNF  α  and  β (Chini et al. 
1995; Sugo et al. 1995b),  endotoxin (So et al. 1996),  bradykinin,  adrenaline 
(Sugo et al. 1995a),  dexamethasone,  thyroid  hormones (Kureishi et al. 1995), 
have been shown to stimulate the production of ADM from Vascular Smooth 
Muscle cells (VSMCs).  Factors such as forskolin, interferon-γ, thrombin, 
transforming growth factor β are said to inhibit the secretion of ADM (Bunton et 
al. 2004). 
 
 Circulating ADM has a half-life of ~20 minutes. Lungs are known to be the 
largest site where ADM is metabolised. Another site of clearance are the kidneys 
since the ADM concentration in urine is 15 times the concentration found in 
plasma (Beltowski and Jamroz 2004).  In the kidney, ADM is filtered by the 
glomeruli and is broken down by Neutral Endopeptidase (NEP) suggesting that 
the high level of ADM in the urine is not from the systemic circulation, but due to 
the intrarenal production of ADM (Beltowski and Jamroz 2004). This diversity in 
expression and release of ADM in various organs shows that ADM plays 
numerous roles in each of these organs/cells.  
 
1.2.3. Signal Transduction 
 
 Unlike the classical concept of single ligand – single receptor, ADM 
functions through a combination of a G-Protein Coupled Receptor and an 
accessory protein (McLatchie et al. 1998; Pinto et al. 1996; Zimmermann et al. 
1996). The signalling mechanism of ADM is extensively reviewed in the following 
sections.  
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1.2.3.1. G-Protein Coupled Receptors (GPCRs) 
 
GPCRs are the largest receptor family and are the most common signalling 
mechanism through which a plethora of proteins, genes and other secondary 
messengers are activated (Kohout and Lefkowitz 2003). The GPCR superfamily 
has been classified into 6 families (Kristiansen 2004),these are: 
 
• Family A, the rhodopsin family – Family A is the largest GPCR family and 
consists of 20 conserved  residues that are confined to the transmembrane 
region. Examples of this family are rhodopsin receptors, platelet activating 
factor. 
 
• Family B, the secretin receptor family – Family B, has a large extracellular 
domain that consists of 6 conserved cysteine residues along with 20 conserved 
residues present in their transmembrane region. An example of this family is 
calcitonin receptor, parathyroid hormone receptor. 
 
• Family C, the metabotropic glutamate/pheromone receptor family – Family 
C, has a long extracellular domain consisting of 20 cysteine residues along with 
the 20 conserved residues present in the transmembrane domain. An example 
for this family of receptors are, taste receptors, calcium-sensing like receptors. 
 
• Family D – fungal pheromone receptors 
 
• Family E – cAMP receptors and 
 
• Family F – frizzled/smoothened receptors 
 
Approximately 80% of neurotransmitters/hormones transduce their signal 
by activating GPCRs (Kristiansen 2004). Due to their wide variety and 
distribution, dysfunction of GPCRs are involved in diseases and are very 
important therapeutic targets. For example anti-depressants and β-blockers are 
two of the best known drugs. An example of a β-blocker is Nebivolol in the 
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treatment of hypertension; it targets the β-adrenergic receptor kinase of the G-
protein Coupled Receptor Kinases family (GRKs) (M. A. Weber 2005). Elevated 
levels of GPCRs and their ligands are found in cancer cells suggesting that they 
are involved in tumour growth and progression (S. Li et al. 2005). For example, 
61% of colon tumours and 53% of ovarian tumours over-express GPR49, which 
is a GPCR. Knockouts of GPR9 receptors in tumours induced apoptosis; this is 
just one example showing the involvement of GPCR in cancer (McClanahan et al. 
2006).  
 
Structure 
 
 As illustrated in figure 5, GPCRs have seven transmembrane helices that 
are linked with both extracellular and intracellular loops. The extracellular 
domain contains the ligand binding pocket while the intracellular domain conveys 
the signal to secondary messengers (Rios et al. 2001).  
 
 
 
 
 
 
Figure 5: Structure of GPCR showing the seven transmembrane helices and 
the G proteins attached to the C terminal end of the receptor. Figure drawn by 
self, adapted from Rios et al, 2001. 
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The GPCRs mediate their action through the G proteins which reside at the C 
terminal tail of GPCRs. 
 
 
G Proteins 
 
G proteins convey signals from GPCRs to a variety of targets. G proteins 
upon activation, cause the induction of secondary messenger systems via 
various effector proteins. This system allows amplification ie, one ligand is able 
to activate GPCRs that in turn activate effectors that are able to stimulate a 
secondary messenger system resulting in the amplification of the entire signal 
(Kristiansen 2004). 
 
The G proteins are comprised of α, β and γ subunits, and the molecular 
weights are approximately, 39-45, 35-39 and 6-8kDa respectively (Kristiansen 
2004). In the resting state of the receptor, the G proteins are bound to each 
other and the αs has GDP (Guanosine diphosphate) bound to it. When a ligand 
binds to the extracellular domain of the GPCR, conformational changes take 
place activating the bound G proteins and α subunit to dissociate and it activates 
an effector molecule (example, adenylate cyclase) and since it is a GTPase it 
converts GDP to GTP (Guanosine triphosphate). βγ subunits exist together and in 
some cases they may also activate a few effector molecules (Cabrera-Vera et al. 
2003) such as type I and type II adenylate cyclase, phosphoinositide-specific 
phospholipase A beta (Ueda et al. 1994). In order to terminate the signalling, 
the Gα subunit converts GTP back to GDP thereby restoring the inactive state of 
the G protein. Another mechanism of GPCR activation is through phosphorylation 
of the receptor by a kinase, which decreases its ability to respond to the ligand. 
This phosphorylation triggers β-arrestin binding which desensitizes the receptor 
and leads to the down-regulation and either degradation or recycling of the 
receptor back to the membrane. In the resting state, α subunit reunites with βγ 
subunits once again (Strader et al. 1994). 
 
There are a wide range of G proteins that interact with different receptors 
and control different effectors. There are about 28 different Gα proteins to which 
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the GPCR can associate with (Kristiansen 2004).The α subunits are classed in 
four groups such as αs (Gs and Golf), αi (Gtf, Gtc, Gg, Gil-3, G0 and Gz), αq (Gq, G11, 
G14 and G15/16) and α12 (G12 and G13). Even the β and γ subunits have been 
subdivided into 12 and 5 subunits respectively, to date (Kroeze et al. 2003). 
Various combinations of these sub-units make up different types of functional G-
proteins, which make them diverse and specific for their signalling (Cabrera-Vera 
et al. 2003). Each of these subunits has been further sub classified according to 
the oncogene they stimulate. For example, studies have shown that when there 
is an increase in intracellular cAMP level, there is increase in proliferation. 
Therefore, in tissues expressing high cAMP levels, hyperplasia is induced by the 
Gαs subunit and this acts on the oncogene called the gsp oncogene, while Gαi2 
induces the gip2 oncogene (Gutkind 1998).The effector proteins through which 
the GPCRs control different aspects of cell functions are 
 
• Adenylatecyclase – Gαs, the enzyme responsible for cAMP formation. 
 
• Phospholipase C – Gαq, the enzyme responsible for inositol phosphate and 
diacylglycerol formation 
 
• Ion channels – Gαiz, specifically calcium and potassium channels 
(Kristiansen 2004). 
 
The family of GPCRs that ADM receptors belong to are the class B GPCR 
family, which include receptors for 30-50 amino acid peptides like the Calcitonin 
family (CT family) of peptides which includes ADM, Amylin (AMY), Calcitonin 
Gene Related Peptide (CGRP). The receptor for these peptides has been found to 
be Calcitonin Receptor (CTR) and Calcitonin Like Receptor (CLR) (McLatchie et al. 
1998).  
 
 
 
 
 
34 
 
1.2.3.1.1. Calcitonin Like Receptor (CLR) 
 
The gene for human CLR is located in chromosome 2q31 and contains fifteen 
exons and spans approximately 100kbps (Conner and Poyner 2001; Nakazawa et 
al. 2001; Nikitenko et al. 2003). 
 
CLR similar to other members of class B GPCRs, contain large N terminal 
domain consisting of highly conserved six cysteine residues resulting in the 
formation of disulphide bonds (Gether 2000). This N-terminal domain is involved 
in ligand binding and function similar to that of other class B GPCRs such as 
receptors for secretin, glucagon and parathyroid hormone (Chauhan et al. 2005). 
CLR shares 50% and 54% sequence identity with rat and human CTR 
respectively (Aiyar et al. 1996; Chang et al. 1993; Fluhmann et al. 1995). CLR is 
expressed in high levels in lungs, heart and kidneys (Elshourbagy et al. 1998).  
 
Mice deficient in CLR die at mid-gestation due to Hydrops Fetalis and severe 
cardiovascular defects. Figure 6a shows the edema seen throughout the body of 
the embryo at E12.5 days. Figure 6b shows the edema being progressed to 
severe Hydrops Fetalis at E13.5 days. There was a significant reduction in 
proliferation of cells in ventricles for CLR-/- when compared to wild type. Similarly 
there was a high rate of apoptosis in CLR-/- mice when compared to wild type. 
This suggests that CLR is required for the embryonic development and mediate 
growth and proliferation of cardiac and vascular smooth muscle cells (R. T. 
Dackor et al. 2006). 
 
 Figure 6: CLR knock out mice. Figure A shows the edema throughout the body 
at E12.5 days, and figure B shows the progression of the edema to severe 
Hydrops Fetalis at E13.5 days. Picture taken from Dackor et al, 2006. 
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 CLR unlike most GPCRs requires the association with Receptor Activity 
Modifying Proteins (RAMPs) to traffic from endoplasmic reticulum to cell surface 
and for ligand specificity (McLatchie et al. 1998). RAMPs confer ligand 
specificity to CLR by regulating glycosylation of CLR. There are three types of 
RAMPs that associate with CLR and the details of RAMPs are reviewed under 
section 1.2.3.1.2. Glycosylation is important for receptor transportation and 
function (Ho et al. 1999; Liu et al. 1993; Mery and Boulay 1993; Ray et al. 
1998; Walsh et al. 1998). RAMP1 confers terminal glycosylation while RAMP2 
and RAMP3 confer core glycosylation of CLR (McLatchie et al. 1998). CLR has 
three putative Asn glycosylation sites in its extracellular domain at positions 66, 
118 and 123 (Aiyar et al. 1996; Fluhmann et al. 1995).  
 
 The implication of glycosylation at Asn66 and/or Asn118 is currently 
unclear as one data suggest that glycosylation at these sites are important for 
the cell surface expression (Buhlmann et al. 2000) while another group 
contradict this report (Kamitani and Sakata 2001). In order to confer binding of 
ADM, CLR has to be glycosylated at position Asn123 (Kamitani and Sakata 
2001). 
 CLR consists of N-terminal α helix (named α1) and two anti-parallel β 
sheets (named β1 and β2) that are connected by five loops. The structure is 
stabilized by three disulphide bonds that exist between Cys-48-Cys74, Cys 65-
Cys105 and Cyc88-Cys127 (Kusano et al. 2011). The extracellular loop 3 (ECL3) 
has shown to be important in ADM binding and subsequent signal transduction 
(Kuwasako et al. 2011a). The ECLs in family A and B GPCRs are known to be 
important in ligand binding and receptor activation (Hawtin et al. 2006; 
Kuwasako et al. 2003b; Lawson and Wheatley 2004; Peeters et al. 2011). ECL1 
and ECL2 in family B GPCRs are known to contain a conserved disulphide bond 
which determines the stability of the receptor (Kuwasako et al. 2003b). Helix8 of 
CLR has already been shown to be involved in Gs signaling (Kuwasako et al. 
2010), recent evidence has shown that ECL3 controls the activation of Gs 
resulting in the accumulation of cAMP (Kuwasako et al. 2011a). 
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 The transmembrane domains 1 to 5 of CLR have been shown to be 
important in transportation of RAMP+CLR to the plasma membrane. The 
difference in trafficking interactions between the three RAMPs might be 
determined by the N terminal domain and/or the third intracellular loop and/or 
transmembrane domain (Kuwasako et al. 2009). The role of transmembrane 
domains and loops in CLR are still unknown (Walker et al. 2010; Wheatley et al. 
2011). 
 
 Since CLR is unable to mediate signal transduction on its own as 
mentioned above, it requires an association with RAMPs for trafficking to the cell 
surface and conferring ligand specificity (McLatchie et al. 1998). RAMPs are 
needed for the cell surface expression and receptor phenotype of CLR. For 
example, the CLR-RAMP complexes originating from the endoplasmic reticulum 
and golgi are co-trafficked to the cell surface and are important for receptor 
activation (Conner et al. 2004; Parameswaran and Spielman 2006). 
 
1.2.3.1.2. Receptor Activity Modifying Proteins (RAMPs) 
 
  RAMPs are single transmembrane proteins that associate with GPCRs to 
facilitate ligand binding and trafficking of the receptor to the cell surface. This 
family of proteins has 3 members – RAMP1, RAMP 2 and RAMP3. RAMP 1 and 
RAMP 3 are 148 amino acids long; while RAMP 2 is 175 amino acids long 
(McLatchie et al. 1998). Puffer Fish expresses five RAMPs, from RAMP1 to 
RAMP5, three CLRs – CLR1 to CLR3 and five ADM proteins – ADM1 to ADM5 (Nag 
et al. 2006; Ogoshi et al. 2003). 
 
 The genes that code for RAMP1, RAMP2 and RAMP2 in humans are present 
in between 2q33 and 2q37, chromosome 17 and 7p11-7p13 respectively (Sexton 
et al. 2001). Mammalian RAMPs share 30% sequence identity and their basic 
structures are similar. Mouse and human amino acid sequence identity for 
RAMP1, RAMP2 and RAMP3 are 70%, 68% and 84% respectively (Husmann et 
al. 2000). 
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 RAMPs have three main structural domains, this is illustrated in figure 7 
(McLatchie et al. 1998). Each RAMP has a short C terminal end that is made up 
of ten amino acids and the transmembrane domain is made up of approximately 
20 amino acids and the N terminal end is the largest and contains the signal 
peptide. RAMP2 has 26 amino acids longer extracellular domain than the other 
RAMPs (Conner et al. 2004). One of the important features that are common to 
all three RAMPs is that the extracellular domain contains two disulphide bonds, 
and if this bond is disturbed RAMPs lose their activity. The disulphide bonds are 
important for stabilizing the receptor in order to facilitate ligand binding and 
activation (Parameswaran and Spielman 2006).  For RAMP1, residues 91-103 are 
essential for CGRP binding, residues 86-92 and residues 59-65 are needed for 
RAMP2 and RAMP3 for ADM binding respectively (Conner et al. 2004). RAMPs are 
abundantly distributed throughout the body, although certain organs and tissues 
have different RAMP phenotypes. For example, the aortic endothelial cells 
respond to ADM but express only RAMP2 (Parameswaran and Spielman 2006).   
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 The distribution of RAMPs is broader than ADM and CLR, indicating that 
RAMPs also interact with other class B GPCRs. Besides class B GPCR family 
receptors, RAMPs also associate with class C GPCR family, for example Calcium-
Sensing Receptor (CaSR) requires association with either RAMP1 or RAMP3 for 
transport from ER to golgi and co-expression to the cell surface. This receptor 
plays a crucial role in calcium homeostasis (Bouschet et al. 2005). Studies have 
Figure 7: Structural domains of RAMP1, RAMP2 and RAMP3. Conserved 
cysteine residues and glycosylation sites are shown as C and N respectively. 
Conserved amino acids in the transmembrane domains are shown. The 
putative phosphorylation sites are shown in blue and the PDZ motif in RAMP3 
is shown in green. Picture taken from Parameswaran & Spielman, 2006. 
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shown that RAMP2 interacts with glucagon and PTH1 parathyroid hormone 
receptors and while RAMP3 interacts with PTH2 receptor (Christopoulos et al. 
2003). Microarray analysis of human and mouse transcriptomes showed that 
RAMP2 is predominantly expressed in lungs, female reproductive organs and 
adipocytes besides other tissues. RAMP3 is expressed highly in heart, thyroid 
and lungs in humans and female reproductive organs in mice (Su et al. 2002). It 
is suggested that RAMP3 may have differential functions in human and mouse 
(Gibbons et al. 2007). 
 
 RAMPs and their receptor partners’ gene expression is altered under various 
pathological conditions such as cardiovascular diseases, renal failure and hypoxia 
(Kuwasako et al. 2004; Morfis et al. 2003; Udawela et al. 2004). For example, in 
models of heart failure ADM and RAMP2 mRNA were present in high levels when 
compared to controls (Nishikimi et al. 2003; Totsune et al. 2000). Experimental 
models of sepsis showed a 40 fold increase in RAMP3 expression and 95% 
decrease in RAMP2 and CLR expression in lungs (Ono et al. 2000). 
 
 In an experiment of cardiac hypertrophy induced by volume overload by 
aortocaval shunt and/or pressure overload by aortic banding, there was an 
increase in ADM1 (RAMP2+CLR) and ADM 2 (RAMP3+CLR) receptor expression 
under pressure overload. But in volume overload induced models there was an 
increase in ADM1 receptor mRNA. Data from these experiments suggest that 
RAMP2 and RAMP3 are transcribed under different pathophysiological conditions 
(Onitsuka et al. 2004). 
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RAMP1 
 
 Association of RAMP1 and CLR results in a receptor for Calcitonin Gene 
Related Peptide (CGRP) (McLatchie et al. 1998). RAMP1 knockout mice showed 
elevated blood pressure without change in heart rate (Tsujikawa et al. 2007). 
This shows that RAMP1+CLR induced CGRP signaling is important in the 
regulation of blood pressure.  
 
 The extracellular domain (ECD) of RAMP1 chimerised with platelet-derived 
growth factor (PDGF) transmembrane domain resulted in a functional CGRP 
receptor with CLR. This suggests that the ECD is responsible for the response of 
ligand and also for the glycosylation of CLR receptor (Fitzsimmons et al. 2003). 
Amino acids Phe93, Tyr100 and Phe101 of RAMP1 are involved in binding with 
CLR and Phe92 and Tyr74 form part of ligand binding pocket of CLR+RAMP1 
heterodimer (Simms et al. 2006). Deletion of amino acid residues from 101-103 
in RAMP1 has shown to abolish the formation of the CGRP receptor (Kuwasako et 
al. 2003a). 
 
 RAMPs contain three serine or threonine residues in their intracellular 
domain, which could be possible phosphorylation sites. Upon CGRP induction on 
CLR+RAMP1 in HEK293 cells, there was no phosphorylation seen in RAMP1 but 
there was phosphorylation of CLR (Hilairet et al. 2001). This suggests that 
RAMP1 phosphorylation might not play a role in agonist induced signal 
transduction.Targeted deletion of RAMP1 cytoplasmic tail does not inhibit the 
trafficking of CLR to the cell surface. Since the cytoplasmic tail of RAMP1 has no 
effect on CGRP signaling, it has been suggested that it is not necessary for CLR 
function (Fitzsimmons et al. 2003). 
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RAMP2 
 
 RAMP2 associates with CLR to form a functional receptor for ADM called 
ADM1 receptor (McLatchie et al. 1998). RAMP2-/- is embryonically lethal as the 
mice die in utero due to severe interstitial edema and defects in development of 
vasculature (R. Dackor et al. 2007; Fritz-Six et al. 2008; Ichikawa-Shindo et al. 
2008). RAMP2+/- mice showed elevated blood pressures with ~10mmHg more 
than wild type. Reduced litter size (R. Dackor et al. 2007) and  edema was 
observed in brain and skin due to impaired neovascularisation (Ichikawa-Shindo 
et al. 2008). Figure 8 shows the RAMP-/- embryos showing severe Hydrops Fetalis 
and hemorraghes (Ichikawa-Shindo et al. 2008). 
 
 
 
  
 
 
 
 
 
 
 
Figure 8: RAMP2-/- mice. RAMP2 mice died in utero at E14.5 days due to 
severe edema resulting in Hydrops Fetalis as it can be seen from pictures A 
and B. Mice suffered severe cardiovascular defects resulting in haemorraghes 
as it can be seen in figure C. Reprinted with permission from Ishikawa-
Shindo et al, 2008. 
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 The ECD of RAMP2 is composed of three α-helices (named as α1, α2 and 
α3) connected by two loops as shown in figure 9. α2 and α3 of RAMP2 interact 
with α1 helix of CLR  (Kusano et al. 2011). Two disulphide bonds at Cys68-Cys99 
and Cys-84-Cys131 stabilise the structure of RAMP. These amino acid residues 
cys68, cys84, cys99 and cys131 are important for N-glycosylation and mutations 
in these cysteine residues result in reduced ADM binding (Kuwasako et al. 
2003b). 
 
 
 
 
 
 
 
 
 
 
 
 
 Recent Studies have shown that the binding pocket of CLR+RAMP2 is 
different from the binding pocket of CLR+RAMP1 (figure 9) (Kusano et al. 2011). 
Residues that are conserved between RAMP1 and RAMP2 do not play a role in 
Figure 9: Crystal Structure of CLR and RAMP2 extracellular domain required 
for ADM binding. (A) Schematic representation of where ADM binds to in 
CLR+RAMP2 complex. (B) Cartoon images of CLR in orange and RAMP2 in 
blue. Disulphide bonds are shown as yellow sticks and the α-helices and β-
sheets in each are numbered. (C) loop position in CLR and RAMP2 (D) 
Representation of Molecular surface of CLR+RAMP2 complex. Glycosylation 
sites are shown in green. Reprinted with permission Kusano et al, 2011. 
43 
 
ligand binding as they engender different specificities for ligands. Amino acid 
residues 77-101 of RAMP2 has been shown to be involved in the interaction with 
CLR, the residues 86-92 is known to play a vital role (Kuwasako et al. 2001). 
His124Ala and His127Ala in RAMP2 ECD is important in ADM binding and 
activation of receptor (Qi et al. 2008). Studies have shown that the cytoplasmic 
tail of RAMP2 is needed for ADM1 receptor expression and function (Hay et al. 
2006; Kuwasako et al. 2006). Deletion of cytoplasmic tail of RAMP2 inhibits the 
trafficking of CLR to cell surface (Fitzsimmons et al. 2003). 
 
 
RAMP3 
 
 CLR associates with RAMP3 to form ADM2 receptor (McLatchie et al. 1998). 
RAMP3-/- mice did not have a significant phenotype as that of RAMP2-/- and CLR-/- 
mice. The RAMP3-/- mice appeared normal upto six months of age after which the 
weights of 9-10 months old RAMP3-/- mice were significantly lower (~9g) than 
wild type controls (R. Dackor et al. 2007). From this study, it has been 
suggested that RAMP3 has a different signaling that is not necessary for growth 
and survival and that it may be induced when necessary for example in a 
diseased condition. For example, in mouse models of sepsis where RAMP3 
expression was elevated in lungs, spleen and thymus (Ono et al. 2000), it has 
been suggested that RAMP3 maybe involved in immune function (Kuwasako et 
al. 2011b). Addition of Platelet Derived Growth Factor (PDGF) in Rat Mesangial 
Cells (RMCs) increased the half life of RAMP3 mRNA from 66.5mins to 
331.6mins. This resulted in an increase in the cell surface expression of RAMP3, 
resulting in increased adenylate cyclase activity (Nowak et al. 2002). 
 
 Besides binding ADM, ADM2 receptor can also effectively bind CGRP with 
atleast 10 fold more affinity than ADM1 receptor. This affinity is suggested to be 
due to the disulphide bond at cys27 and cys82 which is present in RAMP1 and 
RAMP3 but not RAMP2 (Hay et al. 2006; Kuwasako et al. 2011b). One plausible 
reason for this difference in signalling between RAMP2 and RAMP3 is suggested 
by the presence of a PDZ motif (Thr-Leu-Leu) that can interact with N-
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ethylmaleimide-Sensitive Factor (NSF) and Na+/ H+ Exchanger Regulatory 
Factor-1(NHERF). This interaction is known to aide in receptor internalization and 
recycling (Bomberger et al. 2005b).  
 
 Glu74 residue in the ECD of RAMP3 is known to be involved in ADM binding 
(Qi et al. 2011). Six Cysteine residues in RAMP3 and four N-Glycosylated 
residues play a vital role in ADM binding. This was shown by performing a site-
directed mutagenesis on the N- glycosylation sites in RAMP3, which resulted in 
no ADM binding. The glycosylated residues of RAMP3 are Asn28 and Asn54 
(Flahaut et al. 2003). Amino acid residues 59-65 in RAMP3 are suggested to be 
involved in the interaction with CLR to form a functional ADM receptor 
(Kuwasako et al. 2001). Deletion of RAMP3 cytoplasmic tail does not affect the 
trafficking of CLR to cell surface (Fitzsimmons et al. 2003) but is required for 
ADM2 receptor internalization and recycling (Hay et al. 2006; Kuwasako et al. 
2006). 
 
 
ADM1 Receptor and ADM2 Receptor 
 
 The association of RAMP2 and RAMP3 with CLR forms two ADM receptors. 
The ADM antagonists ADM22–52 and CGRP8–37 have specific affinity for RAMP2 and 
RAMP3 respectively. The differences in affinities between these receptors are 
explained by the structures of these proteins. RAMP3 shows greater similarities 
to RAMP1 than RAMP2. RAMP2 is N-terminally extended compared to RAMPs 1 
and 3; on the other hand, RAMP3 have an extra pair of conserved cysteines that 
may create a disulphide-bonded loop that is absent in RAMP2. The consensus 
sequences at either end of this putative loop (NH2CN/QE..GCY/FW..) are very 
different from the RAMP2 sequence (..GTV…DLGF..), and may contribute to the 
different pharmacologies shown by the CLR/RAMP2 and CLR/RAMP3 complexes 
(Hay et al. 2004). 
 
 Another protein found to be involved in the ADM signalling is the Receptor 
Component Protein (RCP). It has been shown that to form a receptor for ADM 
signaling it must have at least three proteins namely CLR, RAMP2/3 and RCP 
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(Prado et al. 2001). Figure 10 shows the schematic representation of activation 
of ADM receptors by ADM, and the dissociation of Gα that triggers the Adenylate 
cyclase pathway resulting in the accumulation of cAMP and activation of 
signalling cascade (Beltowski and Jamroz 2004; Kuwasako et al. 2000; Prado et 
al. 2001). Site-directed mutagenesis carried out at the amino acid positions 86-
92 in RAMP2 and 59-65 in RAMP3 contributed to a loss of ADM binding, showing 
that certain conserved residues exist in RAMPs that specifies ligand binding 
(Kuwasako et al. 2001). Most studies suggest that ADM1 receptors mediates 
most ADM signaling, therefore there is a need to understand the signaling 
mechanisms mediated by ADM1 and ADM2 receptors (Gibbons et al. 2007). 
 
 
 
 
 
 
 
 
 
 
Figure 10: Activation of adenylate cyclase pathway by the association of CLR 
and RAMP2 or 3 upon ADM binding. Picture shows the dissociation of G proteins 
where Gα activates the adenylate cyclase pathway resulting in the activation of 
a signalling cascade. Figure drawn by self, adapted from Kuwasako et al, 2000 
and Prado et al, 2001. 
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1.2.4. Biological Functions of ADM 
  
One of the main functions of ADM is its vital role in vasodilation, which can 
be mediated via both endothelium-dependent and endothelium-independent 
mechanisms (Nuki et al. 1993). NO has a partial role to play in the vasodilation 
effects of ADM in humans (Nakamura et al. 1997).  
 
ADM has important functions during embryogenesis, organogenesis and 
differentiation in various cell types during the developmental stage (Jahnke et al. 
1997; H. Kato et al. 1997; Montuenga et al. 1997; Morrish et al. 1996). This 
data is supported by ADM knockout studies. ADM knockout mice showed that 
ADM is essential for vascular morphogenesis, since ADM knockout mice died at 
embryonic day 14, as seen in figure 11.  The heterozygotes survived until 
adulthood having elevated blood pressure (Caron and Smithies 2001; Fritz-Six et 
al. 2008; Ichikawa-Shindo et al. 2008; Shindo et al. 2001). ADM is expressed 
high in angiogenesis and vasculogenesis of the foetus during early stages of 
pregnancy, showing that it is an important peptide in foetal development 
(Nikitenko et al. 2000). ADM also protects organs such as liver, kidney, heart, 
vasculature from pathological conditions such as hypertension, septic shock, 
ischemia etc, by up-regulating the expression of NO (Shimosawa et al. 2003). 
    
 
 
 
Figure 11:  Comparison of wild type and ADM-/- mice embryos at E14. Edema 
and hemorrhagic changes were observed in various organs (under skin). 
Picture reprinted with permission from Ishikawa-Shindo et al, 2008and Caron 
et al, 2001. 
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 Since similar embryonic lethality and phenotypic defects are seen in   
ADM-/-, RAMP2-/- and CLR-/- mice, it can be concluded that ADM is required for 
embryonic development and its actions are primarily mediated through ADM1 
receptor (Czyzyk et al. 2005). Based on these findings, it has been suggested 
that ADM1 receptor is required for the basal activity of ADM, while ADM2 
receptor is up-regulated under a pathological condition (Czyzyk et al. 2005; R. T. 
Dackor et al. 2006).  
 
Besides being important in the development of vasculature during 
embryogenesis as outlined above, ADM is known to play a vital role in various 
physiological functions such as acting as a bronchodilator (Kanazawa et al. 
1994), regulator of blood glucose metabolism and insulin secretion (Martinez et 
al. 1996), hypotensive effector on ocular pressure (Taniguchi et al. 1999), 
regulator of bone growth (Naot et al. 2001), regulator of stress response 
hormone, corticostrone (Taylor and Samson 2004), dilates blood vessel and 
reduces blood pressure (Nagaya et al. 2000), increases natriuretic response 
(Jougasaki et al. 1995) and increases Glomerular Filtration Rate (GFR) in kidneys 
(Majid et al. 1996) (shown in figure 12). 
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Evidence suggests that the CLR-RAMP2/3 elicit its response via the G 
protein Gs subunit thereby increasing cAMP (figure 8) (Buhlmann et al. 1999). 
ADM when discovered was found to elevate cAMP levels in most of the cell types 
(Eguchi et al. 1994; Kitamura et al. 1993). The most prevalent second 
messenger that is activated by ADM actions is cAMP (Hinson et al. 2000). 
Increase in intracellular cAMP in endothelial cells and VSMCs elevates the 
intracellular concentration of Ca2+ resulting in the activation of Nitric Oxide 
Synthase (NOS) triggering the secretion of NO (Moncada et al. 1991).  
 
ADM also increases the intracellular Ca2+ mobilisation via the ADM 
receptors. Human Embryonic Kidney293 (HEK293) cells, when transfected with 
Figure 12: Some of the many physiological functions where Adrenomedullin 
plays a vital role. Figure drawn by self, adapted from Kanazawa et al, 1994, 
Martinez et al, 1996, Taniguchi et al,1999, Naot et al, 2001, Taylor and 
Samson, 2004, Caron and Smithies, 2001, Nagaya et al,2000, Jougasaki et al, 
1995 and Majid et al, 1996. 
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CLR and any RAMPs, increased the intracellular Ca2+ levels (Kuwasako et al. 
2000). ADM increases /decreases intracellular Ca2+ levels independently of cAMP 
(Mazzocchi et al. 1996; Shimekake et al. 1995).  Whilst ADM increases Ca2+, 
many calcium dependent mechanisms up-regulate the expression of ADM  
(Bunton et al. 2004). 
 
 In Human Microvascular Endothelial Cells (HMECs), exogenously added 
ADM up-regulated the expression of CLR and RAMP2 but not RAMP3. ADM 
stimulated HMECs had an increase in CLR and RAMP2 mRNA levels immediately 
after stimulation (Schwarz et al. 2006). There are many examples where the 
ligand up-regulates/down-regulates the expression of its own receptors (Hukovic 
et al. 1999; Inoue et al. 1999; Siegrist et al. 1994). For example, the expression 
of the somatostatin receptor 1 is up-regulated by somatostatin (Hukovic et al. 
1999) and calcitonin down-regulates the expression of calcitonin receptor mRNA 
(Inoue et al. 1999).  Similarly it is hypothesised that ADM may up-regulate the 
expression of CLR and RAMP2, although RAMP3 might have a different 
mechanism (Schwarz et al. 2006).  
 
 
 Since ADM plays an important role in physiology, deregulation of ADM has 
been implicated in various pathological conditions, some of which are reviewed in 
the following sections. 
 
1.3. Adrenomedullin and Diseases 
 
Elevated levels of ADM have been shown to be associated with many 
disease conditions some of which are arterial hypertension (Kohno et al. 1996), 
heart failure (Hirayama et al. 1999), renal diseases (Kinoshita et al. 2000), 
diabetes mellitus (Hayashi et al. 1997), septic shock (Nishio et al. 1997) and 
cancer (Kitamura et al. 1993; Satoh et al. 1995; Zimmermann et al. 1996).  
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1.3.1. ADM and Septic Shock 
	    
ADM is over-expressed 13 fold more than normal in patients with septic 
shock. Plasma ADM in septic shock patients, (107+/- 139 fmol/ml in sepsis 
patient, while normal subjects range from 7.9+/- 3 fmol/ml) is the highest in 
any pathological condition (Hirata et al. 1996; Nishio et al. 1997). This ADM 
contributes to hypotension and vasodilation (So et al. 1996; P. Wang et al. 
1999). The two stages of septic shock where ADM contributes to progression is 
the,  
 
• Early hyperdynamic phase where there is increase in cardiac output, 
reduction in peripheral resistance and hyperfusion of tissues – ADM 
associated reduction in response to vasculature contributes to this phase 
(Koo et al. 2001; P. Wang et al. 1999). 
 
• Hypodynamic phase where there is reduction in cardiac output and high 
vascular resistance. This results in hyperfusion of tissues and ultimately 
damage of the organ. There is reduction to ADM sensitivity in this phase 
due to the reduction in circulating levels of ABMP-1 – complement factor H 
(S. Yang et al. 2002; Zhou et al. 2002). 
 
RAMP3 expression is also found to be elevated in hyperdynamic stage (Ornan 
et al. 2002). Exogenously added AMBP-1 restores the effect of ADM in blood 
vessels delaying the transition from hyperdynamic phase to hypodynamic phase 
thereby delaying organ damage. Therefore ADM and AMBP-1 is suggested as a 
therapy for septic shock (S. Yang et al. 2002). 
 
1.3.2. ADM and Diabetes Mellitus 
 
 ADM is known to exert an inhibitory effect on insulin secretion. In diabetes 
mellitus, there is an increase in plasma ADM levels resulting from endothelial 
activation and impaired renal clearance in patients with diabetic nephropathy 
(Garcia-Unzueta et al. 1998). ADM deregulation is not the underlying cause of 
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diabetes but it contributes to disease progression (Hayashi et al. 1997; Turk et 
al. 2000). 
 
1.3.3. ADM and Renal Diseases 
 
 Increase in plasma ADM levels and decrease in urinary excretion of ADM is 
observed in glomerulonephritis (Kinoshita et al. 2000; Kubo et al. 1998). Plasma 
ADM levels also increase in patients with renal failure. Whether this increase is 
due to over production or reduction in ADM clearance is unclear (Ishihara et al. 
1999; Nitta et al. 2000). Different groups have seen both increase (Cases et al. 
2000) and decrease (Mallamaci et al. 1998) in plasma ADM levels in patients 
undergoing hemodialysis. 
 
 
1.3.4. ADM and Heart Failure 
 
  
 Studies have shown that there is a correlation between increased plasma 
ADM levels and the severity of congestive heart failure (Hirayama et al. 1999; C. 
M. Yu et al. 2001a). Studies have shown that patients with elevated plasma ADM 
levels benefit from β-adrenergic antagonists (Richards et al. 2001).  
 
 In different animal models of heart failure, ADM and its receptor 
components (CLR, RAMP2 and RAMP3) were up-regulated (Cueille et al. 2002; 
Nishikimi et al. 1997; Totsune et al. 2000; Yoshihara et al. 2000). It has been 
suggested that prolonging the half life of natriuretic proteins by inhibiting NEP 
could augment ADM effect in heart failure (Corti et al. 2001). 
 
1.3.5. ADM and Cancer 
 
 
As described previously, ADM is deregulated in cancer. Evidences show 
that ADM influences tumour growth, survival and angiogenesis. For example 
cancers like breast cancer, glioblastoma, prostate cancer, lung cancer and 
almost 80% of cancers have been shown to have high levels of ADM expression 
(Miller et al. 1996). ADM contributes to cancer cells lymph node metastasis in 
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breast cancer (Oehler et al. 2003). ADM is a clinically important peptide in 
cancer since it is a characteristic feature of cancerous cells (Bunton et al. 2004). 
Various characteristics of cancer where ADM contributes in tumour progression 
are illustrated in figure 13. 
 
 
 
 
 
 
 
1.3.5.1. ADM and Proliferation 
   
ADM was found to promote proliferation for the first time in Swiss 3T3 
mouse fibroblasts, where it increased the intracellular level of cAMP (Withers et 
al. 1996).  ADM also elicits the mobilisation of Ca2++ in bovine aortic endothelial 
cells (Shimekake et al. 1995), although it had no effect in the Swiss 3T3 mouse 
fibroblasts (Withers et al. 1996).  
 
ADM either induces cell proliferation or growth inhibition depending on the 
cell type. ADM induces cell proliferation in Vascular Smooth Muscle Cells by 
activation of Protein Tyrosine Kinase (PTYK)-MAPKB pathway. In cells lacking 
MAPK signalling, ADM inhibits cell proliferation by activation of cAMP through 
Figure 13: Various roles played by ADM in cancer progression. Original 
sketch by Dr. Gareth Richards. 
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adenylate cyclase (Iwasaki et al. 1998; Iwasaki et al. 2001; Shichiri and Hirata 
2003). Figure 14A shows the growth stimulatory effects of ADM via MAPK 
signalling, resulting in the activation of C-Src where Sos catalyses GDP to GTP in 
Ras resulting in the activation of Raf which activates the MAPK signalling, 
resulting in cell proliferation (Shichiri and Hirata 2003). Figure 14B shows the 
growth inhibitory effects of ADM via activation of adenylate cyclase pathway. 
 
 
 
 
 
 
 
 
 
A 
B 
Figure 14: Cell proliferation and growth inhibition effects of ADM. Figure A 
shows the cell proliferation effects of ADM via MAPK pathway by activation 
of Protein Tyrosine Kinase. Figure B shows the growth inhibition effects of 
ADM in cells lacking MAPK signalling, via adenylate cyclase pathway. Figure 
drawn by self, adapted from, Shichiri et al, 2003 and Iwasaki et al, 2001. 
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Human Umbilical Vein Endothelial Cells (HUVECs) express ADM receptor – 
both CLR RAMP2 and CLR RAMP3 (Fernandez-Sauze et al. 2004) and ADM 
induces proliferation of HUVEC cells (Fernandez-Sauze et al. 2004; Y. Zhao et al. 
1998) and helps them to prevent apoptosis in rat endothelial cells (H. Kato et al. 
1997).  ADM has been shown to promote proliferation of cancer cells by various 
groups (Beltowski and Jamroz 2004; Bunton et al. 2004; Frank Cuttitta et al. 
1999; Fernandez-Sauze et al. 2004; Martinez et al. 1997; Martinez et al. 2002; 
Miller et al. 1996). In order to show that ADM promotes proliferation of cancer 
cells, compromising ADM activity by addition of ADM antagonist -ADM22-52 or an 
anti-ADM antibody, has shown a growth suppressing effect in human 
Glioblastoma cells (Ouafik et al. 2002), lung, breast and ovarian cell lines (Miller 
et al. 1996), human oral squamous cell carcinoma cell line (Kapas et al. 1997). 
ADM has also been shown to promote proliferation in non-cancer cells; in vitro 
and in vivo proliferative effects in rodent osteoblasts (Cornish et al. 1997), 
vascular endothelial cells, rat vascular smooth muscle cells (Iwasaki et al. 1998). 
 
 
1.3.5.2. ADM and Apoptosis  
 
As suggested by Hanahan and Weinberg, cancer cells have the capacity to 
evade apoptosis, and ADM is one such factor that helps cancer cells achieve this 
(H. Kato et al. 1997). Similar to cell proliferation effects of ADM, it can act both 
as an anti-apoptotic (Oehler et al. 2001) and a pro-apoptotic factor 
(Parameswaran et al. 1999b; Parameswaran et al. 1999a). 
 
Studies have showed that during serum deprivation, cultured rat 
endothelial cells (RECs) released ADM which helped them survive. They showed 
that ADM acts via a cAMP independent mechanism to evade apoptosis, by 
studying the effects of cAMP agonists and antagonists where they did not affect 
growth or apoptosis of RECs inspite of ADM inducing cAMP levels (H. Kato et al. 
1997; Sata et al. 2000). ADM inhibited hypoxia induced apoptosis by up-
regulation of BCL2 in endometrial cancer cells (Oehler et al. 2001).  It has been 
shown that cells that over-express ADM have lower levels of factors that bring 
about apoptosis, like bid, bax, caspase 8 (Martinez et al. 2002).   
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Published data suggests that ADM acts as an apoptosis survival factor via 
many pathways which are dependent on the cell type. One such method of 
apoptosis survival induced by ADM is by up-regulation of Max. Figure 15, shows 
the apoptosis survival mechanism induced by ADM. Under normal conditions Max 
forms a complex with c-myc which is a proto-oncogene. This complex binds to 
DNA sequence – CACGTG called E Box, which upon activation results in cell 
proliferation, transformation and apoptosis. When ADM expression is high, it 
results in over-production of Max, which then forms dimers with Mxi and Mad 
and homodimers with other Max and competes in binding to E Box (Amati et al. 
1993; Shichiri et al. 1999).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Apoptosis survival mechanism induced by ADM. Green shaded 
area shows the induction of apoptosis under normal circumstances, where 
Max forms dimers with c-myc to bind to E box resulting in apoptosis. Red 
shaded area shows when ADM expression is high, it results in the over- 
production of Max which binds to Mxi and Mad and other Max to bind to E box 
which act as an antagonist to C-myc-Max activity. Picture drawn by self, 
adapted from Shichiri et al, 1999. 
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1.3.5.3. ADM and Angiogenesis 
 
 
  Angiogenesis is a mechanism by which blood vessels sprout from pre-
existing ones, which is observed in many physiological process and pathological 
conditions (Risau 1997). Angiogenesis is a process that is needed for tumour 
growth and survival (Hanahan and Weinberg 2000). As the tumour size grows 
bigger, the centre of the tissue is deprived of oxygen, which results in hypoxia. 
This triggers the expression of many angiogenic factors, one of which is ADM 
(Martinez et al. 2002; Y. Zhao et al. 1998). Figure 16 shows the angiogenesis 
pathways triggered by ADM. 
 
 
 
 
 
 
 
There are many growth factors that promote angiogenesis – Vascular 
Endothelial Growth Factor (VEGF), Fibroblast growth Factor (FGF), angiopoietin-1 
(Carmeliet 2000; W. Kim et al. 2003a; W. Kim et al. 2003b).  Another mediator 
of angiogenesis via ADM administration is NOS (Abe et al. 2003; Iimuro et al. 
Figure 16: ADM and Angiogenesis pathways. ADM activates PI-3K and MAPK 
and transactivates VEGF resulting in the cell survival, proliferation, migration 
and digestion of extracellular matrix. Picture drawn by self, adapted from 
Iimuro et al, 2004. 
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2004). Like ADM, VEGF is also expressed in high levels in case of hypoxic stress 
(Garayoa et al. 2000). It was shown that ADM did not have any effect on the 
expression of the growth factors mentioned above, although it was shown that 
ADM was able to elicit an angiogenic response on par with VEGF. The ADM 
secretion also occurs in the normal uterine endometrium, where it helps in the 
proliferation of endothelial cells (W. Kim et al. 2003a; Nikitenko et al. 2000). 
Neutralising activity of VEGF using anti-VEGF antibody on HUVEC cells, does not 
alter the tube formation on matrigel, showing that ADM acts independently of 
VEGF during angiogenesis (Fernandez-Sauze et al. 2004; Guidolin et al. 2008) 
although ADM is said to up-regulate the expression of VEGF in in vivo models 
(Carmeliet 2000) and in vitro [HMECs (Schwarz et al. 2006) and HUVECs (Iimuro 
et al. 2004)].  ADM induced angiogenic effects can be reduced when the tyrosine 
kinase activity of VEGF Receptor2 (VEGFR2) is selectively inhibited (Guidolin et 
al. 2008), since many GPCRs transactivate Receptor Tyrosine Kinases (RTKs) like 
Epidermal Growth Factor (EGF) (Daub et al. 1996), Insulin-Like Growth Factor-1 
(IGF-1) (Lowes et al. 2002; Luttrell et al. 1999; Marinissen and Gutkind 2001).  
 
1.4. Background to Project 
 
The cancer models that were used in this project are – Glioblastoma, 
Breast, Prostate and Pancreatic cancers. The role of ADM in each of these 
cancers are reviewed next. 
 
1.4.1. ADM and Glioblastoma 
 
 Glioblastomas are aggressive tumours affecting the glial cells of the brain 
(Leon et al. 1996). ADM is one of the peptides that is predominantly over- 
expressed in glioblastoma and is known to contribute to tumour progression 
(Ouafik et al. 2002). 
 
 Cytokines such as interferon-γ, tumour necrosis factor-α and interleukin-
1β is known to induce ADM expression in T98G glioblastoma cells. This induction 
was inhibited by addition of dexamathasone, which is a glucocorticoid used in the 
58 
 
treatment of glioblastoma (K. Takahashi et al. 2003). Therefore it has been 
suggested that cytokines are one of the important factors that influence the 
production of ADM in glioblastoma (K. Takahashi et al. 2003). 
 
ADM is known to up-regulate cyclin D1 protein by activating C-
Jun/JNL/AP-1 pathway and transits U87 cells through cell cycle (Ouafik et al. 
2009). JNK pathway is known to play a significant role in cell transformation and 
growth (Khatlani et al. 2007) and contributes to tumour development and 
progression (Ouafik et al. 2009) in glioblastomas (Cui et al. 2006; Mangiola et al. 
2007), breast cancer (Davidson et al. 2006) and Melanoma (Jorgensen et al. 
2006). 
 
Highly malignant glioblastomas result in loss of PTEN activity (Furnari et 
al. 1997; Knobbe et al. 2002; Rasheed et al. 1995). PTEN inhibits PI-3K pathway 
by blocking Akt activity (Stambolic et al. 1998; X. Wu et al. 1998). PTEN was 
found to inhibit the expression of ADM (Betchen et al. 2006). Since ADM 
expression is increased in highly malignant glioblastoma, in vitro addition of ADM 
to U87 cells resulted in increased proliferation (Ouafik et al. 2002). Besides 
blocking ADM expression, PTEN blocks the expression of CLR by 4-fold in U251 
glioblastoma cells (Betchen et al. 2006). 
 
Studies have shown that neutralising ADM activity using specific 
antibodies for ADM (Ouafik et al. 2002) and its receptors (Kaafarani et al. 2009) 
have significantly reduced glioblastoma cells growth. In vivo data using these 
antibodies have shown decrease in tumour volume, tumour vascular density and 
increase in tumour cell apoptosis (Kaafarani et al. 2009). 
 
1.4.2. ADM and Breast Cancer 
 
 Breast cancer is the most common cancer, affecting women and the 
lifetime risk of developing cancer for women in UK is 1 in 8 (Cancer Research 
UK).  
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 Studies have shown that ADM is up-regulated in breast cancer (Disa et al. 
1998; Martinez et al. 2002; Oehler et al. 2003). Although much is not known 
about the role of ADM in breast cancer, ADM levels of patients with breast cancer 
is significantly higher than controls (132.2±74.3 pg/ml in patients and 
107.9±32.7 pg/ml in controls) (Oehler et al. 2003). It has been seen that breast 
cancer cells transfected with ADM produced more oncoproteins such as Ras, Raf, 
PKC and decreased production of apoptotic factors such as Bax, Bid and caspase 
8 (Martinez et al. 2002). It has been suggested that plasma ADM levels in breast 
cancer patients could be an indicator of tumour severity (Oehler et al. 2003). 
 
1.4.3. ADM and Pancreatic Cancer 
 
 Pancreatic cancer is one of the leading causes of deaths worldwide which 
are usually detected at a late stage due to the location of the pancreas and non-
specific symptoms (Cancer Research UK). The lifetime risk of developing 
pancreatic tumour for men and women in UK is 1 in 77 and 1 in 79 respectively 
(Cancer Research UK).  
 
 ADM is required for the development of pancreas in rats and is therefore 
an important endocrine factor (Martinez et al. 1998). Microarray analysis have 
shown ADM is over-expressed in pancreatic cancer (Logsdon et al. 2003). 
Studies using ADM antagonists resulted in reduced vascular density of pancreatic 
tumour (Ishikawa et al. 2003; Miseki et al. 2007). It has been shown that the 
level of ADM secreted by tumour correlates with tumour growth and metastasis 
(Ramachandran et al. 2007), and it could be a diagnostic marker in cancer 
(Keleg et al. 2007). 
 
1.4.4. ADM and Prostate Cancer 
 
 Prostate cancer is the most common cancer affecting men and the lifetime 
risk of developing cancer for men in UK is 1 in 9 (Cancer Research UK).  
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 ADM is expressed in both normal prostate epithelial cells and in prostate 
cancer cells (Calvo et al. 2002; Jimenez et al. 1999). PAM is also up-regulated in 
prostate carcinomas suggesting a significant role played by biologically active 
ADM (Jimenez et al. 2003; Rocchi et al. 2001). Prostate cancer cell lines DU145 
and PC3 both express ADM1 receptor, but only DU145 and not PC3 expresses 
ADM2 receptor. It has been suggested that DU145 cells resemble prostate 
epithelial cells more than PC3 cells (Mazzocchi et al. 1996). Studies have shown 
that ADM increased cell proliferation in DU145 cells but not in PC3 cells, 
suggesting involvement of ADM2 receptor (Rocchi et al. 2001). It was also seen 
that ADM inhibits proliferation in PC3 cells transfected with ADM (Abasolo et al. 
2004) 
 
 ADM enhances IL-13α2 expression both in vitro and in vivo in PC3 cells 
treated with ADM peptide (Joshi et al. 2008). Interleukin-13 (IL-13) is a cytokine 
that regulates immunity. The receptors for IL-13 are over-expressed in various 
cancers such as glioma, renal cell carcinoma and ovarian cancers. (Debinski et 
al. 1999; Joshi et al. 2000; Obiri et al. 1995; Obiri et al. 1997). Over-expression 
of ADM has known to change the phenotype of cells (Martinez et al. 2002), in 
prostate cancer cells, it was found to increase the appearance of neuroendocrine 
phenotype (Berenguer et al. 2008; Martinez et al. 2002). ADM over-expressing 
PC3 cells were found to up-regulate ~100 genes that were involved in apoptosis, 
cell adhesion, cell cycle arrest, transcription, immune function and extracellular 
matrix (Gonzalez-Moreno et al. 2005). 
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1.5. Hypotheses and Aims 
 
Based on the literature, it is hypothesised that, 
 
ADM is up-regulated under a malignant setting and Inhibition of ADM 
would significantly reduce tumour progression. 
 
In order to test the hypothesis, three different hypotheses were proposed. 
They were, 
 
1. Hypoxia up-regulates the expression of ADM and its receptors 
 
2. ADM and its receptors increases tumour progression and regulates 
receptor expression 
 
3. Neutralising ADM using anti-RAMP3 antibody significantly reduces tumour 
growth. 
 
 
Since ADM is physiologically important, completely abolishing its activity 
would result in adverse complications. Therefore our strategy was to target one 
of its receptor systems, which we hypothesize to be of more pathological 
importance – the RAMP3+CLR receptors. This anti-RAMP3 therapeutic target 
would be beneficial to neutralise ADM mediated effects in cancer progression. 
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CHAPTER II: HYPOXIC REGULATION OF ADM 
AND RECEPTORS 
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2.1. HYPOTHESIS 
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Hypothesis 
 
 Hypoxia up-regulates the expression of ADM and its receptors. 
 
The aim is to determine the mRNA and protein expression of HIF-1α, ADM 
and its receptors in different cancer cell lines under hypoxia. 
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2.2. INTRODUCTION 
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2.2.1. Hypoxia and Cancer 
 
 Hypoxia is a classical feature of large and solid tumours, since the 
vasculature is unable to cope up with the increasing demands of the steadily 
growing tumour mass (Brown and Giaccia 1998; Hockel et al. 1991). The ability 
of cells to adapt to hypoxia is mainly mediated by Hypoxia Inducible Factor 
family of various transcription factors. These transcription factors either enable 
angiogenesis so that there is supply of oxygen or enable cells to sustain hypoxia 
for regulating various growth regulatory factors. The important regulatory factor 
that is stabilised under hypoxia is Hypoxia Inducible Factor-1α (HIF-1α) (Ivan et 
al. 2001; Jaakkola et al. 2001). Since hypoxic regions of tumour require oxygen 
to sustain, there is activation of various angiogenic factors, most notably VEGF 
(Folkman 1992; Shweiki et al. 1992). As shown in figure 17 tumour hypoxia 
enables cancer cells to adapt to low oxygen levels by changing gene expression, 
resulting in an aggressive phenotype and increase in tumour mass (Vaupel 
2004). This vicious cycle is further fuelled by various angiogenic factors.  
 
 
 
 
 
Figure 17:  Hypoxia and cancer progression. Tumour hypoxia results in 
changes in proteosomal changes that give tumours an aggressive phenotype 
that results in an increase in tumour mass. Picture taken from Vaupel, 2004. 
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2.2.2. Effect of hypoxia on cancer treatment 
In cancer therapy, hypoxia plays a crucial role as it enables cancer cells to 
be more resistant to radiotherapy and chemotherapy (Brown and Giaccia 1998). 
 
Hypoxia and Radiotherapy 
Radiotherapy requires oxygen to cause breaks in the DNA double strand 
which is cytotoxic thereby resulting in cell death (Hall 1994; Kallman and Dorie 
1986). Study by Hockel et al (Hockel et al. 1993) on cervical carcinomas 
demonstrated that patients with partial oxygen pressure more than 10mmHg 
responded well to radiotherapy resulting in increased survival rate and reduced 
tumour reoccurrence than patients with less than 10mmHg partial oxygen 
pressure. Therefore a well oxygenated tumour is more likely to respond to 
radiotherapy which is hindered by hypoxia. 
 
Hypoxia and Chemotherapy 
 Chemotherapeutics which are usually administered intravenously requires 
blood vessels to deliver drug to the actively dividing tumour cells. Since hypoxia 
results in a deficiency in a proper vasculature development in the tumour mass, 
this provides an inability to the drug to induce cytotoxicity. Hypoxic regions 
contain cells that are slow dividing therefore anti-cancer drugs are unable to be 
efficacious as they require actively proliferating cells (Comerford et al. 2002). 
Hypoxia has also shown to induce the expression of various multidrug 
transporters which enable the drugs to be transported out the cell thereby 
ensuring resistance to drugs (Wartenberg et al. 2003). 
 
2.2.3. Hypoxia Signalling 
HIF-1α undergoes post-translational stabilisation process and act as 
transcription factor for various hypoxia inducible genes (Ivan et al. 2001; 
Jaakkola et al. 2001). As tumour progresses from being a benign tumour-to-
tumour metastases, level of HIF-1α has shown to markedly increase (Harris 
68 
 
2002; Ke and Costa 2006; Zhong et al. 1999). HIF-1α signalling at normoxia and 
hypoxia are illustrated in figure 18. 
 
 
 
 
 
 
 
Under Normal conditions, HIF-1α is hydroxylated at two proline residues 
by Prolyl-4-hydroxylases (PHDs) and Factor Inhibiting HIF-1 (FIH-1) (Chan et al. 
2002; Chan et al. 2005; Hewitson et al. 2002; Lando et al. 2002b; Masson et al. 
2001). This reaction is catalysed by hydroxylases which require O2, 2-
oxoglutarate, iron and ascorbate (Bruick and McKnight 2001; Masson et al. 
Figure 18: Regulation of HIF-1α under normoxia and hypoxia. Under 
normoxia HIF-1α is rapidly degraded by ubiquitination. Under hypoxia HIF-1α 
is stabilised, forms a dimer with HIF-1β and act as a transcription factor for 
various hypoxia inducible genes. Picture was adapted from Ke and Costa, 
2006. 
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2001) to act as substrates and co-factors. Upon hydroxylation HIF-1α is 
recognised by Von Hippel Lindau (VHL) tumour suppressor which is favoured by 
acetyle transferase Arrest-Defective-1 (ARD-1) (Jeong et al. 2002). This VHL-
HIF-1α association results in the addition of ubiquitin ladders that undergo 
proteosomal degradation (Huang et al. 1998; Semenza 1999; F. Yu et al. 
2001b).  
 Under Hypoxia, PHDs and FIH-1 are inhibited due to lack of oxygen. 
Therefore, HIF-1α-VHL interaction is inhibited resulting in the stabilisation of 
HIF-1α (Huang et al. 1996; Kallio et al. 1997; Lando et al. 2002a). The stabilised 
HIF-1α binds to HIF-1β, which is constitutively expressed regardless of oxygen 
levels (Kallio et al. 1997). This complex acts as transcription factor by binding 
DNA consensus element - 5’ RCGTG 3’, and regulate various factors to help cells 
to adapt to hypoxia (Goldberg et al. 1988; Semenza et al. 1991).  
 Besides PHDs that sense oxygen and regulate HIF-1α, it is also activated 
by phosphorylation, mediated by MAPK (Minet et al. 2001; Richard et al. 1999; 
Sodhi et al. 2000). Phosphorylated HIF-1α has been demonstrated to have 
increased transcriptional activity (Richard et al. 1999). Other factors affecting 
HIF-1α regulation are cytokines, growth factors and other signalling molecules 
under normoxic conditions (Feldser et al. 1999; Gorlach et al. 2001; Haddad and 
Land 2001; Richard et al. 2000). The common pathway that transactivates HIF-
1α and synthesis is via MAPK or PI-3K pathways (J. Li et al. 2004; Zelzer et al. 
1998). 
 
 
2.2.4. Effects of HIF-1α 
 
HIF-1α-/- is embryonically lethal at E11 due to developmental defects of 
the vasculature (Iyer et al. 1998; Ryan et al. 1998). HIF-1α+/- mice survives until 
adulthood but when exposed to hypoxia, they had reduced physiological 
responses (Kline et al. 2002; A. Y. Yu et al. 1999). HIF-1α is important in various 
physiological and pathological processes as illustrated in figure 19 (Brahimi-Horn 
and Pouyssegur 2007; Hickey and Simon 2006; Semenza 1999).  
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Hypoxia and Apoptosis 
Growing tumour mass has diminished apoptotic potential, and hypoxia 
plays a crucial role in enabling this. Reduced oxygen in cells results in apoptosis, 
but since cancer cells contain mutations in various apoptosis regulating pathways 
such as p53, caspase-9, Apaf-1, this results in survival (Graeber et al. 1996; 
Soengas et al. 1999). Hypoxia has also shown to increase genomic stability 
making tumour cells more aggressive (Bindra and Glazer 2005; Huang et al. 
2007; Koshiji et al. 2005).   
 
 
 
 
Figure 19:  Example of some of the genes regulated by HIF-1α. Picture was 
adapted from Semenza et al, 1991, Rolfs et al, 1997, Levy et al, 1995, 
Grosfeld, 2002, Melillo et al, 1995, Feldser et al,1999, Krishnamachary et al, 
2003 and Cormier-Regard et al, 1998. 
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Hypoxia and Angiogenesis 
 Angiogenesis is one of the initial responses to hypoxia (Conway et al. 
2001). VEGF is the most important angiogenic factor that recruits and stimulates 
the proliferation of endothelial cells (Bunn and Poyton 1996; Forsythe et al. 
1996; Giordano and Johnson 2001; Josko et al. 2000; Levy et al. 1995). Besides 
VEGF, HIF-1α regulates the expression of nitric oxide synthase 2 (NOS2) (Melillo 
et al. 1995), heme oxygenase 1 (P. J. Lee et al. 1997), endothelin-1 (Hu et al. 
1998), ADM (Nguyen and Claycomb 1999) and α1B-adrenergic receptor (Eckhart 
et al. 1997). These contribute to angiogenesis and result in tumour survival. 
 
 
Hypoxia - Cell Proliferation and Survival 
 HIF-1α regulates various growth factors such as IGF-1 and TGF-α (Feldser 
et al. 1999; Krishnamachary et al. 2003). These growth factors activate various 
signalling pathways that result in the accumulation of HIF-1α. This vicious cycle 
eventually results in cell proliferation and survival leading to cancer progression 
(Semenza 2003). Besides angiogenesis, apoptosis and cell proliferation, HIF-1α 
acts as a transcription factor for various genes such as genes involved in iron 
metabolism that results in increase in haemoglobin level thereby enabling 
oxygen transport (Rolfs et al. 1997; Semenza et al. 1991), glucose metabolism 
(Chen et al. 2001; O'Rourke et al. 1996; Semenza et al. 1996) and matrix 
metabolism (Ben-Yosef et al. 2002; Y. Takahashi et al. 2000) as illustrated in 
figure 19. 
 
Aim 
Based on these data, the aim of this chapter is to study the effect of 
hypoxia on ADM, its receptors, PAM and Akt regulation. It is hypothesized that 
ADM and its receptors are up-regulated under hypoxia and PAM is also up-
regulated to render ADM active. Since ADM mediates its pro-tumourigenic action 
via Akt signalling, it is hypothesized that under hypoxia Akt is activated by up-
regulation of ADM.  
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2.3. METHODS 
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Materials and Recipes for solutions used are given in Chapter 6, Appendix.   
 
2.3.1. Cell Culture 
 
      Cell culture was carried out under aseptic conditions on Nunclon treated 
tissue culture plastics. The different cell lines and the respective media used 
during the project are outlined in table 1.   
 
 
 
 
 
 
 
The media were supplemented with 10% heat inactivated Fetal Bovine 
Serum and 5% Penicillin/Streptomycin antibiotic.  
 
The frozen cells were thawed in water bath at 37°C for 2 minutes and 
transferred to 75 cm2 flasks with the required amount of media. The culture was 
S.No Cell Line Cancer Type Media 
1 MDA-MB-231  
   Breast Cancer 
 
 
RPMI 
2 MDA-MB-436 
3 Meso Mesothelioma 
4 Hela Cervical Cancer 
5 U-87 Glioblastoma MEM 
6 PC-3 Prostate Cancer  
DMEM 7 Panc2.3 Pancreatic Cancer 
8 Sw-13 Adenocarcinoma 
9 HT-29 Colon Cancer 
10 HCT-116 
Table 1: Different cancer cell lines used in this project. The media used for 
each cell line is also shown.  
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incubated at 37˚C with 5% CO2 to attain confluency. The media was changed 
every three days and subcultured after reaching 80-90% confluency. 
 
A. Subculture of Cells 
 
      Cells were washed with PBS in order to clear any media and dead cells left 
over in the flask. 10% Trypsin EDTA was added to dislodge cells adhered to the 
flask. Cells were centrifuged at 1000 rpm for 3 minutes and the supernatant was 
discarded, the resulting cell pellet was resuspended in fresh media and 
subcultured into the appropriate number of flasks as required for the 
experiments. 
 
B. Cell Counting 
 
Cells were washed with PBS, trypsinised and centrifuged as mentioned above. 
The cell pellet was resuspended in 1ml of appropriate media and a further 1:10 
or 1:100 dilution was made using PBS or media, depending on cell density. Cells 
from this dilution were counted using a haemocytometer. Cells in four corner 
squares (each containing 16 squares) of the haemocytometer was counted and 
averaged. The total number of cells in 1ml of the cell suspension was calculated 
as follows: 
 
Total number of cells = Average of four squares x 10,000 x dilution factor    
 
2.3.2. Induction of Hypoxia 
 
      Hypoxia was induced using three different methods as follows: 
 
A. Cobalt Chloride (CoCl2) 
 
       Since CoCl2 is widely used to mimic hypoxia, 300µM CoCl2 made up in PBS 
was used to induce hypoxia at 0, 2, 5, 7, 24 and 48hrs time points. Cells were 
seeded (~80,000 cells) in a 35mm petriplate the day before treatment was 
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started. At desired time points, the culture media were collected for further 
analysis and cells were extracted using 1ml Tri reagent and frozen at -80°C until 
RNA extraction. 
 
B. Incubator containing 0.1% O2 
 
       An incubator containing 0.1% O2, 5% CO2 and 94.9% N2 at 37˚C was used 
to induce hypoxia.  Cells were cultured in T25cm2 flasks till 60% confluent and 
incubated for 24 and 48hrs. As a control for hypoxia, cells were incubated in a 
regular incubator for 0, 24 and 48hrs. 0hrs was done as a control to see the 
basal level of protein expression. At the appropriate time points, cells were 
extracted using 1ml Tri regent and frozen at -80°C until RNA extraction. 
 
C. Hypoxic media 
 
      Two T175cm2 flask containing 200ml MEM media each was left in the 
hypoxic incubator with conditions as mentioned above for two days. The 
T175cm2 flask was half filled with media so that there was enough space to 
displace O2. Meanwhile, cells were cultured in T25cm2 flasks under regular 
condition until 60% confluent. After two days, the now hypoxic media was added 
to the cells in T25cm2 flasks. The media was added to the brim, so that O2 does 
not get stabilised during the time points. The lids of the flasks containing filters 
were then secured with parafilm. Normoxic controls contained regular media 
filled to the brim and lids secured with parafilm. The time points used were 0, 
15mins, 30mins, 45mins, 1, 2 3 4 6 and 16hrs. At the appropriate time points, 
cells were extracted using 1ml Tri regent and frozen at -80°C until RNA 
extraction. 
 
2.3.3. RNA isolation  
 
The frozen cell extracts were thawed at room temperature and RNA was 
extracted using the protocol as described by Sigma Aldrich.  
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      200µl chloroform was added to the thawed cell extracts and incubated for 5-
10 minutes in room temperature. The samples were centrifuged at 12,000xg for 
15 minutes at 2°C. The upper aqueous phase containing RNA was carefully 
transferred to an RNase free tube. 500µl isopropyl alcohol was added and 
incubated for 15 minutes at room temperature and centrifuged at 12,000xg for 
10 minutes at 2°C. The RNA was washed with 75% ethanol and air-dried. The 
pellet was resuspended in DEPC treated water.  
 
2.3.4. DNase treatment 
 
      In order to eliminate genomic DNA contamination from the RNA sample, 
DNAse treatment was carried out according to the protocol from Applied 
Biosystems.  
 
      0.1 volume of 10xDNase buffer and 2Units of DNase was added to the RNA 
and incubated for 30mins at 37˚C. 0.1volume of DNase inactivation reagent was 
added to the RNA and incubated for 5mins at room temperature. The RNA was 
then centrifuged at 10,000xg for 90secs and the RNA was carefully transferred to 
a UV treated tube. 
 
2.3.5. Quantification of RNA 
 
      The concentration of RNA was quantified using a nanodrop 
spectrophotometer. DEPC water that was used to resuspend RNA was used as 
blank and 1µl of RNA was used to quantify RNA. The quality of RNA was 
determined by the value of 260/280 ratio as determined by the 
spectrophotometer. 260/280 ratio lying between 1.8 and 2 was considered to be 
a good quality RNA and was used for cDNA synthesis. 
 
2.3.6. cDNA Synthesis 
 
1µg of RNA was used for cDNA synthesis. cDNA was synthesised according to 
the protocol from Applied Biosystems. 
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To 1µg of RNA, 10µl of 2X RT buffer and 1µl of enzyme mix was added. Water 
was added to make the final volume to 20µl. A no Reverse Transcriptase control 
(RT-) was done by replacing the enzyme mix with water. The mixture was briefly 
vortexed and centrifuged to eliminate any air bubbles. Reverse Transcription was 
allowed to take place by incubating the tubes for 1hour at 37˚C. The reaction 
was stopped by heating to 95˚C for 5mins and transferred to ice for subsequent 
PCR analysis or frozen for long term storage. The incubation steps were carried 
out using a thermal cycler.  
 
2.3.7. Real Time PCR (qPCR) 
 
 To quantitate the expression of the gene of interest, quantitative PCR 
(qPCR) was carried out using ABI 7900HT sequence detection system from 
Applied Biosystems.  Taqman assays (primers) for RAMP2, RAMP3, CLR, ADM, 
HIF-1α, HPRT1 and β-Actin were inventoried from Applied Biosystems, their 
assay ID and amplicon length can be obtained from table 2. In order to exclude 
any genomic DNA amplification, the taqman assay belonged to m1 group, which 
spans the exon-exon junction thereby eliminating the amplification of genomic 
DNA (gDNA).  
 
The reaction mixture per well contained 5µl of 2x Taqman gene expression 
master mix, .5µl tagman assay, 2.5µl water and 2µl cDNA/RT-/H2O 
 
The qPCR reaction was carried out in triplicates and the standard PCR 
reaction cycle used is as follows: 
 
Step 1: 50˚C for 2 min 
Step 2: 95˚C for 10 min  
Step 3: 95°C for 15sec  
Step 4: 60˚C 1 min 
 
The reaction was carried out for 40 cycles.  
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A. qPCR Data Analysis 
 
qPCR data was analysed using SDS 2.2.1 software. There are two methods of 
calculating qPCR data depending on whether a fold change in expression is 
required or relative quantification of mRNA to a control is required.  
 
    The Ct values obtained from the ABI 7900HT system was used for analysis 
using both the methods determine either fold change or the relative expression 
of a gene of interest. Both the methods require that the Ct value of the gene of 
interest be normalised to an endogenous control, whose expression is unchanged 
in any experimental condition. For this project β-actin and HPRT1 were used as 
an endogenous controls. 
 
    Fold change in expression is calculated using the ΔCt method. The formula for 
calculating fold change is 2-∆Ct, where, 
 
ΔCt = Average Ct of target gene – Average Ct of endogenous control 
 
S.No Gene name Assay ID Amplicon length 
1 RAMP2 Hs00359352_m1 117 
2 RAMP3 Hs00234665_m1 82 
3 CLR Hs00173787_m1 130 
4 ADM Hs00181605_m1 76 
5 HIF-1α Hs00936368_m1 87 
6 HPRT1 Hs01003267_m1 72 
7 β-Actin Hs99999903_m1 171 
Table 2: Gene specific taqman assays, their ID and amplicon length. 
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   Relative Quantification is calculated using the ΔΔCt method. The formula for 
calculating relative quantification is 2-ΔΔCt, where, 
 
ΔΔCt = ΔCt of target gene – ΔCt of endogenous control 
 
2.3.8. Hoechst Staining 
  
In order to measure the cell death index after CoCl2, morphological 
assessment of the apoptotic cells was done using Hoechst 33258 stain. 
 
Cells were seeded on a glass coverslip placed in a standard clear bottom 6 
well plates. 300µM of CoCl2 was added to all the wells belonging to time points 
0h, 2h, 5h, 7h, 24h and 48h.  Once the cells are confluent on the coverslips, 
cells were washed with PBS and fixed using Clarke’s fixative 
(ethanol:aceticacid=3:1) for 10 minutes at room temperature. The fixative was 
then discarded and cells were washed with PBS and Hoechst stain (1:1000 
dilution) was added to the coverslips and incubated for 20 minutes at room 
temperature. The stain was discarded and coverslips were washed with PBS, air 
dried and mounted using mowiol [1 part of Phenylenediamine + 9 parts of 
mowiol]. The slides were viewed under an inverted widefield fluorescence 
microscope (Leica DFC300FX). The apoptotic cells were counted using ImageJ 
software and an apoptotic index was created using the formula,  
 
Cell Death Index, % = 100 X apoptotic cells 
       200 cells 
 
 
2.3.9. Western Blotting 
 
A. Protein Extraction 
 
Cells cultured in T175cm2 flask was briefly washed with PBS and 10% Trypsin 
EDTA was added to dislodge cells from flask. The cells were then centrifuged at 
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1000 rpm for 5mins. The cell pellet was resuspended in 500µl of NP-40 cell lysis 
buffer containing freshly added protease inhibitors. Cells were incubated on ice 
to swell for 20mins. Cells were then sonicated in an ultrasonic water sonicator 
for 10mins. Cells were then centrifuged at 1000 rpm for 5mins. The supernatant 
was transferred to a fresh tube for quantification. 
 
B. BiCinchonic Acid (BCA) Assay 
 
     Protein samples were quantified using BCA assay. BCA reagent A and B were 
mixed in 1:50 ratio. 2µl and 5µl of protein samples were added to 1ml of AB 
mixture, in duplicates. Varying dilutions of BSA was used as a standard to 
measure concentration of protein samples. All samples were incubated for 
30mins at 65˚C. The absorbance was measured using a spectrophotometer at 
562nm. Linear Regression analysis was done using GraphPad Prism software to 
interpolate concentrations of protein samples from BSA standards.  
 
C. Gel Casting 
 
Gels were cast in a 9cmx9cm glass slides with 1.5mm spacer slide. Resolving 
and stacking gels were cast according to the recipe given in chapter 7, appendix. 
 
D. Sample Preparation 
    70µg of protein sample was mixed with 10x protein loading buffer and heated 
to 90˚C for 5mins to denature proteins. Biotinylated protein ladder was also 
heated along with the samples. In order to ensure homogenous migration of 
samples, the final volume of samples was kept the same.  
 
E. PolyAcrylamideGel Electrophoresis 
Samples were loaded into the wells of the gel. A Kaleidoscope ladder was 
also run alongside the biotinylated ladder to track the migration of samples. 
Samples were run in the presence of running buffer at 150V for 30mins or until 
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the dye front reached the bottom of the gel. For 7% gels where ADM was to be 
probed, gel was run half way since the molecular weight of ADM was ~7kDa. For 
15% gels where HIF-1α and PAM was to be probed, gel was run longer since the 
molecular weights were >100kDa.  
Protein samples were then transferred to PVDF (Polyvinylidene Difluoride) 
membrane in the presence of transfer buffer at 100V for 1hr.  
PVDF membrane was blocked with 5% milk solution for an hour to reduce 
non-specific binding of antibodies. PVDF membranes were then incubated with 
appropriate antibodies. 
 
F. Primary Antibody dilutions 
PVDF membranes were incubated with the appropriate primary antibodies 
diluted in 1% milk solution overnight at 4˚C with gentle agitation. The antibody 
dilutions were: RAMP2 = 1/200 to 1/1000; RAMP3 = 1/200 to 1/1000; CLR = 
1/500; ADM = 1/500 to 1/1000; HIF-1α = 1/100; Akt = 1/1000; Phospho-Akt 
=1/2000; PAM = 1/200; β-Actin =1/2000. 
 
G. Secondary Antibody dilutions 
 PVDF membranes were washed with wash buffer two times 5mins each with 
gentle agitation to remove any non-specific binding of primary antibodies. HRP 
conjugated secondary antibodies were diluted in 1% milk solution and PVDF 
membranes were incubated for 1hr at room temperature with gentle agitation. 
The antibody dilutions used were 1/15,000 for both anti-rabbit and anti-goat 
HRP. 1/1000 dilution of HRP conjugated anti-biotin antibody was used for 
biotinylated ladder.  
H. Protein Detection 
After secondary antibody incubation, PVDF membranes were washed thrice 
5mins each with wash buffer. Membranes were incubated with Enhanced 
Chemiluminescent (ECL) substrate for a 1min and sandwiched between two 
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acetate sheets. ECL sensitive Hyperfilm was exposed to membrane for different 
durations and the film was developed and fixed manually.  
 
I. Data Analysis 
Western blots were scanned as .jpeg images. The intensity of bands was 
measured using ImageJ software.  Rectangular box encompassing spaces little 
above, below and sides of the bands were drawn and the same box was used for 
every band to measure intensity of pixels. Similarly pixel intensity was measured 
for controls and test and relative intensity of the test bands were quantified by 
normalizing to control (β-actin). 
 
2.3.10. Flow Cytometry 
 
 Cells for flow cytometry were cultured in T175cm2 flasks until 90% 
confluent. Cells were washed with PBS and fixed with 5ml of 4% PFA for 10mins 
at room temperature. Cells were scrapped gently using cell scrapper and 
transferred into 15ml falcon tubes. Cells used to determine total protein 
expression were permeabilised by incubating with 0.5% Tween/PBS for 15mins. 
Cells used to determine the cell surface expression were not permeabilised. Both 
permeabilised and non-permeabilised cells were blocked with 10% rabbit serum 
for 30mins at room temperature. Cells were centrifuged at 1000xg for 5mins at 
4˚C and resuspended in 1ml of 2% rabbit serum. Cells were counted as 
mentioned in section 3.3.1.  
 
A. Antibody dilutions 
 
Primary antibody was diluted in 500ul of cell suspension in 2% rabbit serum. 
The antibody dilutions used were, 1ug/1x106 cells for RAMP2, RAMP3, CLR and 
isotype control. Cells were incubated with primary antibodies for 1hr at room 
temperature with gentle agitation.  
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     Cells were washed with wash buffer thrice, 5mins each at 1000xg at 4˚C. 
Cells were incubated with FITC labelled secondary antibodies in 500µl volume of 
wash buffer for 45mins at room temperature with gentle agitation. Secondary 
antibody dilutions were same as primary antibodies.  
 
 
B. Cell Sorting 
 
Cells were washed with wash buffer thrice, 5mins each and finally 
resuspended in 500ul wash buffer. Quantiquest software was used to sort the 
cells in flow cytometer. Cells with no antibody treatment were sorted first to 
optimise for background fluorescence. Optimal cell population was gated and 
10,000 cells were counted from the gated population.  
 
 
C. Data Analysis 
 
Quantiquest flow cytometry software was used to analyse the flow cytometric 
data. From the scatter plot of the cells, optimal cell population in order to 
exclude dead cells and cell clumps was chosen. Histometric data analysis was 
done to nullify any fluorescence from isotype control and the same statistics was 
applied to test antibody treated cells. Therefore, number of cells more 
fluorescent than isotype antibody treated cells was considered to be positive for 
test antibody (RAMP2, RAMP3 and CLR).   
 
 
2.3.11. Statistical Analysis 
 
Statistical analysis was carried out for data obtained from the number of 
experimental repeats and not the number of repeats done per experiment (for 
example, duplicates and triplicates). For qPCR anaylsis One Way Analysis of 
Variance (ANOVA) was done to gain statistical analysis. Tukey post hoc test was 
done to compare between groups. Data is expressed as mean±SEM, and p value 
<0.05 was considered to be statistically significant. Linear Regression analysis 
was done for qPCR to test the efficacy of taqman assays where, the slope of the 
line, R2<1 was considered to be significant.  
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2.4. RESULTS 
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2.4.1. HIF-1α Expression 
 
In order to test the protein expression of HIF-1α under hypoxia, 
glioblastoma cells were cultured in an incubator containing 0.1% O2 and whole 
cell lysate was used for western blotting.  
 
      Figure 20 shows the western blotting for HIF-1α in glioblastoma when 
exposed to hypoxia. It can be seen that HIF-1α protein expression was up-
regulated under hypoxia. β-actin used as a loading control is shown in figure 21. 
Upon normalising and quantifying the intensity of the bands, it can be seen in 
figure 22 that the cells responded to hypoxia by up-regulating HIF-1α. Cells 
produced 34% and 92% more HIF-1α under hypoxia at 24 and 48hrs respectively 
when compared to their normoxic counterparts.  
 
 
 
 
 
 
 
 
 
Figure 20: Western blotting result for HIF-1α at normoxia and hypoxia. The 
blots were exposed for 5 minutes and developed. The HIF-1α bands belong to 
120kDa as shown in the picture. 
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Figure 21: Western blotting result for β-actin expression in the glioblastoma 
cells when exposed to hypoxia and normoxia. The blots were exposed for 5 
mins and developed. The β-actin bands belong to 45kDa as shown in the 
picture.  
Figure 22: Quantification of HIF-1α expression in the Glioblastoma cells when 
exposed to hypoxia and normoxia. The band intensities were quantified as 
pixels using ImageJ and normalised to β-actin. n=1. 
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2.4.2. ADM Expression under Hypoxia 
 
Since the cells were responding to hypoxia by up-regulating HIF-1α, next 
the expression of ADM mRNA was quantified using qPCR.  
 Figure 23A shows the ADM mRNA expression in glioblastoma cells when exposed 
to hypoxia. At 24hrs cells produced 7 fold more than normoxia and at 48hrs 
there was a 26.3 fold increase in ADM expression. The graphs are shown as a 
relative expression to 0hrs.  
Figure 23B shows the ADM mRNA expression in prostate cancer cells. Cells up-
regulated ADM at 7.6 fold and 16.6 fold at 24 and 48hrs hypoxia respectively 
when compared to their normoxic counterparts. 
 Figure 23C and D show the ADM mRNA expression in the two breast cancer cell 
lines – MDA-MB-436 and MDA-MB-231. In MDA-MB-436 cells (fig 23C) ADM 
mRNA expression was increased by 9.4 and 158 fold at 24 and 48hrs 
respectively. MDA-MB-231 (fig 23D) produced 20 fold increase at 24hrs and 29 
fold at 48hrs.  
 Figure 23E shows the ADM mRNA expression in pancreatic cells. Cells produced 
an 8.5 fold increase in ADM expression at 24hrs hypoxia and 5.5 fold increase at 
48hrs.  
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Figure 23: mRNA expression of ADM under normoxia and hypoxia at 24hrs and 
48hrs in Glioblastoma, n=4 (A), prostate cancer, n=4 (B), breast cancer – MDA-
MB-436, n=4 (C), MDA-MB-231, n=3 (D) and pancreatic cancer, n=3 (E) cells 
measured by qPCR. The bars are represented in relative to the expression at 0hrs, 
which is 100%. Data is expressed as mean ± SEM. ANOVA and Tukey post test was 
performed to gain statistical significance. p< 0.001 
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2.4.3. ADM Receptor Expression under Hypoxia 
 
 
2.4.3.1. CLR Expression 
 
 Figure 24 shows the CLR mRNA expression in glioblastoma cells, when 
exposed to hypoxia.  CLR expression was down-regulated by 75% at 24hrs and 
50% at 48hrs hypoxia when compared to the normoxic counterparts. 
 
 
 
 
 
 
 
 
 
 
 Next the protein expression of CLR was measured using western blotting. 
50µg of whole cell lysate was separated in a 12% gel. Figure 25 shows the 
western blot for CLR expression on glioblastoma cells. Bands belonging to CLR 
can be seen in between 40kDa and 50kDa.  
Figure 24: mRNA expression of CLR in the glioblastoma cells when exposed to 
hypoxia and normoxia measured by qPCR. The bars are represented in relative 
to the expression at 0hrs, which is 100%. Data is expressed as mean ± SEM. 
ANOVA and Tukey post test was performed to gain statistical significance. n=4, 
p< 0.001 
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       Figure 26, shows the relative intensity of CLR expression normalised to β-
actin. There was no significant difference between CLR protein expression under 
hypoxia when compared to normoxia. 
 
 
Figure 25: Western blot for CLR expression in glioblastoma cells when 
exposed to hypoxia and normoxia. The blots were exposed for 5 mins and 
developed. The CLR bands belong to 42kDa as shown in the picture.  
Figure 26: Protein expression of CLR under hypoxia and normoxia in 
Glioblastoma cells. The bars are shown relative to the band intensity of β-Actin 
at each of these time points, measured as pixels using ImageJ software. n=1.  
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   Figure 27A shows the mRNA expression of CLR in prostate cancer cells. 
There was a significant down-regulation of 40 fold at 24hrs and no significant 
difference at 48hrs. 
 
 Figure 27B shows the mRNA expression of CLR expression in breast cancer 
cells. There was no significant difference between cells exposed to hypoxia when 
compared to normoxic controls at 24hrs and 48hrs. The expression of CLR in 
both hypoxia and normoxia at 24hrs and 48hrs was significantly lower when 
compared to the expression at 0hrs.  
 
 
 
 
 
 
 
 
Figure 27: mRNA expression of CLR in prostate (A) and breast cancer (B) cells 
when exposed to hypoxia and normoxia measured by qPCR. The bars are 
represented in relative to the expression at 0hrs, which is 100%. Data is 
expressed as mean ± SEM. ANOVA and Tukey post test was performed to gain 
statistical significance. n=4, p< 0.001 
A 
B 
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2.4.3.2. RAMP2 and RAMP3 Expression 
 
Please Note: This section contains supplementary figures that were been included 
here at the request of examiners. 
 
mRNA 
 
 qPCR done using taqman assays on different cancer cell lines were usually 
undetermined or sometimes greater than 35 which were inconsistent. 
 
  Primers were tested on COS-7 cells stably transfected with RAMP2 and 
RAMP3. Supplementary figure 2.4.3.2.1. shows that the primers were amplifying 
RAMP2 and RAMP3 in COS-7 cells transfected with RAMP2+CLR and RAMP3+CLR.  
 
 
 
 
 
 
   Since the RAMP2 and RAMP3 primers were detecting the mRNA expression, 
during cDNA synthesis, instead of random primer, gene specific primers from 
Primer Design was used for RAMP2 and RAMP3. RAMP 2 and RAMP 3 could still 
not be detected in different cancer cell lines. 
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Supplementary Figure 2.4.3.2.1 : mRNA expression of RAMP2 and RAMP3 
detected in stably transfected COS-7 cells. Non-transfected COS-7 cells 
showed no expression of RAMP2 and 3.  
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     Since the mRNA expression of RAMP2 and RAMP3 could not be detected, the 
protein expression of RAMPs were done using rat brain protein sample as a 
positive control.  
 
Protein Quantification – Western Blotting 
 
     Supplementary figure 2.4.3.2.2 shows the western blotting for RAMP2 in rat 
brain sample. The bands correspond to 20kDa which could be the monomer 
RAMP2 and the 60kDa band could be RAMP2 + CLR heterodimer. 
 
 
 
 
 
  Supplementary figure 2.4.3.2.3 shows the western blotting for RAMP3 in rat 
brain sample. The band at approximately 16kDa could be the RAMP3 monomer 
and the band at approximately 28kDa could be glycosylated form of monomer 
RAMP3 and the band corresponding to approximately 32kDa could be a 
homodimer of RAMP3. 
 
Supplementary Figure 2.4.3.2.2 : Western blot for RAMP2 in rat brain 
brain. RAMP2 monomer belongs to 20kDa and the CLR+RAMP2 heterodimer 
belongs to 60kDa. 
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  Next western blotting was done for RAMP2 and RAMP3 in whole cell lysate 
of glioblastoma cells when exposed to hypoxia.  
 
        Supplementary figure 2.4.3.2.4 shows the different western blotting results 
obtained from probing glioblastoma cells with RAMP2 antibody. The different 
lanes belong to 0hrs, 24hrs normoxia, 24hrs hypoxia, 48hrs normoxia and 48hrs 
hypoxia. (A) shows a single band varying in intensities over hypoxia and 
normoxia at ~55kDa. (B) shows a prominent band at ~40kDa and bands at 
~22kDa, ~28kDa, ~31kDa, ~50kDa and ~55kDa. (C) shows two bands at 
~40kDa and ~55kDa. (D) shows three bands at ~20kDa, ~40kDa and ~55kDa.   
 
 
 
Supplementary Figure 2.4.3.2.3 : Western blot for RAMP3 in rat brain 
sample. Monomer RAMP3 band can be seen at ~16kDa. RAMP3 homodimer 
can be seen at 28kDa and the band at 32kDa could belong to glycosylated 
RAMP3 homodimer. 
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Supplementary figure 2.4.3.2.5 shows the different western blotting 
results when probed for RAMP3 antibody on Glioblastoma cells when exposed to 
hypoxia. (A) shows multiple bands at ~20kDa, ~30kDa, ~42kDa, ~55kDa and 
≈60kDa. (B) shows multiple bands from ~20kDa to ~80kDa. (C) shows similar 
multiple bands pattern as that of picture B.  
 
 
  
 
 
Supplementary Figure 2.4.3.2.4: Western blotting results when probed for 
RAMP2 antibody on glioblastoma (U87) cells when exposed to hypoxia. The 
results were different each time western blotting was done for the same 
samples. 24N, 48N = 24 Normoxia, 48 Normoxia. ; 24H, 48H = 24 Hypoxia, 
48 Hypoxia. 
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       Since the RAMP2 and RAMP3 western blotting could not be construed as 
specific bands, flow cytometry was carried out to determine the expression of 
RAMP2 and RAMP3 in both permeabilised and non-permeabilised cells.  
 
 
 
Supplementary Figure 2.4.3.2.5 : Western blotting results when probed 
for RAMP3 antibody on glioblastoma (U87) cells when exposed to hypoxia. 
The bands were different each time western blotting was done for the same 
samples. 24N, 48N = 24 Normoxia, 48 Normoxia ; 24H, 48H = 24 Hypoxia, 
48 Hypoxia. 
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Protein Quantification – Flow Cytometry 
 
Supplementary figure 2.4.3.2.6 shows the quantified flow cytometry results. The 
bars are the mean protein expression of 10,000 cells. Bars are drawn after 
normalising the receptor expression values to that of isotype control.  
 
     Cos-7 cells show 18% expression of RAMP2, 19% expression of RAMP3 and 
3% expression of CLR.  
 
    U87 cells showed 96% expression of RAMP2, 86% expression of RAMP3 and 
78% expression of CLR. 
 
 
 
 
 
 Figure 28 shows the quantified flow cytometric results of U87 cells exposed 
to hypoxia.  
 
The total expression at 0hrs was 50% RAMP2, 80% RAMP3 and 10% CLR.  
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Supplementary Figure 2.4.3.2.6 : Percentage of total receptor expression 
in permeabilised glioblastoma (U87) cells after normalising with the isotype 
controls in Cos-7 and U87 cells.  
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At 24hrs normoxia, there was 58% RAMP2, 1% RAMP3 and 18% CLR. 
 
At 24hrs hypoxia, there was 10% RAMP2, 42% RAMP3 and 8% CLR. 
 
At 48hrs normoxia and hypoxia as it can be seen from figures 102 and 103 under 
Appedix section, there was a huge shift in fluorescent intensity in control 
antibody probed cells. The fluorescent intensities of receptors were same as 
control antibody; therefore the protein expression could not be evaluated. 
 
 
 
 
The cell surface receptor expression shown in figure 29 at 0hrs was 47% for 
RAMP2, 28% for RAMP3 and 11% for CLR. 
 
At 24hrs normoxia, there was 21% RAMP2, 13% RAMP3 and 8% CLR. 
 
Figure 28: Total receptor expression when exposed to hypoxia in 
permeabilised glioblastoma (U87) cells. Bars are drawn after being normalised 
to antibody control, and are the mean of values from 10,000 cells.  
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At 24hrs hypoxia, there was 23% RAMP2, 22% RAMP3 and 8% CLR. 
 
As mentioned above, at 48hrs normoxia and hypoxia there was control antibody 
background, the protein expression could not be evaluated.  
 
 
 
 
 
 
 
 
 
 
 
Receptor Expression in MDA-MB-231 cells under hypoxia 
 
  
 The effect of hypoxia on receptor expression was tested on breast cancer cells.  
 
Upon normalising and quantifying, figure 30 shows that the receptors are down-
regulated under hypoxia. 
 
At 24hrs normoxia, there was 80% of RAMP2, 89% RAMP3 and 90% CLR. 
 
Figure 29:  Cell surface receptor expression when exposed to hypoxia in non-
permeabilised glioblastoma (U87) cells. Bars are drawn after being normalised 
to antibody control, and are the mean of values from 10,000 cells. n=1.  
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At 24hrs hypoxia, there was 20% RAMP2, 27% RAMP3 and 18% CLR. 
 
At 48hrs normoxia, there was 45% RAMP2, 78% RAMP3 and CLR. 
 
At 48hrs hypoxia, the expression of RAMP2 was 9%, RAMP3 was 3% and CLR 
was 4%. 
 
 
 
Figure 31 shows the quantified flow cytometric results of receptors expression at 
the cell surface. 
 
At 24hrs normoxia, there was 30% RAMP2, 69% RAMP3 and 72% CLR.  
 
At 24hrs hypoxia, there was 24% RAMP2, 41% RAMP3 and 14% CLR. 
 
At 48hrs normoxia, there was 49% RAMP2, 62% RAMP3 and 69% CLR. 
Figure 30: Total protein expression in permeabilised breast cancer (MDA-MB-
231) cells when exposed to hypoxia. The bars are drawn as a mean expression 
after being normalised to the respective control antibodies. n=1 
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At 48hrs hypoxia, there was 8% RAMP2, 10% RAMP3 and 11% CLR. 
 
 
 
 
 
 
2.4.4. Effect of hypoxia on PAM expression 
 
 
 ADM when being secreted is expressed as an immature peptide as 
previously mentioned. In order to render it active, the C terminal of ADM has to 
be amidated by an enzyme called PAM. Therefore, the effect of PAM expression 
under hypoxia was tested. 
 
Figure 31: Cell Surface receptor expression in non - permeabilised breast 
cancer (MDA-MB-231) cells when exposed to hypoxia. The bars are drawn as 
a mean expression after being normalised to the respective control 
antibodies. n=1 
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Figure 32 shows the western blotting result for glioblastoma cells probed for PAM 
expression. The size of PAM is 100kDa. It can be seen from the intensities of the 
bands that PAM expression was up-regulated at 24hrs hypoxia when compared to 
normoxia.  
 
At 48hrs hypoxia, PAM expression was completely down-regulated when 
compared to normoxia at 48hrs.  
 
 
 
 
 
2.4.5. Akt Signalling under Hypoxia 
 
 In order to test if Akt signalling is turned on under hypoxia, western blotting 
was done for glioblastoma samples. 
 
      Figure 33 shows the western blotting for Akt and phosphorylated Akt as 
indication for Akt activation. It can be seen that under hypoxia Akt 
Figure 32: Western blotting for glioblastoma cells probed for PAM under 
hypoxia and normoxia. Bands belonging to 100kDa belong to PAM whereas 
bands between 50kDa to 70kDa are non-specific bands.  
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phosphorylation is down-regulated when compared to normoxia at both 24 and 
48hrs. 
 
 
 Since ADM is up-regulated under hypoxia, the effect of ADM treatment was 
tested on Akt phosphorylation. Glioblastoma cells cultured at normal conditions 
were treated with 1µM ADM for 2hrs and whole cell lysate was used for western 
blotting.  
 
      Figure 34 shows the western blotting results for glioblastoma cells treated 
with ADM. Akt phosphorylation was down-regulated in ADM treated cells when 
compared to non-treated cells. 
 
 
Figure 33: Western blotting for glioblastoma cells probed for Akt and 
phosphorylated Akt under hypoxia and normoxia. Blots were exposed for 15 
mins and developed. n=1 
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Figure 34: Western blotting for glioblastoma cells probed for Akt and 
phosphorylated Akt when treated with 1µM of ADM for 2hrs. Blots were 
exposed for 15mins and developed.  
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2.5. TECHNICAL DISCUSSION 
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This part of the project was aimed at determining ADM expression under 
hypoxia and to determine the receptor regulation under hypoxia. 
 
2.5.1. ADM expression under hypoxia 
 
ADM mRNA expression was significantly up-regulated under hypoxia. 
 
In glioblastoma, breast, prostate and pancreatic cancer cell lines ADM 
mRNA expression was significantly higher under hypoxia when compared to 
normoxic counterparts at same time points. Various studies have shown that 
ADM expression is up-regulated under hypoxia in vivo and in vitro 
(Boudouresque et al. 2005; Cormier-Regard et al. 1998; Drimal et al. 2006; 
Garayoa et al. 2000; Hofbauer et al. 2000; Hwang et al. 2007; Iimuro et al. 
2004; Jogi et al. 2004; Keleg et al. 2007; Kitamuro et al. 2000; Kitamuro et al. 
2001; Krieg et al. ; Nakanishi et al. 2004; Nakayama et al. 1999; Nguyen and 
Claycomb 1999; Park et al. 2008; Serrano et al. 2008; Steiner 1975; Uemura et 
al. ; S. M. Wang and Yang 2009; B. C. Yang et al. 1996; L. Zhao et al. 1996). 
ADM contains 16 HREs in its gene, out of which 4 to 8 genes are known to 
contribute to ADM expression under hypoxia (Cormier-Regard et al. 1998). 
Various studies have shown that ADM is up-regulated 1.3 to 25 fold under 
hypoxia at different time points in different cell lines (Zudaire et al. 2003). One 
of the targets for HIF-1α is ADM (Cormier-Regard et al. 1998) that results in 
ADM production under hypoxia. Under hypoxia, expression of ADM is stabilised 
at both mRNA and protein levels (Zudaire et al. 2003).  
 
Besides ADM mRNA regulation, studies have demonstrated that ADM 
protein expression is also up-regulated under hypoxia (Keleg et al. 2007; 
Zudaire et al. 2003). But I was unable to quantify the protein expression of ADM 
by western blotting using both whole cell lysate and cell culture media. Different 
concentrations of ADM antibody was used to detect ADM in both these samples. 
Figures 89 in appendix section is a representative western blotting result using 
whole cell lysate to probe for ADM. Molecular weight of ADM is 6kDa (Kitamura 
et al. 1993) and no matching bands were observed. 
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 Next, ADM present in cell culture media was quantified using western 
blotting in glioblastoma cells cultured under normoxia and hypoxia. In figure 90 
in appendix section, bands at ~6kDa were observed, which could be ADM, but 
this western blotting result was not reproducible for the same sample under the 
same experimental conditions. Therefore this result was not considered as a 
conclusive protein band for ADM. Various studies showing western blotting for 
ADM do not mention about any additional higher molecular weight at 50-60kDa 
bands as I have seen. Groups have reported ADM precursor bands at ~14kDa 
(Collantes et al. 2003; Jimenez et al. 1999). 
  
 Many studies have shown the expression of ADM under hypoxia. My 
specific aim was to determine which RAMP was specifically regulated under 
hypoxia so as to determine the RAMP involved in ADM actions under stress. 
 
2.5.2. Receptor Expression under Hypoxia 
 
CLR Expression under hypoxia 
 
There was no significant increase in CLR mRNA expression in glioblastoma, 
prostate and breast cancer cell lines. Why CLR mRNA levels at normoxia are 
highly variable is unclear. In glioblastoma cells, CLR expression at 48hrs 
normoxia was significantly lower than 0hrs and 24hrs. In prostate cancer cells 
CLR expression at 24hrs normoxia was significantly higher than other samples at 
both normoxia and hypoxia. In breast cancer cells, 24hrs and 48hrs normoxia, 
the CLR expression was significantly lower than CLR expression at 0hrs. In U87, 
MDA-MB-436 and PC3 cell lines tested, CLR mRNA was significantly lower under 
hypoxia when compared to normoxia (figure 24 and figure 27). 
 
 Protein expression of CLR was quantified in U87 cells using western 
blotting. Similar to mRNA data, there was no significant difference in CLR 
expression under hypoxia when compared to hypoxia. Various studies have 
shown different CLR responses in cells under hypoxia both in vitro and in vivo. In 
human Coronary Artery Smooth Muscle cells (hCASMC), there was a 3.5 fold 
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increase in CLR protein levels under 1hr of hypoxia. The mRNA levels only 
increased after 3-6hrs of hypoxia, during which time the protein levels decreased 
(Cueille et al. 2005). When neuroblastoma cells were cultured under hypoxia, 
CLR was not detected (Kitamuro et al. 2001), even though there was an increase 
in ADM expression. In pancreatic cancer cells, there was 2.5 fold increase in CLR 
mRNA (Keleg et al. 2007). Rats exposed to chronic hypoxia resulted in increase 
in both mRNA and protein CLR levels in vitro and in vivo in both left and right 
ventricles. Therefore it is suggested that CLR protein levels that can be 
functionally active are  regulated independent of transcription. CLR mRNA may 
have an increased half-life by various factors (Cueille et al. 2005). 
 
 
RAMP2 and RAMP3 expression under hypoxia 
 
RAMP2/3 protein expression under hypoxia was measured by flow 
cytometry. Glioblastoma cells produced more RAMP3 than RAMP2 at 0hrs 
although no RAMP3 could be detected at 24hrs normoxia. This could be due to 
poor sensitivity of the antibody at this particular time point. At 24hrs hypoxia, 
there was 4 times more RAMP3 than RAMP2 total protein expression.  
 
At cell surface, there was a no difference between RAMP2 and RAMP3 
expression at 24hrs normoxia. There was a 1.7 fold increase in RAMP3 cell 
surface expression at 24hrs hypoxia when compared to its normoxic counterpart, 
whereas there was no difference in RAMP2 and CLR expression at 24hrs between 
normoxia and hypoxia.  
 
Although there are no results from various experimental repeats, due to 
reasons discussed later in this chapter, these are results from 10,000 cells. From 
this FACS data, it was seen that the glioblastoma cells up-regulate RAMP3 than 
RAMP2 when subjected to hypoxic stress. 
 
Breast cancer cells (MDA-MB-231) when subjected to hypoxia, resulted in 
reduction in the expression of RAMP2, RAMP3 and CLR at both 24hrs and 48hrs 
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hypoxia. The total protein expression was down-regulated over time under 
hypoxia. RAMP2, RAMP3 and CLR produced similar levels of reduction under 
hypoxia. At 24hrs, 4 fold decrease in RAMP2, 3.3 fold decrease in RAMP3 and 5 
fold decrease in CLR total protein expression. At 48hrs there was 5 fold, 26 fold 
and 19.5 fold decrease in RAMP2, RAMP3 and CLR protein expression 
respectively. 
 
Cell surface expression of receptors showed similar decrease in expression 
under hypoxia. At 24hrs 1.2 fold, 1.7 fold and 5.1 fold decrease in RAMP2, 
RAMP3 and CLR expression respectively. At 48hrs, there was 6.1 fold, 6.2 fold 
and 6.3 fold reduction in RAMP2, RAMP3 and CLR expression respectively. 
 
 In vitro hypoxia studies using human neuroblastoma cells resulted in 46% 
decrease in RAMP2 mRNA although there was an increase in ADM levels. RAMP3 
on the other hand was not determined (Kitamuro et al. 2001). In hCASMC, an 
increase in RAMP2 mRNA was observed after 4hrs of hypoxia, around the same 
time when CLR mRNA levels had increased (Cueille et al. 2005). RAMP3 could 
not be measured due to its low level of expression (Cueille et al. 2005). Lung 
endothelial microvascular cells when subjected to 16hrs of hypoxia resulted in 
elevation of ADM and CLR mRNAs but no changes in both RAMP2 and RAMP3 
mRNAs (Nikitenko et al. 2003). In chronic heart failure rat model, there was an 
increase in RAMP3 mRNA and protein levels which could be due to hypoxia in this 
model (Cueille et al. 2002).  
 
In vivo studies on hypoxic rat lungs resulted in increase in RAMP3 mRNA 
with no observable changes in CLR and RAMP2 mRNA (Qing et al. 2001). 
Increase in RAMP2 and RAMP3 proteins were observed in both ventricles of rats 
exposed to hypobaric hypoxia (barometric pressure = 505hPa; inspired partial 
oxygen pressure = 106hPa). The mRNA levels on the other hand showed that 
RAMP3 expression was high at day 1 and RAMP2 was elevated from day 14 of 
exposure (Cueille et al. 2005). Other studies have shown an increase in ADM and 
CLR mRNA, but a 7.3 fold decrease in RAMP3 mRNA and no changes in RAMP2 
mRNA. Protein levels on the other hand showed prominent staining for RAMP2 
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but RAMP3 was not detected (Keleg et al. 2007); this could mean that the mRNA 
levels for RAMPs are not always the measure for their protein levels. 
 
 From my results and from other studies it can be understood that RAMP3 
mRNA is expressed at low levels in cell lines and are not measured. RAMP2 
mRNA levels could be measured in other studies, using primers designed by 
individual groups. 
 
 From in vivo hypoxic studies it is learnt that RAMP3 responds first after 
which RAMP2 levels are elevated (Cueille et al. 2005). This could mean that 
RAMP3 is up-regulated under stress to convey ADM mediated signalling to aide 
cell survival. Once cell survival is stabilised, RAMP2 which seems to be the 
preferred receptor partner for ADM is then up-regulated to mediate its functions. 
RAMP3 could have other receptor partners for hypoxia response proteins and 
could be up-regulated first hand under hypoxia. 
 
 The reason why RAMP3 could be up-regulated under pathophysiological 
conditions may be due to the presence of a PDZ motif which is not present in 
other RAMPs. PDZ motif which binds to NHERF and NSF is responsible for 
receptor trafficking and internalisation (Bomberger et al. 2005b; Bomberger et 
al. 2005a). Studies on RAMP knockouts have shown that the deletion of RAMP3 
gene does not have an impact on the expression of RAMP2 and CLR (R. Dackor 
et al. 2007), showing that RAMP2-CLR is necessary for the basal activity of ADM 
while under stress, RAMP3-CLR is regulated. 
 
 Studies have shown that Platelet Derived Growth Factor (PDGF) stabilises 
RAMP3 mRNA and also increases its half-life from 66.5mins to 331.6mins 
(Nowak et al. 2002). This maybe the reason why RAMP3 mRNA remains at low 
levels since it is rendered stable and may continue expressing the protein. 
Studies have shown that HIF-1α regulates the expression of PDGF in 
glioblastoma cells (Yoshida et al. 2006), endothelial cells (Kourembanas et al. 
1990), glomerular capillary endothelial and mesangial cells (E. Eng et al. 2005), 
breast cancer (Bos et al. 2005), neuronal cells (S. X. Zhang et al. 2003), lungs, 
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kidneys, heart and liver of hypobaric exposed rats (Bucher et al. 1996) and 
human pulmonary arterial smooth muscle cells (hPASMC) (ten Freyhaus et al.). 
PDGF is over-expressed in many cancers induced by hypoxia (P. Guo et al. 2003; 
Le et al. 2004) and contributes to angiogenesis thereby increasing 
tumourigenecity (Carmeliet and Jain 2000). 
 
 
2.5.3. PAM expression under hypoxia 
 
 Secreted ADM is expressed as an immature peptide as previously 
described. In order to render it active, the C terminal of ADM has to be amidated 
by an enzyme called PAM. In order to see if the ADM that is being over- 
expressed under hypoxia is functionally active, since ~85% of plasma ADM is 
iADM and requires amidation to make it active.  Therefore the aim was to test 
the effect of hypoxia on PAM using western blotting to measure the ratio 
between mADM to iADM. 
 
 In the western blotting, for PAM expression is glioblastoma cells under 
hypoxia PAM (~100kDa) was up-regulated at 24hrs hypoxia and almost 
disappeared at 48hrs hypoxia. Although the no house-keeping gene was probed 
for in these blots, the conclusions drawn are merely from the appearance of the 
blots. Other bands ranging from 50kDa to 70kDa could belong to PHM and PAL 
domains of PAM (Eipper et al. 1992; Sharma et al. 2009). It has been suggested 
that in different cell types PAM undergoes specific proteolytic processing (Eipper 
et al. 1992). 
 
 PAM consists of two domains that are required for its functional activity of 
amidating peptides. Peptidyl glycine α-hydroxylating monooxygenase (PHM) 
domain is located at the N-terminal of PAM and at the mid region is located the 
peptidyl-α-hydroglycine α-amidating lysase (PAL) (Perkins et al. 1990). PAM 
requires O2 to amidate its target peptides (Sharma et al. 2009). Since ADM is 
elicited under hypoxia, an increase in PAM expression could mean that the ADM 
is biologically active. 
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 Studies have reported that intermittent hypoxia increases the activity of 
PAM catalysed by PHM domain. Continuous hypoxia did not result in increase in 
PAM activity (Sharma et al. 2009). 
 
 PAM that is up-regulated at 24hrs hypoxia could render ADM active to aide 
cell survival. Since PAM is possibly down-regulated at 48hrs, it maybe that ADM 
at 48hrs is not functionally active or functionally active ADM at 24hrs could have 
an increased half-life to help in cell survival. Studies have shown that 
intermittent hypoxia elevates the expression of PAM than continuous hypoxia 
(Sharma et al. 2009). 
 
 
2.5.4. Akt Signalling under hypoxia 
 
Akt phosphorylation was measured in glioblastoma cells under hypoxia. At 
both 24hrs and 48hrs a very evident reduction in Akt phosphorylation was 
noticed. Since ADM expression was up-regulated under hypoxia, I wanted to 
determine Akt phosphorylation. 
 
Akt is activated by binding of phospholipid and when phosphorylated at 
Thr308 in the activation loop by PDK1 (Alessi et al. 1996) and/or 
phosphorylation at Ser473 at the C terminus (Nielsen et al. 1990; Sarbassov et 
al. 2005). Various studies have shown that under hypoxia Akt is phosphorylated 
and contributes to cell survival and provide resistance to apoptosis (W. Kim et al. 
2003a; Krishnaswamy et al. 2006). ADM has been shown to activate Akt by 
enabling Akt phosphorylation (W. Kim et al. 2002; W. Kim et al. 2003a; J. Y. Kim 
et al. 2006; Okumura et al. 2004; Park et al. 2008; Yin et al. 2004). In 
hepatocellular carcinoma cells, hypoxia induced ADM has shown to stimulate cell 
proliferation by activation of Akt (Park et al. 2008). Akt remained in activated 
state until 60mins and the level of phosphorylated Akt dropped at 120mins (Park 
et al. 2008). ADM has shown to protect cells from hypoxia by activating γ-
glutamate cysteine ligase (γ-GCL) resulting in up-regulation of glutathione (J. Y. 
Kim et al. 2006). Glutathione is required in cellular redox balance (Arrigo 1999; 
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Meister and Anderson 1983). γ-GCL is activated by PI-3K/Akt pathway (J. Y. Kim 
et al. 2006). 
 
In mannitol induced apoptosis which is a therapy used in brain edema and 
ischemic brain swelling, ADM produced an anti-apoptotic effect mediated by PI-
3K/Akt phosphorylation (W. Kim et al. 2002). 
 
Although Akt phosphorylation was shown to be down-regulated in my 
samples, studies have shown that Akt phosphorylation is an instant reaction 
which usually trails off at 24hrs (Ardyanto et al. 2006; Grymer et al. 1991; W. 
Kim et al. 2003a; S. M. Lee et al. 2006). 
 
In order to test if excessive ADM resulted in down-regulation of Akt 
phosphorylation, glioblastoma cells were treated with 1µM ADM (Park et al. 
2008). Glioblastoma cells treated with ADM peptide for 2hrs down-regulated Akt 
phosphorylation. This result was similar to the result obtained in cells cultured 
under hypoxia. This result correlates with results obtained from other studies 
where Akt phosphorylation had peaked at 30mins and trailed off at 2hrs (Park et 
al. 2008). 
 
Akt activation under hypoxia is an event that occurs instantly and this up-
regulation is sufficient to trigger events that enable cells to survive. Therefore 
the time points that I have chosen would result in elevation of ADM, but its 
downstream signalling might not be active at 24hrs and 48hrs hypoxia. 
 
2.5.5. Validation and Optimisation 
 
Induction of Hypoxia 
 
CoCl2 is a widely used hypoxia mimetic agent that is used in many hypoxic 
studies. CoCl2 does not induce hypoxia per se, but mimics the hypoxic situation. 
One mechanism of action of how it mimics hypoxia is that CoCl2 stabilises HIF-1α 
by inhibiting PHD enzymes that degrade HIF-1α under normoxic conditions 
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(Vengellur and LaPres 2004). Another mechanism is by changing the redox state 
of heme proteins (Gleadle et al. 1995).  
 
HIF-1α expression was taken as a measure to determine if the cells were 
undergoing hypoxia. Therefore, when U87 cells exposed to 300µM CoCl2 did not 
induce an increase in HIF-1α mRNA (figure 80 in appendix), Hoechst staining 
was carried out to determine if 300µM CoCl2 induced cell death due to toxicity. 
Since prolonged exposure or overdose of CoCl2 results in cobalt induced toxicity 
(Vengellur and LaPres 2004). Since CoCl2 stabilises HIF-1α, sustained HIF-1α 
expression results in signalling of BNIP3 and NIX death genes. BNIP3 leads to 
increase in chromatin condensation. Therefore BNIP3 causes activation of 
caspase-3, an early marker for apoptosis (Vengellur and LaPres 2004). Therefore 
as seen in figure 81 in appendix, the cell death index is higher for cells treated 
with 300µM CoCl2. At that time, it was concluded that cell death was the reason 
why there was no increase in HIF-1α mRNA expression. It was noted during the 
experiment that dead cells belonging to 7h-48h hypoxia had got washed away 
during the wash step in Hoechst staining. This might be the reason why the 
apoptotic index went down from 7hrs onwards (figure 81). 
 
Therefore three doses of CoCl2 were used to determine if hypoxia was 
induced (figure 82). Since there was no increase in HIF-1α expression, hypoxia 
was then induced using an incubator containing ~0.1% O2.  
 
A hypoxic incubator uses N2 to control the O2 in the incubator. Although 
using a hypoxic incubator is the closest to mimic real time hypoxic situations, the 
actual onset of hypoxia in cells cannot be determined (Millonig et al. 2009). An 
experimental problem I faced with using hypoxic incubator is that every time the 
incubator is opened, the O2 levels go up and it takes a while (how long it takes 
exactly is not known) to stabilise the O2 levels to 0.1%. Therefore, 24 and 48hrs 
were chosen to be the time points for this experiment. 
 
U87 and MDA-MB-436 cell lines were incubated in hypoxic incubators and 
again there was no HIF-1α mRNA response to hypoxia (figure 83 in appendix). 
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As the time points for inducing hypoxia were 24 and 48hrs, HIF-1α mRNA 
response at 2hrs when exposed to ~0.1% O2 was tested (figure 84 in appendix). 
As there was no increase in HIF-1α mRNA, a different approach to induce 
hypoxia was carried out. 
 
Hypoxia induced by using hypoxic media did not result in increase in HIF-
1α mRNA (figure 86 in appendix), although the cells containing hypoxic media 
was undergoing some kind of stress (figure 85 in appendix).  
 
At this stage, literature search revealed that HIF-1α mRNA remains 
unaltered under hypoxia (Huang et al. 1996; Kallio et al. 1997; Salceda and 
Caro 1997). Therefore protein expression of HIF-1α was determined in U87 cells 
when exposed to 0.1% O2. Cells expressed 34% and 92% more HIF-1α at 24hrs 
and 48hrs hypoxia respectively, when compared to their normoxic controls 
(figure 22). Since cells were responding to hypoxia by up-regulating HIF-1α, 
regulation of ADM and its receptors were studied. 
 
qPCR 
 
Firstly taqman assays were tested on positive controls. A standard curve 
using plasmid DNA as template was done for RAMP2, RAMP3, CLR and ADM was 
carried out. As seen in figure 87 in appendix, concentrations ranging from 1pg to 
1µg in log10 increases were used. Once the accuracy of taqman assays was 
confirmed, ADM expression in different cancer cell lines was carried out to test 
the efficiency of taqman assays on cell lines. 
 
ADM Protein Expression 
 
ADM protein expression could not be determined by western blotting in both 
whole cell lysate and in cell culture media. Despite repeats in western blotting, a 
6kDa band could not be detected in whole cell lysate. Western blotting on cell 
culture media contained various non-specific bands. 
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RAMP2 and RAMP3 protein expression 
 
Western blotting for RAMP2 and RAMP3 on rat brain sample as shown in 
supplementary figures 2.4.3.2.2 and 2.4.3.2.3 showed bands that corresponds to 
homodimers and heterodimers. But using the same antibodies on glioblastoma 
whole cell lysate showed multiple non-specific bands. Despite changing antibody 
concentrations and protein extraction methods, each western blotting showed 
multiple bands or non-specific bands that cannot be reproduced or construed as 
specific bands for RAMP2 or RAMP3 (supplementary figures 2.4.3.2.4 and 
2.4.3.2.5). Therefore the same antibodies were treated on fixed cells for flow 
cytometry.  
  
Flow Cytometry 
 
 RAMP2 and RAMP3 protein expression was quantified on fixed cells by flow 
cytometry. Glioblastoma cells were used to quantify the expression and Cos-7 
cells were taken as negative control. The antibody concentrations used were as 
previously described (Granholm et al. 2008). Control antibody was used to 
exclude any non-specific background. From supplementary figure 2.4.3.2.6 in 
appendix it can be seen that there was very little background in Cos-7 cells and 
over 80% expression of RAMP2 and RAMP3 and over 60% expression of CLR. 
These were tested on fixed permeabilised cells. Figures 91 and 92 in appendix 
show the histograms of receptors in Cos-7 and Glioblastoma cells respectively.  
 
 Figures 93 to 97 in appendix, show the histograms of total and cell surface 
expression of receptors in glioblastoma cells under normoxia and hypoxia. 
Figures 98 and 99 in appendix show the histograms of receptors in breast cancer 
cells under normoxia and hypoxia. 
 
 Flow cytomtery was repeated thrice for each cell line, although after first 
time for each cell line, there was high control antibody background. Despite 
several rounds of washing, reducing antibody concentrations, the control 
antibody background could not be reduced. Therefore the flow cytometry results 
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taken for calculating receptor expression belong to n=1 that accounts for 10,000 
cells. It was noted that the control antibody background was dependent on cell 
type. 
 
 
2.5.6 Conclusion 
 
 Collectively, the hypoxia data suggest that ADM is up-regulated under 
hypoxia. The receptor for ADM in breast cancer cells were down-regulated. And 
in glioblastoma cells at 24hrs hypoxia, cells produced more RAMP3 than RAMP2. 
These results show that the expressions of RAMPs are cell type and 
microenvironment dependent. Although my results show a decrease in Akt 
signalling, it cannot be concluded that ADM does not activate this signalling 
pathway, as Akt activation as a response to hypoxia is instantaneous. 
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CHAPTER III: EFFECT OF ADM OVER-EXPRESSION 
ON TUMOUR PROGRESSION 
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3.1. HYPOTHESIS 
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Hypothesis 
 
Over-Expression of ADM increases tumour progression and over-expresses 
receptor expression. 
 
The objectives are to: 
 
1. Determine the effect of ADM over-expression on cell proliferation, 
migration and invasion 
 
2. Determine the regulation of ADM receptors in cells over-expressing ADM   
 
3. Determine regulation of cells over-expressing ADM receptors 
 
4. Determine the bone homing features in cells over-expressing ADM 
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3.2. INTRODUCTION 
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3.2.1. Background  
 
Adrenomedullin (ADM) is a pluripotent hormone composed of a 52 amino 
acid peptide and carries structural similarity with the calcitonin/CGRP gene 
family. ADM is secreted by various malignant cells such as breast, lung, and 
prostate. The hormone is known to display its physiological effects by paracrine, 
autocrine or endocrine mechanisms. Along with mediating pathological conditions 
like cardiovascular disorders, renal problems, sepsis and inflammation, ADM 
plays an important role in the progression of cancer and metastasis. Over-
expression of ADM in different tumours aggravates the molecular and 
physiological features of malignant cells. ADM hormone is pro-proproliferative, 
anti-apoptotic, pro-angiogenic, and induces new bone formation (Zudaire et al. 
2003).   
 
This chapter was aimed at studying the role of ADM in tumour progression. 
Elevated levels of ADM are a characteristic feature of tumour cells (Bunton et al. 
2004). ADM contributes to cancer cells lymph node metastasis in breast (Oehler 
et al. 2003), pancreatic (Ramachandran et al. 2007) and ovarian cancers (Deng 
et al. 2012). Tumour metastasis is known to be the primary reason for cancer 
fatalities in about >90% of cancers (Gupta and Massague 2006; Jemal et al. 
2010; Steeg 2006). Metastasis of tumour cells involves a complex signalling 
cascade that is controlled by inhibitory growth factors, apoptotic factors, hypoxia 
and extracellular matrix in tumour microenvironment (Geiger and Peeper 2009). 
In order to metastasise successfully, tumour cells undergo various stages that 
are summarised in figure 35.  
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Tumour metastasis cascade briefly involves the following steps (Fidler 2003; 
Valastyan and Weinberg 2011).  
1. Invasion and migration of cells into extracellular matrix 
2. Intravasate into blood vessels 
3. Transportation through the vasculature 
4. Arrest in organs due to small vessels 
5. Extravasate into distant tissues 
6. Survive in metastasized environment by rapid proliferation 
Figure 35:  Metastastic Cascade – 1) Tumour cells at the site of the primary 
tumour proliferate and dissociate by invading the basement membrane. 2) 
Tumour cells acquire spindle shaped morphology as that of mesenchymal cells 
that enables them to migrate. 3) This process is followed by invasion of 
tumour cells into blood/lymph vessels. 4) After circulation in blood vessels, 
tumour cells are arrested in small blood vessels in target organ and 5) 
extravasate and 6) grow to a secondary tumour. Picture adapted from Geiger 
and Peeper, 2009. 
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Since ADM is known to contribute to tumour progression, effect of ADM in cell 
proliferation, migration and invasion was tested in this chapter. An invasive 
cancer cell line (MDA-MB-231) was used to test the effects of ADM over-
expression on bone metastasis in vivo. 
 
3.2.2. Tumour Metastasis 
  
 A “seed-to-soil” hypothesis by Paget in 1889 suggested thar tumour cells 
were like seeds and when they encounter a tissue with appropriate growth 
promoting factors, which is termed as soil, the tumour cells get lodged in the 
tissue and start growing. There seems to be an interaction between tumour cells 
and distal organs. For example, when prostate and breast cancer metastasize to 
bone, there seems to be a communication between tumour cells, osteoblasts and 
osteoclasts. Figure 36 shows the metastatic cascade where primary breast or 
prostate cancer cells migrate and invade into the tumour microenvironment via 
vasculature. The communication seems to result in bone destruction and release 
of various tumour promoting factors (Mundy 2002). In bone microenvironment a 
pre-metastatic niche is established that enables the tumour cells to lodge. The 
tumour cells then trigger a vicious cycle to enable them to grow by interacting 
with bone cells (Palmer et al. 2011; Peinado et al. 2011).  
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  Primary tumours lack the properties of a metastatic cell. These properties 
are acquired when epithelial derived cancers undergo Epithelial-Mesenchymal 
Transition (EMT). During EMT, there is change in the cytoskeletal proteins and 
various transcription factors that enable invasion and migration (Feinberg 2007; 
Kalluri and Weinberg 2009). Absence of EMT results in invasive tumour cells 
migrating as clusters or sheets. This intracellular adhesion is brought about by 
Cadherins and other cell-cell adhesion molecules (Bates et al. 2000; Friedl and 
Wolf 2003). One of the characteristic features of tumour cells during the 
transition is the loss of E-Cadherin which is an important cell-cell adhesion 
molecule (Berx and van Roy 2009; Cavallaro and Christofori 2004). While E-
Cadherin is suppressed, other adhesion molecules, example N-Cadherin that is 
associated with cell migration, is up-regulated (Kalluri and Weinberg 2009). 
Since one of the initial step in metastasis is migration, inhibiting the molecular 
determinants that cause cell motility has been suggested to be a viable 
therapeutic target (Palmer et al. 2011). Integrins, CD44, Immunoglobulin – 
domain Cell Adhesion Molecules (IgCAMs) and various other adhesion and 
Figure 36: Schematic representation of bone metastasis from primary tumour. 
It shows the tumour cells migrating and invading into the bone 
microenvironment via vasculature. A niche is established in the bone where the 
tumour cells lodge themselves. The tumour cells then trigger a vicious cycle to 
enable them to grow by interacting with the bone cells.  Picture taken from 
Palmer et al, 2011. 
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signalling molecules play a crucial role in cell migration and invasion (Cavallaro 
and Christofori 2004; W. Guo and Giancotti 2004; Ponta et al. 2003; G. F. Weber 
2008). 
 For a cell to migrate, the cell membrane protrudes as a result of both 
polymerisation and depolymerisation of actin (Condeelis and Segall 2003). The 
membrane protrusions alongside cofilin pathway result in cell migration. The 
cofilin pathway consists of adhesion of ECM due to cell contraction mediated by 
integrin, FAK containing complexes and actin-myosin2 complexes (Ghosh et al. 
2004). For example, in melanoma, a scaffolding protein called NEDD9 modulates 
RAC1 activity resulting in cell invasion (Sanz-Moreno et al. 2008).  
 Intravasation is when tumour cells enter blood vessels. The tumour cells 
align towards the vessels and migrate towards it (C. Y. Li et al. 2000; Sahai 
2007; J. B. Wyckoff et al. 2000). Tumour Associated Macrophages (TAMs) help 
the tumour cells intravasate via an interaction between a CSF1 receptor on the 
macrophages and an EGFR on the tumour cells, this is called the paracrine loop 
(Lin et al. 2001; J. Wyckoff et al. 2004; J. B. Wyckoff et al. 2007).  
 In the previous chapter, it was seen that hypoxia promotes angiogenesis 
resulting in an invasive and metastatic phenotype (Sullivan and Graham 2007). 
Angiogenesis plays an important part during tumour cell migration and invasion, 
with help from bone marrow derived vascular and hematopoietic progenitor cells 
(Rafii et al. 2002).  HIF-1α and HIF-2α contribute to cell migration and invasion. 
For example, in Renal Cell Carcinoma (RCC), in vitro tests show HIF-1α promotes 
CXCR4 receptor activity resulting in cell migration. It has been known that high 
level of CXCR4 is correlated with poor prognosis in patients with RCC (Staller et 
al. 2003). HIF-1α activates FAK resulting in accumulation of lysyl oxidase (LOX) 
which promotes EMT (Higgins et al. 2007). HIF-1α also activates various factors 
that promote EMT, such as snail, ZEB1, ZEB2 and twist in head, neck and breast 
cancers (Evans et al. 2007; Imai et al. 2003; Krishnamachary et al. 2006; M. H. 
Yang et al. 2008).  
 Besides blood vessels, tumour cells also intravasate into the lymphatic 
system (Cao 2005; Stacker et al. 2002). Signalling molecules promoting tumour 
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hemangiogenesis also contribute to lymphangiogensis, example VEGFR3 
(Kopfstein et al. 2007; Mandriota et al. 2001).  
 Certain types of tumours which have been studied extensively usually 
metastasize to the same organs. For example, breast cancer usually leads to 
metastasis to bone, lung, liver and brain. This ability of these tumours is called 
metastatic tropism (Fidler 2003). Figure 37 shows the metastatic tropism of six 
different cancers. 
 
  
 
 
 
Figure 37: Metastatic Tropism of various cancers. A) The common metastatic 
sites for breast cancer are lung, bone and liver. B) Colorectal cancer usually 
metastasises to liver and lungs. C) Gastric cancer metastasises to esophagus, 
lungs and stomach. D) Non-small cell lung cancer metastasis to lungs, brain 
and adrenal gland. E) Pancreatic cancer metastasises to liver and lungs. F) 
Prostate cancer metastasises to bone. Picture taken from Valastyan & 
Weinberg, 2011.  
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One of the reasons why tumour cells exhibit metastatic tropism, could be 
due to the layout of the vasculature. For example, metastasis of colorectal 
carcinoma into liver. This could be because the portal vein drains the circulation 
into liver (Gupta and Massague 2006). Besides metastatic tropism, tumour cells 
have the ability to be passed into arteriovenous shunts thereby enabling them to 
metastasize into farther organ sites (Valastyan and Weinberg 2011).  
 
3.2.3. ADM and Tumour Metastasis 
 
Results from different range of studies which used many different models 
have strongly implied that ADM has an important role in tumour growth and 
metastasis. Clinical data gathered over years of research confirms that ADM is 
over-expressed in cancer patients. For example, Ehlenz et al, (Ehlenz et al. 
1997)  found that the patients with colon or lung cancer have higher circulating 
levels of ADM as compared to healthy control subjects. The ovarian tumours 
observed by Hata et al in 2000 (Hata et al. 2000) showed increased expression 
of ADM mRNA which was statistically significant and correlated with poor 
prognosis in ovarian cancer patients.  The similar effect of ADM over-expression 
was also seen in prostate cancer where elevated ADM mRNA was associated with 
high Gleason scores (Rocchi et al. 2001). Udono et al (Udono et al. 2000) found 
that statistically high levels of ADM mRNA is found in intraocular and orbital 
tumours and high levels of ADM is significantly related to the lesions in eye with 
cancer. When patients of pituitary tumour were operated for tumour removal, 
ADM levels drastically reduced in the patients with Cushing’s syndrome due to 
pituitary adenoma (Letizia et al. 2000). This finding suggested that ADM is also 
over-expressed by pituitary tumours.  In patients with leiomyomas, high ADM 
expression is associated with increased vascular density (Hague et al. 2000).  
 
To understand the proliferative effect of ADM, Andreis et al in 2000 
(Andreis et al. 2000) investigated rat adrenal cortex in vivo using an in situ 
perfusion technique. It was found that during the 180min perfusion cycle, ADM 
infusion concentration dependently increased the mitotic index and [3H] 
thymidine incorporation into DNA in the zona glomerulosa (ZG). Interestingly, it 
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was found that the agents like adenylate cyclase inhibitor SQ-22536 (10-4 M), 
the cAMP blocker Rp-cAMP-S (10-3 M), and the protein kinase A inhibitor H-89 
(10-5 M), which inhibited cAMP in reduced or inhibited ZG proliferogenic effect of 
10-9 M angiotensin II. The overall findings identified that ADM is capable of 
promoting cell growth in both normal and malignant cells. Growth promoting 
effect of ADM is based on Tyrosin kinase/Mitogen activated protein kinase 
(TK/MAPK) and Akt mechanism. Insulin like growth factor 1 receptor (IGFR1) 
and protein kinase p42/44 MAPK are the main players of tumour progression by 
ADM. Prototypic signalling by MAPK induces cyclin D mediated cell cycle 
transition G0 to G1 and G2 to M and thus promotes cell proliferation (Andreis et 
al. 2000). ADM being an angiogenic peptide exhibits its activity by 
phosphorylation of Akt (W. Kim et al. 2003b). Akt phosphorylation in endothelial 
cells is essential in angiogenesis (Dimmeler and Zeiher 2000; T. Takahashi et al. 
1999; L. W. Wu et al. 2000). Akt phosphorylation is a measure of quantifying PI-
3K activity (Goel et al. 2004). Activation of Akt has been demonstrated to be 
important in cell survival (anti-apoptosis) (Fujio et al. 2000). ADM has known to 
contribute to angiogenesis by activation of Akt (Hinson et al. 2000; Iwase et al. 
2005). 
 
A study on a ovarian cell line revealed that addition of synthetic ADM to 
ECV ovarian tumour cells lead to a dose dependent cell migration through 
membrane. The study discussed that the projection on the cancerous cells are 
focus for ADM over-expression and also responsible for an active plasma 
membrane. The study also recognized elevated levels of gelsolin due to ADM 
over-expression. Gelsolin protein vigorously participates in cytoskeletal 
restructuring that underlies morphological changes and lead to reduction in cell 
adhesion by reducing the cell adhesion molecules like Fak.  All of these data, 
together with the fact that ADM increases tumour cell motility, suggest that 
tumour cells that express high levels of ADM may be more likely to be involved 
in metastasis (Martinez et al. 2002). 
 
ADM is known to be involved in the human implantation process via 
regulating trophoblast proliferation and differentiation. Studies have reported 
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that ADM, CLR and RAMPs-were greatly expressed by human choriocarcinoma 
Jar cells and first-trimester cytotrophoblast HTR-8/SV neo cells. It was observed 
that ADM not only stimulates both JAr and HTR-8/SV neo cell proliferation, but 
increased gelatinolytic activity and reduction in plasminogen activator inhibitor 
mRNA expression, increased invasion by the Jar and neo cells thus suggesting 
invasive properties of ADM (X. Zhang et al. 2005). A study by Keleg et al. (2007) 
found that in pancreatic cancer patients, ADM was induced by hypoxia and 
significantly augmented invasiveness in 3/5 human pancreatic cancer cells. 
Furthermore, the study indicated that blocking of ADM receptor CLR decreased 
invasiveness in 4/5 human pancreatic cancer cells. The study concluded that due 
to its characteristic of elevating invasiveness in pancreatic cancer cell lines, ADM 
over-expression might also influence angiogenesis. 
 
ADM has been reported to cause up-regulation of various receptors. ADM 
over-expression resulted in up-regulation of M2 expression on P19-derived 
cardiomyocytes because of mechanism involving L1/G10D receptor but not 
CLR/RAMPs receptor complexes (Buys et al. 2003). A different study identified 
that ADM levels increased in volume overload-induced cardiac hypertrophy rats. 
The elevated levels of ADM further increased gene expressions of ADM, CLR, 
RAMP2 and RAMP3 (+27%, +76%, +108% and +131%, respectively) in the rats 
(Yoshihara et al. 2005). The findings of both these studies together suggested 
that ADM over-expression has a significant effect on up-regulation of ADM 
receptors. Similar results were observed by Schwarz et al (Schwarz et al. 2006) 
while observing the effect of ADM over-expression on microvascular endothelial 
cells. The in-depth study by Schwarz et al noticed that within 5-45 minutes of 
ADM treatment, cAMP levels increased in the cells followed by increased 
extracellular signal-regulated kinase 1/2 phosphorylation. The entire cascade 
leads to up-regulation of peptide and mRNA expression for VEGF, RAP2 and CLR, 
thus increasing receptor population. 
 
3.2.4. ADM and Bone Metastasis 
 
An important physiological effect of ADM which may lead to bone metastasis 
in various cancers is its efficiency to cause osteoblast proliferation. A study by 
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Cornish et al (Cornish et al. 2001), assessed the effect of systemically 
administered ADM in male mice. It was found that ADM increased the indices of 
osteoblast activity, osteoblast and osteoid perimeter in tibia. A 21% increase in 
cortical width and a 45% increase in trabecular bone volume were observed 
along with highly significant increase in bone strength. There was also a 
significant increase in the width of the epiphyseal growth plate. It has been 
reported that over-expression of ADM stimulated bone formation in a mouse 
calvarial assay, increased bone metastasis and osteoblastic response in prostate 
cancer cell line while reduced ADM expression decreased bone metastasis in lung 
cancer model (Guise 2010). Many patients with cancer develop bone cancer on a 
longer run. Bone metastasis causes extreme bone pain, skeletal fractures, nerve 
compression, and hypercalcemia (Siclari et al. 2006).  Once the tumour cell 
enters bone, they secrete ADM inside the bone cells and induce new bone 
formation.  Dose dependent action of ADM stimulates fresh bone formation at 
picomolar concentration. The hormone exhibits this function by stimulating 
adenyl cyclase activity after binding to CLR+RAMP2 or CLR+RAMP3. Although, 
ADM stimulates osteoblast proliferation, it does not induce bone matrix protein 
mRNA expression. ADM has no direct action on bone sialoprotein, type I 
collagen, osteocalcin and osteopontin mRNA expression. Furthermore, ADM also 
lead to an inflammatory cascade in the affected bone as it increases IL-6 mRNA 
expression in the primary osteoblast (Cornish et al. 2003).  
 
Aim 
 
All these findings confirm ADM as a major regulator of carcinogenesis-
tumour progression. The present study is focused on studying the action of ADM 
on bone metastasis. An invasive cancer line was used for the purpose of the 
study and the cells were studied for the effects of ADM over-expression. The cell 
line was observed for changes in cell migration, proliferation, cell invasion, 
regulation of ADM receptors, and bone homing features.  
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   3.3. METHODS 
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Materials and Recipes for solutions used are given in Chapter 6, Appendix. 
 
3.3.1. ADM over-expression (in vitro) 
 
       ADM cDNA construct was obtained from Genecopoeia. ADM cDNA arrived as 
an insert in pOTB7 vector in filter paper discs. The filter disc was placed in a 
1.5ml microcentrifuge tube and 50µl of 1x TE Buffer (pH 8.0) was added and 
incubated for 30-60mins at room temperature.  
 
pOTB7 vector containing ADM was transformed into E.Coli and cultured for use in 
downstream applications. 
 
3.3.1.1. Transformation 
 
      Top10 E.Coli Chemically Competent cells were thawed on ice and 5-10µl of 
vector mixture was added and incubated on ice for 30mins. Cells were heat 
shocked for 30secs at exactly 42˚C and immediately transferred to ice. 300µl of 
room temperature SOC media was added to the cells and incubated for 1hr at 
37˚C in a shaking incubator at ~225rpm. The transformation mixture was plated 
out onto pre-warmed agar plates containing the appropriate antibiotic as shown 
in table 3. The plate was incubated at 37˚C overnight for 14-18hrs. A single 
bacterial colony was picked for inoculating to extract plasmid cDNA for 
downstream analysis. 
 
Plasmid Antibiotic Dose 
pOTB7 Chloramphenicol 25µg/ml 
pBUDCE4.1 Zeocin 50µg/ml 
pcDNA3.1 Ampicillin 100µg/ml 
pReceiverM61 (IRES-eGFP) 
 
Table 3: Table shows the different plasmids used in ADM over-expression 
studies, their appropriate antibiotics and concentrations. 
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3.3.1.2. Bacterial Culture 
 
A single bacterial colony was picked for inoculating in LB Broth media 
containing the appropriate antibiotic. Bacteria were cultured in a shaking 
incubator at 37˚C at ~225rpm overnight for 14-18hrs. Plasmid DNA was 
extracted following the protocol as described below. 
 
3.3.1.3. Extraction of Plasmid DNA 
 
     Depending upon the culture volume, plasmid DNA was extracted using either 
mini- or midi-prep plasmid DNA extraction kit from Promega.  
 
       Bacterial cultures were centrifuged for 10,000xg for 10mins and the pellets 
were resuspended thoroughly in Cell Resuspension solution. Cells were lysed 
using Cell Lysis Solution for 3mins at room temperature. Cell Lysis was stopped 
by adding neutralization solution and incubated for 3-5mins for the white 
flocculent precipitate to form. Plasmid DNA was separated from rest of the 
cellular debris by passing through clearing columns by centrifuging at 1500xg for 
5mins. The resultant DNA mixture was passed through a binding column to 
ensure DNA binding. The columns were washed to remove endotoxin, protein, 
RNA and endonucleases. DNA was eluted in nuclease free water and quantified.  
 
3.3.1.4. DNA Quantification 
 
       DNA was quantified by diluting it 1:25 in nuclease free water in a disposable 
cuvette and quantified in the spectrophotometer at 260nm. 
 
3.3.1.5. Site Directed Mutagenesis (gradient PCR) 
 
     In order to clone ADM cDNA into pcDNA3.1 vector, site directed mutagenesis 
PCR was carried out to incorporate HindIII and XhoI restriction sites on either 
sides of ADM cDNA. A gradient PCR was done in order to detect the right 
annealing temperatures as below: 
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Forward : 5’ GCA TAT AAG CTT ATG AAG CTG GTT TCC GTC GCC 3’ 
Reverse : 5’ GTC ATA CTC GAG CTA AAG AAA GTG GGG AGC ACT TC 3’  
 
      PCR was done using the Kapa PCR kit from KapaBiosystems. The PCR 
conditions used were as follows: 
 
              95°C – 3mins 
               94°C- 15 secs 
gradient 50°C - 60°C – 15secs 
              72°C – 1min 
              72°C – 1min 
 
3.3.1.6. Gel Electrophoresis 
 
       1g agarose was dissolved in 100ml of Tris Borate EDTA buffer by briefly 
heating it in a microwave for 1-2mins. 2µl (0.02%) of Ethidium Bromide was 
added to agarose and the gel was allowed to set at room temperature. 5µl of 
PCR product mixed with 1µl of xylene loading buffer was loaded in the wells of 
the gel and allowed to migrate for 30mins at 200V.  A 10kBp ladder was added 
alongside the PCR Products. The gel was observed on a bio-imaging system 
under UV light (Bio-rad Gel Doc 2000) using Quantity One Software. The ADM 
cDNA bands were extracted from the gel as described. 
 
3.3.1.7. Gel Extraction of DNA 
 
      DNA was extracted from agarose gels using the Zymoclean Gel DNA 
Recovery Kit.  
 
      In order to recover DNA from agarose gels, DNA was resolved in an agarose 
gel without ethidium bromide. The resolved DNA was stained with 1% crystal 
violet made up in distilled water (w/v). The gel was incubated with crystal violet 
for 30-45mins with gentle agitation. The desired stained DNA bands were 
40 cycles 
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excised using a scalpel and the protocol instructed by the DNA recovery kit was 
followed.  
 
     Three times volume of agarose dissolving buffer was added to the excised gel 
and incubated for 5-10mins at 37˚C until the agarose was completely dissolved. 
Melted agarose solution was added to a spin column to adhere DNA to the 
column filters. Agarose and other contaminants were washed off the spin 
columns using wash buffer by centrifuging at 10,000xg for 30secs.  DNA was 
eluted in 20µl water and quantified by nanodrop spectrophotometer and frozen 
at -20˚C or used for downstream applications. 
 
3.3.1.8. DNA Manipulation 
 
A. DNA Precipitation 
 
       DNA was precipitated according to the volume of DNA and not the 
concentration. Salt Solution during precipitation was added if the DNA was to be 
precipitated after midi/mini-prep. If the DNA was to be precipitated after PCR, 
restriction digestion or ligation, salt solution was not added since the buffers 
contained enough salt to precipitate the DNA. 
 
      For 50µl DNA, 70µl isoproponal was added. 15µl of 2mM Sodium Acetate 
was added if necessary. The mixture was incubated for 15-30mins at -20˚C and 
centrifuged at 20,817xg for 15mins at 4˚C. The DNA pellet was washed with 
either 70% ethanol of DNA>200bp or 95% ethanol if DNA<200bp. The 
resuspended DNA was centrifuged at 20,817xg for 10mins at 4˚C. DNA pellet 
was air dried, resuspended in water and quantified and used for downstream 
applications or frozen at -20˚C. 
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B. Restriction Digestion 
 
Restriction digestion was carried out to produce sticky ends in ADM cDNA so as 
to clone it into the pcDNA3.1 vector. Both the vector and the restriction site 
incorporated ADM was digested with XhoI and HindIII enzymes.  
 
      A 100µl reaction containing vector (10µg) or the precipitated ADM cDNA, 
20units* of XhoI and HindIII and appropriate buffers was incubated at 37˚C 
overnight.  
 
     Restricted products were either precipitated or gel extracted as per 
subsequent applications. 
 
* One unit is the amount of enzyme required to digest 1µg of DNA in 1hr at 
37˚C in 50µl reaction volume.  
 
C. Dephosphorylation 
 
      The restricted vector was precipitated and dephosphorylated to prevent self-
annealing. Antarctic Phosphatase was used to dephosphorylate the vector.  
 
      A 50µl reaction containing the restricted vector, 10 units* of Antartic 
Phosphatase and the appropriate buffer was incubated at 37˚C overnight. 
 
      Dephosphorylated vector was precipitated and resuspended in 20µl water 
and quantified. 
 
* One unit is defined as the amount of enzyme that hydrolyses 1µmol of p-
nitrophenylphosphate to p-nitrophenol in 1ml reaction volume in 1min at 37˚C. 
 
Restricted ADM cDNA was resolved on an agarose gel and DNA was extracted 
and quantified as mentioned above. 
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D. Ligation 
 
      Cloning of ADM cDNA into pcDNA3.1 vector was carried out using T4 DNA 
Ligase enzyme. 
 
      In a 100µl reaction containing 1µg each of dephosphorylated vector and 
restricted ADM cDNA, 2000 units* of T4 DNA Ligase and buffers were incubated 
overnight at room temperature.  
 
* One unit is defined as the amount of enzyme required to give 50% ligation of 
HindIII fragments of DNA (300µg/ml) in a total reaction volume of 20µl in 
30mins at 16˚C.  
 
The ligation mixture was precipitated, resuspended in 50µl water and DNA 
was gel extracted and resuspended in 20µl water. KOD PCR was carried out as 
mentioned above to amplify the entire pcDNA3.1 vector containing ADM cDNA 
using the primers and PCR conditions given below.  
 
Forward: 5’ GAA GTG GAA TAA GTG GGC TCT GAG TC 3’ 
Reverse: 5’ GAC TCA GAG CCC ACT TAT TCC ACT TC 3’ 
 
PCR Cycle setup: 
95°C – 2mins 
95°C – 20secs 
60°C – 15secs 
72°C – 3:30mins 
72°C – 5mins 
 
 
E. Removal of methylated DNA 
 
      In order to removal any residual vector as a result of incomplete restriction, 
PCR product was demethylated using DpnI enzyme. 
 
18 cycles 
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      20units* of DpnI enzyme was added to the PCR product and incubated 
overnight at 37˚C. 
 
     Demethylated DNA was precipitated and transformed as mentioned above. 
 
* One unit is defined as the amount of enzyme required to digest 1µg of pBR322 
DNA (dam methylated) in 1ht at 37˚C in a 50µl reaction volume.  
* Definitions of 1 unit is taken from www.neb.com 
 
The bacterial colonies were cultured and plasmid DNA was extracted. 1µg 
DNA was sent for sequencing using primers for T7 promoter in University of 
Sheffiled’s Core Genetics Facility. DNA was also restricted using XhoI and HindIII 
enzymes for 1hr at 37˚C and resolved in an agarose gel to confirm the size of 
ADM cDNA.  
 
3.3.1.9. Linearisation of Constructs 
 
pcDNA3.1 vector containing ADM cDNA was linearised prior to tranfection in 
order to incorporate into the genome of the cells. pBUDCE4.1 vector containing 
RAMP2+CLR and RAMP3+CLR inserts were kindly provided by Dr.Dave Roberts in 
Prof.Skerry’s lab.  
 
      20-30µg of vector was restricted with 20units of FspI enzyme (pcDNA3.1) 
and MfeI enzyme (pBUDCE4.1) for 1hr at 37˚C. The restricted vector was 
precipitated and quantified.  
 
 
3.3.1.10. Transfection 
 
Cells were transfected with linearised vectors by electroporation.  4-5 million 
cells were trypsinised and resuspended in electroporation buffer containing 2mM 
of ATP and 5mM of glutathione. 400-500µl cell suspension was transferred to a 
4mm gap cuvette. 10µg of linearised vector was added and the cuvette was 
gently flicked to mix the contents. Transfection control cells contained more 
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electroporation buffer instead of DNA. The cells were electroporated as shown in 
table 4 depending on the cell type. 
 
Cell Type Voltage Capacitance 
PC-3 200V (0.2kV)  
960µF 
MDA-MB-231 230V (0.23kV) 
U-87 400V (0.4kV) 
 
 
 
After electroporation, cells were left to rest at room temperature for 2-
5mins and 300µl warm media was added to the cells and gently transferred into 
T175cm2 flasks containing pre-warmed media. Cells were cultured under 
standard conditions for two days in order to stabilise protein expression for 
antibiotic selection. 
 
Antibiotic Doses 
 
      Transfected cells along with control transfections were treated with antibiotic 
containing media. The media was replenished every 2 days, with freshly added 
antibiotics. 1mg/ml of G418 or Zeocin was added for pcDNA3.1 or pBUDCE4.1 
transfected cells respectively. Control transfected cells die from 7-15 days from 
the start of selection. Individual colonies of stably transfected cells were 
trypsinised and cultured under standard conditions. The media contained 
500µg/ml of antibiotics in order to maintain selection pressure.  
 
 
 
Table 4: Electroporation voltage and capacitance used for transfecting 
different cancer cell lines. 
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3.3.1.11. Over-expression of ADM Receptors 
 
 pBUDCE4.1 vector containing either RAMP2+CLR or RAMP3+CLR 
(constructs kindly provided by Dr. Dave Roberts in our lab). The vectors were 
linearised by using FspI enzyme and transfected into PC3 cells as previously 
described. Post transfection, media containing 500mg/ml Geniticin antibiotic was 
added to cells to select for transfected cells. The stably transfected cells were 
then used for MTT assay and wound healing assay. 
 
3.3.1.12. Cell Proliferation 
 
The assessment of cell proliferation was carried out using the MTT assay kit 
obtained from ATCC. Cells were counted and 2x103 cells/well were added into 96 
well plates in 6 replicates for each cell type. At each time point, MTT reagent was 
added and incubated for 2hrs at 37˚C. Once the purple formazan was visible, 
detergent was added to dissolve the formazan overnight with gentle agitation. 
Absorbance at 570nm was measured using a micro plate reader at day 0 to test 
the seeding consistency between cell types. Thereafter, every two days, 
absorbance was measured and media was replaced for other time points. 
Proliferation was assessed for a period of 8-10 days.  
 
3.3.1.13. Wound Healing Assay/Scratch Test 
 
     The assessment of cell migration was done by wound healing assay also 
called as scratch test. Cells were counted and 4x106 cells/well were added to 12 
well plates in duplicates for each cell type. Once the cells were 80-90% 
confluent, which was usually the next day, cells were treated with 30µg/ml 
Mitomycin C to block cell proliferation. Cells were incubated with Mitomycin C for 
30mins at 37˚C. A scratch was created in the monolayer using a 200µl pipette 
tip. The tip was changed for every well so as to maintain consistency in the 
scratch. The cells were then washed with PBS to get rid of any cell debris and 
media were added. At each time point, cells were fixed in ice cold methanol for 
5mins and stained with 1% crystal violet for 5mins. Excess stain was washed 
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with water and the wells were air dried and pictures were taken at 10x 
magnification in Leica DMB4000B microscope using Leica Application Suite V3 
software.  
 
There are two methods to assess the migration of cells in scratch test, one 
by measuring the distance between the edges of the scratch and the other by 
measuring the area of the scratch.  
 
 
Measuring Distance 
 
     The distance between the edges of the scratch was measured using ImageJ 
software. For samples where the distance could not be measure due to the 
closure of the scratch, 0 was taken as the distance.  
 
 Initially the scale on the ImageJ software was set to 500µM scale. 
 
 
 
 
 
 
 
     As shown in figure 38, the distance between the edges of the scratch was 
measured at various points and average taken.  
500µM 
Figure 38:  Measurement of the distance between the edges of the scratch. 
Lines were drawn on the edges of the scratch and distance was measured at 
different points and average was taken.  
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Measuring Area 
 
     The area of the scratch was measured using ImageJ software. The image was 
converted to a black and white image and the outline of the scratch was 
generated. The accuracy of the analysis was determined by overlaying the 
outline of the scratch generated with the original image. Figure 39, shows the 
original image, outline of the scratch and the overlaid image. For scratches, 
where the area could not be measure due to the closure of wound, it was 
considered as 0. 
 
 
 
 
 
 
 
 
 
 
 
The data are expressed as the distance/area migrated by the cells. A 
migration index is expressed as the ratio of the percent migration of test cells 
over the percent invasion of control cells. 
 
a) Percent Migration =      Mean distance/area of test cells                      
                              Mean distance/area of control cells 
 
   Original Image                 Scratch Outline                Image Overlay 
Figure 39: Measurement of area in scratch test. The original image is 
converted into a black and white image and the outline of the wound is 
generated in ImageJ. The accuracy of the generated scratch was determined 
by overlaying the original image with the scratch outline. The original image 
is shown in gray while the scratch is overlaid in red. 
X 100 
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b) Migration Index    =      % Migration of Test Cells 
       % Migration of Control Cells 
 
Test cells       = cells transfected with ADM or ADM receptors 
Control cells   = cells transfected with empty vector (vector control) 
 
3.3.1.14. Cell Invasion 
 
Cell invasion was assessed using Matrigel Invasion Chambers and protocol 
obtained from BD Biosciences. Cells were counted and 2.5x104 cells were seeded 
in the insert with media containing 1% serum in duplicates. The wells below the 
inserts contained media with 10% serum to act as a chemoattractant.  Cells 
were incubated for 20hrs under standard cell culture conditions.  
 
     Non-invading cells were removed from the upper surface of the insert 
membrane by scrubbing with cotton swabs. The cells in the lower surface of the 
membrane were fixed in methanol and stained with 1% crystal violet. Excess 
stain was washed with water and the membrane was air-dried, peeled off the 
inserts and mounted using DPX mountant using glass coverslips. Invaded cells 
were counted in several fields of duplicate membranes in Leica DMB4000B 
microscope using Leica Application Suite V3 software. 
 
   Data are expressed as the number of cells that invaded through the matrigel 
matrix. The Invasion Index is also expressed as the ratio of the percent invasion 
of test cells over the percent invasion of control cells. 
 
a) Percent Invasion =     Mean number of Test Cells 
                                         Mean number of Control Cells 
 
b) Invasion Index   =    % Invasion of Test Cells 
                            % Invasion of Control Cells 
 
Test cells       = cells transfected with ADM or ADM receptors 
Control cells   = cells transfected with empty vector (vector control) 
X 100 
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3.3.1.15. Flow Cytometry 
 
    General flow cytometry protocol using antibody incubations was the same as 
described under section 2.3.10. 
 
To test for GFP intensity, cells cultured in T75cm2 were trysinised and 
centrifuged at 1000xg for 3-5mins. The cell pellet was resuspended in 1ml of 
media and sorted inFL-1 530/30 nm filter. 5x106 cells were counted in a 
population which excluded dead cells and cell clumps. A non-GFP cell line was 
used to optimise basal level of fluorescence and as a negative control.  
 
3.3.2. ADM Over-Expression (in vivo) 
 
3.3.2.1. IRES-eGFP Vector 
 
 The vector to over-express ADM to study the effect of over-expression of ADM in 
bone homing is a bicistronic IRES-eGFP vector, where the expression of GFP is 
directly proportional to the expression of ADM. The vector map containing the 
cDNA for ADM is shown in figure 40. The length of ADM ORF is 558bp which lies 
exclusively in Exon 4 of ADM gene coding sequence.  
 
      MDA-MB-231 Cells were transfected with IRES-eGFP vector according to the 
protocol described in section 3.3.1.10. 
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3.3.2.2. Generation of IRES-eGFP negative control 
 
 In order to generate an IRES-eGFP negative control, two attempts were 
made.  
 
 Initially, the start codon was made to mutate from ATG to GGG, therefore 
transcription of ADM would not take place. KOD PCR was done using the following 
primers: 
 
Forward : 5’ TTC GGT ACC GGG AAG CTG GTT TCC 3’ 
Reverse : 5’ GGA AAC CAG CTT CCC GGT ACC GAA 3’ 
Figure 40: Vector map of the bicistronic IRES-eGFP vector (EX-T0150-M61) 
obtained from Genecopoeia. The vector backbone along with restriction sites 
flanking the ORF can also be seen. 
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The PCR cycle conditions were: 
 
95°C – 2mins 
95°C – 20secs 
60°C – 20 secs 
72°C – 1:10mins 
72°C – 5mins 
 
 Next attempt was made to mutate a stop codon after the generation of four 
amino acids, as IRES-eGFP vector requires transcription to take place in order for 
the ribosome to re-enter and transcribe GFP. Therefore after the generation of 
the first four amino acids – M, K, L, V, two stop codons would end transcription. 
The TCCGTC codons that code for Serine and Valine were made to mutate into 
TAGTGA, which code for amber and opal stop codons respectively. The primers 
used for this KOD PCR are: 
 
Forward : 5’ G AAG CTG GTTTAG TGA GCC CTG ATGTA C 3’ 
Reverse : 5’ GTACATCAGGGCTCACTAAACCAGCTTC  3’ 
 
The PCR conditions were: 
 
95°C – 2mins 
95°C – 30secs 
61°C – 30 secs 
72°C – 4mins 
72°C – 5mins 
 
Since the mutations were not being incorporated, commercially available 
IRES-eGFP negative control was purchased. The negative control for IRES-eGFP 
vector contains a random sequence in place of ADM cDNA. 
 
 
 
35 cycles 
40 cycles 
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3.3.2.3. Fluorescent Activated Cell Sorting (FACS) 
 
     MDA-MB-231 cells transfected with ADM-IRES-GFP and negative control 
vector was sorted for varying GFP intensities using FACSAria flow cytometry. 
Cells cultured under standard cell culture conditions in presence of antibiotics 
were trypsinised and sorted. Non-GFP MDA-MB-231 cells were used to optimise 
for background fluorescence. In a log10 scale of intensity, cells with less than 
102 was sorted as very low group, cells with 102-103 intensity was sorted as low 
group, cells with 103-104 were sorted into medium intensity group and cells with 
>104 were sorted into high intensity group. Two days post sorting, pictures were 
taken of cells for GFP in 90% confluent T75 flasks in Leica DM4000B microscope. 
 
3.3.2.4. Measuring GFP intensity 
 
     Cells sorted for varying intensities for GFP were cultured under antibiotic 
selection in standard cell culture conditions. 1x106 cells/well cells were cultured 
in a six well plate overnight. GFP intensity was measured using a fluorescent 
micro plate reader at 485nm excitation and 480nm emission.  
 
3.3.2.5. RNase Treatment 
 
     In order to remove any contaminating RNA in the cDNA sample, RNase 
treatment was carried out.  
 
     If 1µg of RNA was used for initial cDNA synthesis, then it was considered that 
1µg of cDNA was synthesised. In a 60µl reaction, 1µg cDNA was treated with 
buffers and 20 units* of RibonucleaseH for 20mins at 37˚C. 0.5M EDTA was 
added to stop the reaction. The cDNA was precipitated as described in section 
3.3.6. was used for RT-PCR. 
 
*One Unit of Ribonuclease H is the amount of enzyme required to increase fluorescence 
1.5RFUs per sec at 37˚C using 20pmol of RNaseAlert probe coupled to 1000pmol of a 
complementary oliogonucleotide as substrate.Taken from Applied Biosystems. 
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3.3.2.6. Reverse Transcription – PCR 
 
mRNA expression of ADM and GFP was quantified by RT-PCR using the 
KapaPCR kit. HPRT1 was used as an endogenous control. 
 
     The primers used to amplify ADM, GFP and HPRT1 are: 
 
ADM Forward      : 5’ AAG CTG GTT TCC GTC GCC C 3’ 
ADM Reverse      : 5’ C TGG GGC CGA ATA AGG GTC 3’ 
 
GFP Forward       : 5’ TAA TAA GCT TGC CAC CAT GGT GAG CAA GG 3’ 
GFP Reverse       : 5’ AAT TGG TAC CCT TGT ACA GCT CGT CCA TGC 3’ 
 
HPRT1 Forward   : 5’ TGT AAT GAC CAG TCA ACA GGG 3’ 
HPRT1 Reverse   : 5’ TGG CTT ATA TCC AAC ACT TCG 3’ 
      
The PCR conditions used to amplify ADM are: 
95°C – 3mins 
95°C – 20secs 
56°C – 30 secs 
72°C – 30mins 
72°C – 2mins 
 
Data Analysis 
 
Quantification of the bands was similar to that of quantifying western blotting 
bands as described in 2.3.9. The band intensities were measured in pixels and 
normalised to HPRT1 endogenous control.  
 
 
 
 
35 cycles 
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3.3.2.7. Bone metastases in immunodeficient mice 
 
     All animals and experiments were carried out in accordance with the local 
guidelines and with Home Office approval under project license number 40/2972 
held by Prof. Nicola J Brown, University of Sheffield, United Kingdom. 
 
Female Balb/C nude/nude mice that were 5 weeks old were ordered from 
Harlan, United Kingdom. Mice were allowed to acclimatize for a week before the 
commencement of the experiment. Experiments were carried out with the test 
group containing 16 animals and control groups contained 15 animals each.  
 
     General anaesthesia was induced by 100mg/kg Ketamine and 15mg/kg 
Xylazine. 1x105 cells/mice in 100µl PBS was injected into the left ventricle of the 
heart using a 25Gx5/8” needle. Mice were monitored twice weekly by measuring 
body weights and detecting tumours in hind legs using a Light Tools GFP imaging 
system. Tumours were detectable in most animals two weeks post injection. 
Mice were sacrificed humanely and blood was drawn through inter-cardiac 
punctures to obtain serum for further analyses. Hind legs were removed and 
stripped off excess muscle. Legs were viewed under GFP imaging system and 
pictures were taken. The right legs were fixed in 4% PFA for micro CT analysis. 
Left legs were used for RNA analysis and saved in RNAlater solution.  
 
Counting Tumours 
 
     Tumours were counted as 1, if present in one of the four positions – proximal 
femur, distal femur, proximal tibia and distal tibia as shown in figure 41. Counts 
were made from both inside and outside images and are combined in the 
analysis. Intensity of GFP was not taken into account because a) imaging 
position was variable between bones and b) intensity of GFP expression may 
vary between animal groups.  
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3.3.2.8. Statistical Analysis 
 
     For proliferation assay, scratch test, invasion assay analyses and weights of 
mice in vivo, One Way Analysis of Variance (ANOVA) was done to gain statistical 
analysis. Tukey post hoc test was done to compare between groups. Data are 
expressed as mean±SEM, and p value <0.05 was considered to be statistically 
significant. 
 
 
 
 
 
 
Figure 41: Mouse hind limb. Tumours were counted only if present in any of 
these four postions. 
Proximal	  Femur 
Distal	  Femur Proximal	  Tibia 
Distal	  Tibia 
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3.4. Results 
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3.4.1. Over-Expression of Adrenomedullin 
 
ADM cDNA in pOTB7 vector was obtained from Genecopoeia. The vector after 
transforming into E.Coli was cultured and plasmid DNA was extracted. As 
described previously, KOD gradient PCR was done to incorporate the two 
restriction sites (section 3.3.1.5).  
 
Figure 42 shows the product of gradient PCR for ADM with temperatures from 
50°C, 50.2°C, 50.7°C, 51.6°C, 52.7°C, 54°C, 55.4°C, 56.8°C, 58.1°C, 59.2°C, 
60°C and 60.4°C. The PCR products were around 1500bp long, ADM cDNA is 
~1488bp long. The higher band is >10,000kb, belongs to pOTB7 vector.  
 
                    
  
 
  
 
 
 
 
 
 
 
 ADM amplified from the pOTB7 vector was cloned into pcDNA3.1 vector as 
previously described and the E.Coli clones were cultured and restricted using 
XhoI and HindIII enzymes. The products of restriction were separated by gel 
electrophoresis. Figure 43 shows the ADM bands in all three clones run in 
duplicates belonging to 1500bp and the pcDNA3.1 vector bands belonging to 
5400bp. 
Figure 42: Gel electrophoresis of ADM amplified by gradient PCR. The 
amplified ADM cDNA belongs to ~1500bp. The higher band belongs to pOTB7 
vector. 
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 The plasmid DNA from all three clones was sequenced in University of 
Sheffield Core Facilities Unit. The sequencing result was run in BLAST. Figure 106 
shows the screen shot of BLAST output in appendix section. BLAST returned with 
97% match to the Human Adrenomedullin mRNA sequence (NM_001124). This 
result confirms that ADM had been cloned into the pcDNA3.1 vector.  
 
 
3.4.1.1. Confirmation of ADM over-expression in cell lines 
 
  
 Three cell lines were transfected with pcDNA3.1 vector containing ADM with 
the protocol that is previously described. After antibiotic selection, the cells were 
screened to confirm ADM over-expression in these cell lines when compared to 
non-transfected (native) and vector control transfected cells.  
 
 A fold change in ADM expression as quantified in qPCR was observed in 
prostate cancer (PC3), glioblastoma (U87) and breast cancer (MDA-MB-231) 
cells. Figure 44 shows the quantified qPCR, confirming ADM over-expression. PC3 
transfected with ADM produced 8 times and 13.2 times more ADM than native 
and pcDNA3.1 vector transfected cells respectively. 
Figure 43: Restriction digestion after cloning ADM cDNA into pcDNA3.1 
vector. The three colonies of E.Coli contained the pcDNA3.1 vector containing 
ADM gene.  
pcDNA3.1 
ADM cDNA 
            Clone 1  ¦  Clone 2   ¦  Clone 3 
5000bp 
1000bp 
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    U87 transfected with ADM produced 8.5 and 15.8 times more ADM than native 
and pcDNA3.1 vector transfected cells respectively. 
 
 MDA-MB-231 cells transfected with ADM produced 14.5 and 13.6 times 
more ADM than native and pcDNA3.1 vector transfected cells respectively.  
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Figure 44: Confirmation of over-expression of ADM mRNA prostate cancer 
(PC3), glioblastoma (U87) and breast cancer (MDA-MB-231) cell lines. The 
graphs confirm that cells transfected with vector containing ADM gene 
expressed more ADM than native (non-transfected) and control transfected 
cells. Bars show the fold change in ADM mRNA expression normalised to β-
actin. n=1 
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3.4.1.2. Effect of ADM Over-Expression on Cell Proliferation 
 
 
 The effect of over-expressing ADM was tested on cell proliferation in MDA-
MB-231 and PC3 cells.  
 
 
MDA-MB-231 Cells 
 
  Proliferation analysis was carried out on MDA-MB-231, breast cancer native 
cells and cells transfected with pcDNA3.1 vector containing ADM cDNA, vector 
control. The mean absorbance for days 0, 2, 4, 6 and 8 are shown in table 5. 
Figure 45 shows the assessment of the mean absorbances. It was observed that 
there was no significant difference between native cells, vector control and cells 
transfected with ADM cDNA.  
 
      
 Native pcDNA3.1 ADM 
Day 0 0.17±0.01 0.18±0.07 0.17±0.02 
Day 2 0.23±0.09 0.23±0.05 0.33±0.20 
Day 4 0.56±0.04 0.56±0.10 0.58±0.04 
Day 6 0.64±0.16 0.71±0.25 0.69±0.29 
Day 8 1.30±0.9 1.06±0.77 1.15±0.61 
 
 
 
 
Table 5: Mean absorbances (OD) of proliferation of native, vector control and 
ADM over-expressing MDA-MB-231 cells. Proliferation was assessed using MTT 
assay. OD values were measured at 570nm. The values are mean from three 
replicate experiments. 
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Figure 45: Proliferation of native (non-trasfected), vector control and cells 
transfected with ADM in breast cancer (MDA-MB-231) cells assessed by MTT 
over eight days. The bar shows the OD at 570nm. The  bars represent mean 
absorbance ± SEM (error bars). ANOVA and Tukey post hoc test was done to 
gain statistical significance. n=3, p<0.05 
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 PC3 Cells 
 
 Proliferation analysis on PC3 cells were tested over a period of 10 days. the 
mean absorbances (OD) of native, vector control and ADM transfected cells are 
shown in table 6.  
 
  
 Native pcDNA3.1 ADM 
Day 0 0.31±0.06 0.30±0.05 0.30±0.08 
Day 2 0.30±0.09 0.26±0.05 0.27±0.09 
Day 4 0.39±0.18 0.61±0.30 0.50±0.19 
Day 6 0.42±0.28 0.39±0.10 0.46±0.10 
Day 8 0.49±0.38 0.54±0.29 0.50±0.13 
Day 10 0.44±0.20 0.31±0.10 0.42±0.09 
 
 
 
 
 
 
 
 
 
 
 Figure 46 shows the assessment of the mean absorbances. At days 0, 2, 6 
and 8 there were no significant differences between the groups. At day 4, the 
OD of vector control cells was 1.6 times significantly more than native cells. At 
day 10, the OD of native cells were 1.4 times significantly more than vector 
control cells.  
Table 6: Mean absorbances (OD) of proliferation of native, vector 
control and ADM over-expressing PC3 cells. Proliferation was assessed 
using MTT assay. OD values were measured at 570nm. The values are 
mean from three replicate experiments. 
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Figure 46: Proliferation of native, vector control and ADM transfected 
prostate cancer (PC3) cells assessed by MTT assay over 10 days. The bars 
show OD at 570nm. The error bars represent mean ± SEM. ANOVA and Tukey 
post hoc test was done to gain statistical significance. n=5, p<0.05.  
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3.4.1.3. Effect of ADM Over-Expression on Cell Migration 
 
 
 The effect of over-expressing ADM was next tested on cell migration 
assessed by wound healing assay/scratch test. Scratch test was done in PC3 cells 
and MDA-MB-231 cells. Migration was assessed by distance between scratch 
edges or area of scratch as previously described in Methods section 4.3.1.12.  
 
PC3 Cells 
 
  Table 7 shows the distance between the two edges of the scratch test at 
different time points. 
  
 Native pcDNA3.1 ADM 
0hrs 584.66±8.63 589.20±31.35 576.55±19.09 
24hrs 446.58±31.67 545.48±11.03 554.68±16.05 
48hrs 269.64±54.22 483.91±22.7 210.70±5.04 
72hrs 277.22±25.37 402.28±36.97 150.06±57.51 
    
 
 
 
 
 
 
 
Figure 47 shows the migration of PC3 cells transfected with vector control 
and ADM.  
Table 7: Mean distances between the two edges of the scratch in native, 
vector control and ADM transfected PC3 cells. The distances were measured in 
µm using ImageJ. The values are mean of 5 replicate experiments.  
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Figure 47: In vitro wound healing assay / migration assay to determine the 
migration of prostate cancer (PC3) cells transfected with pcDNA3.1 vector 
control and ADM. The biggest effect in ADM transfected cells is observed 
between 24hrs and 48hrs. The Images were taken in LeicaDMI4000B 
microscope. 
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 Figure 48 contains histograms of the quantified scratch test. At 0hrs, there 
was no significant diference between the distances. At 24hrs, native cells 
migrated 1.2 times faster than vector control and ADM transfected cells. At 48 
hrs, cells transfected with ADM migrated 4 times faster than vector control cells. 
Native cells migrated 1.8 times faster than vector control cells. At 72 hrs, ADM 
transfected cells migrated 2.3 times and 3.5 times than native and vector control 
cells respectively. 
 
Figure 48: Migration of transfected PC3 cells in in vitro wound healing assay. 
Graph shows the distance covered by PC3 cells transfected with ADM, control 
vector (pcDNA3.1) and non-transfected cells, in wound healing assay. The bars 
represent mean ± SEM (error bars). ANOVA and Tukey post hoc test was done 
to gain statistical significance. n=5, p<0.001. 
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MDA-MB-231 Cells 
 
 The effect of ADM over-expression was tested on the migration of MDA-MB-231 
cells over a period of 24hrs. Table 8 shows the mean areas of scratch in native, 
vector control and ADM transfected cells.  
 
     
 Native pcDNA3.1 ADM 
0hrs 28.21±10.83 28.89±11.98 27.43±9.68 
12hrs 19.81±4.51 20.00±6.88 13.32±3.57 
24hrs 11.23±1.88 12.20±3.36 3.33±4.04 
 
 
 
 
 
 
 
 
 
 Figure 49 shows the migration of MDA-MB-231 cells transfected with 
vector control and ADM at different time points. 
 
 Figure 50 contains histograms of the quantified scratch test. At 0hrs, there 
was no significant difference between the areas. At 12 hrs, ADM transfected cells 
migrated 1.5 times more than native and vector control cells. At 24hrs, ADM 
transfected cells migrated 3.6 times and 4 times faster than native and vector 
control cells respectively.  
Table 8: Mean areas of the scratch in native, vector control and ADM 
transfected MDA-MB-231 cells. The areas are a mean from three replicate 
experiments. 
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Figure 49: In vitro wound healing assay / migration assay to determine 
the migration of breast cancer (MDA-MB-231) cells transfected with 
pcDNA3.1 vector control and ADM. Cells transfected with ADM migrated 
faster in closing the wound than pcDNA3.1 transfected cells. Images were 
taken in LeicaDMI4000B microscope. 
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Figure 50: Migration of breast cancer cells in wound healing assay. Graph 
shows the area of the wound in cells transfected with ADM, control vector 
(pcDNA3.1) and non-transfected cells. The error bars represent mean ± SEM. 
ANOVA and Tukey post hoc test was done to gain statistical significance. 
 n=3, p<0.001. 
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3.4.1.4. Effect of ADM Over-Expression on Cell Invasion  
 
     The invasive potential of cells when over-expressing cells were determined by 
Cell Invasion Assay as described in Methods section 4.3.1.13. MDA-MB-231 and 
U87 cells were tested for their invasive potential.  
 
     Figure 51 shows the graphs of the number of cells that have invaded through 
the matrigel coated membrane of a Boyden chamber.  
 
     ADM transfected MDA-MB-231 cells invaded more than pcDNA3.1 transfected 
and native cells. The mean number of cells that invaded was 13.67±1.94, 
11.17±1.64 and 60.67±8.12 for native pcDNA3.1 and ADM transfected cells 
respectively. 3.3 times significantly more ADM transfected cells invaded through 
matrigel than native and pcDNA3.1 transfected cells.  
 
     Preliminary analysis of invasion potential of U87 cells was done, n=1. There 
were more ADM transfected cells that invaded through the matrigel coated 
membrane than native and pcDNA3.1 transfected cells.  
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Figure 51: In vitro matrigel invasion assay in ADM and vector control 
(pcDNA3.1) transfected and non-tranfected breast cancer (MDA-MB-231) and 
glioblastoma (U87) cells. The error bars represent mean ± SEM. ANOVA and 
Tukey post hoc test was done to gain statistical significance. MDA-MB-231, 
n=3, p<0.001; U87, n=1. 
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3.4.1.5. Effect of ADM over-expression on Receptor Regulation 
 
 The effect of ADM over-expression on the regulation of RAMPs and CLR 
was done using Flow Cytometry. Histograms are shown in figures 101 to 103 
under appendix section. 
 
 Table 9 shows the percentage of cell surface and total protein expression in 
MDA-MB-231 cells analysed by flow cytometry. The receptor expression analysis 
was carried out after normalising for any isotype background.  Figure 52 contains 
graphs showing the percentage of cells positive for receptors in both total and 
cell surface. These analysis was carried out one time and due to technical 
difficulties discussed later, only n=1 was carried out.  
       
Total Protein Expression in % of cell population 
 RAMP2 RAMP3 CLR 
Native 25.5% 46.8% 25.2% 
pcDNA3.1 20.1% 60.7% 27% 
ADM 45.5% 72.8% 59.4% 
Cell surface Protein Expression in % of cell population 
Native 1.29% 20.6% 4.7% 
pcDNA3.1 4.6% 4% 1.7% 
ADM 17.6% 29% 12.7% 
 
 
 
 
 
Table 9: Percentage of cell surface and total protein expression in native, 
vector control and ADM transfected MDA-MB-231 cells. Protein expression 
analysis was carried out using flow cytometry. The expression analysis was 
normalised for any isotype background.  
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Figure 52: Flow Cytometric analysis of the expression of RAMP2, RAMP3 and 
CLR in breast cancer (MDA-MB-231) cells transfected with ADM, pcDNA3.1 and 
native cells. Bars show the protein expression at both total and cell surface 
normalised to isotype control. The quantified values are a result of 10,000 cells. 
n=1 
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3.4.1.6. Effect of ADM Over-Expression on bone homing in vivo 
 
 
3.4.1.6.1. Generation of ADM over-expressing cells 
 
Please Note: This section contains supplementary figure that was included here 
at the request of the examiners. 
 
 The effect of over-expressing ADM was tested on the bone homing 
potential of breast cancer cells (MDA-MB-231) in vivo. MDA-MB-231 cells 
transfected with GFP is the parental control. The bicistronic IRES-eGFP vector  
containing ADM cDNA was transfected into MDA-MB-231 cells. Flow cytometry 
was used to sort levels of GFP expression, as GFP expression is directly 
proportional to ADM expression in these cells. The cells after flow cytometry 
sorting were cultured to quantify the ADM expression. The images of these cells 
can be seen in figure Supplementary figure 3.4.1.6.1.1. 
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Supplementary Figure 3.4.1.6.1.1 :  Images of breast cancer cells (MDA-
MB-231) sorted by flow cytometry for different fluorescent intensities into very 
low, low, medium and high. Native cells do not have auto fluorescence. Pictures 
are taken of cells that are 90% confluent in T75 flasks. Bar = 250µm. 
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3.4.1.6.2. Quantification of GFP and ADM 
 
 Since GFP expression is directly proportional to ADM expression in the IRES-
eGFP vector, I measured fluorescence to determine ADM expression. From figure 
53, it can be seen that the GFP intensity was increasing from very low to high 
intensity group. Native cells show fluorescence to the level of the very low group; 
this is due to auto fluorescence of cells.  
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 Since Native cells showed auto fluorescence, in order to be 100% certain 
that MDA-MB-231 cells do not have GFP, RT-PCR was done for GFP expression. 
As it can be seen from figure 54, native cells do not express GFP (700bp). HPRT1 
is expressed by all cell lines (210bp). 
 
 
 
 
 
 
Figure 53: GFP fluorescent intensity of breast cancer cells (MDA-MB-231) 
sorted for varying fluorescent intensities. The GFP intensity was measured 
using a plate reader at 480nm excitation and 500nm emission. 
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        The gel electrophoresis image was quantified in ImageJ by measuring the 
pixels in the bands. From figure 55, it can be seen that the native cells expressed 
no GFP, whereas the GFP expression was less in the very low group when 
compared to the other groups.  
 
 
Figure 54: Gel electrophoresis of GFP and HPRT1 RT-PCR in MDA-MB-231 
cells transfected with IRES negative control vector. For both GFP and HPRT1 
bands, from left, the products belong to native, very low, low, medium and 
high groups. 
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     In order to confirm the over-expression of ADM in transfected cells, RT-PCR 
was done for ADM and HPRT1. Figure 56, shows the gel electrophoresis image of 
ADM and HPRT1. The product sizes of both ADM and HPRT1 were 210bp. 
 
 
200bp 
Figure 56: RT-PCR gel electrophoresis for ADM and HPRT1 as endogenous 
control in ADM transfected breast cancer cells (MDA-MB-231) sorted for 
different GFP intensities.  
Figure 55: GFP mRNA expression by MDA-MB-231 cells correlated with the 
performed intensity of fluorescence of the sorted groups. 
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        The intensities of the bands were measured as pixels in Image J and the 
relative intensity was calculated from the expression of HPRT1 in each sample. 
From figure 57, it can be seen that ADM expression was more in transfected cells 
when compared to native cells. There was 1.2 times more ADM in transfected 
cells (from low to high) than non-transfected cells.  
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3.4.1.6.3. IRES-eGFP Negative Control 
 
 
 The IRES negative control vector for ADM was transfected into MDA-MB-231 
cells. Cells were sorted according to fluorescent intensities into very low, low, 
medium and high, as previously described. Sorted cells were cultured in a six 
wells plate and fluorescent intensity was measured using a plate reader at 
485nm excitation and 480nm emission. From figure 58 it can be seen that the 
GFP intensity increased from very low to high intensity groups. Native cells had 
low levels of auto fluorescence.  
 
Figure 57:  Relative intensity of ADM mRNA expression normalised to HPRT1 
mRNA expression.  
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 Since the IRES negative control vector expresses high amounts of GFP, ADM 
protein expression was measured from the cells after reading the fluorescent 
intensities in the six wells plate. Figure 59 shows the gel electrophoresis from 
native and four different GFP intensity groups. HPRT1 was used as a control. The 
product sizes for ADM and HPRT1 is 210bp. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 58: GFP fluorescent intensity in MDA-MB-231 cells transfected with 
IRES negative control vector. The intensity was measured using a plate reader 
at 485nm excitation and 480nm emission. 
Figure 59: Gel electrophoresis of ADM and HPRT1 RT-PCR in MDA-MB-231 
cells transfected with IRES negative control vector. The product sizes for both 
ADM and HPRT1 are 210bp. 
500bp 
200bp 
100bp 
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 The intensity of ADM and HPRT1 gel electrophoresis was measured in pixels 
and quantified in ImageJ. Figure 60 shows the relative intensity of ADM 
expression to HPRT1 as endogenous control. ADM expression remained same 
across all groups, showing that the cells transfected with IRES negative control 
vector expressed same amount of ADM as that of native cells.  
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 MDA-MB-231 cells containing ADM-IRES vector, IRES negative control 
vector (Scrambled) along with cells (parental) containing just GFP and no GFP 
were cultured in T25 flasks. The cells were sorted for GFP using flow cytometry. 
The flow cytometric histograms of these cells can be seen in figure 61. Upon 
quantifying for high intensity GFP for 500,000 cells, both parental and scrambled 
cells showed ~100% of cells in high intensity region. Only 56% of ADM 
transfected cells were present in the high intensity region.  
 
 
Figure 60: ADM mRNA expression quantified as relative intensity to HPRT1 in 
RT-PCR. The intensity of the bands were measured in pixels and quantified. 
The expression of IRES negative control transfected cells are uniform. 
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Figure 61: The histograms show the GFP positive cells in MDA-MB-231 
parental both positive and negative for GFP, scrambled and ADM IRES 
transfected cells. The graph shows the quantified flow cytometric analysis of 
GFP positive for high intensity GFP out of 500,000 cells that were counted. 
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3.4.1.6.4. In Vivo 
 
 1x105 cells/mice were injected into into the left ventricle of the heart of 
Female Balb/ C nude/ nude mice. Body weights were measured twice weekly. 
The body weights of mice from the three groups are shown in figure 62. There 
was no statistically significant difference in body weights between three groups of 
mice. 
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Figure 62: Body weights of mice injected with MDA-MB-231 cells, over 20 days 
from the start of injection, measured weekly. There was no significant 
difference in body weights between groups. ANOVA and Tukey post hoc test 
was performed to gain statistical significance. 
          Parental, n=13; Scrambled, n=13; ADM, n=14;  
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Two weeks after inter-cardiac injections of cells, animals were culled and 
hind legs were stripped of muscle and tumours were viewed under Light Tools. 
Figure 63 shows representative pictures of left and right legs from the three 
groups of mice. Bright green spots in the proximal femur, distal femur, proximal 
tibia and distal tibia of the bone show presence of tumours. It can be seen that 
both the parental and scrambled have tumour in the bone while mice injected 
with ADM transfected cells did not have any tumour in the legs. 
Images of all the mice can be seen in figures 114, 115 and 116 in appendix 
section. 
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 Left Leg 
Figure 63:  Representative pictures of left and right legs of mice injected with 
MDA-MB-231 cells with three different backgrounds. Tumours in bone can be 
seen as bright green spots due to GFP.  
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Right Leg 
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  Table 10 shows the number of tumours counted in hind legs of each of the 
three groups of mice. Tumours were counted as described in section 3.3.2.7. 
Fluorescent tumours were visible in the parental and scrambled legs (3 and 5 
respectively) but none were visible in the legs from mice injected with ADM over-
expressing cells.  
 
 
 
 
 
 
 
 
 
 
3.4.1.6.5. Over-Expression of ADM Receptors 
 
 
 In order to investigate the effect of over-expression of ADM receptors 
(RAMP2 + CLR and RAMP3 + CLR), cell proliferation and migration were 
measured. 
 
 
Cell Proliferation 
 
 The cell Proliferation of PC3 cells transfected with ADM receptors were 
assessed using MTT assay over a period of 10 days and six independent 
experimental replicates were performed for each time point. The mean 
absorbances of native, pBUDCE4.1, RAMP2+CLR, and RAMP3+CLR transfected 
 No. of Mice Tumour Count Average Tumour Count 
Parental 13 39 3 
Scrambled 13 67 5.1 
ADM 14 0 0 
Table 10:  Number of tumours present in each group of mice. Both legs were 
used to count the number of tumours and groups A and B are pooled together 
for analysis.  
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cells are shown in table 11.  Figure 64 shows the consolidated result of the 
proliferation of PC3 cells. 
  
 Native pBUDCE4.1 RAMP2 RAMP3 
Day 0 0.29±0.02 0.32±0.04 0.30±0.02 0.34±0.30 
Day 2 0.29±0.04 0.35±0.06 0.29±0.05 0.29±0.07 
Day 4 0.43±0.14 0.26±0.04 0.36±0.07 0.39±0.11 
Day 6 0.66±0.49 0.48±0.17 0.40±0.16 0.41±0.16 
Day 8 0.77±0.55 0.45±0.20 0.46±0.28 0.52±0.40 
Day 10 0.50±0.22 0.35±0.11 0.36±0.21 0.40±0.29 
  
 
 
 
 
Table 11: Mean absorbances (OD) of proliferation of native, vector control and 
RAMP2/3+CLR transfected PC3 cells. Proliferation was assessed by MTT assay. 
OD values were measured at 570nm. The values are mean from 6 independent 
experiments. 
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Figure 64: Proliferation of PC3 cells transfected with RAMP2+CLR, 
RAMP3+CLR, and vector (pBUD.CE.4.1) as determined by the MTT assay. OD 
values are plotted as mean± SEM and statistical significance was determined 
by a one way ANOVA and Tukey’s multiple comparison post hoc test. n=6; 
p<0.05 
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Cell Migration 
 
 
 Would healing assay / Scratch test was perfored to assess PC3 cells 
migration. Figure 65 shows the migration of native and PC3 cells transfected with 
RAMP2+CLR and RAMP3+CLR, stained at various time points of the assay. The 
distance between the scratch was measured using ImageJ. 
 
 
 
 
 
 
 
 
 
Figure  65: In vitro wound healing assay / migration assay to determine the 
migration of prostate cancer (PC3) cells transfected with pBUDCE4.1 vector 
control, RAMP2+CLR and RAMP3+CLR in wound healing assay. Cells were fixed in 
methanol and stained with crystal violet at appropriate time points. Images were 
taken in 10X magnification in LeicaDMI4000B microscope. 
186 
 
 The mean distances of Native, pBUDCE4.1, RAMP2 and RAMP3 are shown in 
table 12. Figure 66 shows the consolidated results of the migration assay of three 
independent experimental repeats.  
 
 At 0hrs, 24hrs and 48hrs, there was no significant difference between 
RAMP2/3 over-expressed cells and control cells. Although native cells migrated 
faster from 24hrs. 
 
  At 72hrs, RAMP2+CLR transfected cells migrated 109% to 143% faster 
than control cells. RAMP3+CLR transfected cells migrated 120% to 148% faster 
than control cells.  
 
  
  
 Native pBUDCE4.1 RAMP2 RAMP3 
0hrs 589.70±11.0 577.35±20.90 582.45±32.13 589.98±3.53 
24hrs 440.59±20.53 563.02±63.0 549.22±16.60 535.28±5.80 
48hrs 307.20±50.68 512.40±20.19 519.95±36.78 460.04±46.50 
72hrs 277.22±25.37 529.26±17.45 424.78±42.11 396.70±27.76 
Table 12: Mean distances between the two edges of the scratch in native, 
vector control and RAMP2/3+CLR transfected PC3 cells. The distances were 
measured in µm using ImageJ. The values are a mean of 3 independent 
experiments. 
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Figure 66: Quantification of in vitro wound healing assay / migration assay in 
PC-3 cells transfected with RAMP2+CLR, RAMP3+CLR, pBUDCE4.1 (vector 
control) and non-transfected cells. Bars represent the distance cells migrated 
toward the centre of scratch from the scratch edge. Data is shown as mean ± 
SEM and statistical analysis was performed by using ANOVA and Tukey's 
multiple comparison test. n=3; p<0.05. 
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3.5. Technical Discussion 
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This part of the project was aimed at determining the effect of ADM over-
expression on cells and their ability to metastasize to bone. 
 
3.5.1. Effect of ADM on Cell proliferation 
 
The effects for over-expression of ADM were observed in both the cell 
lines for breast cancer (MDA-MB-231) and prostate cancer (PC-3). No significant 
proliferation was observed in MDA-MB-231 cell lines transfected with pcDNA3.1, 
ADM, and native cells. Similar results were recognized by Martinez et al, 2002 
while working on breast cancer cells (T47D). The study identified that effect of 
ADM over-expression on enhanced proliferation can be observed only in the 
presence of serum otherwise ADM over-expression can also work as non-
proliferative factor (Martinez et al. 2002). Since the observations in the present 
study by us were in the presence of serum, no proliferation was noted this could 
be due to the cells achieving their maximum proliferative potential.  
 
No significant proliferation for prostate cancer line (PC3) transfected with 
pcDNA3.1, ADM and native cells was observed. Similarly study by Rocchi et al, 
2001 recognized that cell lines transfected with ADM has no significant 
proliferation as compared to other cell lines. The study also revealed that cell 
lines transfected with ADM and vector control has no significant difference in cell 
proliferation over 10 days (Rocchi et al. 2001).  However, in the present study 
significant difference in proliferation in native cell line was seen as compared to 
pcDNA3.1 on 10th day. The proliferation in native cell line was 1.4 times more 
than vector control transfected cells. This finding is in the accordance to the 
evaluation of Rocchi et al, 2001 which confirms that ADM over-expression can 
also act as non-proliferative factor. Since the PC3 native and ADM over-
expressing cells have achieved maximum levels of ADM, the cells might have 
stopped ADM transcription. The reduced levels of ADM thus hold the proliferation 
process as a negative feedback system.  Another plausible explanation why ADM 
over-expressing cells do not have an effect on cell proliferation is that cells would 
have already attained their maximal proliferative potential using endogenous 
factors. 
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3.5.2. Effect of ADM over-expression on Cell migration  
 
Cancer cells need to detach from the basement membrane and migrate in 
order to cause metastasis. An immune-histochemical study by Harper et al, in 
1996 identified expression of VEGF in prostate cancer cell lines PC3 and DU-145. 
VEGF in the cytoplasm of neuroendocrine cells is capable of producing response 
by activating its receptors VEGFR1 and VEGFR2 (Harper et al. 1996). Activation 
of these tyrosin kinase receptors can activate PIP3 which in turn activates actin 
polymerization. Continuous activation and deactivation of actin leads to cell 
movement and migration (Cantley 2002).  Over-expression of ADM in this 
project was observed to enhance migration in both breast cancer and prostate 
cancer cell lines. This might be due to transactivation of VEGFR and enhanced 
downstream signalling pathway. Correlating this information, it can be suggested 
that over-expression of ADM enhances cell migration in neuroendocrine cells like 
prostate and breast by enhancing the downstream signalling pathway of VEGF 
receptors.  
 
3.5.3. Effect of ADM over-expression on Cell invasion 
 
 Effect of ADM over-expression on invasive property of cancer cells were 
observed on breast cancer cell line (MDA-MB-231) and Glioblastoma cell line 
(U87). Enhanced invasion in MDA-MB-231 cells was observed under over-
expression of ADM. Since experimental repeats could not be carried out for U-87 
cells, it is not possible to conclude if there was an increase in cell invasion. The 
mechanism of enhanced invasion due to over-expression of ADM was explained 
by Martinez et al in 2002. ADM over-expression causes certain morphological 
changes in cells. ADM leads to elevation of gelsolin protein which is responsible 
for cytoskeletal restructuring of cells. Cells develop projections and the plasma 
membrane become more dynamic along with reducing cell adhesion. All these 
factors together enhance cell migration and thus the cells over-expressing ADM 
become more invasive and thus become more involved in metastasis (Martinez 
et al. 2002).  
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3.5.4. Effect of ADM over-expression in Receptor Regulation 
 
A possible up-regulation of ADM receptor components - RAMP2, RAMP3, 
and CLR in presence of ADM over-expression was observed in MDA-MB-231 cells 
when compared to native and vector control cells in preliminary analysis. It 
cannot be concluded that there was a significant change is receptor regulation 
since the results are obtained from a single experiment. Although, upon 
reviewing the results from this single experiment, RAMP3 (29% cell surface and 
73% total) expression was more when compared to RAMP2 (17% cell surface 
and 45% total) in ADM over-expressing MDA-MB-231 cells. Similar results were 
observed by Schwarz et al in 2006 while observing the effect of ADM over-
expression on microvascular endothelial cells. The results showed that within 5-
45 minutes of ADM treatment, cAMP levels increased in the cells followed by 
increased extracellular signal-regulated kinase 1/2 phosphorylation. The entire 
cascade leads to up-regulation of peptide and mRNA expression for VEGF, RAP2 
and CLR, thus increasing receptor up-regulation (Schwarz et al. 2006). The flow 
cytometric histogram analysis of receptors on ADM over-expressing cells are 
shown in figures 101 to 103 in appendix section.  
 
3.5.5. Effect of ADM over-expression on Bone Homing 
 
Effect of ADM on bone homing was assessed in vivo. Only 56% of 500,000 
MDA-MB-231 cells produced ADM as observed from flow cytometric analysis 
(figure 61). 90% of 500,000 GFP positive parental and scrambled (IRES-eGFP 
Negative control) produced ADM. The fluorescence from ADM-GFP positive cells 
had less intensity when compared to parental and scrambled controls. Since 
ADM-GFP positive cells were already less in number, it is plausible to conclude 
that either there were not enough ADM-GFP positive cells for successful bone 
homing or since cancer cells already produce high levels of ADM, after injecting 
these cells into mice, production of ADM would have been rendered to a stop.  
The failure of mice to produce ADM made the experiment a failure as the effect 
of these invasive cancer cell lines on bone homing was not observed. Similar 
results were observed by Calvo et al in 2002, while studying the effects of ADM 
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on PC3 cell lines. The study explained that the hormone refractory prostate 
carcinoma line is growth inhibited mainly by cAMP. It has been suggested that 
over-expression of ADM causes cAMP elevation which in turn inhibits growth of 
PC3 cell lines. The study also revealed that growth inhibition by the ADM over-
expression is due to the G0/G1 cell cycle arrest. The elevated levels of ADM 
increase the number of cells in G0/G1 phase and thus reduce the percentage of 
cells in S/G2/M phase. The entire cascade finally results in reduced mitosis and 
thus reduced bone homing and tumour formation (Calvo et al. 2002). The same 
effect might have reduced bone homing in MDA-MB-231 cell line transfected with 
ADM in the present study.  
 
3.5.6. Effect of ADM receptor over-expression 
 
To understand the effect of ADM receptor over-expression on cell 
proliferation and cell migration, PC3 cell lines were transfected with ADM 
receptors RAMP2 + CLR and RAMP3 + CLR. Interesting cell proliferation patterns 
were observed. It was found that difference in cell proliferation of lines 
transfected with ADM receptor and the control line was not significant on day 0, 
6, 8, and 10; but significant proliferation in receptor transfected cell lines was 
seen on day 2 and 4. This finding suggests that over-expression of ADM receptor 
initially increased ADM action and thus proliferation increased but after that 
elevated levels of ADM was sensed by the cells and cells stopped ADM 
transcription. Increased ADM levels thus acted as negative feedback mechanism 
and over-expression of ADM mediated by over-expression of ADM receptors 
acted as a non-proliferative factor. This finding was in accordance to the 
negative feedback hypothesis for ADM for cell proliferation as suggested by 
Rocchi et al, 2001. It also concludes that ADM can act as both proliferative and 
non-proliferative factor for cancer development. 
 
It was observed that significant increase in cell migration of cell lines 
transfected with ADM receptors RAMP2 + CLR and RAMP3 + CLR started after 48 
hours and cell migration continued to increase significantly upto 48 hours and 72 
hours. This observation suggests that due to the over-expression of ADM 
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receptors, over-expression of ADM occurred. Over-expression of ADM in the cells 
could have caused transactivation of VEGFR and enhanced downstream 
signalling pathway. The downstream signalling pathway would have caused 
activation PIP3 that in turn activates actin polymerization. Continuous activation 
and deactivation of actin thus leads to cell movement and migration (Cantley 
2002). It is also possible that over-expression of ADM receptors increased ADM 
production, resulting in morphological changes such as increased projection on 
cell membrane, increased dynamicity of plasma membrane, and reduced cell 
adhesion contributing to increased cell migration (Martinez et al. 2002). 
 
3.5.7. Optimisation and Validation 
 
ADM cloning 
 
 ADM cDNA in pOTB7 vector was cloned into pcDNA3.1 vector and 
sequenced. The sequencing result was run in BLAST and it showed a 97% match 
to ADM confirming that ADM was cloned into pcDNA3.1 vector (figure 100 in 
Appendix). 
 
 Various attempts were made to generate a negative control for ADM 
cDNA. Firstly the start codon was mutated from ATG to GGG so that ADM would 
not be generated. But sequencing results after site directed mutagenesis showed 
that the mutation did not take place (figure 104 in Appendix). Next a premature 
stop codon was made to incorporate after transcription of the first four amino 
acids. The sequence TCCGTCG was to be made to TAGTGAG, but again the 
mutation did not take place (figure 105 in Appendix). Since site directed 
mutagenesis was unsuccessful, commercially available negative control for the 
IRES-eGFP vector was bought and sequenced. BLAST result of the sequenced 
product showed 99% identity to a part of the Eukaryotic Translation Initiation 
Factor 4 gamma (figure 106 in Appendix).   
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Assessment of Migration 
 
Migration of cells was assessed at set time points as described. There are 
two ways of assessing cell migration, one is by measuring the distance between 
the margins of the wound (scratch) and the other is by measuring the area of 
the wound (scratch). It was not possible to monitor cell migration on a single 
well over time, as it was very difficult to deduce the wound margin in a phase 
contrast microscope. Therefore fixing and staining cells at appropriate time 
points and either measuring distance or area would give a good measure of cell 
migration. The distance measured in the scratch was not very accurate as the 
scratch was not in a straight line and the linings of scratch were haphazard. 
Problems were also observed while measuring surface area as the wounded area 
gets converted to non-wounded area due to scratches and dust on the surface of 
the plate. 
 
Monitoring ADM-IRES-eGFP over-expression in cells 
 
 MDA-MB-231 cells were transfected with GFP (parental), ADM-IRES-eGFP 
and IRES-GFP (scrambled or negative control). After transfection, cells were 
sorted by fluorescent intensities into very low, low, medium and high. Since the 
GFP expression is directly proportional to ADM expression in IRES-eGFP vector, 
the GFP intensity and corresponding ADM and GFP expression was measured. 
The results showed that higher the GFP expression, higher was the ADM 
expression. On the other hand, endogenous control HPRT1 remained the same in 
all groups. In the scrambled control, level of ADM did not vary with different GFP 
intensities. Therefore the cells with highest GFP intensity were chosen for in vivo 
experiment. 
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3.5.8. Conclusion 
 
It can be concluded that ADM acts as both proliferative and non-
proliferative factor for the development of both prostatic and breast cancer. ADM 
over-expression reduces proliferation in the cancerous cells as elevated levels of 
ADM acts as negative feedback (Mazzocchi et al. 1996). ADM over-expression 
could cause transactivation of VEGFR and enhances downstream signalling which 
leads to increased cell migration of cancerous cells. Studies have shown that 
morphological changes in plasma membrane of cells caused by over-expression 
of ADM leads to reduced cell adhesion and thus increased cell migration as well 
as cell invasion. Ability of ADM to increase the number of cells in G0/G1 phase 
and thus reduce the percentage of cells in S/G2/M phase could have led to 
reduction in cell mitosis and thus ADM over-expression reduces bone homing and 
tumour formation in cancer.  The flow cytometry for screening GFP positive cells 
showed less fluorescence in ADM transfected cells when compared to parental 
and scrambled controls; this suggests that inside the animal system the vector 
switched off the production of ADM. This could be due to the presence of high 
levels of ADM within the tumour containing mice.  
 
Over-expression of ADM receptors provides similar results for cell 
proliferation and cell migration as that of ADM over-expression. Study of over-
expression of ADM receptor provides best support to the hypothesis that ADM 
can act as both proliferative and non-proliferative factor.  Observations of cell 
migration pattern for ADM receptor over-expression concludes that the cell 
migration in cancer cells also increase with increase in number of ADM receptors. 
 
Collectively, it is plausible to conclude that ADM acts as an important 
player for cancer progression and metastasis.  
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CHAPTER IV: NEUTRALISATION OF ADM  ACTIVITY 
USING ANTI-RAMP3 ANTIBODY 
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4.1. HYPOTHESIS 
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Hypothesis 
 
 Neutralising RAMP3 significantly reduces cell growth in vitro and tumour 
growth in vivo 
 
The aim is to determine the effects of the in-house generated anti-RAMP3 
antibody (JF2) on cell proliferation in vitro and tumour growth in vivo. 
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4.2. INTRODUCTION 
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4.2.1. Treatment options for cancer 
 
With better understanding of cancer pathophysiology along with 
development in diagnostic and treatment interventions, cancer can be diagnosed 
and treated in its early stages. The growing research in the field of cancer 
treatment has opened multimodality management and treatment plans for 
cancer patients. The research and development in the field of cancer is helping 
to develop and modify the present treatment options, hence to be more 
effective, precise, and lifesaving. The traditional treatment options for cancer 
include surgery, chemotherapy, and radiation therapy. Treatment options like 
immunotherapy and monoclonal antibody therapy are under rapid development 
phase. The cancer physician decides the treatment plan for any patient in 
accordance to the location and grade of the tumour as well as cancer stage and 
general state of patient. Goal of any cancer treatment is to completely remove 
the disease with minimal damage to rest of the body (Franklin 2007). This 
section discusses the presently available treatment options for breast, prostate, 
glioblastoma and pancreatic cancers.  
 
Surgery 
 
Surgery is normally considered as first line of treatment for cancers of 
breast, prostate, glioblastoma and pancreas. Although theoretically a surgery 
can entirely remove the cancer from the patient, it is practically not always 
possible due to the tendency of cancer cells to metastasize and affect the 
adjacent normal tissue or distant organs (Mayoclinic, 2011). Different studies 
over the years have shown that precisely performed surgical procedure can 
increase patient survival rate and reduce the chances of metastasis. The 
extremely malignant and fatal pancreatic cancer requires initial treatment with 
surgical process known as Whipple’s procedure. Another study found that 10-
20% patients treated with surgery followed by adjuvant therapy with Gemcitabin 
have higher chances of survival above five years as compared to non-operated 
patients (Oettle and Neuhaus 2007).  A twenty year follow up study suggested 
that both radical mastectomy and breast conservative surgery of breast cancer 
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increases survival rate in almost 59% patients (Veronesi et al. 2002). Similar 
beneficial effects of oncosurgery are also observed by glioblastoma patients. 
Although glioblastoma is extremely fatal, complete resection along with 
lobectomy extends the survival time by 12.6-12.9 months (Hollerhage et al. 
1991). 
 
Chemotherapy 
 
Since surgery do not provide guarantee for complete cure of cancer, the 
patients are always treated with multimodality approach. Chemotherapy with 
cytotoxic drugs is a treatment approach following surgery. The anti-cancer drugs 
interfere with cell division in various ways, e.g. with the duplication of DNA or 
the separation of newly formed chromosomes. Although chemotherapy presents 
certain adverse effects like compromised immunity, fatigue, alopecia and 
gastrointestinal distress; it is known to enhance overall life quality in many 
cancers (Balducci and Beghe 2001).  A 17 year observatory study of breast 
cancer patients identified that induction chemotherapy followed to breast surgery 
not only increases disease free survival rate but also causes tumour regression 
and thus benefits in controlling breast cancer metastasis (Schwartz et al. 1993). 
Guidelines indicate surgery, hormone treatment and radiation as management 
for prostate cancer. Reviews suggest that advanced adenocarcinoma of the 
prostate after hormonal manipulation becomes relatively chemotherapeutic 
nonresponsive tumour and only 8.7% of such patients respond to any 
chemotherapy (Yagoda and Petrylak 1993). However, another study suggested 
that chemotherapy with mitoxantrone plus prednisone or prednisone alone for 
symptomatic hormone-resistant prostate cancer provides palliation by reducing 
pain and improving life quality. Similar palliative use of chemotherapeutic agents 
is done for the treatment of pancreatic cancer (Tannock 1996). Another study 
suggests that erlotinib (Tarceva) in combination with gemcitabine as a palliative 
regimen for pancreatic cancer can exhibit improved survival rates, improved 
tumour response and improved progression-free survival rates. On the other 
hand FDA (1998) approved gemcitabin only as palliative treatment for pancreatic 
cancer as it is known to improve survival rate by 5 weeks along with providing 
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symptomatic relief (Moore et al. 2007). Study by Stupp et al in 2005 observed 
no significant enhancement in survival rates of Glioblastoma patients treated 
with surgery plus radiation alone (12.1 months) as compared to Glioblastoma 
patients treated with surgery plus radiation plus Temozolomide (14.2 months) 
(Stupp et al. 2005). 
 
Radiotherapy 
 
Radiotherapy is another adjuvant therapy to surgery. If the cancer is 
localized to one area of the body, ionizing radiations can act as a curative 
therapy. The therapy can also be used to prevent tumour recurrence after 
surgery and to remove remnants of original malignant tumours after surgery. 
Radiation therapy is synergistic with chemotherapy, and has been used before, 
during, and after chemotherapy in susceptible cancers. Although radiations affect 
normal tissue, the fractionated treatment procedure allows the normal cells to 
repair themselves. The high effectiveness of radiation in reducing recurrences 
nullifies its minor side effects like gastrointestinal disturbances, mouth sores, 
edema, fibrosis, cognitive decline, and possibility for development of secondary 
cancer (Bomford et al, 2005, pg, 311). Radiotherapy is widely applied for 
treatment of breast cancer and prostate cancer. For women with localized ductal 
breast carcinoma in situ, radiation along with surgery reduces the recurrence 
chances by 10.4% to 7.5% for non-invasive cancers and from 10.5% to 2.9% 
for invasive cancers as compared to surgery alone approach (Fisher et al. 1993). 
Similarly for clinically localized prostate cancer, radiation therapy following 
surgery can increase 5 year survival rate of patients by 81-85% (Shipley et al. 
1999). Radiation therapy in addition to surgery or surgery combined with 
chemotherapy has been reported to extend survival in Glioblastoma Multiforme 
(GBM) patients as compared to surgery alone. The adjuvant therapy increases 
survival from 3-4 months to 7-12 months (Stupp et al. 2005). However, the 
responsiveness of Glioblastoma Multiforme to radiotherapy varies and may even 
induce phase of remission. Regrettably, any type of response is transitory as the 
tumour typically recurs within 1 year, thus leading to further clinical 
deterioration and the emergence of a region of contrast enhancement (Stupp et 
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al. 2006). Due to the systemic nature of pancreatic cancer, use of radiation as 
adjuvant therapy is still debated. Considering the short survival span of such 
patients, radiation therapy is normally not applied to them (National 
Comprehensive Cancer Network, NCCN, 2011). 
 
Recent advancements in cancer management include immunotherapy, 
targeted therapy, hormonal therapy, and angiogenesis inhibitor. Hormonal 
therapy’s main principle involves the management of the endocrine system by 
administering certain hormones (eg.steroid hormones) or drugs which interferes 
with production or activity of these hormones. Since steroid hormones are 
responsible for gene expression in various cancers, manipulating levels or 
activity of these hormones lead to cancer growth cessation. Hormonal therapy is 
now used in treatment of prostate and breast cancer (Souhami et al. 2009). 
Researchers are also trying to develop angiogenesis inhibitor drugs which can 
prevent blood vessel formation and reducing cancer progression. In spite of 
problems like route of administration, maintenance of stability and activity and 
targeting at the tumour vasculature, angiogenesis inhibitor Bevacizumab is now 
officially used in treatment of breast cancer and glioblastoma (Kleinman and Liau 
2001). Reports suggest that Bevacizumab is not very effective in treatment of 
breast cancer (Couzin-Frankel and Ogale 2011) but it provides significant 
improvement in cases of Glioblastoma (Burkhardt et al. 2012). Research and 
development for immunotherapy treatment is in a nascent stage. Cancer 
immunotherapy refers to an assorted set of curative strategies proposed to 
stimulate the patient's own immune system to fight the tumour. Trials are 
researching a vaccine-like immunotherapy strategy for prostate cancer namely 
Sipuleucel-T in which dendritic cells from the patient are stacked with prostatic 
acid phosphatase peptides to stimulate a specific immune response against 
prostate-derived cells. The targeted antibody treatment for cancer is discussed in 
detail in the next section.  
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4.2.1.1. Antibody treatment in cancer 
 
Antibodies are crucial components of human immune system. Antibodies 
or immunoglobulin are huge heterodimeric molecules (150 KDa) and possess two 
different polypeptide chains. These chains are called heavy (~50kDa) and the 
light chain (~25kDa). The antibody recognizes a unique part of the foreign 
target, called an antigen. Figure 67 shows the diagrammatic representation of 
antibody. The main functions of these antibodies are to identify and neutralize 
any foreign material in the body like microbes. Structurally immunoglobulins G 
are Y-shaped proteins which are produced by B-cells. The structure of 
immunoglobulin has two main parts namely Fab (fragment-antigen binding) and 
Fc (fragment constant). The tip of Y shaped antibody (Fab) carries a portion 
called paratope composed of three hypervariable amino acid domain. These 
specific amino acids provide specificity to each antibody. Paratop acts by lock & 
key mechanism and thus binds to specific epitope. By this binding technique, an 
antibody tags the foreign material like microbes or abnormal cell and easily 
displays the target to the further immune cascade. The antibody can also directly 
neutralize the target by binding in this manner with the antigen, e.g. by blocking 
essential part of microbe, which is crucial for invasion and survival (Janeway, 
2001).  
 
      
 
 
Figure 67: Structure of antibody showing the light chain and heavy chain. The 
antigen binding site is shown where the antigen binds to. Figure drawn by self. 
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There are five known antibody subclasses all of which are involved in 
Antibody-dependent cellular cytotoxicity. The IgA subtype is found in areas 
consisting mucous like gut and respiratory track and is mainly responsible for 
preventing colonization of antigen. Immunoglobulin IgD acts as antigen receptor 
on B-cell and initiates basophil and mast cell activity after antigen-antibody 
binding. IgE is mainly involved in allergic reaction and triggers histamine 
secretion from basophils and mast cells after binding with allergens. The 
majority of antibody-mediated immunity to fight the invading pathogens is 
provided by four subclasses of immunoglobulin IgG. The other advantage of IgG 
over others is its capacity to pass placenta and provide fetal immunity. The 
immunoglobulins IgM is expressed on the surface of B-cells and are responsible 
for killing pathogens in very preliminary stage, before the action of IgG, via B-
cell mediated immunity (Roux 1999). 
 
 
4.2.1.2. Monoclonal Antibody Therapy for Cancer 
 
Monoclonal antibody therapy for cancer utilizes monoclonal antibodies to 
specifically bind to a particular target like cancer cells or receptors present on 
cells. Monoclonal antibodies (mAb or moAb) are specific antibodies which are 
developed by sophisticated techniques and are identical to each other as they 
are clones of unique parental immune cell. Monoclonal antibodies differ from 
polyclonal antibodies, which are composed of different types of immune cells. 
This property of monoclonal antibody provides it monovalent affinity where 
unwanted immune response to other non-target cells can be prevented (Rang & 
Dale, 2003).  
 
This specific activity of mAbs is now getting utilized in the treatment of 
cancer. Monoclonal antibodies like Bevacizumab, Cetuximab, Panitumumab, and 
Trastuzumab bind only to the specific antigens present on cancer cells only. Such 
binding of mAb to cell specific-antigen induces immunological cascade and 
ultimately vanishes the target cancer cell (Hudis 2007). Recent research in field 
of monoclonal antibody therapy is trying to develop mAb which can deliver 
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toxins, radioisotope, cytokine or other active conjugate to the target cell by 
binding to its cell-specific antigen (NCCN, 2011). Three main variances of 
modified mAb used in cancer treatment are radioimmunotherapy, antibody-
directed enzyme prodrug therapy, and antibody-conjugated liposomes 
(immunoliposome) (Carter 2001). 
 
US FDA approval of the anti-VEGF antibody for the treatment of metastatic 
colorectal cancer was based on the in vivo testing results of the treatment. It 
was found that the anti-VEGF antibody reduced the tumour growth in the mice 
implanted with grafts of colorectal tumour. The detailed analysis of related 
factors and histological samples of the tumour showed that the anti-VEGF 
antibody reduced the angiogenesis process mediated by VEGF (Ferrara 2004).  
 
Presently, the human IgG1 isotype antibody is most widely used in cancer 
treatment due to its ability to induce human complement and get NK cells 
employed for ADCC (antibody-dependent cellular cytotoxicity). Also IgG1 has 
extended plasma half-life, which allows it to provide extended pharmacological 
action. Human IgG2 isotypes are used in conditions where mAb is expected to 
act only via its antigen binding property, e.g. anti-epidermal growth factor 
receptor antibody (Adams and Weiner 2005). However, another work identified 
that the most effective cytotoxic human cell, the neutrophills, are more 
effectively recruited by IgA as compared to IgG. Furthermore, IgA antibodies 
provide additional advantages like capacity to form dimmers naturally, improve 
tumour cell signaling for immunological response, and characteristic for active 
transportation into mucosal secretion. Thus IgA can prove to be better mAb for 
cancer of luminal surface as compared to IgG (Dechant and Valerius 2001). 
Research by Karagiannis et al in 2007 highlighted that antibody isotype IgE is 
more effective in treating ovarian cancer lines in mice as compared to the 
conventional IgG. The ability of IgE to engage cell surface IgE receptors on 
ovarian tumour cells and initiating phagocytic and cytotoxic mechanism helps it 
to reduce ovarian cancer cells more rapidly as that of IgG (Karagiannis 2007). 
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 It was believed that IgM istoype cannot be utilized as monoclonal 
antibody due to its big size and limited capacity to move around and inside the 
target cell (Roux 1999). However, recent studies have suggested that IgM would 
have a slower penetration rate and would reach their tumour targets. Their 
slower penetration and accumulation would be advantageous if their role is to 
induce apoptosis (Vollmers and Brandlein 2006). For example, an IgM mAb – 
PAT-SM6 that binds to GRP78, a member of heat shock protein 70 family, is a 
potential anti-cancer drug. This drug has been cleared as a potential treatment 
for melanoma in phase I clinical trials (Rosenes et al. 2012).  
 
4.2.1.2.1. Mechanism of tumour cell killing by Monoclonal Antibody 
 
 mAbs for cancer treatment acts by three main mechanisms namely direct 
tumour cell killing, immune mediated cell killing, and vascular and stromal cell 
ablation.  
 
Direct tumour cell killing by mAb can be either achieved by receptor 
agonist activity or receptor antagonist activity. Acting as an agonist, the mAb 
bind to tumour cell surface receptor and initiates apoptosis as a normal 
physiological process to eliminate abnormal cells. mAbs can also act as 
antagonist and may cease crucial physiological functions of receptor and target 
cell like dimerisation, kinase activation, and downstream signalling. Inhibition of 
such important function may thus lead to reduced cell proliferation and even cell 
apoptosis. Many antibodies can also bind to important enzymes and cause 
enzyme neutralization and signal abrogation, ultimately leading to cell death.  
For immune mediated tumour cell killing, mAbs induce immune response after 
binding to the cell-specific antigen. Such tumour killing can be achieved by 
various properties of mAb like induction of phagocytosis; ability for complement 
activation; and activation of antibody dependent cellular cytotoxicity. Certain 
mAbs also act on T-cells to provide immune mediated cell killing. Single chain 
variable fragment (scFv) of antibody targets genetically modified T-cells to the 
tumours. T-cells are also activated by antibody-mediated cross-presentation of 
antigen to dendritic cells. Many mAbs block the T-cell inhibitory receptors like 
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CTLA4 (cytotoxic T-lymphocyte-associated antigen) and allows the progression 
of T-cell mediated immune cascade (Scott et al. 2012). 
 As an additional mode of action, some mAbs induce vascular and stromal 
cell ablation by different methods such as vasculature receptor antagonism, 
ligand trapping, inhibition of stromal cells, direct delivery of toxins to stromal 
cells or vasculature (Scott et al. 2012). These mechanisms of action of mAbs are 
diagramatically represented below:  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 68: Mechanism of action of monoclonal antibody on tumour cells. A) shows 
the direct tumour killing in mitochondria, mediated by antibody binding to cell 
surface receptor B) immune mediated tumour killing in phagocytosis, complement 
activation, antibody-dependent cellular cytotovicity (ADCC), genetically modified T 
cells by single-chain variable fragment (ScFv, antibody mediated T cell activation in 
dendritic cells and inhibition of cytotoxic T lymphocyte-associated antigen 4 
(CTLA4) C) shows the vascular and stromal cell ablation by antagonist binding to 
vasculature receptor and delivering toxins to stromal cells and vaculature. MAC – 
Membrane Attack Complex; MHC – Major Histocompatibility Complex; NK – Natural 
Killer. Picture taken from Scott et al, 2012.  
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4.2.1.3. Anti-Adrenomedullin Therapy 
 
ADM plays an important role in the progression of cancer and metastasis. 
Over-expression of ADM in different tumours aggravates the molecular and 
physiological features of malignant cells. Different studies have identified that 
blocking the action of ADM by ADM antagonist (ADM22-52) destabilizes tumour 
vascularisation and inhibit the growth of xenografted pancreatic cancer cells and 
glial tumour cells (Ishikawa et al. 2003; Ouafik et al. 2002). The role of ADM in 
cancer progression and characteristics of CLR and RAMPs make them important 
targets for research in monoclonal antibody therapy. 
 
Anti-ADM monoclonal antibody have been observed to neutralize ADM 
activity in different tumours like breast cancer (Martinez et al. 2002), 
glioblastoma cell lines (Ouafik et al. 2002), ovarian cancer cell lines (Giacalone 
et al. 2003), and in patients with primary hyperparathyroidism (Letizia et al. 
2004). It has been suggested that mixture of anti-CLR/anti-RAMP2 antibodies as 
well as anti-CLR/anti-RAMP3 antibodies can specifically inhibit ADM binding to its 
receptors on tumour cell and induce apoptosis, reduce cell proliferation and block 
the formation of vascular tubes (Fernandez-Sauze et al. 2004). An international 
application numbered WO/2007/045927 (patentscope, 2007) has displayed that 
anti-RAMP2 or anti-RAMP3 antibodies can inhibit angiogenesis and proliferation 
of cancer cells and thus can be used for treating cancers.   
 
The project investigates the effect of anti-RAMP3 antibody on cell 
proliferation in cancer cell lines of the previously described cancers. In vivo 
investigation of anti-RAMP3 on tumour growth was carried out using pancreatic 
cancer cells. Thus the aim of the present study is to identify the effect of anti-
RAMP3 antibody in neutralizing ADM mediated cell proliferation and tumour 
growth in vitro and in vivo. 
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4.3. METHODS 
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Materials and Recipes for solutions used are given in Chapter 6, Appendix.  
 
4.3.1. Optimal Cell Count 
 
      In order to determine the right cell concentration and incubation period for 
proliferation assay for each cell line, an optimal cell count experiment was done. 
Cells were cultured and counted as previously described. Serial dilutions of cells 
from 1x103 cells/well to 1x105 cells/well were seeded in a 96 well plate, in 
triplicates. MTT assay as previously described was carried out and absorbance 
was measured at 570nm. Cell numbers belonging to the linear portion of the 
optimal cell count curve was used for proliferation assay. 
 
4.3.2. Proliferation Assay 
 
Proliferation of cells was assessed by MTT assay. Anti-RAMP3 antibody named as 
JF2 was developed in the Antibody Resource Unit, University of Sheffield, United 
Kingdom.  
 
Antibody Doses 
 
      An antibody dose response was done for varying concentrations of JF2 
antibody. The dilutions were done in PBS and the concentrations were 1ng, 
10ng, 100ng, 1µg, 10µg and 20µg. Antibody control was accomplished by using 
an IgG isotype control for the highest dose of JF2 concentration. PBS was used 
as a vehicle control and a no treatment control was used to assess the general 
proliferation of cells.  
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4.3.3. Xenograft Modelling  
 
A. Mice 
 
      All animals and experiments were carried out in accordance with the local 
guidelines and with Home Office approval under project license number 40/2972 
held by Prof. Nicola J Brown, University of Sheffield, United Kingdom. 
 
     Six weeks old NOD-SCID male mice were obtained from Harlan, United 
Kingdom. Mice were allowed to acclimatize for a week before start of the 
experiment.  Pancreatic Cancer Cells (Panc-2.3) was used for xenograft 
modelling to test the effect of JF2 on tumour growth.  
 
B. Injection of tumour cells 
 
     Panc-2.3 cells were cultured under standard cell culture conditions. Cells 
were counted and 4x107 cells were resuspended in 4ml matrigel diluted in 4ml 
PBS. Cell suspension in matrigel was maintained in ice until injection to prevent 
solidification.  
 
     General anaesthesia was induced using Isofluorane in a glass chamber. Six 
mice were used as no tumour control and 1x106 cells/mice in 200µl matrigel/PBS 
of Panc2.3 was injected into twenty four mice subcutaneously using 23G needle.  
 
C. Treatment 
 
      Tumours were palpable ten days post-injection. Upon initial observation, 
mice were divided into small, medium and large tumour groups. Each treatment 
group contained four mice from small group, and two from medium and large 
groups. Therefore, the treatment groups contained eight mice each.  
 
     The dose of JF2 and Isotype antibody used in this experiment was 200µg in 
100µl volume. This dose was based on extrapolation of the maximum dose used 
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in proliferation assay. Mice were treated twice weekly; tumour size was 
measured using digital vernier callipers and body weight measured.  No tumour 
control, received 100µl of PBS. 
 
D. End of Treatment 
 
Mice were sacrificed in a humane way after six weeks post injection. 
Treatment had to be terminated at six weeks since control mice developed large 
tumours which could affect the well-being of mice. Inter-cardiac punctures were 
done to withdraw blood. Blood was centrifuged at 10,000xg for 10mins and 
serum was stored at -80˚C.  
 
    Tumours were excised, weighed and cut longitudinally, where one half was 
stored in 75% ethanol for histology and the other half was snap frozen using 
liquid nitrogen for protein extraction. 
 
E. Analysis 
 
i. Tumour volume was calculated using the formula: 
 
 
Tumour Volume, TV (mm3) = (width2 x length) 
             2 
 
ii. Tumour volume at day “n” is expressed as,  
 
Relative Tumour Volume (RTV) =     TVn 
            TV0  
 
Where, TVn = Tumour volume at day n 
           TV0 = Tumour volume at day 0 
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iii. The tumour growth inhibition rate (IR) is calculated as 
 
IR% =  1- TWt 
             TWc 
 
Where, TWt = mean tumour weight of treated (JF2) 
           TWc = mean tumour weight of control (Isotype) 
 
 
4.3.4. Histology 
 
Tumours stored in 75% ethanol were processed for paraffin embedding. 
Tissues were embedded in paraffin and serial sections of 5µm thickness were cut 
in the Histology Unit of University of Sheffield, United Kingdom. 
 
A. Haemotoxylin and Eosin (H&E) Staining 
 
Sectioned tissues were prepared for H&E staining as follows: 
 
i. Dewaxing 
 
Sections were dewaxed in two washes of xylene each lasting for 5mins each. 
Sections were hydrated from 99% IMS through till 70% IMS each step lasting 
5mins.  
 
ii. Staining 
 
     Rehydrated sections were briefly washed in tap water and stained with Gill’s 
haemotoxylin to stain nucleus for 90-120 secs. The slides were washed with tap 
water for 3mins to turn the stain blue in order to give better contrast with 
cytoplasm. Sections were next stained with 1% aqueous eosin with 1% calcium 
carbonate in order to stain the cytoplasm for 5mins.  
 
X 100 
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iii. Dehyrating and Mount 
 
     Sections were dehydrated quickly through 70% IMS to xylene. Sections were 
dehydrated quickly since eosin would wash out easily. Sections were mounted in 
glass coverslips using DPX mountant. Sections were air dried and used for 
analysis.  
 
B. Evaluation for Necrosis 
 
Sections were evaluated for necrosis kindly by Dr. Steve Shynder from 
University of Bradford.  
 
      At 5X objective magnification, ten whole fields per slide was evaluated (or 
less if smaller samples) for tumour necrosis using 96-point grid overlay. The 
number of points overlying necrotic areas was counted and the percentage 
necrosis for each section was evaluated. 
 
 
4.3.5. Statistical Analysis 
 
      For Proliferation assay, tumour volume, tumour weight and necrosis 
evaluation, One Way Analysis of Variance (ANOVA) was done to gain statistical 
analysis. Tukey post hoc test was done to compare between groups. Data are 
expressed as mean±SEM and p value <0.05 was considered to be statistically 
significant. Statistical analyses were carried out in GraphPad Prism 5 software. 
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4.4. RESULTS 
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4.4.1. Optimal Cell count 
 
Please Note: This section contains supplementary figure that were been included 
here at the request of the examiners. 
 
 In order to determine the optimal cell count and the incubation period for 
each cell type to determine cell proliferation using MTT assay, an optimal cell 
count assay was carried out. Supplementary figure 4.4.1.1 shows the optimal cell 
count for Panc2.3, MDA-MB-231 and U87 cells.  
 
  
 
Supplementary Figure 4.4.1.1 : Optimal Cell Count measured by MTT assay 
in Panc2.3 pancreatic cells, MDA-MB-231 breast cancer cells and U87 
glioblastoma cells.  
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The effect of JF2, anti-RAMP3 antibody on cell proliferation was tested in MDA-
MB-231, Panc 2.3, MDA-MB-436 and U87 cells. 
 
4.4.2. Effect of JF2 on MDA-MB-231 cells  
 
 Proliferation of MDA-MB-231 cells assessed by MTT assay is shown in figure 
69. At Day 0, the average absorbance of all groups was 0.24± 0.00. There was 
no significant difference between groups. 
 
 At day 2, there was no significant difference in OD between groups. The 
mean absorbances were 0.55±0.01, 0.56±0.01, 0.46±0.00, 0.54±0.00, 
0.55±0.00, 0.52±0.01, 0.46±0.00 and 0.42±0.02 for blank, PBS, Isotype, 10ng 
JF2, 100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively. 
 
 At day 4, there was no significant difference in OD between groups. The 
mean absorbances were 0.33±0.02, 0.39±0.02, 0.37±0.01, 0.44±0.04, 
0.37±0.00, 0.36±0.02, 0.33±0.00 and 0.38±0.02 for blank, PBS, Isotype, 10ng 
JF2, 100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively.  
 
 At day 6, there was no significant difference in OD between groups. The 
mean absorbances were 0.79±0.02, 0.86±0.03, 0.80±0.02, 0.83±0.02, 
0.80±0.01, 0.77±0.04, 0.75±0.03 and 0.82±0.06 for blank, PBS, isotype, 10ng 
JF2, 100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively.  
 
 At day 8, there was a significant reduction in proliferation between isotype 
and antibody treated cells, except for 20µg JF2 dose. The mean absorbances 
were 1.11±0.04, 1.06±0.01, 1.28±0.04, 1.06±0.01, 1.16±0.02, 1.02±0.03, 
1.06±0.05 and 1.12±0.04 for blank, PBS, isotype, 10ng JF2, 100ng JF2, 1µg JF2, 
10µg JF2 and 20µg JF2 respectively. The percentage reduction in proliferation 
were, 17% for 1ng JF2, 9.4% for 10ng, 20.3% for 100ng JF2 and 17.2% for 1µg 
JF2. 
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Figure 69: Proliferation of breast cancer cells treated with 20µg isotype, PBS 
and different doses for JF2 antibody. Proliferation was assessed by MTT 
assay for 8 days. The OD was measured at 570nm and data is shown as 
mean ± SEM. ANOVA and Tukey post hoc test was done to gain statistical 
significance. n=3; p<0.05  
 
220 
 
 
4.4.3. Effect of JF2 on Panc2.3 cells 
 
 
 Proliferation of pancreatic cells assessed by MTT is shown in figure 
70. 
 
 At day 0, there was no statisticaly significant difference in OD between the 
groups. The mean of absorbances for all groups were 0.19±0.02. 
  
 At day 2, there was no statistically significant difference in OD between the 
groups. The mean absorbances were, 0.41±0.02, 0.36±0.01, 0.35±0.02, 
0.36±0.01, 0.36±0.01, 0.37±0.02, 0.35±0.01 for blank, PBS, isotype, 10ng JF2, 
100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively.  
 
 At day 4, there was significant reduction in 20µg JF2 treated cells when 
compared to isotype control. There was a 21.4% reduction in proliferation with 
mean absorbances of 0.42±0.03 and 0.33±0.01 for isotype and 20µg JF2 treated 
cells. 
 
 At day 6, there was a significant reduction in 20µg JF2 treated cells when 
compared to isotype control. There was a 24% reduction in proliferation with 
mean absorbances of 0.46±0.01 and 0.35±0.01 for isotype and 20µg JF2 treated 
cells. 
 
 At day 8, there was a significant reduction in cells treated with 10ng JF2 to 
20µg JF2 treated cells when compared to isotype control. There was 28.6%, 
23%, 28.6%, 28.6% and 25.7% reduction in proliferation for 10ng JF2, 100ng 
JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells. 
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Figure 70: Proliferation of pancreatic cancer cells treated with 20µg isotype, 
PBS and different doses for JF2 antibody. Proliferation was assessed by MTT 
assay for 8 days. The OD was measured at 570nm and data is shown as 
mean ± SEM. ANOVA and Tukey post hoc test was done to gain statistical 
significance. n=3; p<0.05  
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4.4.4. Effect of JF2 on MDA-MB-436 cells 
 
Proliferation of breast cancer cells assessed by MTT is shown in figure 71. 
 
 At day 0, there was no significant difference in OD between groups. The 
mean OD of all groups were 0.23±0.00. 
 
 At day 2, there was no significant difference in OD between groups. The 
mean absorbances were 0.55±0.01, 0.56±0.01, 0.46±0.00, 0.54±0.00, 
0.55±0.00, 0.52±0.01, 0.46±0.00, 0.42±0.02 for blank, PBS, isotype, 10ng JF2, 
100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively.  
 
 At day 4, there was no significant difference in OD between groups. The 
mean absorbances were 0.33±0.02, 0.39±0.02, 0.37±0.01, 0.44±0.04, 
0.37±0.00, 0.36±0.02, 0.33±0.00, 0.38±0.02 for blank, PBS, isotype, 10ng JF2, 
100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively.  
 
 At day 6, there was no significant difference in OD between groups. The 
mean absorbances  were 0.79±0.02, 0.86±0.03, 0.80±0.02, 0.83±0.01, 
0.80±0.01, 0.77±0.04, 0.75±0.03, 0.82±0.06 for blank, PBS, isotype, 10ng JF2, 
100ng JF2, 1µg JF2, 10µg JF2 and 20µg JF2 treated cells respectively. 
 
 At day 8, there was a significant reduction in proliferation for 10ng JF2, 
100ng JF2, 1µg JF2 and 10µg JF2 when compared to isotype control. Percentage 
reduction compared to isotype were 15.6%, 11.5%, 15.6%, 11.5% for 10ng JF2, 
100ng JF2, 1µg JF2 and 10µg JF2 treated cells respectively.  
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Figure 71: Proliferation of breast cancer cells (MDA-MB-436) treated with 
20µg isotype, PBS and different doses for JF2 antibody. Proliferation was 
assessed by MTT assay for 8 days. The OD was measured at 570nm and data 
is shown as mean ± SEM. ANOVA and Tukey post hoc test was done to gain 
statistical significance. n=3; p<0.05  
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4.4.5. Effect of JF2 on U87 cells 
 
 
 Proliferation of U87 cells  assessed by MTT assay is shown in figure 72. 
 
 At day 0, there was no significant difference between groups. The average 
of their means was 0.14±0.01.  
 
 At day 2, there was no significanct difference in OD between groups. The 
mean absorbances were 0.22±0.02, 0.21±0.02, 0.21±0.01, 0.20±0.02, 
0.20±0.01, 0.19±0.01, 0.20±0.01, 0.19±0.01 for blank, PBS, isotype, 1ng JF2, 
10ng JF2, 100ng JF2, 1µg JF2 and 10µg JF2 treated cells respectively. 
 
 At day 4, there was a significant reduction for 1µg JF2 treated cells when 
compared to isotye control. The percentage reduction in proliferation was 10.3%. 
 
 At day 6, there was a significant reduction for 10ng JF2, 100ng JF2, 1µg 
JF2, 10µg JF2 when compared to isotype control. The percentage reduction in 
proliferation was 14%, 25%, 11%, 32.8% for 10ng JF2, 100ng JF2, 1µg JF2, 
10µg JF2 treated cells respectively.  
 
 At day 8, there was a significant reduction for 10ng JF2, 100ng JF2, 1µg 
JF2, 10µg JF2 treated cells when compared to isotype control. The percentage 
reduction in proliferation was 22.5%, 26.8%, 39.4%, 50.7% for 10ng JF2, 100ng 
JF2, 1µg JF2, 10µg JF2 treated cells respectively.  
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Figure 72: Proliferation of Glioblastoma cells treated with 10µg isotype, PBS 
and different doses for JF2 antibody. Proliferation was assessed by MTT assay 
for 8 days. The OD was measured at 570nm and data is shown as mean ± 
SEM. ANOVA and Tukey post hoc test was done to gain statistical significance. 
n=3; p<0.05  
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4.4.6. Effect of JF2 in vivo 
 
 The effect of JF2 antibody was tested in vivo using Panc2.3 cells. Over the 
six week period of the in vivo experiment, the general health of mice was 
monitored by measuring body weights. Figure 73 shows body weights of NOD 
SCID mice injected with pancreatic cancer. There was no significant difference in 
mice under treatment and no tumour control group. The average body weights 
were 29.13g, 28.66g, 28.76g and 26.39g for no tumour control, JF2, PBS and 
isotype control groups respectively.  
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Figure 73: Body weights of NOD-SCID mice injected with pancreatic cancer 
cells. There was no significant difference in mice under treatment and no 
tumour control group. The mice in isotype group however had lower body 
weights from Day 0 of injection, but their body weights seemed to be as 
normal as that of the other groups. n=6 for no tumour group and n=8 for 
others.  
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 Figure 74 shows the tumour volumes from mice injected with pancreatic 
cancer. Week 0 is the start of treatment post tumour cell injection. The average 
tumour volumes were 603.73mm3, 530.62mm3, 323mm3 for isotype control, PBS 
control and JF2 injected cells. There was significant difference between tumour 
volumes between isotype control and JF2 treated cells. By the end of the 
experiment, the tumour volumes were 1145.44mm3 for isotype control, 
1060.29mm3 for PBS control and 616.3mm3 for JF2 treated cells. The relative 
tumour volumes at the end of the experiment were 5.15, 3.84 and 2.69 for 
isotype, PBS and JF2 treated mice. 
 
 
 
 
 
 
 
 
 
 
 
Figure 74: Tumour Volumes from mice injected with pancreatic cancer cells. 
Tumour volumes were measured twice weekly during treatment using digital 
vernier callipers. There was a statistically significant difference in tumour 
volumes between JF2 treatment and controls. ANOVA and Tukey post hoc test 
was done to gain statistical significance. n=8 ; p<0.001 
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 After six weeks of treatment, the tumours were excised and weighed 
immediately. Figure 75 shows the tumour weights of mice from three groups. 
There was no statistically significant difference between isotype control, PBS 
control and JF2 treated mice. The average tumour weights were 0.578g for JF2, 
1.023g for isotype control and 0.819g for PBS control.  Although the tumour 
weights were not statistically significant, the growth inhibition at the end of the 
experiment was 43% reduction of tumour weight in JF2 treated mice when 
compared to isotype controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 75: Tumour Weights from mice injected with pancreatic cancer cells. 
Tumours were excised after 6 weeks of treatment and weighed immediately. 
There was no significant difference between tumour weights in all three groups. 
ANOVA and Tukey multiple comparison test was done to gain statistical 
significance.  
            n=6 for JF2 and n=8 for PBS/isotype; 
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 The excised tumours were fixed and processed as mentioned under section 
4.3.4. The processed sections were stained with haemotoxylin and eosin and 
analysed and evaluated for necrosis – figure 76. There was no significant 
difference between the groups. The mean necrosis was 36%, 37% and 36% for 
PBS, Isotype and JF2 respectively. 
 
 
         
 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
             PBS                              Isotype                           JF2 
Figure 76: H&E sections from pancreatic xenografts mice after six weeks of 
treatment with PBS/isotype/JF2. Necrosis evaluation was done at 5X 
magnification. 10 whole fields per sample were evaluated for necrosis using a 
96-point grid overlay. No significant difference in amounts of necrosis for the 
3 groups. ANOVA and Tukey multiple comparison test was done to gain 
statistical significance.  n=5 for JF2 and n=8 for PBS/Isotype; p<0.05. 
 Bars = 200µm. 
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4.5. Technical Discussion 
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4.5.1. Blocking RAMP3 
 
RAMPs are crucial for action of various transmembrane receptors. RAMPs 
have key role in executing physiological effect of ADM and other receptors. 
Research has proved that ADM presents significant mitogenic stimulating activity 
in several cancers and also encourages more severe tumour phenotype. ADM is 
also known to get up-regulated in the hypoxic proximity of solid tumours 
(Zudaire et al. 2003).  
  
A hypothesis by Martinez et al in 2002 explained that over-expression of 
ADM under various circumstances result in over-expression of ADM receptors -
CLR+RAMP2 and CLR+RAMP3. Over activity of ADM receptors may in turn 
increase the activity of ADM at the cellular level. Excessive action of ADM on 
cancer cells causes morphological changes like increased projection on cell 
membrane, increased dynamicity of plasma membrane, and reduced cell 
adhesion contributing to increased cell migration and cancer metastasis. 
(Martinez et al. 2002). Considering this background, it can be hypothesized that 
blocking of RAMP3 can reduce the over activity of excessive ADM and thus may 
help in reducing or stopping cancer cell metastasis 
 
Continuous research is going on for identifying the ways to block RAMP3 
inorder to inhibit ADM activity in cancer cells. One study identified that N-
Glycosylation and conserved cysteine residues in RAMP3 can play an important 
role for the functional expression of CLR/RAMP3 ADM receptor. When CLR and 
RAMP3 assemble they form a heterodimeric receptor which acts as high affinity 
ADM receptor. Since RAMP3 carries an extracellular N-terminus which contains 
six highly conserved cysteine residue and four N-glycolysation consensus sites, it 
helps in ADM binding with receptor.  Thus removal of all N-glycans in RAMP3 
leads to a noteworthy inhibition of receptor and thus reduced ADM binding. 
Removal of N-glycan also increases the EC50 value for ADM. On the other hand, 
removal of all cysteine eliminates ADM binding and leads to a complete loss of 
receptor function (Flahaut et al. 2003).  
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The role of RAMP2 and RAMP3 were studied in gene knockout studies by 
Dackor et al in 2007 as mentioned previously. Their results showed that the 
RAMP2 knockout mice were embryonically lethal, while RAMP3 knockout mice 
survived until adulthood with the only repercussion being loss in body weight 
during oldage (R. Dackor et al. 2007). These studies show that RAMP2 is 
important for physiology while RAMP3 knockout could be up-regulated under a 
physiological stress or under a pathological condition. Therefore we hypothesise 
that neutralising ADM activity by blocking RAMP3 would not result in adverse 
effects. 
 
 
4.5.2. Effect of JF2 on MDA-MB-231 cells 
 
MDA-MB-231 cell line represents breast cancer and is widely used to 
identify the effect of various drugs on the improvement of breast cancer. A study 
by Brekhman et al in 2011 explained the action of RAMP3 on MDA-MB-231 cell 
line. Researchers compared the action of RAMP3 with LOXL2. LOXL2 (Lysyl 
oxidase-like protein 2) is responsible for inducing epithelial to mesenchymal 
transition and in turn promote invasiveness. It was found that LOXL-2 also up-
regulated the expression of RAMP3 on MDA-MB-231 cell line. However, if the 
LOXL2 expression was inhibited in any cell line, RAMP3 expression restored the 
cellular actions like vimentin expression, invasiveness, and tumour development. 
The study also found that inhibition of RAMP3 has the similar effects as that of 
LOXL2 inhibition along with p38 phosphorylation. These findings suggested that 
RAMP3 is strongly co-expressed in breast cancer. Besides functioning as 
transducer for mediating autocrine signals by ADM, RAMP3 also mediates pro-
tumorigenic effect of LOXL2 in MDA-MB-231 cell line. Thus inhibition of RAMP3 
can help in reducing tumourogenic activity in breast cancer (Brekhman et al. 
2010).  
 
We observed that there was no significant percentage reduction in cell 
viability until day 6 in both JF2 antibody treated cells or isotype control cells. 
This data suggests that though RAMP3 is widely distributed over MDA-MB-231 
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cell line (Brekhman et al. 2010), anti-RAMP3 antibody is not very effective in 
preventing cell proliferation in it. This conclusion is again strengthened by the 
fact that varied doses of JF2 were also not showing any significant difference in 
cell proliferation until day 6. However, on day 8 a small significant difference in 
cell proliferation was observed between isotype control and 20µg JF2 treated 
cells. This suggests that initiation of complement activation and antibody-
dependent cell cytotoxicity by JF2 antibody takes longer duration in MBA-MD-231 
cell line or treatment of the particular cell line require higher or repeated dosing 
of JF2. The motility of JF2 could be cell type specific; therefore, testing the 
effects of JF2 on cell proliferation for longer periods in these cells should be 
investigated. 
 
 
4.5.3. Effect of JF2 on Panc 2.3 cells 
 
Panc2.3 cells treated with JF2, 18-23% reduction in proliferation was 
observed in 20µg JF2 treated Panc 2.3 cells when compared to isotype control on 
day 4. On day 6, 20-27% reduction in proliferation was observed. On day 8, all 
doses of JF2 produced a reduction in proliferation ranging from 18% to 34%, 
although it was not a dose response. This suggests that JF2 antibody is effective 
in reducing cell survival and cell growth in the pancreatic cancer cell line. Our 
findings concur with previous studies where anti-ADM therapies have 
significantly reduced tumour cell growth both in vitro and  in vivo. Intra-
tumoural injection of ADM antagonist (AMA) peptide for 10 days suppresses in 
vivo growth of human pancreatic cancer cells in SCID mice by suppressing 
angiogenesis and large blood vessel formation (Ishikawa et al. 2003). Another 
study found that single intra-tumoural or intra-muscular injection of naked DNA 
encoding AMA was extremely efficient in suppressing the growth of pancreatic 
cancer cell lines in SCID mice. A complete regression of blood vessel formation 
was observed in the tumours treated with naked DNA encoding AMA. These 
findings suggest that there is strong correlation between ADM activity and 
tumour progression in pancreatic cancer (Miseki et al. 2007).  
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Although JF2 showed a significant effect on the Panc 2.3; a study found 
that pancreatic adenocarcinoma cells (PAC) of BxPC-3 cell line do not express 
RAMP3. The study found that mRNA levels of both ADM and CLR are very high in 
PAC and they expressed RAMP1 and RAMP2 but not RAMP3. The study also 
stated that RAMP3 is only expressed in 1 out of 5 cancer cells (Keleg et al. 
2007). This finding is in contrast with our results, which show prominent anti-
RAMP3 effect in the pancreatic cancer cell line. This contrast can be justified by 
the fact that BxPC-3 is a cancer cell line which was derived from a 61-year-old 
woman’s adenocarcinoma of the body of the pancreas, while the Panc2.3 cell line 
was derived from a 56-year-old male with an adenocarcinoma in the head of the 
pancreas which invaded the duodenal wall (Deer et al. 2010). So, it can be 
considered that anti-RAMP3 antibody can work on pancreatic adenocarcinoma of 
pancreatic head but its effectiveness in treating pancreas body cancer needs to 
be investigated.  
 
 
4.5.4. Effect of JF2 on U87 cells 
 
Effects of JF2 were observed in this project on the U87 cell line, which had 
an epithelial morphology and was cultured from a stage IV cancer patient (ATCC, 
2010). Therefore these U87 cells are an aggressive cell line. Treatment with JF2 
started showing reduction in proliferation from day 4 at 1µg dose (9-14% 
reduction) when compared to isotype control. At day 6, a reduction of 11-39% 
was observed from doses 10ng to 10µg. On day 8, a dose response with a 
reduction of 15-49% for the same doses was observed. This finding suggests 
that as explained by previous studies that anti-RAMP3 antibody reduces cell 
proliferation and enhances apoptosis in glioblastoma cells in vitro and reduces 
tumour growth in in vivo conditions (Robinson et al. 2009) (Kaafarani et al. 
2009). A significant dose response was also observed among the cells treated 
with different doses of JF2. Fernandez et al. (2004) demonstrated that U87 
glioblastoma xenograft tumours treated with anti-ADM antibody were less 
vascularized than control tumours. This outcome suggested that ADM play an 
important role in neovascularisation and vessel stabilization in glioblastoma. The 
study further investigated that the action of ADM mediated via CLR/RAMP2 and 
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CLR/RAMP3 promoted migration and invasion in a dose dependent manner in 
glioblastoma. When VEGF was blocked by specific antibodies, ADM continued to 
promote capillary tube formation in glioblastoma. These findings concluded that 
ADM and its receptors can be investigated as a new potential target for anti-
angiogenic therapy for glioblastoma. A precise and optimized dose for JF2 
antibody must be determined for each cell line in order to use JF2 as a possible 
therapy. 
 
 
4.5.5. Effect of JF2 on MDA-MB-436 cells 
 
The widely used MDA-MB-231 cell lines are very aggressive, metastatic 
cells characterized as rapidly growing metastatic breast cancer. It represents 
ductal carcinoma and slow growing breast cancer. The MDA-MB-436 cells were 
first cultured form pleural fluid obtained from a 43-year-old breast cancer 
patient. MDA-MB-436 cells are pleomorphic and react intensively with anti-
tubulin antibody. When the MDA-MB-436 cells are experimented in vitro they 
show abundant activity in both the Boyden chamber chemoinvasion and 
chemotaxis assay. The other advantages of MDA-MB-436 cell line over other 
breast cancer cell lines are that it is able to grow on agarose which can precisely 
indicate transformation and tumourigenicity. Additionally, this cell line displays a 
relatively high colony forming efficiency and forms mammary fat pad tumours in 
nude mice (Burdall et al. 2003; Holliday and Speirs 2011).  
 
Published data suggest that slow growing but tumorigenic MDA-MB-436 
breast cancer cells were very useful in understanding the role of extracellular 
matrix metalloproteinase inducer (EMMPRIN) in the tumour progression. When 
the MDA-MB-436 cells were transfected with EMMPRIN cDNA and injected 
orthotopically into mammary tissue of female NCr nu/nu mice, increase in 
expression of matrix metalloproteinase (MMPs) was observed which lead to 
increased gelatinase A and gelatinase B expression along with elevated stromal 
or inflammatory cell reaction ultimately leading to tumor progression. Thus the 
experiment on MDA-MB-436 cell lines helped to conclude that EMMPRIN plays an 
important role in cancer progression (Zucker et al. 2001).  
237 
 
A patent application by Ouafik et al in 2011 claimed that a mixture of 
antibodies against CLR, RAMP2 and RAMP3 was able to cause 30% reduction in 
cell proliferation in the treated MDA-MB-436 cell line as compared to the isotype 
antibody treated cell cultures. The study also showed that mice xenografted with 
MDA-MB-436 cell line and treated with mixture of anti-ADM receptor antibodies 
showed suppression in tumour growth as compared to mice treated with pre-
immune serum. These findings suggested that mixture of anti-ADM receptor 
antibodies could be developed as a possible treatment for slow growing ductal 
breast carcinoma. (Ouafik et al. 2002; Ouafik et al. 2009). The MDA-MB-436 
cells treated with JF2 showed significant reduction in proliferation on day 8 when 
compared with isotype control. Doses from 10ng upto 10µg showed a decrease 
in cell proliferation. However non similar to the previous published work, the 
MDA-MB-436 cell line did not exhibit dose dependent cell reduction when treated 
with JF2.   
 
 
4.5.6. Effect of JF2 in vivo 
 
Several murine models have been made available by researchers to study 
and investigate human cancer. These models helps to identify the factors 
involved in malignant transformation, invasive property of cancer cells, 
metastasis of cancer cells, and also to quantify the response of therapy.  
 
Researchers investigating the effect of CTGF-specific monoclonal antibody 
(FG-3019) in mouse model injected with Panc-1 cells, observed that 
administration of FG-3019 decreased tumour growth and metastasis and 
attenuated tumour angiogenesis and cancer cell proliferation (Aikawa et al. 
2006). Recently a dual combination therapy of anti- EMMPRIN (extracellular 
matrix metalloprotease inducer) antibody and anti-DR5 antibody were 
investigated for pancreatic adenocarcinoma in orthotopic mouse models. It was 
observed that tumour growth was significantly restrained by the combined 
antibody therapy in both MIA PaCa-2 and PANC-1 tumour models of pancreatic 
cancer (H. Kim et al. 2011). 
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In this project six weeks old NOD-SCID with xenograft of pancreatic 
cancer cells Panc 2.3 were used to examine the in vivo effect of JF2. It was 
observed that by the sixth week of experiment, the mice treated with 200µg JF2 
showed suppression in tumour growth when compared to mice treated with 
isotype antibody. Suppression in tumour growth was established by both the 
reduction in tumour weight and tumour volume. These findings justify that 
blocking ADM action by anti-RAMP3 antibody increased apoptosis of cancer cells 
and suppressed angiogenesis as well as cell proliferation. While the apoptosis of 
cancer cell was responsible for reduction in tumour weight, suppression of 
angiogenesis and cell proliferation reduced the tumour growth and thus reduced 
the tumour volume. Although there is no significant difference in tumour weights 
and IHC analysis, the tumours excised from JF2 treated mice had considerably 
lower weights. The non-statistical significance could be due to loss of two mice in 
the JF2 group during the course of the experiment due to an overdose of 
anesthesia during treatment. Out of the six mice that were alive, one mouse had 
a very small tumour, which looked like a pustule. This tumour could not be 
processed; therefore the total number of tumours from JF2 treated mice was 
five. Therefore the less numbers could be the reason why there was no 
significance in tumour necrosis profile. 
 
Somehow the random allocation of mice in different groups caused 
allotment of comparatively low weight mice to the isotype group but all the mice 
were healthy. No drastic changes in weights of mice in any groups were 
observed, especially JF2 treated mice, which indicates that although the 
treatment with the anti-RAMP3 antibody JF2 is effective as anti-cancerous it is 
also non-toxic.  
 
Since the changes in tumour volume and tumour size suggest anti-
cancerous effect of JF2 antibody, the histopathological findings can be 
considered false. Although hematoxylin and eosin staining is widely used for 
histopathological examination of tumours, in the present case analysis of 
necrosis lead to contradictory results. ADM is well known for its property to stop 
apoptosis and initiate angiogenesis. Since mast cells play a huge role in 
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apoptosis, toluidine blue dye can be used to stain mast cells present in the 
tumours. Presence of mast cells in tumour treated with JF2 may suggest its 
effectiveness in stopping ADM induced prevention of apoptosis. Since anti-RAMP3 
antibody inhibits ADM mediated angiogenesis and neovascularisation in the 
tumour grafts, staining with anti-CD31 and F VIII RAg IHC can be helpful in 
differentiating effects of control and JF2 on cancerous tumours (D. Wang et al. 
2008).  
 
 
4.5.7. Optimization of cell count in MTT assay 
 
The MTT colorimetric assay is a well-known and tested method of 
identifying viable cells and cytotoxicity studies. The main principal of assay is 
that the mitochondrial enzymes of live cancer cell cleaves the yellow tetrazolium 
salt MTT and converts it to a soluble blue/purple formazan. The OD of formazan 
thus obtained is directly proportional to the number of living cells. Although MTT 
assay is extremely popular for quantifying the number of viable due to rapid, 
convenient and economical outcome, there are various factors, which affects the 
precision of MTT assay. Different factors that can either affect cellular 
metabolism or other factors, which can modify MTT specific activity may lead in 
calculation of false results. Thus it is extremely crucial to optimize assay 
conditions by establishing strict assay parameters. These parameters must 
include determining correct cell densities, culture medium, optimal 
concentrations and exposure times for MTT, fresh culture medium at the time of 
assay to avoid nutrient depletion, and controlling for drug treatment effects that 
may influence cellular metabolism. By controlling these important parameters, 
the MTT colorimetric assay provides accurate and reliable quantification of viable 
cell number (Sylvester 2011). 
 
In figures 45, 46, 64 and 70, the OD values were either the same as it 
was two days ago or it reduced. This could be due to cell death since these are 
rapidly proliferating cells and are getting pushed through the cell cycle. Another 
plausible conclusion is that the 10% serum in the media is enabling the cells to 
reach their maximum proliferative potential that they are unaffected by 
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treatment/experimental conditions. Therefore these cells would not be in the 
linear phase of cell growth and must have attained plateau phase.  
 
 
4.5.8. Conclusion 
 
The in vitro and in vivo findings of this project suggest that anti-RAMP3 is 
effective in reducing tumour growth in both slow and fast growing breast cancer 
cells, glioblastoma cells, prostate cancer cells and adenocarcinoma in the head of 
the pancreas. Furthermore, the absence of drastic weight changes in mice 
models treated with JF2 suggests that it a safe option for treatment. However, 
safety profile of JF2 as a drug must be investigated on a larger profile. 
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CHAPTER V: DISCUSSION 
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5.1. Discussion 
 
Adrenomedullin (ADM) is a pluripotent peptide secreted by various 
malignant cells like breast, lung, pancreas and prostate. ADM is known to display 
its physiological effects by paracrine, autocrine or endocrine mechanism. Along 
with mediating pathological conditions like cardiovascular disorders, renal 
problems, sepsis and inflammation; ADM plays an important role in the 
progression of cancer and metastasis (Zudaire et al. 2003). Results from 
different range of studies which used many different models have strongly 
implied that ADM has an important role in tumour growth and metastasis. 
Clinical data gathered over years of research confirms that ADM is over-
expressed in cancer patients like colon and lung cancer (Ehlenz et al. 1997), 
ovarian cancer (Hata et al. 2000), prostate cancer (Rocchi et al. 2001), 
intraocular and orbital tumour (Udono et al. 2000), leiomyomas (Hague et al. 
2000), and pituitary tumour (Letizia et al. 2004).  Based on these, it was 
hypothesized that inhibiting ADM would be a viable therapy for cancer. Therefore 
the project was divided into three sections, namely 
 
1. Effect of hypoxia, which is a classical feature of tumour cells, on ADM 
and its receptors 
2. Determine the role of ADM in cell proliferation, migration and invasion 
by enabling cells to over-express ADM 
3. Neutralise ADM activity by targeting its receptor component, namely 
RAMP3, using an anti-RAMP3 antibody (JF2) both in vitro and in vivo. 
 
 
5.1.1. Effect of hypoxia on Cancer, ADM and Receptors 
 
As an important physiological effect, HIF (hypoxia inducible factors) 
signalling cascade gets mediated in the state of low oxygen. Since hypoxia often 
controls cell differentiation, role of HIF cascade becomes important for normal 
cell differentiation and survival. The stabilized HIF-1 causes up-regulation of 
several genes coding for glycolysis enzymes and vascular endothelial growth 
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factor (VEGF) and thus promotes cell survival in low-oxygen conditions. While 
the glycolysis enzymes allow ATP synthesis, VEGF promotes angiogenesis. 
However, chronic effect of HIF is self-perpetuating and is responsible for 
distorting cell microenvironment by inducing aberrantly active transcription 
factors. The changes in levels of growth factors, chemokines, cytokines and ROS 
in response to chronic activity of HIF provide the environment for proliferation 
and survival required for development of cancer and metastasis (Benizri et al. 
2008). Hypoxia is also referred as “Janus face” in tumour biology because it is 
associated with controlled proliferation, differentiation, necrosis, apoptosis and 
can initiate or enhance the development of an aggressive phenotype. 
 
5.1.1.1. HIF-1 and ADM levels 
 
Hypoxia induced ADM gene expression is governed by HIF-1 transcription 
factor. The transcription factor binds with HIF-1 responsive element localized on 
ADM promoter region and therefore enhances ADM gene expression. Since ADM 
has cancer proliferative and anti-apototic mechanism of action, over-expression 
of ADM under chronic hypoxia worsens the cancerous status of the cells (Nguyen 
and Claycomb 1999).  
 
This project evaluated the implications of hypoxia in different cancer cell 
lines. When glioblastoma cells were exposed to hypoxia, a significant elevation in 
the levels of HIF-1 was observed after 24 and 48 hours. Similar elevation in the 
levels of HIF-1 within 24 hours following hypoxia in glioblastoma has been 
previously reported (Damert et al. 1997). The study found that increased HIF-1 
levels also caused increased levels of VEGF and caused tumour angiogenesis. 
Therefore it is concluded that VEGF mediated by HIF-1 in glioblastoma cells 
following hypoxia has a major role in progression of cancer. Impact of HIF-1 
elevation following hypoxia in glioblastoma was also observed in another study. 
The study reported that different glioblastoma models with complete knock-down 
of HIF-1 complement showed impairment in cell migration in vivo and their 
invasion in vivo. All the findings together imply that hypoxia has a major role in 
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glioblastoma progression induced by elevated levels of HIF-1 (Mendez et al. 
2010).  
 
The U87 cell line exposed to hypoxia also showed increased levels of ADM 
within 48 hours and thus reflected the relationship between hypoxia, elevated 
HIF-1 levels and increased ADM expression. Various studies have identified ADM 
as a hypoxia-inducible factor. While studying the effect of hypoxia on ADM 
expression in glioblastoma cells, Metellus et al in 2011, found that hypoxic 
condition (CoCl2, DFX) significantly increased ADM mRNA levels in vitro by 
increasing transcriptional rate of ADM gene and enhanced ADM mRNA stability 
mediated by HIF-1. The study also found that the GBM (Glioblastoma) specimen 
exposed to hypoxia presented co-localized ADM mRNA and protein particularly 
abundant around areas of vascular proliferation and in pallissading cells 
surrounding necrotic foci (Metellus et al. 2011). 
 
The other cell lines in the present study like prostate cancer cell line (PC-
3) and breast cancer cell lines (MDA-MB-436 and MDA-MB-231) also showed 
significant increase in ADM levels within 24-48 hours hypoxia. ADM elevation in 
different cell lines under hypoxic conditions is described by a strong evidence 
based research (Garayoa et al. 2000). The study demonstrated that reduced 
oxygen tension (1% O2) or exposure to hypoxia mimetics such as 
desferrioxamine mesylate (DFX) or CoCl2 highly induce the expression of ADM 
mRNA in numerous human tumour cell lines in a time-dependent manner. Such 
ADM expression is observed to be regulated by HIF-1, since HIF-1α and HIF-1β 
knockout mouse cell lines presents ablated or greatly reduced hypoxia mediated 
ADM mRNA induction. Similarly blocking or enhancing the HIF-1 activity in 
human tumour cells shows an analogous modulation of ADM mRNA. ADM mRNA 
stabilization has been shown to be partially responsible for the hypoxic up-
regulated expression of ADM in the study. Furthermore, the study also reflects 
the fact that enhanced ADM gene expression followed by hypoxia is also because 
of the several putative hypoxia response element (HREs) in the human ADM 
gene. Therefore the transient co-expression of HIF-1α results in an augmented 
transactivation of the reporter gene after DFX treatment and increase ADM 
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levels. Since most solid human tumours have focal hypoxic areas and that ADM 
functions as a mitogen, angiogenic factor, and apoptosis-survival factor, all these 
published data along with our findings implicate the HIF-1/ADM link as a possible 
promotion mechanism of carcinogenesis (Garayoa et al. 2000). 
 
Although all the cancer cell lines in the present study showed elevated 
levels of ADM after 48 hours of hypoxia, pancreatic cancer cell line showed 
reduction in ADM levels. This unexpected result may have developed due to cell 
death in the culture. Pancreatic cancer cell lines are known to be very sensitive 
to change in culture media or exposure to any disrupting element (M. Kato et al. 
1999). Therefore a regular cell viability testing for pancreatic cell line must be 
performed at regular intervals. 
 
Since ADM is an angiogenic factor, its up-regulation under hypoxia elicits 
angiogenic response resulting in tumour survival. Therefore it is suggested that 
blocking ADM would also be beneficial in blocking hypoxia induced angiogenesis.  
  
5.1.1.2. Down-regulation of ADM receptors 
 
A significant down-regulation of ADM receptors CLR, RAMP2, and RAMP3 
under 48 hour hypoxia was observed in both breast cancer cell line and 
glioblastoma cell line. Similar results were obtained by Kitamuro et al in 2001 
while studying the effect of hypoxia on human neuroblastoma cells (Kitamuro et 
al. 2001). While another group observed no changes in ADM levels in human 
chondrocyte cells under hypoxia while CLR remained undetectable, RAMP1 and 
RAMP2 were down-regulated and RAMP3 expression was up-regulated. Both the 
researchers concluded that this non-uniform behaviour of ADM receptor 
expression in different types of cells is not yet clear and may be constituted due 
to any possible adaptation mechanism in response to hypoxic stress (Velard, 
2012, Rheumatology conference). Cromier-Regard in 1998 explains the 
underlying mechanism to this issue. It was found that ADM expression during 
hypoxia is controlled by ADM promoter. During hypoxia, ADM promoter 
expression increases by 1.8 fold during initial 6 hours and then gradually decline 
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(Cormier-Regard et al. 1998). Based on these findings, it can be suggested that 
ADM and ADM receptor expression initially increase under hypoxia and then 
decline due to adaptation mechanism.  
 
5.1.1.3. Hypoxia and PAM 
 
ADM is expressed as an immature peptide and in order to render it active, 
the C terminal of ADM has to be amidated by an enzyme called PAM, as 
previously described. PAM expression was measured under hypoxia to test our 
hypothesis that the up-regulated ADM under hypoxia is mature and fully active.    
 
In our study, PAM levels were possibly elevated at 24hrs hypoxia and the 
levels dropped at 48hrs. Previous studies showed that PAM expression was 
down-regulated at the end of 48 hour hypoxia (Cormier-Regard et al. 1998). 
Similar to ADM, pro-ADM expression is also controlled by cellular adaptation 
mechanism, which may be regulated by ADM promoter expression. Assessment 
of PAM under continuous hypoxia (CH) and intermittent hypoxia (IH) in brain 
stem of rats suggest that IH, not CH, caused production of reactive oxygen 
species (ROS) which in turn elevated PAM levels by increasing activity and levels 
of O2-sensitive peptidylglycine α-hydroxylating monooxygenase (PHM) (Sharma 
et al. 2009).  
 
These findings suggest that frequent and intermittent hypoxia conditions 
can increase PAM levels in tumours and thus increase mature ADM levels. Since 
continuous hypoxia was presented to the experimental cell lines, a down-
regulation in levels of PAM at 48hours was observed in this project. Although 
PAM levels were not high, it cannot be concluded that the up-regulated ADM is 
not fully active/mature. Levels of PAM required rendering ADM mature/active 
and/or quantifying the amidated ADM in culture media could convey that the up-
regulated ADM under hypoxia is active and that it would act as a tumour 
promoting factor. 
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5.1.1.4. Hypoxia and AKT signalling 
 
It was observed that there was a strong AKT signalling from 6 hour to 24 
hour of hypoxia and then it declined. The result is in association with the results 
of a study that analysed the effect on PC12 cells (pheochromocytoma). Hypoxia 
dramatically increased phosphorylation of Akt (Ser473) in the study. The AKT 
signalling effect peaked at 6 hours after hypoxia and remained persistent till 24 
hours.  The effect of hypoxia on phosphorylation of Akt was completely blocked 
by pretreatment of the cells with wortmannin (100 nM), indicating that this effect 
is mediated by phosphatidylinositol 3-kinase (P13K) (Beitner-Johnson et al. 
2001). A study by Kim et al in 2003 identified the relationship between ADM and 
AKT. The study found that ADM (10-7 mol/L)) induced by any conditions (like 
hypoxia) increased phosphorylatin of AKT within 10 minutes which reached its 
peak value within 30 minutes. The study also demonstrated that ADM has dose 
dependent action on phosphorylation of AKT and it can be inhibited by ADM 
antagonist ADM22-52 (W. Kim et al. 2003a). Since the consequences of ADM action 
causes enhanced AKT signalling, blocking the action of ADM using anti-RAMP3 
can be helpful in reducing AKT signalling and thus inducing apoptosis in the 
cancerous cells.  
 
 
5.1.1.5. ADM and the vicious cycle  
 
Adrenomedullin is a HIF-1 mediated factor which mainly helps cell survival 
and proliferation by virtue of its angiogenic action. Furthermore, ADM also plays 
a major role in regulating blood flow to the tumour cells by the modulation of 
vascular tone and thus help it to proliferate. Features of ADM like anti-apoptosis 
action, mediation of cell migration, and up-regulation of ADM receptors acts as 
additional supporters for malignant cell proliferation and tumour growth. In 
majority cases, the rate of tumour growth exceeds the rate of new blood vessel 
formation and thus the newly formed patches of tumour faces hypoxia and thus 
the vicious cycle of hypoxia followed by ADM elevation again followed by hypoxia 
continues (Ryan et al. 2000). Research also highlights that the newly formed 
tumour cell, in response to hypoxia, eventually becomes the dominant tumour 
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cell type and also become chemoresistant. In this project, hypoxia up-regulated 
the expression of ADM by several folds in all of the cell lines tested. Therefore it 
can be concluded that ADM is up-regulated under a potentially lethal 
microenvironment and increase other tumour promoting factors resulting in an 
aggressive tumour phenotype. 
 
 
5.1.2. ADM over-expression and cancer 
 
Over-expression of ADM in different tumours aggravates the molecular 
and physiological features of malignant cells (Zudaire et al. 2003).   
 
Morphologic changes like increased projections, more dynamic plasma 
membrane and increased migration in response to ADM over-expression have 
been previously reported (Weisberg et al. 1997).  The projection on the 
cancerous cells are hub for ADM over-expression and also responsible for more 
dynamic plasma membrane and elevated levels of gelsolin due to ADM over-
expression (Martinez et al. 2002). Gelsolin protein vigorously participates in 
cytoskeletal restructuring that underlies morphological changes and lead to 
reduction in cell adhesion by reducing the cell adhesion molecules like Fak (Deng 
et al. 2012).  All of these data, together with the fact that ADM increases tumour 
cell motility, suggest that tumour cells that express high levels of ADM may be 
more likely to be involved in metastasis. 
 
 Figure 77 shows the morphological changes observed in PC3 cells when 
transfected with vector control (pBUD CE 4.1), RAMP2+CLR and RAMP3+CLR. 
This study was done in our group by an M.Sc student Nasim Eskandari, while 
studying the effects of ADM receptor over-expression in PC3 cells. The PC3 cells 
contained a mixture of phenotypes, although majority of them are more spindle 
shaped than an epithelial like morphology. Besides spinde shaped and epithelial 
like, some cells were giant multipolar with flattened appearance. Spindle shaped 
morphology suggests an early stage of invasiveness (Ding et al. 2010).  Cells 
transfected with vector control contained a mixture of spindle shaped and 
epithelial morphology. RAMP3+CLR transfected cells contained longer projections 
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with spindle shaped morphology. RAMP2+CLR transfected cells were large and 
contained irregular surface when compared to native PC3 cells and vector 
control. These results show that the neuroendocrine phenotype in prostate 
cancer correlates with an aggressive phenotype (Abrahamsson 1999). Our 
findings show that RAMP3+CLR transfected cells are more aggressive looking 
than RAMP2+CLR transfected cells. 
     
 
 
 
 
 
 
 
 
 
 
 
Figure 77: Morphological assessment of PC3 cells transfected with 
pBUDCE4.1 vector control, RAMP2+CLR and RAMP3+CLR. Cells were viewed 
under phase contrast microscope. The bar represents 75µm.  
Image Courtesy: Over-expression of ADM and its receptors affect cancer cell 
invasiveness by Nasim Eskandari, 2010. 
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5.1.2.1. Implication of ADM over-expression in cancer 
 
5.1.2.1.1. Cell proliferation 
 
No proliferation was observed in the breast cancer (MDA-MB-231) and 
prostate cancer (PC3) cell lines in the present study. Previous studies on breast 
cancer cells (T47D) identified that effect of ADM over-expression on enhanced 
proliferation can be observed only in the presence of serum otherwise ADM over-
expression can also work as a non-proliferative factor (Martinez et al. 2002).  
Growth promoting effect of ADM is based on Tyrosin kinase/Mitogen activated 
protein kinase (TK/MAPK) mechanism. Insulin like growth factor 1 receptor 
(IGFR) and protein kinase p42/44 MAPK are the main players of tumour 
progression by ADM. Prototypic signalling by MAPK induces cyclin D mediated 
cell cycle transition G0 to G1 and G2 to M and thus promotes cell proliferation 
(Andreis et al. 2000). Even though the present study was done in presence of 
serum, no proliferation was noted which contrasted with the earlier findings by 
other researchers. It is plausible that the cells already contained elvated levels of 
ADM and have reached their full proliferative potential where ADM over-
expression would not enhance the proliferation of cells. ADM induced 
proliferative and non-proliferative effect could be cell type dependent, which 
needs to be elucidated. 
 
 
 5.1.2.1.2. Cell migration 
 
 Cancer cell needs to detach from the basement membrane and migrate in 
order to cause metastasis. An immune-histochemical study  identified the 
activation of tyrosin kinase receptors can activate PIP3 which in turn activates 
actin polymerization (Harper et al. 1996). Continuous activation and deactivation 
of actin leads to cell movement and migration (Cantley 2002).  Changes in local 
microenvironment such as over-expression of ADM can increase migratory 
characteristic of cancer cells which in turn invade the surrounding tissue and the 
vasculature (H. Yamaguchi et al. 2005).  Over-expression of ADM in this project 
was observed to enhance migration in both breast cancer and prostate cancer 
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cell lines. Molecular mechanisms downstream of ADM over-expression resulting 
in increased cell migration needs to be studied. 
 
 
5.1.2.1.3. Cell invasion 
 
Enhanced invasion as an effect of ADM over-expression on invasive 
property of cancer cells were observed on breast cancer cell line (MDA-MB-231) 
and glioblastoma cell line (U87). One study explains that ADM over-expression 
causes certain morphological changes in cells. ADM leads to elevation of gelsolin 
protein which is responsible for cytoskeletal restructuring of cells that enhance 
cell migration and thus the cells over-expressing ADM become more invasive and 
more involved in metastasis (Martinez et al. 2002). Another study supports the 
present outcomes that ADM is strongly induced by hypoxia in pancreatic cancer 
cell lines and treatment with anti-ADM drugs and anti-CLR antibodies reduces 
cell invasiveness. However, the study reports that anti-RAMP3 drug cannot be 
used to treat adenocarcinoma of pancreas as such types of tumour lacks RAMP3 
(Keleg et al. 2007). Therefore it is crucial to identify the presence of RAMP3 
receptors in any solid tumour before treating it with anti-RAMP3 drugs. 
 
 
5.1.2.1.4. Receptor regulation 
 
An up-regulation of ADM receptors RAMP2, RAMP3, and CLR was observed 
in MDA-MB-231 cells over-expressing ADM. An overall increase of ADM receptors 
in ADM over-expressing cells when compared to native and vector control cells 
was observed. Similar findings were observed in a study, which noticed that 
within 5-45 minutes of ADM treatment, cAMP levels increased followed by 
increased extracellular signal-regulated kinase 1/2 phosphorylation. The entire 
cascade leads to up-regulation of peptide and mRNA expression for VEGF, 
RAMP2 and CLR, thus increasing receptor up-regulation (Schwarz et al. 2006). 
The findings suggest that blocking ADM involvement in proliferation, 
angiogenesis and inhibition of apoptosis can be effectively achieved by blocking 
ADM receptors.  
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5.1.2.1.5. ADM and Bone Homing 
  
 Bone homing of breast cancer cells transfected with ADM-GFP could not be 
determined as the cells stopped producing GFP post inter-cardiac injections. 
Therefore upon analysing the hind legs of mice, animals injected with cells 
transfected with ADM-GFP did not produce any tumours on the bone. µCt bone 
analysis can be carried out to determine if there is any tumour growth on bone. 
µCt analysis would reveal small niches where tumour cells would lodge and 
proliferate. Histological analysis of the bone sections would be beneficial as it is 
possible to determine any abnormality in cell morphology.  
  
 
5.1.3. Effect of blocking ADM activity in cancer 
 
The role of ADM in cancer progression and characteristics of CLR and 
RAMP2/3 make them important targets for research in monoclonal antibody 
therapy. Anti-ADM inhibitor GRP77427 (Gastrin releasing peptide) treated mice 
resulted in a significant reduction in tumour growth (Martinez et al. 2005). This 
is one example of how blocking ADM activity can be beneficial in treatment. 
Published data suggests that mixture of anti-CLR/anti-RAMP2 antibodies as well 
as anti-CLR/anti-RAMP3 antibodies can specifically inhibit ADM binding to its 
receptors on tumour cell and thus can induce apoptosis, reduce cell proliferation 
and block the formation of vascular tubes (Ouafik et al. 2002). An international 
application numbered WO/2007/045927 (patentscope, 2007) has displayed that 
pharmaceutical composition consisting of anti-RAMP2 or anti-RAMP3 antibodies 
can inhibit angiogenesis and proliferation of cancer cells and thus can be used for 
treating cancers. Different anti-ADM therapies like ADM antagonist, anti-ADM 
monoclonal antibody, and anti-ADM receptor antibodies are being investigated.  
 
In the current project, in vitro studies using JF2, an anti-RAMP3 antibody 
resulted in reduction in cell proliferation measured by MTT assay. There was 
18% reduction in proliferation for MDA-MB-231 cells, 25% reduction in Panc2.3 
cells, 11% reduction in MDA-MB-436 cells and 42% reduction in U87 cells.  
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 For the highest dose of 10µg JF2, at day 8 of treatment, MDA-MB-231 
cells showed a reduction in proliferation ranging from 4.3% to 9.2%, Pan2.3 cells 
showed 22.5% to 33.5% reduction, MDA-MB-436 cells showed 10% to 14% 
reduction and U87 cells showed 35.9% to 49.4% reduction in proliferation. 
During evisceration, of heart, lungs, liver, spleen and kidneys were analysed for 
any secondary tumours. Although histologial assessments will have to be carried 
out to confirm the absence of secondary tumours.  
 
 
5.1.3.1. ADM receptors and implications of blocking them 
 
G-protein coupled receptors have been found to play important role in 
different biological and pathological processes and thus are most desirable 
targets for drug development. GPCRs like endothelin receptors, chemokine 
receptors, protease-activated receptors and lysophosphatidic acid receptors are 
known to have action in tumourigenesis and metastasis of multiple human 
cancers like non-small cell lung cancer, breast cancer, prostate cancer, 
melanoma, gastric cancer, and diffused large B cell lymphoma. Prominent up-
regulation of GPCRs has been observed in these primary and metastatic cancer 
cells  (S. Li et al. 2005). 
  
 Two different studies identified that blocking the action of ADM by 
antagonist (ADM22-52) destabilizes tumour vascularisation and thus inhibit the 
growth of xenografted pancreatic cancer cells and glial tumour cells (Ishikawa et 
al. 2003; Ouafik et al. 2002). The role of ADM in cancer progression and 
characteristics of CLR and RAMPs make them important targets for research in 
monoclonal antibody therapy. Anti-ADM monoclonal antibody has been observed 
to neutralize ADM activity in different tumours like breast cancer (Martinez et al. 
2002), human glioblastoma (Ouafik et al. 2002) and ovarian cancer cell lines 
(Giacalone et al. 2003). Figure 78 shows the regulation of ADM and targeting 
ADM2 receptor would be a viable option for cancer treatment. 
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5.1.3.2. Targetting RAMP3 
 
There are three important features of RAMP3 that makes it a better target 
for cancer therapy when compared to RAMP2.  
 
1. CLR/RAMP3 can be recycled to the cell surface for resensitization after 
the internalization process while the CLR/RAMP2 complex does not get recycled. 
Figure 78: ADM regulates tumour progression and is important for physiology. Two 
receptors for ADM mediate its functions. It is hypothesized that ADM1 receptor is 
essential for the basal activity of receptor while ADM2 receptor is important in a 
pathological conditions. Anti-RAMP3 antibody (JF2) reduces cell proliferation in vitro 
and in vivo. Anti-RAMP3 antibody could be a potential therapy for cancer. 
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Thus prolonged effect can be observed for RAMP3 antagonist than RAMP2 
antagonist.  
 
2. Although RAMP3 exhibits three different types of polymorphism, it is 
resistant to any alterations in coding sequence. This suggests that RAMP3 is less 
prone to mutation and thus it cannot develop resistance to anti-RAMP3 drug 
soon.  
3.  Lysyl oxidase (LOX) produced during hypoxic stress inside tumour up-
regulates RAMP3 expression and thus RAMP3 can be targeted for the treatment 
of solid tumours (Brekhman et al. 2010).  
 
 
 
 
 
 
 
 
 
 
 
The two facts that 
 
1. RAMP3 gets up-regulated during hypoxia by LOX and 
 
2. Hypoxia can be correlated with poor prognosis in cancer patients;  
 
Figure 79: Hypothetical repercussion of blocking RAMP3. The effect of 
hypoxia on inducing LOX, which in turn activates RAMP3 resulting in 
migration and invasion of tumour cells. Therefore the hypothesis is to block 
RAMP3, which results in less HIF, LOX and eventual suppression of tumour 
progression. Figure drawn by self. 
256 
 
provides a combined conclusion that RAMP3 has a strong potential to be 
developed as an anti-cancer drug target. LOX-2 levels elevated during hypoxia 
gets bound to the RAMP3 and affect signalling, transcription and translation 
(both directly and indirectly), leading to changes in cell adhesion, motility and 
proliferation (Barker et al. 2012). Figure 79, shows the hypothetical model put 
forth by this research. 
 
 
5.3. Limitations of study 
 
 Results obtained this far are not a conclusive evidence for what has been 
discussed. The discussion merely suggests the possible outcomes of the results 
obtained. Limitations of the study have been discussed below: 
1. It was unable to quantify the amount of ADM that was being 
secreted by the cells. This would have enabled a better 
understanding of the actual protein levels as mRNA levels does not 
correlate with protein levels. 
 
2. Accurate quantification of ADM receptors is one of the biggest 
limitation to this study. As discussed under validation studies, 
RAMP2 and RAMP3 could not be determined using western blotting. 
Whether it is the specificity of the antibodies or protein extraction 
methods is unclear. Since the antibodies produce non-specific bands 
in western blotting, FACS data seem to show otherwise. 
 
3. Flow cytometry results although is shown as 10,000 cells per 
experiment, experimental repeats resulted in high control IgG 
binding. This control IgG binding could not be hindered despite 
several attempts such as blocking for non-specific epitopes using 
serum, different concentrations of antibodies and different cell 
numbers. 
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4. The time points taken for hypoxia experiment (24hrs and 48hrs) are 
not ideal to determine intracellular signalling and receptor 
expression. Although this time point would be sufficient to 
determine changes in ADM and other secretory peroteins. Since 
shorter time points are not possible using the current incubator that 
we have. Determining the right concentration of CoCl2 that elicits 
HIF-1α protein could be used to mimic hypoxia. This could then be 
used to determine intracellular changes at very short time points. 
 
5. The unavailability of stable ADM over-expressing vector was a 
major disadvantage. Unfortunately, the ADM-IRES-GFP vector 
inserted in the experimental mice stopped producing ADM. The 
failure of mice to produce ADM made the experiment a failure as 
the effect of these invasive cancer cell lines on bone homing was 
not observed.  
 
6. Result assessment for migration assay was also cumbersome. The 
distance measured in the scratch was not very accurate as the 
scratch was not in a straight line and the linings of scratch were 
haphazard. Problems were also observed while measuring surface 
area as the wounded area gets converted to non wounded area due 
to scratches and dust on the surface of the plate. 
 
7. The binding of JF2 to RAMP3 was not confirmed by western blot or 
by FACS. Despite using high JF2 concentrations, it was not possible 
to get a RAMP3 blot in both cell membrane and whole cell lysate 
samples. Although this was not possible by me, this has been done 
previously by Dr. Gareth Richards in our Lab while optimising and 
validating JF2 antibody (unpublished data). 
 
8. Although cell proliferation is a good measure of determing the 
activity of JF2, apoptosis assay to measure the rate of cell death,  
functional assays such as cAMP, cell migration, cell invasion assays 
in presence of JF2 would have been a stronger advocate of its 
activity.  
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9. Measuring circulating ADM levels during in vivo experiments would 
have been a good marker for the role of ADM in cancer. It would 
have been interesting to know if circulating ADM levels were 
reduced in JF2 treated mice.  
 
10. IHC for angiogenesis, apoptosis, CLR, RAMP2 and RAMP3 for in vivo 
samples would have provided information on receptor expression 
levels in treatment and control groups in in vivo  studies. 
 
11. In some experiments, n = 1 makes statistical analysis impossible 
and therefore no real conclusions could be determined. 
 
5.4. Future Work 
 
 Since the mechanism of action of ADM1 and ADM2 receptors are unclear, 
hene knock down studies of RAMP2 or RAMP3 or both can be established in 
cancer cell lines. Microarray analysis of these gene knockdown models would 
provide information on the differential signalling mechanism between RAMP2 and 
RAMP3. These knockdown models can also be assessed for cell migration and 
invasion.  
 
Although the findings of the study suggested anti-RAMP3 antibody as an 
efficient treatment for pancreatic, glioblastoma and breast cancers, there was no 
dose response. Functional studies using anti-RAMP3 antibody such as migration 
assay, apoptosis assay, invasion assay, cAMP assay would be beneficial.  
Information on the toxicity, stability and potency of the antibody would establish 
it as a potential therapeutic agent. It would be beneficial to compare the effects 
of RAMP3+CLR complex antibody with that of RAMP3 antibody, as this would be 
specifically neutralise the ADM2 receptor.  
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5.5. Conclusion 
 
 In conclusion, the present study has shown that ADM is up-regulated in a 
malignant setting, concurring with previously published data. Hypoxia was used 
as a measure of an aggressive tumour characteristic. ADM expression in 
response to hypoxia was increased by several folds in glioblastoma, pancreatic, 
breast and prostate cancer cells. Effect of ADM up-regulation resulted in no 
difference in cell proliferation since ADM is known to be pro-proliferative. Despite 
no significant difference in cell proliferation, there was an increase in cell 
migration, invasion and receptor up-regulation, specifically RAMP3 receptor 
under ADM over-expression. This led to hypothesize that RAMP3 component is 
crucial for ADM activity in cancer. Our in-house generated anti-RAMP3 antibody – 
JF2 was used to neutralise/inhibit ADM mediated cell proliferation in various 
cancer cells and tumour growth in xenograft model. Our preliminary results show 
that JF2 is efficient in blocking ADM mediated proliferation at ng and µg levels in 
glioblastoma, pancreatic, breast and prostate cancer cell lines. In vivo studies 
using pancreatic cancer cells resulted in significant reduction in tumour size and 
volume. Tumour regression in xenograft models suggested the the tumour was 
responding to anti-RAMP3 treatment. No physiological abnormalities were 
observed in all vital organs in mice receiving JF2 treatment. This suggests that 
targeting RAMP3 using JF2 antibody does not result adverse side effects. Further 
research into the toxicity, reactivity, pharmacokinetics and pharmacodynamics of 
JF2 is required in order to establish it as a potential anti-cancer therapeutic 
agent. 
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CHAPTER VI: APPENDIX 
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6.1. Recipes and Materials 
 
6.1.1. Hypoxic Regulation of Adrenomedullin and its Receptors 
 
6.1.1.1. Western Blotting 
 
A. Resolving gel 
 
 
 
7% 
(HIF-1α, 
PAM)  
12% 
(RAMP2, RAMP3, 
CLR, Actin, Akt) 
15% 
(ADM) 
ddH2O 5ml 3.3ml 2.3ml 
30% Acrylamide 2.33ml 4ml 5ml 
1.5M Tris pH8.8 2.5ml 
10% SDS 100µl 
10% APS 100ul 
TEMED 10ul 
Total 10ml 
 
B. Stacking gel 
 4% 
ddH2O 3ml 
30% Acrylamide 670µl 
0.5M Tris pH6.8 1.25ml 
10% SDS 50µl 
10% APS 50µl 
TEMED 5µl 
Total 5ml 
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C. NP-40 Cell lysis Buffer 
 
1% NP40 2ml 
50mM Tris pH8 1.21g 
150mM NaCl 1.5g 
2mM EDTA 148.88mg 
  
Make upto 200ml in ddH2O. 
+ Protease inhibitors added during cell lysis. 
 
D. 10x Protein Loading Buffer 
 
DTT 500mg 
20% SDS 3.33ml 
1M Tris HCl pH 6.8 800µl 
Glycerol 6.65ml 
2% Bromophenol blue 665µl 
 
Aliquot and freeze at -20˚C. 
 
E. 5x Running Buffer 
 
Glycine 72g 1M 
Tris Base 15.5g 130mM 
20% SDS 25ml  
ddH2O 975ml  
 
F. Transfer Buffer 
 
Tris Base 3g 25mM 
Glycine 14.4g 200mM 
Methanol 200ml 20% (v/v) 
ddH2O 800ml  
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G. 10X TBS 
NaCl 80g 
KCl 2g 
Tris Base 30g 
ddH2O 800ml 
 
Adjust pH to 7.4 and make upto 1L.  
 
H. Blocking Buffer 
Non-fat powdered milk 5g 5% (w/v) 
TBS 100ml  
 
I. Washing Buffer 
Tween 20 500µl 
TBS 1L 
 
2. Flow Cytometry 
 
A. 4% PFA 
 
Add 8g paraformaldehyde to 100ml water and heat to 60˚C in a fume hood. Add 
few drops of 1M NaoH to help dissolve. When the solid had completely dissolved, 
allow the solution to cool to room temperature and add 100ml 2X PBS. Aliquot 
and freeze at -20˚C.  
 
B. Permeabilisation solution 
 
Tween      250µl     0.5% (v/v) 
PBS          50ml  
 
C. Wash Buffer 
BSA        2.5g         0.5%(w/v) 
PBS       500ml 
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Materials 
 
Cell Culture 
 
Media GIBCO 
PBS 
Trypsin EDTA Sigma Aldrich 
Pencillin/Streptomycin 
Fetal Calf Serum Invitrogen 
Haemocytometer Hawksleys 
 
 
Hypoxia 
Cobalt Chloride Sigma Aldrich 
 
 
RNA Isolation 
 
Tri Reagent  
Sigma Chloroform 
DEPC treated water 
Isopropyl Alcohol Fisher Scientific 
DNase treatment 
TURBO DNA-free kit Applied Biosystems 
cDNA Synthesis 
High Capacity RNA-cDNA Kit Applied Biosystems 
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Real Time PCR 
 
Taqman Gene Expression Master Mix Applied Biosystems 
DEPC treated water Sigma 
 
 
Hoechst Staining 
 
Hoechst stain Sigma 
Ethanol Fisher Scientific 
Acetic Acid VWR – Prolabo 
Mowiol Polysciences 
Phenylenediamine Sigma 
 
Western Blotting 
 
NP-40 Fluka 
Protease Inhibitors CalBioChem 
Protein Quantification 
BCA Assay Kit Sigma 
BSA 
Poly Acrylamide Gel Electrophoresis 
Glass sides BioRad 
30% Acrylamide National Diagnostics 
SDS Sigma 
APS agtcBioproducts 
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TEMED Sigma 
Tween Fisher Scientific 
Biotinylated protein ladder Fisher Scientific 
Kaleidoscope ladder 
PVDF- Amersham Hybond-P GE Healthcare 
Milk Powder Marvel 
Protein Detection 
ECL – Super Signal West Dura 
Extended Duration Substrate 
Thermo Scientific 
Amersham Hyperfilms GE Healthcare 
 
Flow Cytometry 
 
PFA Fisher Scientific 
Normal Rabbit Serum Vector Laboratories 
IgG Control 
 
Antibodies for Western Blotting and Flow Cytometry 
 
Primary Antibodies 
RAMP2 SantaCruz/ Catalogue no: sc-8852 
RAMP3 SantaCruz/ Catalogue no: sc-8854 
CLR SantaCruz/ Catalogue no: sc-18007 
ADM SantaCruz/ Catalogue no: sc-33187 
HIF-1α SantaCruz/ Catalogue no: sc-8711 
Akt Cell Signalling/ Catalogue no: 4691 
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Phospho-Akt Cell Signalling/ Catalogue no: 4060 
PAM Abcam/ Catalogue no: ab77592 
β-actin Abcam/ Catalogue no: ab16039 
Western Blotting Secondary Antibodies 
Anti-goat HRP  Sigma/Catalogue no: A5420-1ML 
Anti-rabbit HRP Sigma/ Catalogue no: A9169-2ML 
Anti-biotin HRP Cell Signalling 
Flow Cytometry Secondary Antibodies 
Anti-goat FITC Dako/ Catalogue no: F0250 
 
 
6.1.2. Effect of Over-Expression of ADM and its Receptors 
 
6.1.2.1. Transfection 
 
Electroporation Buffer 
 
Water          5ml 
KCl              50.3mg        135mM 
MgCl2          952.1µg        2mM 
HEPES         23.83mg       20mM 
Ficoll 400     25µl             0.5% 
 
Adjust pH to 7.6. Filter Sterlise and add ATP and Glutathione fresh during 
transfection.  
 
Xylene DNA Loading Buffer 
 
Xylene Cyanol     25mg 
Sucrose              4g 
Water                 10ml 
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6.1.2.2. Kapa PCR 
 
In a 25µl reaction volume, combine the following: 
 
Reaction Component Final Concentration 
2X Kapa Ready mix 1X 
Primer mix 0.5µM each 
Template DNA 10-100ng 
 
 
6.1.2.3. KOD PCR 
 
In a 50µl reaction volume, combine the following: 
 
Reaction Component Final Concentration 
10X Buffer 1X 
25mM MgSO4 1.5mM 
dNTPs (2mM each) 0.2mM each 
Primer mix 0.3µM each 
Template DNA 100ng 
KOD DNA Polymerase (1U/µl) 0.02U/µl 
 
 
   Materials 
 
Bacterial Culture 
 
LB Broth  
 
Sigma 
LB Agar 
Ampicillin 
Chloramphenicol 
Zeocin Invivogen 
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Top 10 E.Coli Chemically 
Competent Cells 
Invitrogen 
 
Vectors 
 
pcDNA3.1 Invitrogen 
 pBUDCE4.1 
EX-Receiver-M61 (IRES-eGFP) Genecopoeia 
 
 
Plasmid DNA Extraction 
 
Plasmid DNA Extraction kit Promega 
 
 
PCR 
Kapa 2G Readymix PCR Kit KapaBiosystems 
KOD PCR Kit Novagen Toyobo 
Primers MWR 
 
 
 
Gel Electrophoresis 
 
Agarose  
Sigma Tris Borate EDTA 
Xylene Cyanol 
Sucrose Fisher Scientific 
DNA ladder Promega 
 
 
Gel Extraction of DNA 
 
Zymoclean Gel DNA Recovery Kit Zymoresearch 
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DNA Manipulation 
 
   Precipitation 
Ethanol Fisher Scientific 
Sodium Acetate  
Restriction Digestion 
Xho I New England 
Biolabs (NEB) Hind III 
Dephosphorylation 
Antartic Phosphatase NEB 
Ligation 
T4 DNA Ligase NEB 
Demethylation 
Dpn I NEB 
RNase Treatment 
Ribonuclease H, E.Coli Ambion 
 
 
Transfection 
 
Linearisation 
Fsp I NEB 
Mfe I 
Electroporation 
4mM gap Cuvette Cell Projects 
ATP  
Glutathione Sigma 
Antibiotics 
G418 (Geneticin) Sigma 
 
 
Proliferation assay 
 
MTT Cell Proliferation Assay Kit ATCC 
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RT-PCR 
 
RNase Zap Ambion 
 
In vivo 
 
Mice Harlan, UK 
Ketamine Fort Dodge Animal Health 
Xylazine Bayer Plc 
25Gx5/8” Needle BD Microlance 
 
 
6.1.3. Neutralisation of ADM activity using anti-RAMP3 
antibody 
 
Materials 
 
Proliferation Assay 
 
 
MTT Assay Kit ATCC 
IgG1 Isotype  Antibody Resource Unit, 
University of Sheffield. JF2 
 
 
Xenograft Modelling 
 
 
Matrigel BD Biosciences 
Isoflurane IsoFlo 
23G Needle BD Microlance 
Ethanol Fisher Scientific 
 
 
Histology 
 
Haemotoxylin Fluka 
Eosin 
Xylene Fisher Scientific 
DPX Mountant BDH Laboratory Supplies 
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6.2. Results 
 
6.2.1. Hypoxic Regulation of Adrenomedullin and its Receptors 
 
6.2.1.1. Hypoxia using Cobalt Chloride (CoCl2)  
  
        Glioblastoma (U87) cells were treated with 300µM CoCl2 to induce hypoxia 
since it is known to mimic hypoxic environments. Cells respond to hypoxia by up-
regulating the expression of HIF-1α. HIF-1α is the marker for hypoxia and is 
stabilised under hypoxic conditions.  
 
Figure 80, shows the preliminary analysis of HIF-1α mRNA expression 
quantified by qPCR. The bars show the HIF-1α mRNA in relation to the mRNA 
expression of HPRT1. It is seen that HIF-1α mRNA is not up-regulated at any of 
the time points when compared to the respective normoxic controls.  
 
 
 
 
Figure 80: Preliminary analysis of HIF-1α mRNA expression in Glioblastoma 
cells when exposed to hypoxia and normoxia. β-Actin was used as an 
endogenous control to normalise the results. The bars are shown as a relative 
expression to HIF-1α expression at 0hrs. n=1.  
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6.2.1.2. Hoechst Staining 
 
      In order to test if the CoCl2dose was toxic to the cells, Hoechst staining was 
done to morphologically assess the dead cells. Figure 81, shows the cell death 
index of cells belonging to both CoCl2 treated and untreated groups. It can be 
seen that cells were undergoing apoptosis as a result of either overdose of or 
prolonged exposure to CoCl2. Since cells in normoxa seemed less dead, it is 
plausible to conclude that the cells were dying as a result of CoCl2. 
 
 
 
 
 
 
 
 
 
 
 
6.2.1.3. CoCl2 Dose Response 
 
       In order to determine the optimal concentration of CoCl2; a dose response 
over a 6hr period was done. 
 
Figure 81: Cell death index of Glioblastoma cells when exposed to 300µM of 
CoCl2. Cells were stained with Hoechst and pictures were taken at 10X 
magnification in Leica 4000B microscope and counted using ImageJ. Cells 
exposed to CoCl2 seemed to be more apoptotic than cells in normoxia. n=1. 
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     Figure 82A, shows the mRNA expression of HIF-1αin the Glioblastoma cells 
when treated with 50µM CoCl2. The bars are drawn relative to the expression of 
HIF-1αat 0hrs.It can be seen that there is no time dependent increase in the 
mRNA expression, although there was a several fold increase at 30mins. Similar 
result was observed when the CoCl2 dose was increased to 100µM (figure 82B).  
 
     A 150µM dose showed a time dependent decrease, but the levels were never 
above the base line (0hrs) as shown in figure 82C. 
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A 
Figure 82: Graph shows the mRNA expression of HIF1-α under different time 
points in Glioblastoma cells when treated with 50µM (A), 100µM (B) and 150µM 
(C) Cobalt Chloride. The bars are shown relative to the expression at 0hrs at the 
respective doses. n=1. 
 
B 
C 
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6.2.1.4. Hypoxia using 0.1% O2 
 
 Since HIF-1α mRNA expression was not up-regulated when treated with 
various doses of CoCl2, hypoxia was induced using an incubator containing 0.1% 
O2.  
 
 Figure 83A shows the mRNA expression of HIF-1α in Glioblastoma cells and 
figure 83B shows the expression in breast cancer cells (MDA-MB-436). Both 
these cell lines did not show an increase in the HIF-1α expression when 
compared to normoxic controls.  
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 Since 24hrs could be a long time point, a 2hr exposure to hypoxia was 
done. Figure 84 shows the HIF-1α expression at 2hrs hypoxia in the Glioblastoma 
and breast cancer cells.  
 
      The breast cancer cells did not show an increase in the HIF-1α expression, 
while the Glioblastoma cells showed an increase when compared to its normoxic 
Figure 83: mRNA expression of HIF-1α under hypoxia and normoxia in 
glioblastoma (A) breast cancer (B) cells measured by qPCR. The bars show 
relative expression to the expression at 0hrs. n=4 each, p<0.005 
 
A 
B 
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counterparts although it was not a significant increase from the expression at 
0hrs.  
 
 
 
 
 
 
 
 
6.2.1.5. Induction of Hypoxia using hypoxic media 
 
       Another strategy was undertaken to induce hypoxia – the media was 
incubated in the hypoxic incubator for 24hrs and Glioblastoma cells were treated 
with this media and cultured in a regular incubator.  
 
     Figure 85 shows the image of cells treated with regular and hypoxic media for 
an hour. It can be seen that cells treated with hypoxic media look stressed while 
cells cultured in regular media look normal with their usual morphology. 
 
Figure 84: mRNA expression of HIF-1α in two different cell lines under 2hrs 
hypoxia measured by qPCR. The bars show relative expression to the 
expression at 0hrs for each cell line. n=1 
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      Figure 86 shows the mRNA expression of HIF-1α in Glioblastoma cells when 
treated with hypoxic media. The bars are drawn in relative to the expression at 
0hrs. It can be seen that the HIF-1α mRNA was not up-regulated under hypoxia 
when compared to normoxia.  
 
 
 
 
   Normoxia                                    Hypoxia             
Figure 86: mRNA expression over different time points in glioblastoma cells 
when treated with hypoxic media measured by qPCR. The bars are represented 
in relative to the expression at 0hrs, which is 100%. n=1.  
Figure 85: Pictures of the stress experienced by U87 cells when treated with 
regular and hypoxic media for 1hr. Cells treated with regular media looks 
healthy. Bar = 50µm. 
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6.2.1.6. Validation of qPCR primers 
 
 qPCR primers obtained from applied biosystems were validated using 
plasmid DNA containing RAMP2, RAMP3, CLR and ADM. Concentrations of 
plasmid DNA ranging from 1pg to 1µg in log10 increments was done – figure 87. 
The goodness of fit was considered good if R2 was 0.95≤ R2<1. The R2 for RAMP2 
is 0.99, RAMP3 is 0.95, CLR is 0.97 and ADM is 0.98. Actin primers were 
validated using Human Dermal Micro Endothelial Cells (HuDMEC). RAMP2 
primers was also tested in this cell line. The R2 values for Actin and RAMP2 in 
HuDMEC samples were 0.98 and 0.97 respectively. 
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Figure 87: Linear Regression analysis of qPCR amplification of plasmid DNA for 
RAMP2, RAMP3, CLR and ADM in pcDNA3.1 vector. Actin and RAMP2 was 
amplified in HuDMEC cell line. The R2 values for each regression analysis are 
shown as a goodness of fit.  
281 
 
 ADM qPCR primers were tested on various cancer cell lines to determine the 
level of expression.  
 
Preliminary analysis of the mRNA expression of ADM is shown in figure 88. 
The bars are drawn as a relative expression to the HPRT1 housekeeping gene. 
That is, the mRNA expression of HPRT1 is considered to be 100% and the 
expression of ADM is relative to HPRT1. ADM and the calibrator HPRT1 were 
normalised to β-actin.  
 
 
 
      
 
 
 
 The mRNA expression of RAMP2 and RAMP3 could not be determined under 
both normoxic and hypoxic conditions.  
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Figure 88: mRNA analysis of ADM expression in nine different cancer cells 
measured by qPCR. The expression is shown in relative percentage to HPRT1, 
the expression of which is considered 100% (not shown). qPCR data was 
analysed using the ∆∆Ct method. n=1. 
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6.2.1.7. ADM Protein Expression 
 
 Figure 89 shows the western blotting for ADM expression in glioblastoma 
cells when exposed to hypoxia and normoxia. The protein sample was 50µg of 
whole cell lysate of cells. The bands seen belong to 40kDa and 50kDa. A faint 
band at 20kDa can be seen for 24hrs hypoxia sample. 
 
 
 
 
 
 
 
 
 Figure 90 shows the western blotting for ADM expression in Glioblastoma 
cultures media when exposed to hypoxia and normoxia. Multiple bands belonging 
to 120kDa, 50kDa, 30kDa and 7kDa were observed. The 7kDa bands could 
belong to ADM. 
 
Figure 89: Western blot for ADM expression in whole cell lysate of 
Glioblastoma cells when exposed to hypoxia and normoxia.  
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6.2.1.8. Quantification of RAMP2 and RAMP3 
  
 Figure 91 shows the flow cytometric analysis of receptor expression in 
native (non-transfected cells) cos-7 cells used as negative control. M1 is the 
histogram statistics after normalising for control IgG. 
 
 
Figure 90: Western blot for ADM expression in culture media of glioblastoma 
cells when exposed to hypoxia and normoxia.  
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  Figure 92 shows the flow cytometric analysis of receptor expression in U87-
glioblastoma cells. M1 is the histogram statistics after normalising for isotype 
control.  
 
   
Figure 91: Histograms show the fluorescent intensities for ADM receptors, 
isotype control, secondary control and non-stained Cos-7 cells.  
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 Figure 93 shows the histograms of U87 cells at 0hrs normoxia/hypoxia. 
Figure 93A shows the total protein expression in permeabilised U87 cells whereas 
figure 93B shows the cell surface protein expression in non-permeabilised U87 
cells. M1 shows the histogram statistics of the region after being gated for 
isotype control. 
 
 
 
 
Figure 92: Histograms show the fluorescent intensities for ADM receptors, 
isotype control, secondary control and non-stained glioblastoma (U87) cells.  
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A 
 
 
B 
 
 
 
Figure 93: Flow cytometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, secondary control and non-
stained Glioblastoma (U87) cells at 0hrs. Histograms under A show the total 
protein expression and histograms under B show the cell surface protein 
expression. 
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      Figure 94 shows the histograms of U87 cells at 24hrs normoxia. Figure 94A 
shows the total protein expression whereas figure 94B shows the cell surface 
protein expression of U87 cells. M1 is the region gated for histogram statistics for 
normalising isotype background. 
A 
 
B 
 
 
Figure 94: Flow Cytrometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, secondary control and non-
stained glioblastoma (U87) cells at 24hrs normoxia. Histograms under A show 
the total protein expression and histograms under B show the cell surface 
protein expression. 
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 Figure 95 shows the histograms of U87 cells at 24hrs hypoxia. Figure 95A 
shows the total protein expression whereas figure 95B shows the cell surface 
protein expression of U87 cells. M1 is the region gated for histogram statistics for 
normalising isotype background. 
A 
 
B 
 
 
Figure 95: Flow Cytometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, secondary control and non-
stained Glioblastoma (U87) cells at 24hrs hypoxia. Histograms under A show 
the total protein expression and histograms under B show the cell surface 
protein expression. 
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  Figure 96 shows the histograms of U87 cells at 48hrs normoxia. Figure 
96A shows the total protein expression whereas figure 96B shows the cell surface 
protein expression of U87 cells. M1 is the region gated for histogram statistics for 
normalising isotype background. 
 
A 
 
B 
 
 
Figure 96 : Flow Cytometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, secondary control and non-
stained Glioblastoma (U87) cells at 48hrs normoxia. Histograms under A 
show the total protein expression and histograms under B show the cell 
surface protein expression. 
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  Figure 97 shows the histograms of U87 cells at 48hrs hypoxia. Figure 97A 
shows the total protein expression whereas figure 97B shows the cell surface 
protein expression of U87 cells. M1 is the region gated for histogram statistics for 
normalising isotype background. 
 
A 
 
B 
 
Figure 97 : Flow Cytometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, secondary control and non-
stained Glioblastoma cells at 48hrs hypoxia. Histograms under A show the total 
protein expression and histograms under B show the cell surface protein 
expression. 
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 Figure 98, shows the histograms of the total protein expression of receptors and 
controls under normoxia and hypoxia. Each histogram contains “blank” or non-
stained cells shaded in grey and the controls and receptor histograms are 
overlaid onto it. The secondary control is shown in green, isotype control in pink, 
RAMP2 in blue, RAMP3 in orange and CLR in yellow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 98: Flow Cytometry histogram for secondary control (green), isotype 
control (pink), RAMP2 (blue), RAMP3 (orange) and CLR (yellow) in breast 
cancer (MDA-MB-231) cells when exposed to hypoxia. The histograms 
represent the total protein expression in 10,000 cells.  
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        Figure 99 shows the histograms of the cell surface protein expression of 
receptors and controls under normoxia and hypoxia. The colours are similar to 
that of figure 98, except the shaded brown region in this case belongs to the 
unstained cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 99 : Flow Cytometry histograms for secondary control (green), isotype 
control (pink), RAMP2 (blue), RAMP3 (orange) and CLR (yellow) in breast cancer 
(MDA-MB-231) cells when exposed to hypoxia. The histograms represent the cell 
surface protein expression in 10,000 cells. 
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6.2.2. Effect of Over-Expression of ADM and its receptors 
 
6.2.2.1. ADM cloning 
 
 
 
 
 Figure 100 shows BLAST result on comparing the sequencing result after 
cloning ADM into pcDNA3.1 vector. BLAST resulted in 97% match between 
human ADM mRNA and the sequenced product. 
 
Figures 101 to 103 contain histograms for native (non-transfected), 
pcDNA3.1 and ADM transfected cells probed for Isotype control, RAMP2, RAMP3 
and CLR. Histograms under A belong to permeabilised cells which show the total 
protein expression and histograms under B belong to non-permeabilised cells 
which show the cell surface protein expression.  
Figure 100 : BLAST result showing 97% match between ADM mRNA and the 
sequenced product after cloning. This confirms that ADM is cloned into 
pcDNA3.1 vector.  
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6.2.2.2. ADM receptor expression in cells over-expressing ADM 
 
A 
 
 
B 
 
Figure 101 : Flow Cytometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, non-stained cells and secondary 
control in breast cancer (MDA-MB-231) cells. Histograms under A show the total 
protein expression and histograms under B show the cell surface protein 
expression for native MDA-MB-231 cells. 
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A 
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Figure 102 : Flow Cytometry histograms under A and B show the 
fluorescent intensities for ADM receptors, isotype control, non-stained cells 
and secondary control in breast cancer (MDA-MB-231) cells. Histograms 
under A show the total protein expression and histograms under B show the 
cell surface protein expression for control vector (pcDNA3.1) transfected 
MDA-MB-231 cells. 
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A 
 
 
B 
 
 
 
 
Figure 103 : Flow Cytometry histograms under A and B show the fluorescent 
intensities for ADM receptors, isotype control, non-stained cells and secondary 
control in breast cancer (MDA-MB-231) cells. Histograms under A show the 
total protein expression and histograms under B show the cell surface protein 
expression for ADM transfected MDA-MB-231 cells. 
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6.2.2.3. Site Directed Mutagenesis 
 
 Figure 104 contains the sequencing result after site directed mutagenesis of 
the start codon. As it can be seen clearly, ATG was not mutated into GGG, 
instead the sequencing result showed NTG, the N clearly belongs to A as it can be 
clearly seen that the peaks in finch TV was clearly green indicating it belongs to 
A.  
 
 
 
 
NNNNNGNNNNGNNNTCNNTCGAAGGATTCGGTACCNTGAAGCTGGTTTCCGTCGCCCTGATGT
ACCTGGGTTCGCTCGCCTTCCTAGGCGCTGACACCGCTCGGTTGGATGTCGCGTCGGAGTTTCG
AAAGAAGTGGAATAAGTGGGCTCTGAGTCGTGGGAAGAGGGAACTGCGGATGTCCAGCAGCTAC
CCCACCGGGCTCGCTGACGTGAAGGCCGGGCCTGCCCAGACCCTTATTCGGCCCCAGGACATGA
AGGGTGCCTCTCGAAGCCCCGAAGACAGCAGTCCGGATGCCGCCCGCATCCGAGTCAAGCGCTA
CCGCCAGAGCATGAACAACTTCCAGGGCCTCCGGAGCTTTGGCTGCCGCTTCGGGACGTGCACG
GTGCAGAAGCTGGCACACCAGATCTACCAGTTCACAGATAAGGACAAGGACAACGTCGCCCCCA
GGAGCAAGATCAGCCCCCAGGGCTACGGCCGCCGGCGCCGGCGCTCCCTGCCCGAGGCCGGCC
CGGGTCGGACTCTGGTGTCTTCTAAGCCACAAGCACACGGGGCTCCAGCCCCCCCGAGTGGAAG
TGCTCCCCACTTTCTTTAGCTCGAGTGCGGCCGCAACCCAGCTTTCTTGTACAAAGTGGTTCGATC
TAGAATGGCTAGCGAGCAGAAACTCATCTCTGAAGAGGATCTGTAGTGATCAGCCTCGACTGTGC
CTTCACGTAGTGAGATGGGGGTCCTGGGCCCCAGGGTGTGCAGCCACTGACTTNNGGACTGCTG
GTGGGGTAGGGATGAGGGANGGAGGGGCATTGTGATGTACAGGGCTGCTCTGTGAGATCNANG
GGTCTCTTANNGGTGGGANCTGGGGCANGGNCTACNANAGCAGCCNGANGGGCTGAAAGNGG
NANNTCNNGGGGTTTCTGGNACCTACCTACCTGCTTNCCNCNGGGGGGGNGGGGGNNNTNGNC
CCNNANTNNTNTGGGGNNNNAGNNGGGNNCNTCNGCTAGCTTTTTTCCC 
 
 Figure 104 : Sequencing result after site directed mutagenesis PCR. The start 
codon was made to mutate from ATG to GGG. The sequencing result shows 
that ATG was not mutated, the N clearly belonged to A as it can be seen from 
the image from finch TV. 
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The sequencing result from figure 105 shows that the mutation did not occur 
during site directed mutagenesis PCR.  
 
 
 
GNNNNNNNNNNTTGNNANTNNNTCGAAGGAATTCGGTACCATGAAGCTGGTTTCCGTCGCCCT
GATGTACCTGGGTTCGCTCGCCTTCCTAGGCGCTGACACCGCTCGGTTGGATGTCGCGTCGGAG
TTTCGAAAGAAGTGGAATAAGTGGGCTCTGAGTCGTGGGAAGAGGGAACTGCGGATGTCCAGCA
GCTACCCCACCGGGCTCGCTGACGTGAAGGCCGGGCCTGCCCAGACCCTTATTCGGCCCCAGGA
CATGAAGGGTGCCTCTCGAAGCCCCGAAGACAGCAGTCCGGATGCCGCCCGCATCCGAGTCAAG
CGCTACCGCCAGAGCATGAACAACTTCCAGGGCCTCCGGAGCTTTGGCTGCCGCTTCGGGACGT
GCACGGTGCAGAAGCTGGCACACCAGATCTACCAGTTCACAGATAAGGACAAGGACAACGTCGC
CCCCAGGAGCAAGATCAGCCCCCAGGGCTACGGCCGCCGGCGCCGGCGCTCCCTGCCCGAGGC
CGGCCCGGGTCGGACTCTGGTGTCTTCTAAGCCACAAGCACACGGGGCTCCAGCCCCCCCGAGT
GGAAGTGCTCCCCACTTTCTTTAGCTCGAGTGCGGCCGCAACCCAGCTTTCTTGTACAAAGTGGT
TCGATCTAGAATGGCTAGCGAGCAGAAACTCATCTCTGAAGANGNNCTGTAGTGATCAGCCTCGA
CTGTGCCTTCACGTANTGAGATGGGGGTCCTGGGCCCCAGGGNGTGCAGCCNCTGACNTGGGG
ACTGCTGGNGGGGT 
 
 
 
 
 
 
 
 
 
Figure 105: Sequencing result after site directed mutagenesis PCR. Stop 
codons were made to incorporate after transcription of four amino acids. The 
TCCGTCG sequence (highlighted in yellow) was supposed to have been mutated 
into TAGTGAG, but as it can be seen it was not mutated. 
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6.2.2.5. Sequencing Result fot IRES-eGFP Negative control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 106: The commercially available negative control for the IRES-eGFP 
vector was sequenced and the picture shows the BLAST result of the sequenced 
product. BLAST resulted in 99% identity to part of the Eukaryotic Translation 
initiation factor 4 gamma.  
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6.2.2.6. Bone Metastases in Immunodeficient mice 
 
 
 
Fi
g
u
re
  
1
0
7
: 
Pi
ct
ur
es
 o
f 
le
ft
 a
nd
 r
ig
ht
 l
eg
s 
of
 m
ic
e 
in
je
ct
ed
 w
it
h 
pa
re
nt
al
 M
D
A
-M
B
-2
31
 c
el
ls
. 
Pi
ct
ur
es
 
la
be
lle
d 
w
it
h 
L 
be
lo
ng
s 
to
 t
he
 le
ft
 le
gs
 a
nd
 p
ic
tu
re
s 
la
be
lle
d 
w
it
h 
R
 b
el
on
gs
 t
o 
ri
gh
t 
le
gs
 o
f 
m
ic
e.
 I
n 
ea
ch
 
pi
ct
ur
e,
 t
he
 l
ef
t 
si
de
 i
m
ag
e 
be
lo
ng
s 
to
 t
he
 i
ns
id
e 
of
 t
he
 l
eg
s 
w
hi
le
 t
he
 r
ig
ht
 s
id
e 
im
ag
es
 b
el
on
g 
to
 
ou
ts
id
e 
of
 t
he
 le
g.
 
301 
 
 
Fi
g
u
re
  
1
0
8
: 
Pi
ct
ur
es
 o
f 
le
ft
 a
nd
 r
ig
ht
 l
eg
s 
of
 m
ic
e 
in
je
ct
ed
 w
it
h 
IR
ES
-e
G
FP
 n
eg
at
iv
e 
co
nt
ro
l 
M
D
A
-M
B
-2
31
 c
el
ls
. 
Pi
ct
ur
es
 l
ab
el
le
d 
w
it
h 
L 
be
lo
ng
s 
to
 t
he
 l
ef
t 
le
gs
 a
nd
 p
ic
tu
re
s 
la
be
lle
d 
w
it
h 
R
 b
el
on
gs
 t
o 
ri
gh
t 
le
gs
 o
f 
m
ic
e.
 I
n 
ea
ch
 
pi
ct
ur
e,
 t
he
 le
ft
 s
id
e 
im
ag
e 
be
lo
ng
s 
to
 t
he
 in
si
de
 o
f 
th
e 
le
gs
 w
hi
le
 t
he
 r
ig
ht
 s
id
e 
im
ag
es
 b
el
on
g 
to
 o
ut
si
de
 o
f 
th
e 
le
g.
 
302 
 
 
 Fi
g
u
re
  
1
0
9
: 
Pi
ct
ur
es
 o
f 
le
ft
 a
nd
 r
ig
ht
 l
eg
s 
of
 m
ic
e 
in
je
ct
ed
 w
it
h 
A
D
M
 t
ra
ns
fe
ct
ed
  
M
D
A
-M
B
-2
31
 c
el
ls
. 
Pi
ct
ur
es
 
la
be
lle
d 
w
it
h 
L 
be
lo
ng
s 
to
 t
he
 l
ef
t 
le
gs
 a
nd
 p
ic
tu
re
s 
la
be
lle
d 
w
it
h 
R
 b
el
on
gs
 t
o 
ri
gh
t 
le
gs
 o
f 
m
ic
e.
 I
n 
ea
ch
 
pi
ct
ur
e,
 t
he
 le
ft
 s
id
e 
im
ag
e 
be
lo
ng
s 
to
 t
he
 in
si
de
 o
f 
th
e 
le
gs
 w
hi
le
 t
he
 r
ig
ht
 s
id
e 
im
ag
es
 b
el
on
g 
to
 o
ut
si
de
 o
f 
th
e 
le
g.
 
303 
 
 
 
 
 
CHAPTER VII: Bibliography 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bibliography 
 
Abasolo, I., et al. (2004), 'Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP-
independent autocrine mechanism', Biochem Biophys Res Commun, 322 (3), 878-86. 
304 
 
Abe, M., et al. (2003), 'Adrenomedullin augments collateral development in response to acute ischemia', 
Biochem Biophys Res Commun, 306 (1), 10-5. 
Abrahamsson, P. A. (1999), 'Neuroendocrine differentiation in prostatic carcinoma', Prostate, 39 (2), 135-48. 
Adams, G. P. and Weiner, L. M. (2005), 'Monoclonal antibody therapy of cancer', Nat Biotechnol, 23 (9), 1147-
57. 
Aikawa, T., et al. (2006), 'Connective tissue growth factor-specific antibody attenuates tumor growth, 
metastasis, and angiogenesis in an orthotopic mouse model of pancreatic cancer', Mol Cancer Ther, 5 
(5), 1108-16. 
Aiyar, N., et al. (1996), 'A cDNA encoding the calcitonin gene-related peptide type 1 receptor', J Biol Chem, 
271 (19), 11325-9. 
Alessi, D. R., et al. (1996), 'Mechanism of activation of protein kinase B by insulin and IGF-1', EMBO J, 15 (23), 
6541-51. 
Amati, B., et al. (1993), 'Oncogenic activity of the c-Myc protein requires dimerization with Max', Cell, 72 (2), 
233-45. 
Andreis, P. G., et al. (2000), 'Adrenomedullin enhances cell proliferation and deoxyribonucleic acid synthesis in 
rat adrenal zona glomerulosa: receptor subtype involved and signaling mechanism', Endocrinology, 141 
(6), 2098-104. 
Ardyanto, T. D., et al. (2006), 'CoCl2-induced HIF-1alpha expression correlates with proliferation and apoptosis 
in MKN-1 cells: a possible role for the PI3K/Akt pathway', Int J Oncol, 29 (3), 549-55. 
Arrigo, A. P. (1999), 'Gene expression and the thiol redox state', Free Radic Biol Med, 27 (9-10), 936-44. 
Balducci, L. and Beghe, C. (2001), 'Cancer and age in the USA', Crit Rev Oncol Hematol, 37 (2), 137-45. 
Barker, H. E., Cox, T. R., and Erler, J. T. (2012), 'The rationale for targeting the LOX family in cancer', Nat Rev 
Cancer, 12 (8), 540-52. 
Bates, R. C., Edwards, N. S., and Yates, J. D. (2000), 'Spheroids and cell survival', Crit Rev Oncol Hematol, 36 
(2-3), 61-74. 
Beitner-Johnson, D., et al. (2001), 'Hypoxia activates Akt and induces phosphorylation of GSK-3 in PC12 cells', 
Cell Signal, 13 (1), 23-7. 
Beltowski, J. and Jamroz, A. (2004), 'Adrenomedullin--what do we know 10 years since its discovery?', Pol J 
Pharmacol, 56 (1), 5-27. 
Ben-Yosef, Y., et al. (2002), 'Regulation of endothelial matrix metalloproteinase-2 by hypoxia/reoxygenation', 
Circ Res, 90 (7), 784-91. 
Benizri, E., Ginouves, A., and Berra, E. (2008), 'The magic of the hypoxia-signaling cascade', Cell Mol Life Sci, 
65 (7-8), 1133-49. 
Berenguer, C., et al. (2008), 'Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, 
stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells', Oncogene, 27 (4), 506-18. 
Berx, G. and van Roy, F. (2009), 'Involvement of members of the cadherin superfamily in cancer', Cold Spring 
Harb Perspect Biol, 1 (6), a003129. 
Betchen, S. A., et al. (2006), 'PTEN inhibits adrenomedullin expression and function in brain tumor cells', J 
Neurooncol, 79 (2), 117-23. 
Bhowmick, N. A., Neilson, E. G., and Moses, H. L. (2004), 'Stromal fibroblasts in cancer initiation and 
progression', Nature, 432 (7015), 332-7. 
Bindra, R. S. and Glazer, P. M. (2005), 'Genetic instability and the tumor microenvironment: towards the 
concept of microenvironment-induced mutagenesis', Mutat Res, 569 (1-2), 75-85. 
305 
 
Blattner, W. A. (1999), 'Human retroviruses: their role in cancer', Proc Assoc Am Physicians, 111 (6), 563-72. 
Blume-Jensen, P. and Hunter, T. (2001), 'Oncogenic kinase signalling', Nature, 411 (6835), 355-65. 
Bomberger, J. M., et al. (2005a), 'Receptor activity-modifying protein (RAMP) isoform-specific regulation of 
adrenomedullin receptor trafficking by NHERF-1', J Biol Chem, 280 (25), 23926-35. 
Bomberger, J. M., et al. (2005b), 'Novel function for receptor activity-modifying proteins (RAMPs) in post-
endocytic receptor trafficking', J Biol Chem, 280 (10), 9297-307. 
Bos, R., et al. (2005), 'Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of 
bFGF, PDGF-BB, and EGFR in invasive breast cancer', Histopathology, 46 (1), 31-6. 
Boudouresque, F., et al. (2005), '[Role of adrenomedullin in glioblastomas growth]', Bull Cancer, 92 (4), 317-
26. 
Bourdon, J. C. (2007), 'p53 and its isoforms in cancer', Br J Cancer, 97 (3), 277-82. 
Bouschet, T., Martin, S., and Henley, J. M. (2005), 'Receptor-activity-modifying proteins are required for 
forward trafficking of the calcium-sensing receptor to the plasma membrane', J Cell Sci, 118 (Pt 20), 
4709-20. 
Bradley, C. J., Given, C. W., and Roberts, C. (2002), 'Race, socioeconomic status, and breast cancer treatment 
and survival', J Natl Cancer Inst, 94 (7), 490-6. 
Brahimi-Horn, M. C. and Pouyssegur, J. (2007), 'Harnessing the hypoxia-inducible factor in cancer and ischemic 
disease', Biochem Pharmacol, 73 (3), 450-7. 
Brekhman, V., et al. (2010), 'Receptor activity modifying protein-3 mediates the protumorigenic activity of lysyl 
oxidase-like protein-2', FASEB J, 25 (1), 55-65. 
Brown, J. M. and Giaccia, A. J. (1998), 'The unique physiology of solid tumors: opportunities (and problems) for 
cancer therapy', Cancer Res, 58 (7), 1408-16. 
Bruick, R. K. and McKnight, S. L. (2001), 'A conserved family of prolyl-4-hydroxylases that modify HIF', 
Science, 294 (5545), 1337-40. 
Bucher, M., et al. (1996), 'Cobalt but not hypoxia stimulates PDGF gene expression in rats', Am J Physiol, 271 
(3 Pt 1), E451-7. 
Buhlmann, N., et al. (1999), 'A receptor activity modifying protein (RAMP)2-dependent adrenomedullin receptor 
is a calcitonin gene-related peptide receptor when coexpressed with human RAMP1', Endocrinology, 140 
(6), 2883-90. 
Buhlmann, N., et al. (2000), 'Glycosylation of the calcitonin receptor-like receptor at Asn(60) or Asn(112) is 
important for cell surface expression', FEBS Lett, 486 (3), 320-4. 
Bunn, H. F. and Poyton, R. O. (1996), 'Oxygen sensing and molecular adaptation to hypoxia', Physiol Rev, 76 
(3), 839-85. 
Bunton, D. C., et al. (2004), 'The clinical relevance of adrenomedullin: a promising profile?', Pharmacol Ther, 
103 (3), 179-201. 
Burdall, S. E., et al. (2003), 'Breast cancer cell lines: friend or foe?', Breast Cancer Res, 5 (2), 89-95. 
Burkhardt, J. K., et al. (2012), 'Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for 
the treatment of recurrent glioblastoma: progression-free survival and overall survival', World 
Neurosurg, 77 (1), 130-4. 
Buys, S., et al. (2003), 'Adrenomedullin upregulates M2-muscarinic receptors in cardiomyocytes from P19 cell 
line', Br J Pharmacol, 139 (6), 1219-27. 
Cabrera-Vera, T. M., et al. (2003), 'Insights into G protein structure, function, and regulation', Endocr Rev, 24 
(6), 765-81. 
306 
 
Calvo, A., et al. (2002), 'Adrenomedullin and proadrenomedullin N-terminal 20 peptide in the normal prostate 
and in prostate carcinoma', Microsc Res Tech, 57 (2), 98-104. 
Cantley, L. C. (2002), 'The phosphoinositide 3-kinase pathway', Science, 296 (5573), 1655-7. 
Cao, Y. (2005), 'Opinion: emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis', Nat 
Rev Cancer, 5 (9), 735-43. 
Carmeliet, P. (2000), 'Mechanisms of angiogenesis and arteriogenesis', Nat Med, 6 (4), 389-95. 
Carmeliet, P. and Jain, R. K. (2000), 'Angiogenesis in cancer and other diseases', Nature, 407 (6801), 249-57. 
Caron, K. M. and Smithies, O. (2001), 'Extreme hydrops fetalis and cardiovascular abnormalities in mice 
lacking a functional Adrenomedullin gene', Proc Natl Acad Sci U S A, 98 (2), 615-9. 
Carter, P. (2001), 'Improving the efficacy of antibody-based cancer therapies', Nat Rev Cancer, 1 (2), 118-29. 
Cases, A., et al. (2000), 'Increased plasma adrenomedullin levels in hemodialysis patients with sustained 
hypotension', Kidney Int, 57 (2), 664-70. 
Cavallaro, U. and Christofori, G. (2004), 'Cell adhesion and signalling by cadherins and Ig-CAMs in cancer', Nat 
Rev Cancer, 4 (2), 118-32. 
Chan, D. A., et al. (2002), 'Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-
1alpha', J Biol Chem, 277 (42), 40112-7. 
Chan, D. A., et al. (2005), 'Coordinate regulation of the oxygen-dependent degradation domains of hypoxia-
inducible factor 1 alpha', Mol Cell Biol, 25 (15), 6415-26. 
Chang, C. P., et al. (1993), 'Identification of a seven transmembrane helix receptor for corticotropin-releasing 
factor and sauvagine in mammalian brain', Neuron, 11 (6), 1187-95. 
Chauhan, M., Rajarathnam, K., and Yallampalli, C. (2005), 'Role of the N-terminal domain of the calcitonin 
receptor-like receptor in ligand binding', Biochemistry, 44 (2), 782-9. 
Chen, C., et al. (2001), 'Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras 
and hypoxia', J Biol Chem, 276 (12), 9519-25. 
Cheng, N., et al. (2008), 'Transforming growth factor-beta signaling-deficient fibroblasts enhance hepatocyte 
growth factor signaling in mammary carcinoma cells to promote scattering and invasion', Mol Cancer 
Res, 6 (10), 1521-33. 
Chini, E. N., et al. (1995), 'Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway', 
Biochem Biophys Res Commun, 215 (3), 868-73. 
Christopoulos, A., et al. (2003), 'Novel receptor partners and function of receptor activity-modifying proteins', J 
Biol Chem, 278 (5), 3293-7. 
Collantes, M., et al. (2003), 'Distribution of adrenomedullin and proadrenomedullin N-terminal 20 peptide 
immunoreactivity in the pituitary gland of the frog Rana perezi', Gen Comp Endocrinol, 133 (1), 50-60. 
Comerford, K. M., et al. (2002), 'Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance 
(MDR1) gene', Cancer Res, 62 (12), 3387-94. 
Condeelis, J. and Segall, J. E. (2003), 'Intravital imaging of cell movement in tumours', Nat Rev Cancer, 3 (12), 
921-30. 
Conner, A. C. and Poyner, D. R. (2001), 'The perils of using the human genome sequence: lessons from 
CALCRL', Trends Pharmacol Sci, 22 (6), 272. 
Conner, A. C., et al. (2004), 'Heterodimers and family-B GPCRs: RAMPs, CGRP and adrenomedullin', Biochem 
Soc Trans, 32 (Pt 5), 843-6. 
307 
 
Conway, E. M., Collen, D., and Carmeliet, P. (2001), 'Molecular mechanisms of blood vessel growth', 
Cardiovasc Res, 49 (3), 507-21. 
Cormier-Regard, S., Nguyen, S. V., and Claycomb, W. C. (1998), 'Adrenomedullin gene expression is 
developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes', J Biol Chem, 273 
(28), 17787-92. 
Cornish, J., Naot, D., and Reid, I. R. (2003), 'Adrenomedullin--a regulator of bone formation', Regul Pept, 112 
(1-3), 79-86. 
Cornish, J., et al. (1997), 'Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo', Am 
J Physiol, 273 (6 Pt 1), E1113-20. 
Cornish, J., et al. (2001), 'Systemic administration of adrenomedullin(27-52) increases bone volume and 
strength in male mice', J Endocrinol, 170 (1), 251-7. 
Corti, R., et al. (2001), 'Vasopeptidase inhibitors: a new therapeutic concept in cardiovascular disease?', 
Circulation, 104 (15), 1856-62. 
Couzin-Frankel, J. and Ogale, Y. (2011), 'FDA. Once on 'fast track,' avastin now derailed', Science, 333 (6039), 
143-4. 
Cueille, C., et al. (2002), 'Increased myocardial expression of RAMP1 and RAMP3 in rats with chronic heart 
failure', Biochem Biophys Res Commun, 294 (2), 340-6. 
Cueille, C., et al. (2005), 'Post-transcriptional regulation of CRLR expression during hypoxia', Biochem Biophys 
Res Commun, 326 (1), 23-9. 
Cui, J., et al. (2006), 'c-Jun NH(2)-terminal kinase 2alpha2 promotes the tumorigenicity of human glioblastoma 
cells', Cancer Res, 66 (20), 10024-31. 
Cuttitta, F., et al. (2002), 'Adrenomedullin functions as an important tumor survival factor in human 
carcinogenesis', Microsc Res Tech, 57 (2), 110-9. 
Cuttitta, Frank, et al. (1999), 'The Role of Adrenomedullin as a Growth Regulatory Peptide in the Normal and 
Malignant Setting', J. Anim Sci., 77 (suppl_3), 55-69. 
Czyzyk, T. A., et al. (2005), 'Deletion of peptide amidation enzymatic activity leads to edema and embryonic 
lethality in the mouse', Dev Biol, 287 (2), 301-13. 
Dackor, R., et al. (2007), 'Receptor activity-modifying proteins 2 and 3 have distinct physiological functions 
from embryogenesis to old age', J Biol Chem, 282 (25), 18094-9. 
Dackor, R. T., et al. (2006), 'Hydrops fetalis, cardiovascular defects, and embryonic lethality in mice lacking the 
calcitonin receptor-like receptor gene', Mol Cell Biol, 26 (7), 2511-8. 
Damert, A., et al. (1997), 'Up-regulation of vascular endothelial growth factor expression in a rat glioma is 
conferred by two distinct hypoxia-driven mechanisms', Cancer Res, 57 (17), 3860-4. 
Daub, H., et al. (1996), 'Role of transactivation of the EGF receptor in signalling by G-protein-coupled 
receptors', Nature, 379 (6565), 557-60. 
Davidson, B., et al. (2006), 'The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor 
progression in breast carcinoma', Gynecol Oncol, 102 (3), 453-61. 
Debinski, W., et al. (1999), 'Receptor for interleukin 13 is a marker and therapeutic target for human high-
grade gliomas', Clin Cancer Res, 5 (5), 985-90. 
Dechant, M. and Valerius, T. (2001), 'IgA antibodies for cancer therapy', Crit Rev Oncol Hematol, 39 (1-2), 69-
77. 
Deer, E. L., et al. (2010), 'Phenotype and genotype of pancreatic cancer cell lines', Pancreas, 39 (4), 425-35. 
308 
 
Deng, B., et al. (2012), 'Adrenomedullin expression in epithelial ovarian cancers and promotes HO8910 cell 
migration associated with upregulating integrin alpha5beta1 and phosphorylating FAK and paxillin', J Exp 
Clin Cancer Res, 31, 19. 
Dimmeler, S. and Zeiher, A. M. (2000), 'Akt takes center stage in angiogenesis signaling', Circ Res, 86 (1), 4-5. 
Ding, W., et al. (2010), 'Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion', 
Hepatology, 52 (3), 945-53. 
Disa, J., et al. (1998), 'Interaction of adrenomedullin with calcitonin receptor in cultured human breast cancer 
cells, T 47D', Peptides, 19 (2), 247-51. 
Drimal, J., Drimal, J., Jr., and Drimal, D. (2006), 'Hypoxic stress-enhanced expression and release of 
adrenomedullin (AM) and up-regulated AM receptors, while glucose starvation reduced AM expression 
and release and down-regulated AM receptors in monkey renal cells', Physiol Res, 55 (5), 535-42. 
Eckhart, A. D., et al. (1997), 'Characterization of the alpha1B-adrenergic receptor gene promoter region and 
hypoxia regulatory elements in vascular smooth muscle', Proc Natl Acad Sci U S A, 94 (17), 9487-92. 
Eguchi, S., et al. (1994), 'Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in 
cultured rat vascular smooth muscle cells', Endocrinology, 135 (6), 2454-8. 
Ehlenz, K., et al. (1997), 'High levels of circulating adrenomedullin in severe illness: correlation with C-reactive 
protein and evidence against the adrenal medulla as site of origin', Exp Clin Endocrinol Diabetes, 105 
(3), 156-62. 
Eipper, B. A., et al. (1992), 'Alternative splicing and endoproteolytic processing generate tissue-specific forms 
of pituitary peptidylglycine alpha-amidating monooxygenase (PAM)', J Biol Chem, 267 (6), 4008-15. 
Elshourbagy, N. A., et al. (1998), 'Molecular cloning and characterization of the porcine calcitonin gene-related 
peptide receptor', Endocrinology, 139 (4), 1678-83. 
Eng, C. (1999), 'RET proto-oncogene in the development of human cancer', J Clin Oncol, 17 (1), 380-93. 
Eng, E., et al. (2005), 'Hypoxia regulates PDGF-B interactions between glomerular capillary endothelial and 
mesangial cells', Kidney Int, 68 (2), 695-703. 
Evans, A. J., et al. (2007), 'VHL promotes E2 box-dependent E-cadherin transcription by HIF-mediated 
regulation of SIP1 and snail', Mol Cell Biol, 27 (1), 157-69. 
Feinberg, A. P. (2007), 'Phenotypic plasticity and the epigenetics of human disease', Nature, 447 (7143), 433-
40. 
Feldser, D., et al. (1999), 'Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like 
growth factor 2', Cancer Res, 59 (16), 3915-8. 
Fernandez-Sauze, S., et al. (2004), 'Effects of adrenomedullin on endothelial cells in the multistep process of 
angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors', Int J Cancer, 108 (6), 797-804. 
Ferrara, N. (2004), 'Vascular endothelial growth factor as a target for anticancer therapy', Oncologist, 9 Suppl 
1, 2-10. 
Fidler, I. J. (2003), 'The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited', Nat Rev 
Cancer, 3 (6), 453-8. 
Fisher, B., et al. (1993), 'Lumpectomy compared with lumpectomy and radiation therapy for the treatment of 
intraductal breast cancer', N Engl J Med, 328 (22), 1581-6. 
Fitzsimmons, T. J., Zhao, X., and Wank, S. A. (2003), 'The extracellular domain of receptor activity-modifying 
protein 1 is sufficient for calcitonin receptor-like receptor function', J Biol Chem, 278 (16), 14313-20. 
Flahaut, M., et al. (2003), 'N-Glycosylation and conserved cysteine residues in RAMP3 play a critical role for the 
functional expression of CRLR/RAMP3 adrenomedullin receptor', Biochemistry, 42 (34), 10333-41. 
309 
 
Fluhmann, B., et al. (1995), 'A human orphan calcitonin receptor-like structure', Biochem Biophys Res 
Commun, 206 (1), 341-7. 
Folkman, J. (1992), 'The role of angiogenesis in tumor growth', Semin Cancer Biol, 3 (2), 65-71. 
Forsythe, J. A., et al. (1996), 'Activation of vascular endothelial growth factor gene transcription by hypoxia-
inducible factor 1', Mol Cell Biol, 16 (9), 4604-13. 
Franklin, D. J. (2007), 'Cancer rehabilitation: challenges, approaches, and new directions', Phys Med Rehabil 
Clin N Am, 18 (4), 899-924, viii. 
Frazer, I. H. (2004), 'Prevention of cervical cancer through papillomavirus vaccination', Nat Rev Immunol, 4 
(1), 46-54. 
Friedl, P. and Wolf, K. (2003), 'Tumour-cell invasion and migration: diversity and escape mechanisms', Nat Rev 
Cancer, 3 (5), 362-74. 
Fritz-Six, K. L., et al. (2008), 'Adrenomedullin signaling is necessary for murine lymphatic vascular 
development', J Clin Invest, 118 (1), 40-50. 
Fujio, Y., et al. (2000), 'Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-
reperfusion injury in mouse heart', Circulation, 101 (6), 660-7. 
Furnari, F. B., et al. (1997), 'Growth suppression of glioma cells by PTEN requires a functional phosphatase 
catalytic domain', Proc Natl Acad Sci U S A, 94 (23), 12479-84. 
Futreal, P. A., et al. (2001), 'Cancer and genomics', Nature, 409 (6822), 850-2. 
Garayoa, M., et al. (2000), 'Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in 
human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis', 
Mol Endocrinol, 14 (6), 848-62. 
Garcia-Unzueta, M. T., et al. (1998), 'Plasma adrenomedullin levels in type 1 diabetes. Relationship with clinical 
parameters', Diabetes Care, 21 (6), 999-1003. 
Geiger, T. R. and Peeper, D. S. (2009), 'Metastasis mechanisms', Biochim Biophys Acta, 1796 (2), 293-308. 
Gether, U. (2000), 'Uncovering molecular mechanisms involved in activation of G protein-coupled receptors', 
Endocr Rev, 21 (1), 90-113. 
Ghosh, M., et al. (2004), 'Cofilin promotes actin polymerization and defines the direction of cell motility', 
Science, 304 (5671), 743-6. 
Giacalone, P. L., et al. (2003), 'Expression of adrenomedullin in human ovaries, ovarian cysts and cancers. 
Correlation with estrogens receptor status', Eur J Obstet Gynecol Reprod Biol, 110 (2), 224-9. 
Gibbons, C., et al. (2007), 'Receptor activity-modifying proteins: RAMPing up adrenomedullin signaling', Mol 
Endocrinol, 21 (4), 783-96. 
Gibbs, G. W. and Berry, G. (2008), 'Mesothelioma and asbestos', Regul Toxicol Pharmacol, 52 (1 Suppl), S223-
31. 
Giordano, F. J. and Johnson, R. S. (2001), 'Angiogenesis: the role of the microenvironment in flipping the 
switch', Curr Opin Genet Dev, 11 (1), 35-40. 
Gleadle, J. M., et al. (1995), 'Regulation of angiogenic growth factor expression by hypoxia, transition metals, 
and chelating agents', Am J Physiol, 268 (6 Pt 1), C1362-8. 
Goel, R., et al. (2004), 'Alpha-thrombin-mediated phosphatidylinositol 3-kinase activation through release of 
Gbetagamma dimers from Galphaq and Galphai2', J Biol Chem, 279 (8), 6701-10. 
Goldberg, M. A., Dunning, S. P., and Bunn, H. F. (1988), 'Regulation of the erythropoietin gene: evidence that 
the oxygen sensor is a heme protein', Science, 242 (4884), 1412-5. 
310 
 
Gonzalez-Moreno, O., et al. (2005), 'Gene expression profiling identifies IL-13 receptor alpha 2 chain as a 
therapeutic target in prostate tumor cells overexpressing adrenomedullin', Int J Cancer, 114 (6), 870-8. 
Gorlach, A., et al. (2001), 'Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular 
smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase', Circ Res, 89 (1), 47-54. 
Graeber, T. G., et al. (1996), 'Hypoxia-mediated selection of cells with diminished apoptotic potential in solid 
tumours', Nature, 379 (6560), 88-91. 
Granholm, S., Lundberg, P., and Lerner, U. H. (2008), 'Expression of the calcitonin receptor, calcitonin 
receptor-like receptor, and receptor activity modifying proteins during osteoclast differentiation', J Cell 
Biochem, 104 (3), 920-33. 
Grymer, L. F., Pallisgaard, C., and Melsen, B. (1991), 'The nasal septum in relation to the development of the 
nasomaxillary complex: a study in identical twins', Laryngoscope, 101 (8), 863-8. 
Guidolin, D., et al. (2008), 'Adrenomedullin stimulates angiogenic response in cultured human vascular 
endothelial cells: Involvement of the vascular endothelial growth factor receptor 2', Peptides, 29 (11), 
2013-23. 
Guise, T. (2010), 'Examining the metastatic niche: targeting the microenvironment', Semin Oncol, 37 Suppl 2, 
S2-14. 
Guo, P., et al. (2003), 'Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular 
endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment', Am J 
Pathol, 162 (4), 1083-93. 
Guo, W. and Giancotti, F. G. (2004), 'Integrin signalling during tumour progression', Nat Rev Mol Cell Biol, 5 
(10), 816-26. 
Gupta, G. P. and Massague, J. (2006), 'Cancer metastasis: building a framework', Cell, 127 (4), 679-95. 
Gutkind, J. S. (1998), 'The pathways connecting G protein-coupled receptors to the nucleus through divergent 
mitogen-activated protein kinase cascades', J Biol Chem, 273 (4), 1839-42. 
Haddad, J. J. and Land, S. C. (2001), 'A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent 
regulation of HIF-1alpha', FEBS Lett, 505 (2), 269-74. 
Hague, S., et al. (2000), 'Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates 
with uterine leiomyoma vascular density', Clin Cancer Res, 6 (7), 2808-14. 
Hall, E. J. (1994), 'Molecular biology in radiation therapy: the potential impact of recombinant technology on 
clinical practice', Int J Radiat Oncol Biol Phys, 30 (5), 1019-28. 
Hanahan, D. and Weinberg, R. A. (2000), 'The hallmarks of cancer', Cell, 100 (1), 57-70. 
Hanahan, D. and Weinberg, R. A. (2011), 'Hallmarks of cancer: the next generation', Cell, 144 (5), 646-74. 
Harper, M. E., et al. (1996), 'Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its 
relationship to neuroendocrine cells', Br J Cancer, 74 (6), 910-6. 
Harris, A. L. (2002), 'Hypoxia--a key regulatory factor in tumour growth', Nat Rev Cancer, 2 (1), 38-47. 
Hata, K., et al. (2000), 'Expression of thymidine phosphorylase and vascular endothelial growth factor in 
epithelial ovarian cancer: correlation with angiogenesis and progression of the tumor', Anticancer Res, 
20 (5C), 3941-9. 
Hawtin, S. R., et al. (2006), 'Charged extracellular residues, conserved throughout a G-protein-coupled 
receptor family, are required for ligand binding, receptor activation, and cell-surface expression', J Biol 
Chem, 281 (50), 38478-88. 
Hay, D. L., Poyner, D. R., and Sexton, P. M. (2006), 'GPCR modulation by RAMPs', Pharmacol Ther, 109 (1-2), 
173-97. 
311 
 
Hay, D. L., et al. (2004), 'The pharmacology of adrenomedullin receptors and their relationship to CGRP 
receptors', J Mol Neurosci, 22 (1-2), 105-13. 
Hayashi, M., et al. (1997), 'Plasma adrenomedullin in diabetes', Lancet, 350 (9089), 1449-50. 
Hewitson, K. S., et al. (2002), 'Hypoxia-inducible factor (HIF) asparagine hydroxylase is identical to factor 
inhibiting HIF (FIH) and is related to the cupin structural family', J Biol Chem, 277 (29), 26351-5. 
Hickey, M. M. and Simon, M. C. (2006), 'Regulation of angiogenesis by hypoxia and hypoxia-inducible factors', 
Curr Top Dev Biol, 76, 217-57. 
Higgins, D. F., et al. (2007), 'Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-
mesenchymal transition', J Clin Invest, 117 (12), 3810-20. 
Hilairet, S., et al. (2001), 'Agonist-promoted internalization of a ternary complex between calcitonin receptor-
like receptor, receptor activity-modifying protein 1 (RAMP1), and beta-arrestin', J Biol Chem, 276 (45), 
42182-90. 
Hinson, J. P., Kapas, S., and Smith, D. M. (2000), 'Adrenomedullin, a multifunctional regulatory peptide', 
Endocr Rev, 21 (2), 138-67. 
Hirata, Y., et al. (1996), 'Increased circulating adrenomedullin, a novel vasodilatory peptide, in sepsis', J Clin 
Endocrinol Metab, 81 (4), 1449-53. 
Hirayama, N., et al. (1999), 'Molecular forms of circulating adrenomedullin in patients with congestive heart 
failure', J Endocrinol, 160 (2), 297-303. 
Ho, H. H., et al. (1999), 'Glycosylation is important for binding to human calcitonin receptors', Biochemistry, 38 
(6), 1866-72. 
Hockel, M., et al. (1991), 'Oxygenation of carcinomas of the uterine cervix: evaluation by computerized O2 
tension measurements', Cancer Res, 51 (22), 6098-102. 
Hockel, M., et al. (1993), 'Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix', 
Radiother Oncol, 26 (1), 45-50. 
Hofbauer, K. H., et al. (2000), 'Tissue hypoxygenation activates the adrenomedullin system in vivo', Am J 
Physiol Regul Integr Comp Physiol, 278 (2), R513-9. 
Hofbauer, K. H., et al. (2002), 'Inflammatory cytokines stimulate adrenomedullin expression through nitric 
oxide-dependent and -independent pathways', Hypertension, 39 (1), 161-7. 
Hollerhage, H. G., et al. (1991), 'Influence of type and extent of surgery on early results and survival time in 
glioblastoma multiforme', Acta Neurochir (Wien), 113 (1-2), 31-7. 
Holliday, D. L. and Speirs, V. (2011), 'Choosing the right cell line for breast cancer research', Breast Cancer 
Res, 13 (4), 215. 
Hu, J., et al. (1998), 'Hypoxia regulates expression of the endothelin-1 gene through a proximal hypoxia-
inducible factor-1 binding site on the antisense strand', Biochem Biophys Res Commun, 245 (3), 894-9. 
Huang, L. E., et al. (1996), 'Activation of hypoxia-inducible transcription factor depends primarily upon redox-
sensitive stabilization of its alpha subunit', J Biol Chem, 271 (50), 32253-9. 
Huang, L. E., et al. (1998), 'Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent 
degradation domain via the ubiquitin-proteasome pathway', Proc Natl Acad Sci U S A, 95 (14), 7987-92. 
Huang, L. E., et al. (2007), 'Hypoxia-induced genetic instability--a calculated mechanism underlying tumor 
progression', J Mol Med (Berl), 85 (2), 139-48. 
Hudis, C. A. (2007), 'Trastuzumab--mechanism of action and use in clinical practice', N Engl J Med, 357 (1), 
39-51. 
312 
 
Hukovic, N., et al. (1999), 'Agonist-dependent up-regulation of human somatostatin receptor type 1 requires 
molecular signals in the cytoplasmic C-tail', J Biol Chem, 274 (35), 24550-8. 
Husmann, K., et al. (2000), 'Mouse receptor-activity-modifying proteins 1, -2 and -3: amino acid sequence, 
expression and function', Mol Cell Endocrinol, 162 (1-2), 35-43. 
Hwang, I. S., et al. (2007), 'Age-related changes in adrenomedullin expression and hypoxia-inducible factor-1 
activity in the rat lung and their responses to hypoxia', J Gerontol A Biol Sci Med Sci, 62 (1), 41-9. 
Ichikawa-Shindo, Y., et al. (2008), 'The GPCR modulator protein RAMP2 is essential for angiogenesis and 
vascular integrity', J Clin Invest, 118 (1), 29-39. 
Iimuro, S., et al. (2004), 'Angiogenic effects of adrenomedullin in ischemia and tumor growth', Circ Res, 95 (4), 
415-23. 
Imai, T., et al. (2003), 'Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian 
carcinoma cells', Am J Pathol, 163 (4), 1437-47. 
Inoue, D., et al. (1999), 'Calcitonin-dependent down-regulation of the mouse C1a calcitonin receptor in cells of 
the osteoclast lineage involves a transcriptional mechanism', Endocrinology, 140 (3), 1060-8. 
Ishihara, T., et al. (1999), 'Increased plasma levels of mature form of adrenomedullin in patients with chronic 
renal failure', Clin Nephrol, 52 (2), 119-23. 
Ishikawa, T., et al. (2003), 'Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer 
cells in SCID mice by suppressing angiogenesis', Oncogene, 22 (8), 1238-42. 
Ishimitsu, T., et al. (1994), 'Genomic structure of human adrenomedullin gene', Biochem Biophys Res 
Commun, 203 (1), 631-9. 
Ivan, M., et al. (2001), 'HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications 
for O2 sensing', Science, 292 (5516), 464-8. 
Iwasaki, H., et al. (2001), 'Adrenomedullin stimulates proline-rich tyrosine kinase 2 in vascular smooth muscle 
cells', Endocrinology, 142 (2), 564-72. 
Iwasaki, H., et al. (1998), 'Adrenomedullin as a novel growth-promoting factor for cultured vascular smooth 
muscle cells: role of tyrosine kinase-mediated mitogen-activated protein kinase activation', 
Endocrinology, 139 (8), 3432-41. 
Iwase, T., et al. (2005), 'Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat 
model of hindlimb ischemia', Circulation, 111 (3), 356-62. 
Iyer, N. V., et al. (1998), 'Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 
alpha', Genes Dev, 12 (2), 149-62. 
Jaakkola, P., et al. (2001), 'Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-
regulated prolyl hydroxylation', Science, 292 (5516), 468-72. 
Jahnke, G. D., et al. (1997), 'Adrenomedullin expression in the mouse mammary gland: evidence for the 
mature form in milk', J Mol Endocrinol, 19 (3), 279-89. 
Jemal, A., et al. (2010), 'Cancer statistics, 2010', CA Cancer J Clin, 60 (5), 277-300. 
Jeong, J. W., et al. (2002), 'Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation', Cell, 
111 (5), 709-20. 
Jimenez, N., et al. (1999), 'Expression of adrenomedullin and proadrenomedullin N-terminal 20 peptide in 
human and rat prostate', J Histochem Cytochem, 47 (9), 1167-78. 
Jimenez, N., et al. (2003), 'Androgen-independent expression of adrenomedullin and peptidylglycine alpha-
amidating monooxygenase in human prostatic carcinoma', Mol Carcinog, 38 (1), 14-24. 
313 
 
Jogi, A., et al. (2004), 'Human neuroblastoma cells exposed to hypoxia: induction of genes associated with 
growth, survival, and aggressive behavior', Exp Cell Res, 295 (2), 469-87. 
Jorgensen, K., Davidson, B., and Florenes, V. A. (2006), 'Activation of c-jun N-terminal kinase is associated 
with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma', Mod 
Pathol, 19 (11), 1446-55. 
Joshi, B. H., Plautz, G. E., and Puri, R. K. (2000), 'Interleukin-13 receptor alpha chain: a novel tumor-
associated transmembrane protein in primary explants of human malignant gliomas', Cancer Res, 60 
(5), 1168-72. 
Joshi, B. H., et al. (2008), 'Human adrenomedullin up-regulates interleukin-13 receptor alpha2 chain in 
prostate cancer in vitro and in vivo: a novel approach to sensitize prostate cancer to anticancer therapy', 
Cancer Res, 68 (22), 9311-7. 
Josko, J., et al. (2000), 'Vascular endothelial growth factor (VEGF) and its effect on angiogenesis', Med Sci 
Monit, 6 (5), 1047-52. 
Jougasaki, M., et al. (1995), 'Renal localization and actions of adrenomedullin: a natriuretic peptide', Am J 
Physiol, 268 (4 Pt 2), F657-63. 
Kaafarani, I., et al. (2009), 'Targeting adrenomedullin receptors with systemic delivery of neutralizing 
antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice', 
FASEB J, 23 (10), 3424-35. 
Kallio, P. J., et al. (1997), 'Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and 
conformational change by recruitment of the Arnt transcription factor', Proc Natl Acad Sci U S A, 94 
(11), 5667-72. 
Kallman, R. F. and Dorie, M. J. (1986), 'Tumor oxygenation and reoxygenation during radiation therapy: their 
importance in predicting tumor response', Int J Radiat Oncol Biol Phys, 12 (4), 681-5. 
Kalluri, R. and Weinberg, R. A. (2009), 'The basics of epithelial-mesenchymal transition', J Clin Invest, 119 (6), 
1420-8. 
Kamitani, S. and Sakata, T. (2001), 'Glycosylation of human CRLR at Asn123 is required for ligand binding and 
signaling', Biochim Biophys Acta, 1539 (1-2), 131-9. 
Kampa, M. and Castanas, E. (2008), 'Human health effects of air pollution', Environ Pollut, 151 (2), 362-7. 
Kanazawa, H., et al. (1994), 'Adrenomedullin, a newly discovered hypotensive peptide, is a potent 
bronchodilator', Biochem Biophys Res Commun, 205 (1), 251-4. 
Kapas, S., et al. (1997), 'Adrenomedullin has mitogenic effects on human oral keratinocytes: involvement of 
cyclic AMP', FEBS Lett, 418 (3), 287-90. 
Karagiannis, T. C. (2007), 'Antibody-based cancer treatment with ultra-short range Auger electron-emitting 
radionuclides: dual receptor and DNA targeting strategies', Hell J Nucl Med, 10 (3), 155-9. 
Kato, H., et al. (1997), 'Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial 
cells', Endocrinology, 138 (6), 2615-20. 
Kato, M., et al. (1999), 'Characterization of six cell lines established from human pancreatic adenocarcinomas', 
Cancer, 85 (4), 832-40. 
Ke, Q. and Costa, M. (2006), 'Hypoxia-inducible factor-1 (HIF-1)', Mol Pharmacol, 70 (5), 1469-80. 
Keleg, S., et al. (2007), 'Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion', 
Int J Cancer, 121 (1), 21-32. 
Khatlani, T. S., et al. (2007), 'c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes 
neoplastic transformation in human bronchial epithelial cells', Oncogene, 26 (18), 2658-66. 
314 
 
Kim, H., et al. (2011), 'Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma', 
Mol Cancer Ther, 11 (2), 405-15. 
Kim, J. Y., et al. (2006), 'Adrenomedullin regulates cellular glutathione content via modulation of gamma-
glutamate-cysteine ligase catalytic subunit expression', Endocrinology, 147 (3), 1357-64. 
Kim, W., et al. (2003a), 'Adrenomedullin reduces VEGF-induced endothelial adhesion molecules and 
adhesiveness through a phosphatidylinositol 3'-kinase pathway', Arterioscler Thromb Vasc Biol, 23 (8), 
1377-83. 
Kim, W., et al. (2003b), 'Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein 
kinase, and focal adhesion kinase in endothelial cells', FASEB J, 17 (13), 1937-9. 
Kim, W., et al. (2002), 'Protective effect of adrenomedullin in mannitol-induced apoptosis', Apoptosis, 7 (6), 
527-36. 
Kinoshita, H., et al. (2000), 'Increased plasma levels of mature adrenomedullin in chronic glomerulonephritis', 
Nephron, 86 (3), 333-8. 
Kitamura, K., et al. (1993), 'Adrenomedullin: a novel hypotensive peptide isolated from human 
pheochromocytoma', Biochem Biophys Res Commun, 192 (2), 553-60. 
Kitamuro, T., et al. (2000), 'Induction of adrenomedullin during hypoxia in cultured human glioblastoma cells', 
J Neurochem, 75 (5), 1826-33. 
Kitamuro, T., et al. (2001), 'Differential expression of adrenomedullin and its receptor component, receptor 
activity modifying protein (RAMP) 2 during hypoxia in cultured human neuroblastoma cells', Peptides, 22 
(11), 1795-801. 
Kleinman, H. K. and Liau, G. (2001), 'Gene therapy for antiangiogenesis', J Natl Cancer Inst, 93 (13), 965-7. 
Kline, D. D., et al. (2002), 'Defective carotid body function and impaired ventilatory responses to chronic 
hypoxia in mice partially deficient for hypoxia-inducible factor 1 alpha', Proc Natl Acad Sci U S A, 99 (2), 
821-6. 
Knobbe, C. B., Merlo, A., and Reifenberger, G. (2002), 'Pten signaling in gliomas', Neuro Oncol, 4 (3), 196-211. 
Kohno, M., et al. (1996), 'Plasma adrenomedullin concentrations in essential hypertension', Hypertension, 27 
(1), 102-7. 
Kohout, T. A. and Lefkowitz, R. J. (2003), 'Regulation of G protein-coupled receptor kinases and arrestins 
during receptor desensitization', Mol Pharmacol, 63 (1), 9-18. 
Koo, D. J., et al. (2001), 'The role of adrenomedullin in producing differential hemodynamic responses during 
sepsis', J Surg Res, 95 (2), 207-18. 
Kopfstein, L., et al. (2007), 'Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and 
metastasis', Am J Pathol, 170 (4), 1348-61. 
Koshiji, M., et al. (2005), 'HIF-1alpha induces genetic instability by transcriptionally downregulating MutSalpha 
expression', Mol Cell, 17 (6), 793-803. 
Kourembanas, S., Hannan, R. L., and Faller, D. V. (1990), 'Oxygen tension regulates the expression of the 
platelet-derived growth factor-B chain gene in human endothelial cells', J Clin Invest, 86 (2), 670-4. 
Krieg, A. J., et al. 'Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances 
hypoxic gene expression and tumor growth', Mol Cell Biol, 30 (1), 344-53. 
Krishnamachary, B., et al. (2006), 'Hypoxia-inducible factor-1-dependent repression of E-cadherin in von 
Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B', 
Cancer Res, 66 (5), 2725-31. 
Krishnamachary, B., et al. (2003), 'Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1', 
Cancer Res, 63 (5), 1138-43. 
315 
 
Krishnaswamy, V., et al. (2006), 'South Indian men with reduced CAG repeat length in the androgen receptor 
gene have an increased risk of prostate cancer', J Hum Genet, 51 (3), 254-7. 
Kristiansen, K. (2004), 'Molecular mechanisms of ligand binding, signaling, and regulation within the 
superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to 
receptor structure and function', Pharmacol Ther, 103 (1), 21-80. 
Kroeze, W. K., Sheffler, D. J., and Roth, B. L. (2003), 'G-protein-coupled receptors at a glance', J Cell Sci, 116 
(Pt 24), 4867-9. 
Kubo, A., et al. (1998), 'Plasma and urinary levels of adrenomedullin in chronic glomerulonephritis patients 
with proteinuria', Nephron, 80 (2), 227-30. 
Kureishi, Y., et al. (1995), 'Adrenomedullin decreases both cytosolic Ca2+ concentration and Ca(2+)-sensitivity 
in pig coronary arterial smooth muscle', Biochem Biophys Res Commun, 212 (2), 572-9. 
Kusano, S., et al. (2011), 'Structural basis for extracellular interactions between calcitonin receptor-like 
receptor and receptor activity-modifying protein 2 for adrenomedullin-specific binding', Protein Sci. 
Kuwasako, K., et al. (2009), 'Flow cytometric analysis of the calcitonin receptor-like receptor domains 
responsible for cell-surface translocation of receptor activity-modifying proteins', Biochem Biophys Res 
Commun, 384 (2), 249-54. 
Kuwasako, K., et al. (2003a), 'Identification of the human receptor activity-modifying protein 1 domains 
responsible for agonist binding specificity', J Biol Chem, 278 (25), 22623-30. 
Kuwasako, K., et al. (2004), 'Adrenomedullin receptors: pharmacological features and possible 
pathophysiological roles', Peptides, 25 (11), 2003-12. 
Kuwasako, K., et al. (2010), 'Function of the cytoplasmic tail of human calcitonin receptor-like receptor in 
complex with receptor activity-modifying protein 2', Biochem Biophys Res Commun, 392 (3), 380-5. 
Kuwasako, K., et al. (2003b), 'The function of extracellular cysteines in the human adrenomedullin receptor', 
Hypertens Res, 26 Suppl, S25-31. 
Kuwasako, K., et al. (2006), 'Functions of the cytoplasmic tails of the human receptor activity-modifying 
protein components of calcitonin gene-related peptide and adrenomedullin receptors', J Biol Chem, 281 
(11), 7205-13. 
Kuwasako, K., et al. (2011a), 'The third extracellular loop of the human calcitonin receptor-like receptor is 
crucial for the activation of adrenomedullin signalling', Br J Pharmacol. 
Kuwasako, K., et al. (2011b), 'Shared and separate functions of the RAMP-based adrenomedullin receptors', 
Peptides, 32 (7), 1540-50. 
Kuwasako, K., et al. (2001), 'The seven amino acids of human RAMP2 (86) and RAMP3 (59) are critical for 
agonist binding to human adrenomedullin receptors', J Biol Chem, 276 (52), 49459-65. 
Kuwasako, K., et al. (2000), 'Visualization of the calcitonin receptor-like receptor and its receptor activity-
modifying proteins during internalization and recycling', J Biol Chem, 275 (38), 29602-9. 
Lando, D., et al. (2002a), 'Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch', 
Science, 295 (5556), 858-61. 
Lando, D., et al. (2002b), 'FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional 
activity of hypoxia-inducible factor', Genes Dev, 16 (12), 1466-71. 
Lawson, Z. and Wheatley, M. (2004), 'The third extracellular loop of G-protein-coupled receptors: more than 
just a linker between two important transmembrane helices', Biochem Soc Trans, 32 (Pt 6), 1048-50. 
Le, Y., et al. (2004), 'Silencing the formylpeptide receptor FPR by short-interfering RNA', Mol Pharmacol, 66 
(4), 1022-8. 
316 
 
Lee, P. J., et al. (1997), 'Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-
1 gene in response to hypoxia', J Biol Chem, 272 (9), 5375-81. 
Lee, S. M., et al. (2006), 'Hypoxia confers protection against apoptosis via PI3K/Akt and ERK pathways in lung 
cancer cells', Cancer Lett, 242 (2), 231-8. 
Leon, S. P., Folkerth, R. D., and Black, P. M. (1996), 'Microvessel density is a prognostic indicator for patients 
with astroglial brain tumors', Cancer, 77 (2), 362-72. 
Letizia, C., et al. (2000), 'Circulating adrenomedullin is increased in patients with corticotropin-dependent 
Cushing's syndrome due to pituitary adenoma', Metabolism, 49 (6), 760-3. 
Letizia, C., et al. (2004), 'Adrenomedullin immunoreactivity tissue distribution in parathyroids of the patients 
with primary hyperparathyroidism', Horm Metab Res, 36 (7), 480-4. 
Levy, A. P., et al. (1995), 'Transcriptional regulation of the rat vascular endothelial growth factor gene by 
hypoxia', J Biol Chem, 270 (22), 13333-40. 
Li, C. Y., et al. (2000), 'Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers 
in rodent models', J Natl Cancer Inst, 92 (2), 143-7. 
Li, J., et al. (2004), 'Nickel compounds act through phosphatidylinositol-3-kinase/Akt-dependent, p70(S6k)-
independent pathway to induce hypoxia inducible factor transactivation and Cap43 expression in mouse 
epidermal Cl41 cells', Cancer Res, 64 (1), 94-101. 
Li, S., Huang, S., and Peng, S. B. (2005), 'Overexpression of G protein-coupled receptors in cancer cells: 
involvement in tumor progression', Int J Oncol, 27 (5), 1329-39. 
Lin, E. Y., et al. (2001), 'Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy', 
J Exp Med, 193 (6), 727-40. 
Liu, X., Davis, D., and Segaloff, D. L. (1993), 'Disruption of potential sites for N-linked glycosylation does not 
impair hormone binding to the lutropin/choriogonadotropin receptor if Asn-173 is left intact', J Biol 
Chem, 268 (3), 1513-6. 
Logsdon, C. D., et al. (2003), 'Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis 
identifies multiple genes differentially regulated in pancreatic cancer', Cancer Res, 63 (10), 2649-57. 
Lowes, V. L., Ip, N. Y., and Wong, Y. H. (2002), 'Integration of signals from receptor tyrosine kinases and g 
protein-coupled receptors', Neurosignals, 11 (1), 5-19. 
Lowy, D. R. and Willumsen, B. M. (1993), 'Function and regulation of ras', Annu Rev Biochem, 62, 851-91. 
Luttrell, L. M., Daaka, Y., and Lefkowitz, R. J. (1999), 'Regulation of tyrosine kinase cascades by G-protein-
coupled receptors', Curr Opin Cell Biol, 11 (2), 177-83. 
Majid, D. S., et al. (1996), 'Renal responses to intra-arterial administration of adrenomedullin in dogs', Am J 
Physiol, 270 (1 Pt 2), F200-5. 
Mallamaci, F., et al. (1998), 'Plasma adrenomedullin during acute changes in intravascular volume in 
hemodialysis patients', Kidney Int, 54 (5), 1697-703. 
Mandriota, S. J., et al. (2001), 'Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes 
tumour metastasis', EMBO J, 20 (4), 672-82. 
Mangiola, A., et al. (2007), 'Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor 
areas of glioblastoma multiforme: possible prognostic implications', Clin Cancer Res, 13 (23), 6970-7. 
Marinissen, M. J. and Gutkind, J. S. (2001), 'G-protein-coupled receptors and signaling networks: emerging 
paradigms', Trends Pharmacol Sci, 22 (7), 368-76. 
Martinez, A., Cuttitta, F., and Teitelman, G. (1998), 'Expression pattern for adrenomedullin during pancreatic 
development in the rat reveals a common precursor with other endocrine cell types', Cell Tissue Res, 
293 (1), 95-100. 
317 
 
Martinez, A., et al. (2005), 'Gastrin-releasing peptide (GRP) induces angiogenesis and the specific GRP blocker 
77427 inhibits tumor growth in vitro and in vivo', Oncogene, 24 (25), 4106-13. 
Martinez, A., et al. (1997), 'Expression of adrenomedullin and its receptor in normal and malignant human 
skin: a potential pluripotent role in the integument', Endocrinology, 138 (12), 5597-604. 
Martinez, A., et al. (1996), 'Regulation of insulin secretion and blood glucose metabolism by adrenomedullin', 
Endocrinology, 137 (6), 2626-32. 
Martinez, A., et al. (2002), 'The effects of adrenomedullin overexpression in breast tumor cells', J Natl Cancer 
Inst, 94 (16), 1226-37. 
Marutsuka, K., et al. (2003), 'Immunohistological localization and possible functions of adrenomedullin', 
Hypertens Res, 26 Suppl, S33-40. 
Masson, N., et al. (2001), 'Independent function of two destruction domains in hypoxia-inducible factor-alpha 
chains activated by prolyl hydroxylation', EMBO J, 20 (18), 5197-206. 
Mazzocchi, G., et al. (1996), 'Adrenomedullin and calcitonin gene-related peptide inhibit aldosterone secretion 
in rats, acting via a common receptor', Life Sci, 58 (10), 839-44. 
McClanahan, T., et al. (2006), 'Identification of overexpression of orphan G protein-coupled receptor GPR49 in 
human colon and ovarian primary tumors', Cancer Biol Ther, 5 (4), 419-26. 
McLatchie, L. M., et al. (1998), 'RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-
like receptor', Nature, 393 (6683), 333-9. 
Meister, A. and Anderson, M. E. (1983), 'Glutathione', Annu Rev Biochem, 52, 711-60. 
Melillo, G., et al. (1995), 'A hypoxia-responsive element mediates a novel pathway of activation of the inducible 
nitric oxide synthase promoter', J Exp Med, 182 (6), 1683-93. 
Mendez, O., et al. (2010), 'Knock down of HIF-1alpha in glioma cells reduces migration in vitro and invasion in 
vivo and impairs their ability to form tumor spheres', Mol Cancer, 9, 133. 
Mery, L. and Boulay, F. (1993), 'Evidence that the extracellular N-terminal domain of C5aR contains amino-acid 
residues crucial for C5a binding', Eur J Haematol, 51 (5), 282-7. 
Metellus, P., et al. (2011), 'Adrenomedullin expression and regulation in human glioblastoma, cultured human 
glioblastoma cell lines and pilocytic astrocytoma', Eur J Cancer, 47 (11), 1727-35. 
Miller, M. J., et al. (1996), 'Adrenomedullin expression in human tumor cell lines. Its potential role as an 
autocrine growth factor', J Biol Chem, 271 (38), 23345-51. 
Millonig, G., et al. (2009), 'Hypoxia-inducible factor 1 alpha under rapid enzymatic hypoxia: cells sense 
decrements of oxygen but not hypoxia per se', Free Radic Biol Med, 46 (2), 182-91. 
Minet, E., et al. (2001), 'Transduction pathways involved in Hypoxia-Inducible Factor-1 phosphorylation and 
activation', Free Radic Biol Med, 31 (7), 847-55. 
Miseki, T., et al. (2007), 'Suppression of tumor growth by intra-muscular transfer of naked DNA encoding 
adrenomedullin antagonist', Cancer Gene Ther, 14 (1), 39-44. 
Moncada, S., Palmer, R. M., and Higgs, E. A. (1991), 'Nitric oxide: physiology, pathophysiology, and 
pharmacology', Pharmacol Rev, 43 (2), 109-42. 
Montuenga, L. M., et al. (1997), 'Expression of adrenomedullin and its receptor during embryogenesis suggests 
autocrine or paracrine modes of action', Endocrinology, 138 (1), 440-51. 
Moore, M. J., et al. (2007), 'Erlotinib plus gemcitabine compared with gemcitabine alone in patients with 
advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials 
Group', J Clin Oncol, 25 (15), 1960-6. 
318 
 
Morfis, M., Christopoulos, A., and Sexton, P. M. (2003), 'RAMPs: 5 years on, where to now?', Trends Pharmacol 
Sci, 24 (11), 596-601. 
Morrish, D. W., et al. (1996), 'Identification by subtractive hybridization of a spectrum of novel and unexpected 
genes associated with in vitro differentiation of human cytotrophoblast cells', Placenta, 17 (7), 431-41. 
Mundy, G. R. (2002), 'Metastasis to bone: causes, consequences and therapeutic opportunities', Nat Rev 
Cancer, 2 (8), 584-93. 
Nag, K., et al. (2006), 'Molecular and functional characterization of adrenomedullin receptors in pufferfish', Am 
J Physiol Regul Integr Comp Physiol, 290 (2), R467-78. 
Nagaya, N., et al. (2000), 'Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients 
with congestive heart failure', Circulation, 101 (5), 498-503. 
Nakamura, M., et al. (1997), 'Potent and long-lasting vasodilatory effects of adrenomedullin in humans. 
Comparisons between normal subjects and patients with chronic heart failure', Circulation, 95 (5), 1214-
21. 
Nakanishi, K., et al. (2004), 'Expressions of adrenomedullin mRNA and protein in rats with hypobaric hypoxia-
induced pulmonary hypertension', Am J Physiol Heart Circ Physiol, 286 (6), H2159-68. 
Nakayama, M., et al. (1999), 'Induction of adrenomedullin by hypoxia in cultured human coronary artery 
endothelial cells', Peptides, 20 (6), 769-72. 
Nakazawa, I., et al. (2001), 'Human calcitonin receptor-like receptor for adrenomedullin: genomic structure, 
eight single-nucleotide polymorphisms, and haplotype analysis', J Hum Genet, 46 (3), 132-6. 
Naot, D., et al. (2001), 'A potential role for adrenomedullin as a local regulator of bone growth', Endocrinology, 
142 (5), 1849-57. 
Narisawa-Saito, M. and Kiyono, T. (2007), 'Basic mechanisms of high-risk human papillomavirus-induced 
carcinogenesis: roles of E6 and E7 proteins', Cancer Sci, 98 (10), 1505-11. 
Nguyen, S. V. and Claycomb, W. C. (1999), 'Hypoxia regulates the expression of the adrenomedullin and HIF-1 
genes in cultured HL-1 cardiomyocytes', Biochem Biophys Res Commun, 265 (2), 382-6. 
Nielsen, F. C., Gammeltoft, S., and Christiansen, J. (1990), 'Translational discrimination of mRNAs coding for 
human insulin-like growth factor II', J Biol Chem, 265 (23), 13431-4. 
Nikitenko, L. L., et al. (2000), 'Adrenomedullin is an autocrine regulator of endothelial growth in human 
endometrium', Mol Hum Reprod, 6 (9), 811-9. 
Nikitenko, L. L., et al. (2003), 'Transcriptional regulation of the CRLR gene in human microvascular endothelial 
cells by hypoxia', FASEB J, 17 (11), 1499-501. 
Nishikimi, T., et al. (1997), 'Cardiac production and secretion of adrenomedullin are increased in heart failure', 
Hypertension, 30 (6), 1369-75. 
Nishikimi, T., et al. (2003), 'Ventricular adrenomedullin system in the transition from LVH to heart failure in 
rats', Hypertension, 41 (3), 512-8. 
Nishio, K., et al. (1997), 'Increased plasma concentrations of adrenomedullin correlate with relaxation of 
vascular tone in patients with septic shock', Crit Care Med, 25 (6), 953-7. 
Nitta, K., et al. (2000), 'Increased plasma levels of adrenomedullin in patients with hemodialysis', Nephron, 85 
(4), 360-2. 
Nowak, W., et al. (2002), 'Novel regulation of adrenomedullin receptor by PDGF: role of receptor activity 
modifying protein-3', Am J Physiol Cell Physiol, 282 (6), C1322-31. 
Nuki, C., et al. (1993), 'Vasodilator effect of adrenomedullin and calcitonin gene-related peptide receptors in rat 
mesenteric vascular beds', Biochem Biophys Res Commun, 196 (1), 245-51. 
319 
 
O'Reilly, K. M., et al. (2007), 'Asbestos-related lung disease', Am Fam Physician, 75 (5), 683-8. 
O'Rourke, J. F., et al. (1996), 'Identification of hypoxically inducible mRNAs in HeLa cells using differential-
display PCR. Role of hypoxia-inducible factor-1', Eur J Biochem, 241 (2), 403-10. 
Obiri, N. I., et al. (1995), 'Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does 
not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15', J Biol 
Chem, 270 (15), 8797-804. 
Obiri, N. I., et al. (1997), 'The IL-13 receptor structure differs on various cell types and may share more than 
one component with IL-4 receptor', J Immunol, 158 (2), 756-64. 
Oehler, M. K., et al. (2001), 'Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial 
cancer cells: a possible promotion mechanism for tumour growth', Oncogene, 20 (23), 2937-45. 
Oehler, M. K., et al. (2003), 'Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast 
cancer', Br J Cancer, 89 (10), 1927-33. 
Oettle, H. and Neuhaus, P. (2007), 'Adjuvant therapy in pancreatic cancer: a critical appraisal', Drugs, 67 (16), 
2293-310. 
Ogoshi, M., Inoue, K., and Takei, Y. (2003), 'Identification of a novel adrenomedullin gene family in teleost 
fish', Biochem Biophys Res Commun, 311 (4), 1072-7. 
Okumura, H., et al. (2004), 'Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury 
through the phosphatidylinositol 3-kinase/Akt-dependent pathway', Circulation, 109 (2), 242-8. 
Onitsuka, H., et al. (2004), 'Differential gene expression of adrenomedullin receptors in pressure- and volume-
overloaded heart--role of angiotensin II', Peptides, 25 (7), 1107-14. 
Ono, Y., et al. (2000), 'Decreased gene expression of adrenomedullin receptor in mouse lungs during sepsis', 
Biochem Biophys Res Commun, 271 (1), 197-202. 
Ornan, D. A., Chaudry, I. H., and Wang, P. (2002), 'Saturation of adrenomedullin receptors plays an important 
role in reducing pulmonary clearance of adrenomedullin during the late stage of sepsis', Biochim Biophys 
Acta, 1586 (3), 299-306. 
Ouafik, L., Berenguer-Daize, C., and Berthois, Y. (2009), 'Adrenomedullin promotes cell cycle transit and up-
regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 
signal transduction pathway', Cell Signal, 21 (4), 597-608. 
Ouafik, L., et al. (2002), 'Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines 
in vitro and suppresses tumor xenograft growth in vivo', Am J Pathol, 160 (4), 1279-92. 
Palmer, T. D., et al. (2011), 'Targeting tumor cell motility to prevent metastasis', Adv Drug Deliv Rev, 63 (8), 
568-81. 
Parameswaran, N. and Spielman, W. S. (2006), 'RAMPs: The past, present and future', Trends Biochem Sci, 31 
(11), 631-8. 
Parameswaran, N., et al. (1999a), 'SB203580 reverses adrenomedullin's effect on proliferation and apoptosis in 
cultured mesangial cells', Eur J Pharmacol, 371 (1), 75-82. 
Parameswaran, N., et al. (1999b), 'Regulation of glomerular mesangial cell proliferation in culture by 
adrenomedullin', Eur J Pharmacol, 372 (1), 85-95. 
Park, S. C., et al. (2008), 'Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth', 
Cancer Lett, 271 (2), 314-22. 
Peeters, M. C., et al. (2011), 'Importance of the extracellular loops in G protein-coupled receptors for ligand 
recognition and receptor activation', Trends Pharmacol Sci, 32 (1), 35-42. 
Peinado, H., Lavotshkin, S., and Lyden, D. (2011), 'The secreted factors responsible for pre-metastatic niche 
formation: old sayings and new thoughts', Semin Cancer Biol, 21 (2), 139-46. 
320 
 
Perkins, S. N., Husten, E. J., and Eipper, B. A. (1990), 'The 108-kDA peptidylglycine alpha-amidating 
monooxygenase precursor contains two separable enzymatic activities involved in peptide amidation', 
Biochem Biophys Res Commun, 171 (3), 926-32. 
Pinkel, D. and Albertson, D. G. (2005), 'Array comparative genomic hybridization and its applications in 
cancer', Nat Genet, 37 Suppl, S11-7. 
Pinto, A., et al. (1996), 'Effects of adrenomedullin and calcitonin gene-related peptide on airway and pulmonary 
vascular smooth muscle in guinea-pigs', Br J Pharmacol, 119 (7), 1477-83. 
Pio, R., et al. (2001), 'Complement factor H is a serum-binding protein for adrenomedullin, and the resulting 
complex modulates the bioactivities of both partners', J Biol Chem, 276 (15), 12292-300. 
Ponta, H., Sherman, L., and Herrlich, P. A. (2003), 'CD44: from adhesion molecules to signalling regulators', 
Nat Rev Mol Cell Biol, 4 (1), 33-45. 
Prado, M. A., et al. (2001), 'The role of the CGRP-receptor component protein (RCP) in adrenomedullin receptor 
signal transduction', Peptides, 22 (11), 1773-81. 
Qi, T., et al. (2008), 'Identification of N-terminal receptor activity-modifying protein residues important for 
calcitonin gene-related peptide, adrenomedullin, and amylin receptor function', Mol Pharmacol, 74 (4), 
1059-71. 
Qi, T., et al. (2011), 'Structure-function analysis of amino acid 74 of human RAMP1 and RAMP3 and its role in 
peptide interactions with adrenomedullin and calcitonin gene-related peptide receptors', Peptides, 32 
(5), 1060-7. 
Qing, X., Svaren, J., and Keith, I. M. (2001), 'mRNA expression of novel CGRP1 receptors and their activity-
modifying proteins in hypoxic rat lung', Am J Physiol Lung Cell Mol Physiol, 280 (3), L547-54. 
Rabbitts, T. H. (1994), 'Chromosomal translocations in human cancer', Nature, 372 (6502), 143-9. 
Rafii, S., et al. (2002), 'Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?', 
Nat Rev Cancer, 2 (11), 826-35. 
Rahman, N. and Stratton, M. R. (1998), 'The genetics of breast cancer susceptibility', Annu Rev Genet, 32, 95-
121. 
Ramachandran, V., et al. (2007), 'Adrenomedullin is expressed in pancreatic cancer and stimulates cell 
proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR', Cancer Res, 
67 (6), 2666-75. 
Rasheed, B. K., et al. (1995), 'Chromosome 10 deletion mapping in human gliomas: a common deletion region 
in 10q25', Oncogene, 10 (11), 2243-6. 
Ray, K., et al. (1998), 'Identification of the sites of N-linked glycosylation on the human calcium receptor and 
assessment of their role in cell surface expression and signal transduction', J Biol Chem, 273 (51), 
34558-67. 
Richard, D. E., Berra, E., and Pouyssegur, J. (2000), 'Nonhypoxic pathway mediates the induction of hypoxia-
inducible factor 1alpha in vascular smooth muscle cells', J Biol Chem, 275 (35), 26765-71. 
Richard, D. E., et al. (1999), 'p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible 
factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1', J Biol Chem, 274 (46), 
32631-7. 
Richards, A. M., et al. (2001), 'Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic 
utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-
New Zealand Heart Failure Group', J Am Coll Cardiol, 37 (7), 1781-7. 
Rios, C. D., et al. (2001), 'G-protein-coupled receptor dimerization: modulation of receptor function', Pharmacol 
Ther, 92 (2-3), 71-87. 
Risau, W. (1997), 'Mechanisms of angiogenesis', Nature, 386 (6626), 671-4. 
321 
 
Robert, C. and Dubertret, L. (1995), '[Cancers of the skin, relations to ultraviolet rays]', Presse Med, 24 (34), 
1610-6. 
Robinson, S. D., et al. (2009), 'Novel peptide antagonists of adrenomedullin and calcitonin gene-related peptide 
receptors: identification, pharmacological characterization, and interactions with position 74 in receptor 
activity-modifying protein 1/3', J Pharmacol Exp Ther, 331 (2), 513-21. 
Rocchi, P., et al. (2001), 'Expression of adrenomedullin and peptide amidation activity in human prostate 
cancer and in human prostate cancer cell lines', Cancer Res, 61 (3), 1196-206. 
Rolfs, A., et al. (1997), 'Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1', J 
Biol Chem, 272 (32), 20055-62. 
Rosenes, Z., et al. (2012), 'The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the 
unfolded protein response regulator GRP78', PLoS One, 7 (9), e44927. 
Roux, K. H. (1999), 'Immunoglobulin structure and function as revealed by electron microscopy', Int Arch 
Allergy Immunol, 120 (2), 85-99. 
Ryan, H. E., Lo, J., and Johnson, R. S. (1998), 'HIF-1 alpha is required for solid tumor formation and embryonic 
vascularization', EMBO J, 17 (11), 3005-15. 
Ryan, H. E., et al. (2000), 'Hypoxia-inducible factor-1alpha is a positive factor in solid tumor growth', Cancer 
Res, 60 (15), 4010-5. 
Sahai, E. (2007), 'Illuminating the metastatic process', Nat Rev Cancer, 7 (10), 737-49. 
Salaspuro, M. (2007), 'Interrelationship between alcohol, smoking, acetaldehyde and cancer', Novartis Found 
Symp, 285, 80-9; discussion 89-96, 198-9. 
Salceda, S. and Caro, J. (1997), 'Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by 
the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on 
redox-induced changes', J Biol Chem, 272 (36), 22642-7. 
Sanz-Moreno, V., et al. (2008), 'Rac activation and inactivation control plasticity of tumor cell movement', Cell, 
135 (3), 510-23. 
Sarbassov, D. D., et al. (2005), 'Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex', 
Science, 307 (5712), 1098-101. 
Sata, M., et al. (2000), 'Adrenomedullin and nitric oxide inhibit human endothelial cell apoptosis via a cyclic 
GMP-independent mechanism', Hypertension, 36 (1), 83-8. 
Satoh, F., et al. (1995), 'Adrenomedullin in human brain, adrenal glands and tumor tissues of 
pheochromocytoma, ganglioneuroblastoma and neuroblastoma', J Clin Endocrinol Metab, 80 (5), 1750-
2. 
Schwartz, G. F., et al. (1993), 'Clinical applications of serum and tissue markers in malignant disease: breast 
cancer as the paradigm', Clin Chem, 39 (11 Pt 2), 2404-12. 
Schwarz, N., et al. (2006), 'Adrenomedullin increases the expression of calcitonin-like receptor and receptor 
activity modifying protein 2 mRNA in human microvascular endothelial cells', J Endocrinol, 190 (2), 505-
14. 
Scott, A. M., Wolchok, J. D., and Old, L. J. (2012), 'Antibody therapy of cancer', Nat Rev Cancer, 12 (4), 278-
87. 
Semenza, G. L. (1999), 'Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1', Annu Rev 
Cell Dev Biol, 15, 551-78. 
Semenza, G. L. (2003), 'Targeting HIF-1 for cancer therapy', Nat Rev Cancer, 3 (10), 721-32. 
Semenza, G. L., et al. (1991), 'Hypoxia-inducible nuclear factors bind to an enhancer element located 3' to the 
human erythropoietin gene', Proc Natl Acad Sci U S A, 88 (13), 5680-4. 
322 
 
Semenza, G. L., et al. (1996), 'Hypoxia response elements in the aldolase A, enolase 1, and lactate 
dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1', J Biol 
Chem, 271 (51), 32529-37. 
Serrano, J., et al. (2008), 'Adrenomedullin expression is up-regulated by acute hypobaric hypoxia in the 
cerebral cortex of the adult rat', Brain Pathol, 18 (3), 434-42. 
Sexton, P. M., et al. (2001), 'Receptor activity modifying proteins', Cell Signal, 13 (2), 73-83. 
Sharma, S. D., et al. (2009), 'Intermittent hypoxia activates peptidylglycine alpha-amidating monooxygenase 
in rat brain stem via reactive oxygen species-mediated proteolytic processing', J Appl Physiol, 106 (1), 
12-9. 
Shichiri, M. and Hirata, Y. (2003), 'Regulation of cell growth and apoptosis by adrenomedullin', Hypertens Res, 
26 Suppl, S9-14. 
Shichiri, M., et al. (1999), 'Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes 
endothelial apoptosis', Mol Endocrinol, 13 (8), 1353-63. 
Shimekake, Y., et al. (1995), 'Adrenomedullin stimulates two signal transduction pathways, cAMP accumulation 
and Ca2+ mobilization, in bovine aortic endothelial cells', J Biol Chem, 270 (9), 4412-7. 
Shimosawa, T., et al. (2003), 'Organ-protective effects of adrenomedullin', Hypertens Res, 26 Suppl, S109-12. 
Shindo, T., et al. (2001), 'Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin 
gene', Circulation, 104 (16), 1964-71. 
Shipley, W. U., et al. (1999), 'Radiation therapy for clinically localized prostate cancer: a multi-institutional 
pooled analysis', JAMA, 281 (17), 1598-604. 
Shweiki, D., et al. (1992), 'Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-
initiated angiogenesis', Nature, 359 (6398), 843-5. 
Siclari, V. A., Guise, T. A., and Chirgwin, J. M. (2006), 'Molecular interactions between breast cancer cells and 
the bone microenvironment drive skeletal metastases', Cancer Metastasis Rev, 25 (4), 621-33. 
Siegrist, W., Stutz, S., and Eberle, A. N. (1994), 'Homologous and heterologous regulation of alpha-
melanocyte-stimulating hormone receptors in human and mouse melanoma cell lines', Cancer Res, 54 
(10), 2604-10. 
Simms, J., et al. (2006), 'Characterization of the structure of RAMP1 by mutagenesis and molecular modeling', 
Biophys J, 91 (2), 662-9. 
So, S., et al. (1996), 'Up-regulation of rat adrenomedullin gene expression by endotoxin: relation to nitric oxide 
synthesis', Life Sci, 58 (19), PL309-15. 
Sodhi, A., et al. (2000), 'The Kaposi's sarcoma-associated herpes virus G protein-coupled receptor up-regulates 
vascular endothelial growth factor expression and secretion through mitogen-activated protein kinase 
and p38 pathways acting on hypoxia-inducible factor 1alpha', Cancer Res, 60 (17), 4873-80. 
Soengas, M. S., et al. (1999), 'Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition', 
Science, 284 (5411), 156-9. 
Souhami, L., et al. (2009), 'Impact of the duration of adjuvant hormonal therapy in patients with locally 
advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31', J Clin Oncol, 
27 (13), 2137-43. 
Stacker, S. A., et al. (2002), 'Lymphangiogenesis and cancer metastasis', Nat Rev Cancer, 2 (8), 573-83. 
Staller, P., et al. (2003), 'Chemokine receptor CXCR4 downregulated by von Hippel-Lindau tumour suppressor 
pVHL', Nature, 425 (6955), 307-11. 
Stambolic, V., et al. (1998), 'Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor 
PTEN', Cell, 95 (1), 29-39. 
323 
 
Steeg, P. S. (2006), 'Tumor metastasis: mechanistic insights and clinical challenges', Nat Med, 12 (8), 895-
904. 
Steiner, S. (1975), '[Rheumatic fever in soldiers]', Vojnosanit Pregl, 32 (6), 619-22. 
Strader, C. D., et al. (1994), 'Structure and function of G protein-coupled receptors', Annu Rev Biochem, 63, 
101-32. 
Stupp, R., et al. (2006), 'Changing paradigms--an update on the multidisciplinary management of malignant 
glioma', Oncologist, 11 (2), 165-80. 
Stupp, R., et al. (2005), 'Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma', N Engl J 
Med, 352 (10), 987-96. 
Su, A. I., et al. (2002), 'Large-scale analysis of the human and mouse transcriptomes', Proc Natl Acad Sci U S 
A, 99 (7), 4465-70. 
Sugo, S., et al. (1995a), 'Effects of vasoactive substances and cAMP related compounds on adrenomedullin 
production in cultured vascular smooth muscle cells', FEBS Lett, 369 (2-3), 311-4. 
Sugo, S., et al. (1994a), 'Production and secretion of adrenomedullin from vascular smooth muscle cells: 
augmented production by tumor necrosis factor-alpha', Biochem Biophys Res Commun, 203 (1), 719-26. 
Sugo, S., et al. (1995b), 'Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate 
production of adrenomedullin in vascular smooth muscle cells', Biochem Biophys Res Commun, 207 (1), 
25-32. 
Sugo, S., et al. (1994b), 'Endothelial cells actively synthesize and secrete adrenomedullin', Biochem Biophys 
Res Commun, 201 (3), 1160-6. 
Sullivan, R. and Graham, C. H. (2007), 'Hypoxia-driven selection of the metastatic phenotype', Cancer 
Metastasis Rev, 26 (2), 319-31. 
Sylvester, P. W. (2011), 'Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and 
viability', Methods Mol Biol, 716, 157-68. 
Takahashi, K., et al. (2003), 'Suppression of cytokine-induced expression of adrenomedullin and endothelin-1 
by dexamethasone in T98G human glioblastoma cells', Peptides, 24 (7), 1053-62. 
Takahashi, T., Ueno, H., and Shibuya, M. (1999), 'VEGF activates protein kinase C-dependent, but Ras-
independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells', Oncogene, 18 
(13), 2221-30. 
Takahashi, Y., et al. (2000), 'Hypoxic induction of prolyl 4-hydroxylase alpha (I) in cultured cells', J Biol Chem, 
275 (19), 14139-46. 
Taniguchi, T., et al. (1999), 'Ocular effects of adrenomedullin', Exp Eye Res, 69 (5), 467-74. 
Tannock, I. F. (1996), 'Treatment of cancer with radiation and drugs', J Clin Oncol, 14 (12), 3156-74. 
Taylor, M. M. and Samson, W. K. (2004), 'A possible mechanism for the action of adrenomedullin in brain to 
stimulate stress hormone secretion', Endocrinology, 145 (11), 4890-6. 
ten Freyhaus, H., et al. 'Hypoxia enhances platelet-derived growth factor signaling in the pulmonary 
vasculature by down-regulation of protein tyrosine phosphatases', Am J Respir Crit Care Med, 183 (8), 
1092-102. 
Totsune, K., et al. (2000), 'Increased gene expression of adrenomedullin and adrenomedullin-receptor 
complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in 
the hearts of rats with congestive heart failure', Clin Sci (Lond), 99 (6), 541-6. 
Tsujikawa, K., et al. (2007), 'Hypertension and dysregulated proinflammatory cytokine production in receptor 
activity-modifying protein 1-deficient mice', Proc Natl Acad Sci U S A, 104 (42), 16702-7. 
324 
 
Turk, H. M., et al. (2000), 'Relationship between plasma adrenomedullin levels and metabolic control, risk 
factors, and diabetic microangiopathy in patients with type 2 diabetes', Diabetes Care, 23 (6), 864-7. 
Udawela, M., Hay, D. L., and Sexton, P. M. (2004), 'The receptor activity modifying protein family of G protein 
coupled receptor accessory proteins', Semin Cell Dev Biol, 15 (3), 299-308. 
Udono, T., et al. (2000), 'Increased expression of adrenomedullin mRNA in the tissues of intraocular and orbital 
tumors', Am J Ophthalmol, 129 (4), 555-6. 
Ueda, N., et al. (1994), 'G protein beta gamma subunits. Simplified purification and properties of novel 
isoforms', J Biol Chem, 269 (6), 4388-95. 
Uemura, M., et al. 'Hypoxia-inducible adrenomedullin in colorectal cancer', Anticancer Res, 31 (2), 507-14. 
Valastyan, S. and Weinberg, R. A. (2011), 'Tumor metastasis: molecular insights and evolving paradigms', Cell, 
147 (2), 275-92. 
Vaupel, P. (2004), 'The role of hypoxia-induced factors in tumor progression', Oncologist, 9 Suppl 5, 10-7. 
Vengellur, A. and LaPres, J. J. (2004), 'The role of hypoxia inducible factor 1alpha in cobalt chloride induced cell 
death in mouse embryonic fibroblasts', Toxicol Sci, 82 (2), 638-46. 
Veronesi, U., et al. (2002), 'Twenty-year follow-up of a randomized study comparing breast-conserving surgery 
with radical mastectomy for early breast cancer', N Engl J Med, 347 (16), 1227-32. 
Vollmers, H. P. and Brandlein, S. (2006), 'Natural IgM antibodies: the orphaned molecules in immune 
surveillance', Adv Drug Deliv Rev, 58 (5-6), 755-65. 
Walker, C. S., et al. (2010), 'Regulation of signal transduction by calcitonin gene-related peptide receptors', 
Trends Pharmacol Sci, 31 (10), 476-83. 
Walsh, M. T., Foley, J. F., and Kinsella, B. T. (1998), 'Characterization of the role of N-linked glycosylation on 
the cell signaling and expression of the human thromboxane A2 receptor alpha and beta isoforms', J 
Pharmacol Exp Ther, 286 (2), 1026-36. 
Wang, D., et al. (2008), 'Immunohistochemistry in the evaluation of neovascularization in tumor xenografts', 
Biotech Histochem, 83 (3), 179-89. 
Wang, P., et al. (1999), 'Reduction in vascular responsiveness to adrenomedullin during sepsis', J Surg Res, 85 
(1), 59-65. 
Wang, S. M. and Yang, W. L. (2009), 'Circulating hormone adrenomedullin and its binding protein protect 
neural cells from hypoxia-induced apoptosis', Biochim Biophys Acta, 1790 (5), 361-7. 
Ward, E. (1995), 'Overview of preventable industrial causes of occupational cancer', Environ Health Perspect, 
103 Suppl 8, 197-203. 
Wartenberg, M., et al. (2003), 'Regulation of the multidrug resistance transporter P-glycoprotein in multicellular 
tumor spheroids by hypoxia-inducible factor (HIF-1) and reactive oxygen species', FASEB J, 17 (3), 503-
5. 
Weber, G. F. (2008), 'Molecular mechanisms of metastasis', Cancer Lett, 270 (2), 181-90. 
Weber, M. A. (2005), 'The role of the new beta-blockers in treating cardiovascular disease', Am J Hypertens, 18 
(12 Pt 2), 169S-76S. 
Weisberg, E., et al. (1997), 'Role of focal adhesion proteins in signal transduction and oncogenesis', Crit Rev 
Oncog, 8 (4), 343-58. 
Wheatley, M., et al. (2011), 'Lifting The Lid On G-Protein-Coupled Receptors: The Role Of Extracellular Loops', 
Br J Pharmacol. 
Withers, D. J., et al. (1996), 'Adrenomedullin stimulates DNA synthesis and cell proliferation via elevation of 
cAMP in Swiss 3T3 cells', FEBS Lett, 378 (1), 83-7. 
325 
 
Witschi, H., et al. (1997), 'The carcinogenicity of environmental tobacco smoke', Carcinogenesis, 18 (3), 575-
86. 
Wu, L. W., et al. (2000), 'Utilization of distinct signaling pathways by receptors for vascular endothelial cell 
growth factor and other mitogens in the induction of endothelial cell proliferation', J Biol Chem, 275 (7), 
5096-103. 
Wu, X., et al. (1998), 'The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of 
the phosphoinositide 3-kinase/Akt pathway', Proc Natl Acad Sci U S A, 95 (26), 15587-91. 
Wyckoff, J., et al. (2004), 'A paracrine loop between tumor cells and macrophages is required for tumor cell 
migration in mammary tumors', Cancer Res, 64 (19), 7022-9. 
Wyckoff, J. B., et al. (2000), 'A critical step in metastasis: in vivo analysis of intravasation at the primary 
tumor', Cancer Res, 60 (9), 2504-11. 
Wyckoff, J. B., et al. (2007), 'Direct visualization of macrophage-assisted tumor cell intravasation in mammary 
tumors', Cancer Res, 67 (6), 2649-56. 
Yagoda, A. and Petrylak, D. (1993), 'Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer', 
Cancer, 71 (3 Suppl), 1098-109. 
Yamaga, J., et al. (2003), 'Direct measurement of glycine-extended adrenomedullin in plasma and tissue using 
an ultrasensitive immune complex transfer enzyme immunoassay in rats', Hypertens Res, 26 Suppl, 
S45-53. 
Yamaguchi, H., Wyckoff, J., and Condeelis, J. (2005), 'Cell migration in tumors', Curr Opin Cell Biol, 17 (5), 
559-64. 
Yamaguchi, T., et al. (1995), 'Effect of adrenomedullin on aldosterone secretion by dispersed rat adrenal zona 
glomerulosa cells', Life Sci, 56 (6), 379-87. 
Yang, B. C., et al. (1996), 'Adrenomedullin dilates rat pulmonary artery rings during hypoxia: role of nitric 
oxide and vasodilator prostaglandins', J Cardiovasc Pharmacol, 28 (3), 458-62. 
Yang, M. H., et al. (2008), 'Direct regulation of TWIST by HIF-1alpha promotes metastasis', Nat Cell Biol, 10 
(3), 295-305. 
Yang, S., et al. (2002), 'Novel approach to prevent the transition from the hyperdynamic phase to the 
hypodynamic phase of sepsis: role of adrenomedullin and adrenomedullin binding protein-1', Ann Surg, 
236 (5), 625-33. 
Yin, H., Chao, L., and Chao, J. (2004), 'Adrenomedullin protects against myocardial apoptosis after 
ischemia/reperfusion through activation of Akt-GSK signaling', Hypertension, 43 (1), 109-16. 
Yoshida, D., et al. (2006), 'Hypoxia inducible factor 1-alpha regulates of platelet derived growth factor-B in 
human glioblastoma cells', J Neurooncol, 76 (1), 13-21. 
Yoshihara, F., et al. (2000), 'Ventricular adrenomedullin concentration is a sensitive biochemical marker for 
volume and pressure overload in rats', Am J Physiol Heart Circ Physiol, 278 (2), H633-42. 
Yoshihara, F., et al. (2005), 'Upregulation of intracardiac adrenomedullin and its receptor system in rats with 
volume overload-induced cardiac hypertrophy', Regul Pept, 127 (1-3), 239-44. 
Yu, A. Y., et al. (1999), 'Impaired physiological responses to chronic hypoxia in mice partially deficient for 
hypoxia-inducible factor 1alpha', J Clin Invest, 103 (5), 691-6. 
Yu, C. M., et al. (2001a), 'Increase in plasma adrenomedullin in patients with heart failure characterised by 
diastolic dysfunction', Heart, 86 (2), 155-60. 
Yu, F., et al. (2001b), 'HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation', Proc 
Natl Acad Sci U S A, 98 (17), 9630-5. 
326 
 
Zelzer, E., et al. (1998), 'Insulin induces transcription of target genes through the hypoxia-inducible factor HIF-
1alpha/ARNT', EMBO J, 17 (17), 5085-94. 
Zhang, S. X., et al. (2003), 'Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived 
growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A 
neuronal cells', FASEB J, 17 (12), 1709-11. 
Zhang, X., et al. (2005), 'Adrenomedullin enhances invasion by trophoblast cell lines', Biol Reprod, 73 (4), 619-
26. 
Zhao, L., et al. (1996), 'Adrenomedullin activity in chronically hypoxic rat lungs', Am J Physiol, 271 (2 Pt 2), 
H622-9. 
Zhao, Y., et al. (1998), 'PCR display identifies tamoxifen induction of the novel angiogenic factor 
adrenomedullin by a non estrogenic mechanism in the human endometrium', Oncogene, 16 (3), 409-15. 
Zhong, H., et al. (1999), 'Overexpression of hypoxia-inducible factor 1alpha in common human cancers and 
their metastases', Cancer Res, 59 (22), 5830-5. 
Zhou, M., et al. (2002), 'Adrenomedullin binding protein-1 modulates vascular responsiveness to 
adrenomedullin in late sepsis', Am J Physiol Regul Integr Comp Physiol, 283 (3), R553-60. 
Zimmermann, U., et al. (1996), 'Identification of adrenomedullin receptors in cultured rat astrocytes and in 
neuroblastboma x glioma hybrid cells (NG108-15)', Brain Res, 724 (2), 238-45. 
Zucker, S., et al. (2001), 'Tumorigenic potential of extracellular matrix metalloproteinase inducer', Am J Pathol, 
158 (6), 1921-8. 
Zudaire, E., Martinez, A., and Cuttitta, F. (2003), 'Adrenomedullin and cancer', Regul Pept, 112 (1-3), 175-83. 
 
 
Books 
1. C.K. Bomford, I.H. Kunkler, (2002). Walter and Miller’s textbook of Radiotherapy: Radiation 
Physics, Therapy and Oncology. 6E, Churchill Linvingstone, UK. 
2. Charles A Janeway, (1997). Immunobiology: The immune system in health and disease. 3E, 
Current Biology Limited. 
Humphrey P Rang, Maureen M Dale, James M Ritter, Rod J Flower, Graeme Henderson, (2011). 
Rang & Dale’s Pharmacology. 7E, Churchill Livinstone, UK. 
 
Conferences 
a) Rheumatology conference, SECC, Glasgow, UK. 
www.rheumatology.org.uk/includes/documents/cm_docs/2012/0930_is_adrenomedullin_a_potenti
al_therapeutic_forosteoarthritis_while_its_truncated_peptide_2252_acts_as_a.pdf 
